OA17341A

OA17341A - Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents.

Info

Publication number: OA17341A
Application number: OA1201400398
Authority: OA
Inventors: Burkhard Klenke; Irith Wiegand; Guido Schiffer; Heike Broetz-Oesterhelt; MAITI Samarendra N.; Jehangir Khan; Andhe Reddy; Zhixiang Yang; Mostafa Hena; Guofeng Jia; Ou Ligong; Hong Liang; Judy Yip; Chuanjun Gao; Sabiha Tajammul; Rahim Mohammad; Ganguli Biswajeet
Original assignee: Aicuris Gmbh & Co. Kg
Priority date: 2012-01-24
Filing date: 2013-01-23
Publication date: 2016-05-25

Abstract

The present invention relates to novel ßlactam compounds of formula (I), their preparation and use. In particular, this invention relates to novel ß-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.

Description

Amidine substituted beta-lactam compounds, their préparation and use as antibacterial agents [0001] This invention relates to novel /Llactam compounds, their préparation and use. In particular, this invention relates to novel /Mactam compounds which are amidine substituted monobactam dérivatives useful as antimicrobial agents and their préparation.

[0002] Public health experts and officiais consider the emergence and spread of antibiotic résistant bacteria as one of the major public health problems of the 21st century. Although not a new phenomenon per se, the spread of antibiotic résistant bacteria has reached an unprecedented dimension. While the most résistant isolâtes continue to emerge in the hospital settîng, physiciens and epidemiologists are encountering increasing numbers of résistant bacteria tn the community among people without previous healthcare contact. The number of patients who are dying from untreatable nosocomial infections continues to grow. Therapeutic options are especially limited for infections due to multi-drug-resistant Gram-negative pathogens including Enterobacteriaceae and non-fermenters, a situation made worse by the fact that the pipelines of the pharmaceutical industrycontain few compounds with promising résistance breaktng profiles (H.W. Boucher étal.; Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America; Clin Inf Dis 2009,48,1-12).

[0003] The highly successful and well-tolerated dass of /î-lactam antibiotics has historically been one mainstay for the treatment of infections caused by Gram-negative pathogens. Among these especially 3rd-generatîon cephalosporins, carbapenems and monobactams are extensively used for the treatment of infections with Gram-negative bacteria. However, a vast array of more than 1000 /Mactamases (a constantly updated list of /ï-lactamases can be found under http //www lahey.orp/Studies/) and further résistance mechanîsms severely endanger the mid-term usability of the current compounds in these subclasses. Especially extended-spectrum βlactamases (ESBLs) and carbapenemases are important drivers of résistance. New /Llactams with résistance breaking properties are urgently needed to fill the gap.

[0004] With aztreonam as the single FDA approved monobactam used worldwide and a second analogue marketed exdusively in Japan (tigemonam), the monobactams are a dearly under-explored subclass among the /Mactams. Reviews on aztreonam are available: W.C. Hellinger, N.S. Brewer; Carbapenems and Monobactams - Imipenem, Meropenem and Aztre onam; Mayo Clin. Proc. 1999,74,420-434. R.B. Sykes, D.P. Bonner; Discovery and Development of the monobactams; Rev. Infect. Dis. 1985,7 (Suppl. 4), 579-593.

[00051 The attempt to enhance the cellular uptake of the /Mactams by using ironsiderophore uptake Systems in microorganisms is one concept that has been explored in the monobactam field by Basilea (WO 2007065288), Naeja Pharmaceuticals (WO 2002022613) and Squibb & Sons (US 5290929, EP 531976, EP 484881). The heteroaryl units mimicing siderophores can also be attached to the side-chain as hydrazides as demonstrated by Squibb & Sons (US 5318963, US 5112968). Recently, Pfizer re-investigated monocarbams, mono-cyclic /Mactams that carry a sulfonylaminocarbonyl activating group at the Nl-positlon (WO 2010070523). Additionally, in WO 2008116813 Basilea has described combination therapy approaches using a combination of monobactams with carbapenems.

[0006] In view of the increasing résistance development of pathogenic bacterîa against known antibacterial agents, including multiple résistances, there is an ongoing need to find novel antibacterial substances, in particular compounds that hâve different structural motives.

[0007] The présent invention relates to compounds of formula (I)

A

CH₂)₍

in which

R¹ and R² independently of one another represent hydrogen, aminocarbonyl or (C!-C<)-aTkyl, or

R¹ and R² together with the carbon atom to which they are bonded form a (Cî-Cgî-cycloalkyl,

R³ represents -{CH₂)_m-(SO₂)OH or -O-(CH₂)_o-(SO₂)OH, wherein m and o independently of one another represent an integer 0,1,2 or 3, and wherein any CH₂-group contarned in the residues which R³ represents may be substituted with one or two (Ci-CiJ-alkyl-residues,

X represents CR* or N,

R⁴ represents hydrogen or halogen,

Z represents a bond or an alkyl-chain having one, two, three or four carbon atoms, whereby the alkyl-chain may be substituted with one, two, three or four substîtuents, selected independently of one another from the group consistïng of carboxy, aminocarbonyl and (Ci-C«)-alky1, whereby alkyl in tum may be substituted with a substituent selected from the group consisting of hydroxy, carboxy and aminocarbonyl,

Y represents a bond, O, NH or S,

A represents (Cj-Cio)-aryl or 5- to 10-membered heteroaryl, — whereby aryl and heteroaryl are substituted with a substituent of the following formula

wherein

R^lb, R^îb and R^îb independently of one anotherrepresent hydrogen, amino, hydroxy, (Ci-C^-alkyl, (Ci-QJ-alkoxy, (Cj-C^-cycloalkyl, 4-, 5-, 6- or 7membered heterocyclyl or 5- or 6-membered heteroaryl, whereby amino and hydroxy may be substituted with one or two substituents selected independently of one another from the group consisting of carbonyl, (Ci-Cj-alkylcarbonyl, mono- or di(Ci-Qj-alkylaminocarbonyl, and (Ci-Ql-alkyl, whereby alkoxy, heterocyclyl and heteroaryl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, (Ci-Qj-alkylcarbonyl, (Ci-C«)-alkoxy, mono- or di-fCi-CiJ-alkylamino, mono- or di-tC^J-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -C(=NH)CH₃ and (CrQj-alkyt, and whereby alkyl and cycloalkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, carbonyloxy, aminocarbonyl, carbonylamino, (C1-C4)alkylcarbonyl, {Cj-Cjalkoxy, mono- or di-tCi-QJ-alkylamino, mono- or dî-fCi-Qj-alkylaminocarbonyl, -NH-CH(=NH), -NHC(=NH)(NHî), -CH(=NH)CHj, (Ce-Cio)-aryl, 5- or 6-membered heteroaryl and 5- or 6-membered heterocyclyl, whereby heteroaryl and heterocyclyl in turn may be substituted with (Ci-CtJ-alkyl, whereby amino in turn may be substituted with 5- or 6membered heteroaryl, or

R¹⁶ and R^3b together with the nitrogen atom to which they are bonded form a 5- to 7-membered heterocyde including one, two or three further heteroatoms selected from the sériés N, O and S and R¹¹* is as defined above,

R^4b represents hydrogen, amino, hydroxy, (Cx-C^J-alkyl or (CrCj-alkoxy, whereby amino and hydroxy may be substituted with one or two substituents selected independently of one another from the group consisting of (Cj-QJ-alkylcarbonyl, mono- or di-(Ci-C«)alkylaminocarbonyl and (C_s-C«)-alkyl, whereby alkoxy may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, (C1-C4)alkylcarbonyl, (CpC^-alkoxy, mono- or di-(Ci-C<)-alkylamÎno, mono- or di-fCi-CiJ-alkylaminocarbonyï, -NH-CH(=NH), -NHC(=NH)(NH_I),-CH(=NH)CH_îand (Ci-Q)-alkyl, and whereby alkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, aminocar- μ/ ' bonyl, (CrQJ-alkylcarbonyl, (Ci-C<)-alkoxy, mono-or di-(Ci-C<)alkylamino, mono-ordi-(Ci-C«)-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -CH(=NH)CH3, (Ci-qi-alkyl, (CrCio)-aryl and 5or6-membered heteroaryl,

R⁸*¹ represents hydrogen or (Ci-C<)-alkyl,

Q represents a bond, CH₂ or NH, k represents an integer 1 or 2, and * is the lînkage site to the residue represented by A, and whereby aryl and heteroaryl further may be substituted with one or two substituents selected independently of one another from the group consisting of halogen, cyano, amino, hydroxy, (Ci-C«)-alkyl, (Ci-C«)-alkoxy, mono- or di-fCi-Cjalkylamino, amino-(Ci-C<)-alkyl, hydroxy-(Ci-C*)-alkyl or carboxy, whereby alkyl, alkoxy, alkylamino, amînoalkyl, hydroxyalkyl and carboxy in tum may be substituted with a substituent selected from the group consisting of halogen, (Ci-Cj-alkyl and carbonyl, and

I represents an integer 0,1,2 or 3, and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

[0008] Compounds of the invention are the compounds of formula (I) and the salts, solvatés and solvatés of the salts thereof, as well as the compounds which are encompassed by formula (I) and are mentioned hereinafter as exemplary embodiment(s), and the salts, solvatés and solvatés of the salts thereof, insofar as the compounds encompassed by formula (1} and mentioned hereinafter are not already salts, solvatés and solvatés of the salts.

[0009] The compounds of the invention may, depending on their structure, exist in stereoisomeric forms (enantiomers, diastereomers). The invention therefore also encompasses the enantiomers or diastereomers and respective mixtures thereof. The stereoisomerically uniform constituées can be isolated In a known manner from such mixtures of enantiomers and/or diastereomers.

[0010] If the compounds of the invention may occur in tautomeric forms, the présent invention encompasses ail tautomeric forms.

[0011] Salts preferred for the purposes of the présent invention are physiologically acceptable salts of the compounds of the invention. Also encompassed however are salts which are themselves not suitable for pharmaceutical applications but can be used for example for the isolation or purification of the compounds of the invention.

[0012] Examples of pharmaceutically acceptable salts of the compounds of formula (I) include salts of inorganic bases like ammonium salts, alkali métal salts, in particular sodium or potassium salts, alkaline earth métal salts, in particular magnésium or calcium salts; salts of organic bases, in particular salts derived from cydohexylamine, benzylamine, octylamine, ethanolamine, diethanolamine, diethylamine, triethylamine, ethylenediamine, procaine, morpholine, pyrroline, piperidine, N-ethylpiperidine, N-methylmorpholîne, pïperazine as the organic base; or salts with basic amino acids, In particular lysine, arginine, ornithine and histidine.

[0013] Examples of pharmaceutically acceptable salts of the compounds of formula (I) also include salts of inorganic acids like hydrochlorides, hydrobromides, sulfates, phosphates or phosphonates; salts of organic acids, in particular acétates, formates, propionates, lactates, citrates, fumarates, maleates, benzoates, tartrates, malates, methanesulfonates, ethanesulfonates, toluenesulfonates or benzenesulfonates; or salts with acidic amino acids, in particular aspartate or glutamate.

[0014] Solvatés for the purposes of the invention refer to those forms of the compounds of the invention which in the solid or liquid state form a complex by coordination with solvent molécules. Hydrates are a spécifie form of solvatés in which the coordination takes place with water.

[0015] In the context of this invention the substituents hâve the following définitions unless specified otherwise.

[0016] The term alkyl refers to branched or straight-chain (Ci-CsJ-alkyl, preferably (CiQj-alkyl, such as in particular methyl, ethyl, propyl, butyl, isopropyl, isobutyl and tert-butyl. The term alkylamino refers to an alkyl substituent linked via an amino group. The term alkylcarbonyl refers to an alkyl substituent linked via a carbonyl group. The term alkylaminocarbonyl refers to an alkylamino substituent linked via a carbonyl group.

[0017] The term cycloalkyl refers to aliphatic Cî-Cs, preferably Cî-Q, rings such as in particular cyclopropyl, cyclobutyl, cyclopentyl and cydohexyl.

[0018] The term alkoxy refers to branched or straight-chain (Ci-Ce)-alkoxy, preferably (C_rC«)-alkoxy, such as in particular methoxy, ethoxy, propoxy, butoxy, isopropoxy, isobutoxy and tert.-butoxy. The term alkoxycarbonyl refers to an alkoxy substituent linked via a carbonyl group.

[0019] The term heteroaryl refers to cydic heteroaromatic groups with 5-10 ring atoms, preferably with 5-6 ring atoms, and with up to 4, preferably with up to 2, heteroatoms selected from the group consisting of N, O, S, in which N can also form an N-oxide. Preferred are monocydic heteroaryl groups with 5-6 ring atoms including up to 2 hetero atoms selected from the group consisting of N, O and S, such as in particular thiophene, benzothiophene, furan, benzofuran, pyrrole, pyrazole, imidazole, thiazole, thiadiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, purine, quinolîne or isoquinoline. Many other suitable heteroaryl groups for the purpose of the invention are known to the person skilled in the art or can be readily found in the literature.

[0020] The term heterocyclyl refers to saturated or partially unsaturated heterocydic groups with 4-10 ring atoms, preferably with 5-6 ring atoms, and with up to 3, preferably with up to 2, heteroatoms selected from the group consisting of N, O, S, SO and SO2, in which N can also form an N-oxide. Preferred are saturated monocyclic heterocyclyl groups with 5-6 ring atoms including up to 2 hetero atoms selected from the group consisting of N, O and S, such as in particular pyrrolidine, pyrroline, tetrahydrofuran, tetrahydrothiophene, thiazolidine, imidazolidine, imidazoline, piperidine, pyran, tetrahydropyran, thîopyran,tetrahydrothiopyran, morpholine, thiomorpholine, piperazine, piperidazine. Many other suitable heterocyclyl groups for the purpose of the invention are known to the person skilled in the art or can be readily found in the literature.

[0021] The term halogen refers to fluorine, chlorine, bromïne or iodine; preferably fluorine or chlorine.

[0022] The term aminocarbonvl refers to an amino group linked via a carbonyl group.

[0023] The term carbonylamino refers to a carbonyl group linked via an amino group.

[0024] The term carboxy refers to a carboxylic acid group, i.e. a -COOH group.

[0025] The term carbonvloxv refers to a carbonyl group linked via an oxygen.

[0026] The présent invention also relates to compounds of formula (1) in which

R¹ and R² independently of one another represent hydrogen or (Ci-Ci)-alkyl, or

R¹ and R² together with the carbon atom to which they are bonded form a (Ci-C₈)-cydoalkyl,

R³ represents -(CH₂)_m-(SO₂)OH or -0-(CH₂)_o-(S0₂)0H, wherein m and o independently of one another represent an integer 0, or 1 and wherein any CH₂-group contained in the residues which R³ represents may be substituted with one or two (Ci-C*)-alkyl-residues, nf” ίο

X represents CR* or N,

R⁴ represents hydrogen or halogen,

Z represents a bond or an alkyl-chain having one, two or three carbon atoms, whereby the alkyl-chain may be substituted with one, two or three substituents, selected independently of one another from the group consîsting of carboxy, aminocarbonyl and (Ci-Cj-alkyl, whereby alkyl in tum may be substituted with a substituent se-lected from the group consîsting of hydroxy and carboxy,

Y represents a bond, O, NH or S,

A represents (C«-Cio)-a ry I or 5- to 10-membered heteroaryl, whereby aryl and heteroaryl are substituted with a substituent of the following formula

wherein

R^tt, R²⁶ and R^îh independently of one another represent hydrogen, amino, hydroxy, (Cj-C^-alkyl, 4-, 5-, 6- or 7-membered heterocyclyl or 5- or 6membered heteroaryl, whereby heterocyclyl and heteroaryl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, (Ci-C«)-alkylcarbonyl, (CrQj-alkoxy, mono- ordi-(Ci-C«)alkylamino, mono- or di-tCi-Qj-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -C(=NH)CH3 and (CrQ)-alkyl, and whereby alkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, carbonyloxy, aminocarbonyl, carbonylamîno, (Ci-C«)-a!kylcarbonyl, (C_rQJ-alkoxy, mono- or di-{Ci-C4)-alkylamino, mono- or di-(Ci-Cjalkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -CH(=NH)CH3, (CrCio)-aryl, 5- or 6-membered heteroaryl and 5- or

6-membered heterocyclyl, whereby heteroaryl and heterocyclyl in turn may be substituted with (Ci-Qj-alkyl, or

R^ïb and R^3b together with the nitrogen atom to which they are bonded form a S- to 7-membered heterocyde including one, two or three further heteroatoms selected from the sériés N, O and S and R^lb is as defined above,

R*^b represents hydrogen, amino, hydroxy, (Ci-GO-alkyt or (CrQ-alkoxy, whereby amino and hydroxy may be substituted with one or two substituents selected independently of one another from the group consisting of (Cj-C^-alkylcarbonyl, mono- or di-(CrC<)alkylaminocarbonyl and (Cj-CO-alkyl, and whereby alkyi may be substituted with one, two or three substituées selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, aminocarbonyl, (Ci-Qj-alkyl carbonyl, (Cj-C<)-alkoxy, mono- or di-fCj-C,)alkylamino, mono- ordi-fCi-Qj-alkylamînocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -CH{=NH}CH3, (CrQJ-alkyl, (CrCwl-aryl and 5or 6-membered heteroaryl,

R^Sb represents hydrogen or (CpCj-alkyi,

Q represents a bond, CH₂ or NH, k represents an integer 1 or 2, and • Is the linkage site to the residue represented by A, and whereby aryl and heteroaryl further may be substituted with one or two substitueras selected Independently of one another from the group consisting of halogen, cyano, amino, hydroxy, (C^-Qj-alkyl, (CrCil-alkoxy, mono- or di-tCi-Q)atkylamino, amino-fCi-Qj-alkyl, hydroxy-(Ci-C4)-alkyl or carboxy, whereby alkyi, alkoxy, alkylamino, aminoalkyl, hydroxyalkyl and carboxy in turn may be substituted with a substituent selected from the group consisting of halogen, (Ci-CO-alkyl and carbonyl, and

I represents an integer 0 or 1 and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

[0027] The présent invention also relates to compounds of formula (I) in which

R¹ and R² independently of one another represent hydrogen or (Cj-GJ-alkyl, or yy—'

R¹ and R² together with the carbon atom to which they are bonded form a (Cî-CeJ-cycloalkyl,

R³ represents -(SOJOH or -O-(CH₂)₀-(S0₂)0H, wherein o is an integer 0 or 1, and wherein any CH₂-group contained in the residues which R³ represents may be sub5 stituted with one or two (Ci-Cj-aikyl-residues,

X represents CH,

Z represents an alkyl-chain having two or three carbon atoms, whereby the alkyl-chain may be substituted with one or two substituents selected independently of one another from the group consisting of carboxy, aminocar10 bonyl, methyl, hydroxymethyl, hydroxyethyl,

Y represents O

A represents phenyl or 5- or 6-membered heteroaryl, whereby phenyl and heteroaryl are substituted with a substituent of the following formula

wherein

R^tt, R^Zb and R^îb independently of one another represent hydrogen, amino, hydroxy, (Ci-Qj-alkyl or 4-, 5-, 6- or 7-membered heterocyclyl, whereby heterocyclyl may be substituted with one or two substituents selected independently of one another from the group consisting of amino, carboxy, mono- or di-(Ci-C4)-alkylamino, and (Ci-Qj-alkyl, and whereby alkyl may be substituted with one or two substituents selected independently of one another from the group consisting of hydroxy, amino, carboxy, carbonyloxy, aminocarbonyl, carbonylamino, mono- or di-fCt-Qj-alkylamino, mono- or di-(CiGl-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH_Ï), phenyl, 6-membered heteroaryl and 5- or 6-membered heterocyclyl, or

R^2b and R^3b together with the nïtrogen atom to which they are bonded form a 6membered heterocyde including one or two nitrogen atoms and R^u is hydrogen,

R*^b represents hydrogen or amino, whereby amino may be substituted with one or two (Ci-C^-alkyl substituents,

R^Sb represents hydrogen,

Q represents a bond, k represents an integerl or 2, and * is the linkage site to the residue represented by A, and —17341 whereby phenyl und heteroaryl further may be substituted with one or two substituents selected independently of one another from the group consisting of halogen, cyano, amino, hydroxy, (Cj-C^-alkyl or hydroxy-tCrO-alkyl, whereby hydroxyalkyl in tum may be susbstituted with a carbonyl substituent, and

I represents 0 and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

[0028] The présent invention also relates to compounds of formula (I) in which

R¹ and R² independently of one another represent hydrogen or methyl,

R³ represents-(SO₂)OH or-O-tSOjOH,

X represents CH,

Z represents an alkyl-chain having two or three carbon atoms, whereby the alkyl-chain may be substituted with one or two substituents, selected independently of one another from the group consisting of carboxy and me15 thyi,

Y represents O,

A represents phenyl or 6-membered heteroaryl, whereby phenyl and heteroaryl are substituted wîth a substituent of the following formula

wherein

R¹¹¹ and R^Ib represent hydrogen,

R³⁶ represents hydrogen, amino, hydroxy, (Ci-C«)-aIkyl or 4-, 5- or 6membered nitrogen-containing heterocyclyl, whereby alkyl may be substituted with a substituent selected from the group consisting of hydroxy, amino, carboxy, carbonyloxy, mono- or di-lCr-C^-alkylamino, -NHCH{=NH), -NH-C(=NH){NHi), 5- or 6-membered nitrogencontaining heteroaryl and 5- or 6-membered nitrogencontaining heterocyclyl,

Q represents a bond, * is the linkage site to the residue represented by A, and whereby aryl and heteroaryl further may be substituted with one substituent selected from the group consisting of halogen, cyano, amino, hydroxy, (Ci-Qj-aîkyl or hydroxy-fCi-Qj-alkyl

(0029] The présent invention also relates to compounds of formula (I) in which R¹ and R² represent methyl,

R³ represents -O-(SO₂)OH,

X represents CH,

Z represents an alkyl-chain having two carbon atoms, whereby the alkyl-chain may be substituted with a carboxy substituent,

Y represents O,

A represents phenyl substituted with a substituent of the following formula

wherein

R^tt and R^2b represent hydrogen,

R^îb represents aminoethyl, azetidine, pyrrolidine or piperidine,

Q represents a bond.

is the linkage site to the residue represented by A, and

I represents 0 and the salts thereof, the solvatés thereof and the solvatés ofthe salts thereof.

[0030] The présent invention also relates to compounds of formula (I) in which

R^x a nd R¹ re prese nt methyl,

R³ represents -O-(SO₂)OH,

X represents CH,

Z represents a two carbon alkyl-chain, substituted with a carboxy substituent.

Y represents 0,

A represents phenyl substituted with a substituent of the following formula

wherein

R“ and R^Ib represent hydrogen,

R³* represents aminoethyl, azetidine, pyrrolidine or piperidine,

Q represents a bond, w— is the linkage site to the residue represented by A, and l representsO and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

[00311 In particular the présent invention relates to compounds of formula (I) in which

A represents a group selected from the following formulae

and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

[0032] The présent invention also relates to methods for the préparation of compounds of formula (I). The compounds of the présent invention may be prepared by removïng the protecting group from compounds of formula

A I

(II) in which Pg represents a protecting group and R³-R³, A, I, X, Y and Z are as defined above, under acidic conditions.

[0033] Acidic conditions may involve treating the compounds of formula (11) with formîc acid, acetic acid, trifluoroacetic acid or hydrochloric acid at températures ranging from 0*C to 100*C for a time ranging from 10 min to 16 hours, preferably with 90% formic acid at a tempera15 ture of 30-60*C for 30-60 min.

[0034] The compounds of formula (II) can be synthesized by reacting compounds of formula

A

i

(III) in which Pg represents a protecting group and A, I, X, Y and Z are as defined above, with compounds of formula

R¹

in which R¹, R² and R³ are as defined above.

[0035] The reaction generally takes place in inert solvents in the presence of a coupling reagent and where applicable with addition of a base at a température ranging from -20’C to 80’C for 1-24 hours, preferably at a température of 20-30’C ovemight. Inert solvents are for example dichloromethane (DCM), trichloromethane, benzene, toluene, tetrahydrofuran (THF), 1,4-dioxane, Ν,Ν-dimethylformamide (DMF), Ν,Ν-dimethylacetamide (DMA), N-methylpyrrolidin2-one (NMP) and acetonitrile as well as mixtures of the aforementioned solvents. A preferred solvent is Ν,Ν-dimethylformamide.

[0036] Suitable coupîing reagents are for example carbodiimides such as Ν,Ν'-diethyl, Ν,Ν,'-dipropyl-, N,N'-diisopropyl-, Ν,Ν'-dicyclohexylcarbodiimide, N-(3-dimethylamïnoisopropyl)N'-ethylcarbodiimîd-hydrochloride (EDC), N-cydohexylcarbodiimid-N'-propyloxymethylpolystyrene (PS-Carbodiimide) or carbonyl compounds such as carbonyldiimidazole (CDI), or 1,2oxazolium compounds such as 2-ethyl-5-phenyl-l,2-oxazolium-3-sulfate or 2-tert-butyl-5-methylisoxazolium-perchlorate, or acylamino compounds such as 2-ethoxy-l-ethoxycarbonyl-l,2-dihydrochinoline, or propanphosphonic acid anhydride, or isobutylchloroformate, or bis-(2-oxo-3oxazolidinyl)-phosphorylchloride,orO-(benzotriazol-l-y1)-N,N,N*,N'-tetramethyluroniumhexafluorophosphate (HBTU), 2-(2-oxo-l-(2H)-pyridyl)-l,l,3,3-tetramethyluroniumtetrafluoroborate (TPTU) or O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyl- <y-— uroniumhexafluorophosphate (HATU), or 1-hydroxybenzotriazole (HOBt), or benzotriazol-l-yloxytris{dimethylamino)-phosphonîumhexafluorophosphate (BOP), or benzotriazo!-l-y!oxytris(pyrrolidino)-phosphoniumhexafluorophosphate (PyBOP), or N-hydroxysuccinimide as well as mixtures of the aforementioned coupling reagents with or without the addition of a base. In the latter case both inorganîc and organic bases may be used. Suitable bases are for example carbonates and bicarbonates, triethylamine, diisopropylethylamine, N-methylmorpholine, N-methylpiperidine or 4-dimethylaminopyridine. Preferably, reactions are carried out with a mixture of a carbodiimide and 1-hydroxybenzotriazole with or without the addition of sodium bicarbonate as base.

(0037] The compounds of formula (III) can be prepared selectively with the preferred

Z-orientation of the oxime by reacting compounds of formula

in which Pg represents a protecting group, and X is as defined above with compounds of formula

in which A, I, Y and Z are as defined above.

[0038] The reaction generally takes place în protic solvents or in solvent mixtures containing at least one protic solvent at a température ranging from O’C to 100’C for 1-24 hours. Suitable protic solvents are for example methanol, éthanol, tso-propanol, tert.-butano!, water or acetic acid. Solvents suitable to form mixtures are for example dichloromethane, trichloro- — methane, tetrahydrofuran, 1,4-dîoxane, acetonitrile and Ν,Ν-dimethylformamide. Preferably, the reaction is carried out in a mixture of anhydrous éthanol and chloroform at 2O-3O*C ovemight.

[0039] Compounds of formula (IV) can be synthesized according to the following I itératif re référencés: J. Org. Chem. 1982,47 (26), 5160-5167; WO 2007/65288; J. Antibiotics 1985,38 (11), 1536-1549; WO 2008/116813; Org. Proc. Res. Dev. 2002, 6 (6), 863-868; EP 336667; DE 3336262; BE 904699 or by adapting the referenced procedures in a way known to a person skilled in the art.

[0040] Compounds of formula (V) can be synthesized according to the following literature référencés: Chem. & Pharm. Bull., 1990,38(12), 3476-3479; Bioorg. Med. Chem., 2007, 38 (21), 6716-6732; Chem. & Pharm. Bull., 1990,38(12), 3476-3479 or Bioorg. Med. Chem., 2007, 38(21), 6716-6732.

[0041] The compounds of formula (VI) can be prepared by deprotecting compounds of formula

in which A, I, Y and Z are as defined above.

[0042] The deprotection reaction generally takes place with hydrazine, ammonia or methylamine or a sait or a solvaté thereof în protic solvents or in solvent mixtures containing at least one protic solvent at a température ranging from 0*C to 100*C for 1-24 hours. Protic solvents are for example methanol, éthanol, iso-propanol, tert.-butanol, water or acetic acid. Suitable solvents to form mixtures are for example dichloromethane, trichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile and N,N-dimethylformamide. Preferably, the reactions are carried out with hydrazine monohydrate in anhydrous éthanol at 20-30*C for 2-6 hours.

[0043] The compounds of formula (VII) can be prepared by reacting compounds of formula

A r^yLO (VIII) in which Lg represents a leaving group and A, I, Y and Z are as defined above with N-hydroxy-phthalimide.

[0044] The reaction can be performed as an alkylation type (Lg = halide, mesylate, tosylate, triflate or similar) or a Mitsunobu type (Lg = OH) reaction. Alkylation type reactions generally take place in the presence of an inorganic or organic base in aprotic solvents at a température ranging from O’C to 100’C for 1-24 hours.

[0045] Mitsunobu type reactions are generally carried out in the presence of triphenylphosphïne and an alkyl azodicarboxylate in aprotic solvents at a température ranging from 0*C to 100’C for 1-24 hours. Suitable aprotic solvents are for example acetonitrile, tetrahydrofuran, dichloromethane, trichloromethane, 1,4-dioxane, W,W-dimethylformamide, N_tNdimethylacetamîde and W-methyl-pyrolidin-2-one. Preferably, the reaction takes place under Mitsunobu conditions (Lg = OH) in the presence of triphenylphosphine and diisopropyl azodicarboxylate in anhydrous tetra hydrofuran at O’C to 30’C for 2-6 hours.

[0046] In an alternative preferred method the reaction takes place under alkylation conditions in the presence of potassium carbonate or l,8-diazabicydo[5.4.0]undec-7-ene (DBU) in acetonitrile or Ν,Ν-dimethylformamide at 20’C to 80’C for 2-16 hours. Examples for preferred compounds of formula (VIII) are compounds of formulae \J^~

(Villa)

OH (Vlllb) in which Pg represents an alkyl- or arylalkylester protecting group and A is as defined above.

[0047] The compounds of formula (Villa) and (Vlllb) can be synthesised by converting the cyano group in compounds of formula

Br (IXa) /CN (HeteroJAryA

OH (IXb) in which Pg represents an alkyl- or arylalkylester protecting group into the required substituted or unsubstituted amidine functionality.

[0048] The conversion of the cyano(hetero)aryl to the corresponding amidine can be achieved under a range of different acidic and alkaline conditions.

[0049] One possibility is to treat the cyano(hetero)aryl with hydrochloric acid gas in a protic solvent, like methanol or éthanol, at O’C to 30*C for 2-24 hours. The formed O-alkyl amidate intermediate is then treated with an ammonia solution or an amine in the same solvent at 20*C to 50*Cfor 1-16 hours. Hydrochloric acid gas may also be formed in-situ from acetylchloride or thionylchloride; ammonium chloride in the presence of a base like triethylamine or diisopro15 pylethylamine may also be used instead of an ammonia solution.

[0050] A further possibility is to react the cyano(hetero)aryl with an amine, ammonium chloride or an amine sait in the presence of trimethylaluminium in a non-protic solvent, like toluene or dichlorobenzene, at 20*C to 120*C for 1-16 hours.

[0051] A further option is to treat the cyano(hetero)aryl with hydroxylamine in polar solvents, like éthanol, water or dimethylsulfoxide or a mixture of the aforementioned solvents, at 20*C to 80’C for 1-16 hours. The formed amidoxime Intermediate is then de-oxygenated using hydrogen over palladium on carbon in acetic acid at 20*C to 50*C for 4-24 hours. Hydroxylamine hydrochloride in the presence of triethylamîne or diisopropylethylamine may be used instead of hydroxylamine; the de-oxygenation may also be carried out using a co-solvent, like methanol, éthanol or 1,4-dioxane, or with the additional acetic acid anhydride.

[0052] A further option is to treat the cyano(hetero)aryl with sodium alkoxide in the corresponding alcohol, preferably with sodium methoxïde In methanol, at 20’C to 50’C for 2-20 hours. The formed O-alkyl amidate intermediate is then treated with an ammonia solution or an amine as described above.

[0053] A further option 1s to treat the cyano(hetero)aryl with lithium hexamethyldisîlazide in an inert solvent like tetrahydrofuran at O’C to 20*C for 2-20 hours. The formed sïlyl pro te et ed amidine intermediate is then de-protected by treating with an acid in a polar solvent, preferably with hydrochloric acid in éthanol, at 0*C to 20’C for 1-16 h. The lithium hexamethyldisilazide may thereby be formed tn-situ e.g. from n-butyl lithium and hexamethyldisilazane.

[0054] Compounds of formula (IXa) and (IXb) can be synthesized from compounds of formula .CN

XHetero JAryr

HO (X) by adapting alkylation procedures reported in the literature, e.g. in J. Am. Chem. Soc. 2009,131 (10), 3762-3771 and WO 2008096189, or by adapting epoxide ring opening procedures reported in the literature, e.g. in ChemMedChem. 2007,2 (S), 641-654; Heterocydes 2005,65 (11), 26672674 and Tetrahedron Lett. 2001,42 (50), 8743-8745. V-'' [0055] Before carrying out the alkylation or epoxide opening, compounds of formula (X) may also first be converted to the corresponding amidine using the methods detailed above.

[0056] The compounds of the invention show a valuable range of pharmacological effects which could not hâve been predicted.

[0057] They are therefore suitable for use as médicaments for the treatment and/or prophylaxis of diseases in humans and animais.

[0058] The compounds of the présent invention are distinguished in particular by an advantageous range of antîbacterial effects.

[0059] The présent invention therefore further relates to the use of the compounds of the invention for the treatment and/or prophylaxis of diseases caused by bacteria, especially gram-negative bacteria.

[0060] The présent invention further relates to the use of the compounds of the invention for the treatment and/or prophylaxis of diseases, especially of the diseases mentioned below.

[0061] The présent invention further relates to the use of the compounds of the invention for the manufacture of a médicament for the treatment and/or prophylaxis of diseases, especially of bacterial infections and in particular the diseases mentioned below.

[0062] The présent invention further relates to a method for the treatment and/or prophylaxis of diseases, especially of bacterial infections and in particular the diseases mentioned below, using a therapeutically effective amount of the compounds of the invention.

[0063] The compounds of the invention exhibit an antîbacterial spectrum against gram-negative bacteria and selected gram-positive bacteria combined with lowtoxïcity. Compounds of this invention are particularly useful in human and veterinary medicine for the prophy

Iaxis and treatment of local and systemic infections which are caused for example by the following pathogens or by mixtures of the following pathogens:

[0064] Aérobic gram-positive bacteria: Including but not limited to Staphylococcus spp. (5. aureus), Streptococcus spp. {S. pneumoniae, S. pyogenes, S. agalactiae, Streptococcus group C and G) as well as Bacillus spp. and Listeria monocytogenes.

[0065] Aérobic gram-negative bacteria: Enterobacteriaceae, including but not limited to Escherichia spp. (F. coli), Citrobacter spp. (Gfreundii, G diversus), Klebsiella spp. {K. pneumoniae, K. oxytoca), Enterobacter spp. (F. cloacae, E. aerogenes), Morganella morganii. Hafnia alvei, Serratia spp. (S. marcescens), Proteus spp. (P. mirabilis, P. vulgaris, P. penneri), Providencia spp. (P. stuartii, P. rettgeri}, Yersinia spp. (Y. enterocolitica, Y. pseudotuberculosts), Salmonella spp., Shigella spp. and also non-fermenters including but not limited to Pseudomonas spp. (P. aeruginosa), Burkholderia spp. {B. cepacia), Stenotrophomonas maltophilia, and Acinetobacter spp. (A. baumannii, Acinetobacter gen. sp. 13TU, Acinetobacter gen. sp. 3) as well as Bordetella spp. (B. bronchiseptica), Moraxella catarrhalis and Légionella pneumophila; furthermore, Aeromonas spp., Haemophilus spp. (H. influenzae), Neisseria spp. (N. gonorrhoeae, N. meningitidis) as well as Alcaligenes spp. (including Æ xylosoxidans), Pasteurella spp. (P. multocida), Vibro spp. (V. cholerae), Campylobacterjejuni and Hélicobacterpylori.

[0066] Moreover, the antibacterial spectrum also covers strictly anaérobie bacteria including but not limited to Bacteroides spp. (B. frogilis), Peptostreptococcus spp.(P. anaerobius), Prevotella spp., Brucella spp. (B. abortus), Porphyromonas spp., and Clostridium spp. (Clostridium perfringens).

[0067] The above listing of pathogens is merely exemplary and in no way to be regarded as limiting. Examples ofdiseases which may be caused by the said pathogens and which may be prevented, improved or cured by the compounds according to the invention are, for example:

[0068] Respiratory tract infections such as lower respîratory tract infections, lung infection in cystic fibrosis patients, acute exacerbation of chronic bronchïtis, community aquired pneumonia (CAP), nosocomial pneumonia (including ventilator-associated pneumonie (VAP)), diseases of the upper airways, diffuse panbronchiolitis, tonsillitis, pharyngitis, acute sinusitis and otitis including mastoiditis; urinary tract and génital infections for example cystitis, uretritis, pyelonephritis, endometritis, prostatitis, salpingitis and epididymitis; ocular infections such as conjunctivitis, comeal ulcer, iridocyditis and post-operative infection in radial keratotomy surgery patients; blood infections, for example septicaemia; infections of the skin and soft tissues, for example infective dermatitis, infected wounds, infected bums, phlegmon, folliculitis and impétigo; bone and joint infections such as osteomyelitis and septic arthritis; gastrointestinal infections, for example dysentery, enteritis, colitis, necrotising enterocolitis and anorectal infections; întraabdominal infections such as typhoid fever, infectious diarrhea, peritonitis with appendicitis, pelviperitonitis, and intra-abdominal abscesses; infections in the oral région for example infections after dental operations; other infections for example, meliodosis, Infectious endocarditis, hepatic abscesses, cholecystitis, cholangitis, mastitis as well as meningitis and infections of the nervous Systems.

[0069] In addition to humans, bacterial infections can also be treated in animais, such as primates, pigs, ruminants (cow, sheep, goat), hors es, cats, dogs, poultry (such as hen, turkey, quail, pigeon, ornemental birds) as well as productive and ornemental fish, reptiles and amphibians.

[0070] The compounds of the invention may act systemically and/or locally. They can for this purpose be administered in a suitable way, such as, for example, parenterally, pulmonarily, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, oticatly or as an implant or stent.

[0071] For these administration routes the compounds of the invention can be administered In suitable administration forms.

[0072] Parentéral administration can take place with avoidance of an absorption step (e.g. intravenous, intraarterial, intracardiac, intraspinal or intralumbar) or with inclusion of an absorption step (e.g. întramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal}. Administration forms suitable for parentéral administration are, inter alia, préparations for injection and infusion in the form of solutions, suspensions, émulsions, lyophilizates or stérile powders.

(0073] Suitable for the other administration routes are, for example, pharmaceutical forms for inhalation (inter alia powder inhalers, nebulizers), nasal drops, solutions, sprays; tablets, films/wafers or capsules, for lingual, sublingual or buccal administration, suppositories, préparations for ears or eyes, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilie suspensions, ointments, creams, transdermal therapeutîc Systems (such as for example patches), milk, pastes, foams, dusting powders, implants or stents.

[0074] The compounds of the invention can be converted into the stated administration forms. This can take place in a manner known perse by mixing with inert, non-toxic, pharmaceutically acceptable excipients. These excipients include inter alia carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersants orwetting agents (for example sodium dodecyl sulfate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and naturel polymers (for example albumin), stabilizers (e.g. antioxidants such as, for example, ascorbic acid), colors (e.g. inorganic pigments such as, for example, iron oxides) and taste and/or odor corrigents.

(0075] The présent invention further relates to médicaments which comprise at least one compound of the invention, usually together with one or more inert, non-toxic, pharmaceutically acceptable excipients, as well as to their use for the aforementioned purposes.

[0076] The présent invention further relates to médicaments which comprise at least one compound of the invention in combination with at least one further active compound, as well as to their use for the aforementioned purposes.

[0077] Examples for the further active compound include /Mactamase inhibitors.

[0078] Examples for suitable /Mactamase inhibitors to be used in combination with the compounds of the invention include davulanic acid, tazobactam, sulbactam, avibactam (NXL104), and MK-7655.

[00791 The minimum amount of the compounds of the invention to be administered is a therapeutically effective amount. The term therapeutically effective amount* means an amount of compound which prevents the onset of, alleviates the symptoms of, stops the progression of, and/or éliminâtes a bacterial infection in humans or animais.

[0080] Typically, an effective dosing schedule of the compounds of the invention for adults is about 50 mg to about 3000 mg of a compound of formula (I) in a single dose; in another embodiment, an effective single dose is about 100 mg to about 2000 mg. In another embodiment, an effective single dose is about 500 mg to about 1200 mg. Typically the dosages are given 1 to 4 times per day. In one embodiment, the dosages are given 3 times per day. In some cases, it may be necessary to use dosages outside these limits.

[0081] It may nevertheless be necessary where appropriate to deviate from the stated amounts, in particular as a fonction of body weight, administration route, individual response to the active ingrédient, type of préparation and time or interval over which administration takes place. Thus, in some cases it may be sufficient to make do with less than the aforementioned minimum amount, whereas in other cases the upper limit mentioned must be exceeded. In the case of an administration of larger amounts, it may be advisable to distribute these in a pluraîîty of single doses over the day.

[0082] The percentage data in the following tests and examples are, unless indicated otherwise, percentages by weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data of liquid/liquid solutions are based in each case on volume. The statement w/v means weight/volume. Thus, for example, 10% w/v means: 100 ml of solution or suspension contain 10 g of substance.

Examples

Abbreviations

6:

chemical shift in ppm

brs:	broad singlet in NMR
CDCI₃:	deuterated chloroform
d:	doublet in NMR
dd:	doublet of doublet in NMR
DCM:	dichloromethane
DMF:	N,N-dimethylformamide
DMSO:	dimethyl sulfoxide
EtOAc:	ethyl acetate
ES':	négative ion mode in electrospray ionization mass spectrometry
ES*:	positive ion mode in electrospray ionization mass spectrometry
e:	gram(s)
h:	hour(s)
HPLC:	high performance liquid chromatography
Hz: J: L:	hertz coupling constant in NMR liter(s)
M:	molarity
m:	multiplet in NMR
mg:	milligram(s)
MHz:	mégahertz
min:	minute(s)
mL:	milliliter(s)
mmol:	millimole(s)

mol:	mole(s)
MS:	mass spectrometry
N:	normality
NMR:	nudear magnetic résonance
q:	quartet in NMR
s:	singlet in NMR
t:	triplet in NMR
t-BuOH:	tert-butyl alcohol
TFA:	trifluoroacetic acid
THF:	tetrahydrofuran
TIC:	thin layer chromatography
TMS:	tetramethylsilane

Analytical Methods [0083] Ail *H and ¹⁹F NMR spectra were recorded on a Varian Oxford AS 400 NMR operating at 400 MHz for ²H, and 376 MHz for ^UF respectively. NMR data is recorded in chemical shifts relative to tetramethylsilane (TMS) as internai standard. NMR spectra were run either in CDCI₃ contaîning 0.05 % TMS, CDjOD contaîning 0.05 % TMS, or DMSO-<f₆ contaîning 0.03 % TMS.

[0084] HPLC analyses were performed using a Waters 2695 Séparation Module and a Waters 2996 Photodiode Array Detector System or a Waters 600 Controller including a Waters 717plus Autosampler and a Waters 2996 Photodiode Array Detector System on an Atlantis T3C18-3pm-4.6xl50mm column with an acetonitrile/aqueous 0.1 % H3PO4 gradient at 22’C, and a flow rate of 1 mL/minute.

[0085] Préparative HPLC was performed on a Waters Prep LC 2767 System utilizing a Waters Prep HPLC Controller, and a Waters 2487 Dual Wave Absorbance Detector on a Gem-C-1810pm-50xl00mm (flow rate of 70 mL/minute), X-Bridge-C-18-5pm-30xl00mm (flow rate of 42 mL/minute), Ace-C-18-5gm-30x2S0mm (flow rate of 40 mL/mînute), or GemNX-C-18-10pm50x250mm (flow rate of 80 mL/minute) column, using an acetonitrile/aqueous 0.1 % trifluoroacetic acid gradient or an acetonitrile/aqueous 0.1 % formic acid gradient at 22 *C.

[0086] Mass spectra were recorded on a Waters 2795 Séparation Module using either ES^- or ES* îonization modes.

[0087] Column chromatography was performed using Desican Inc. Silica Gel: CC Grade (230-400 Mesh).

[0088] Commercial solvents and reagents were generally used without further purification. Ail products were dried before characterization and use in subséquent synthetic steps.

General Synthetic Methods

1. Synthesis of the /Mactam building blocks

1.1 (3S,4S)-3-Amino-4-methyl-2-oxoazetidine-l-sulfonic acid

[00891 Compound 1_1_1 was synthesized according to David M. Floyd, Alan W. Fritz,

Josip Pluscec, Eugene R. Weaver, Christopher M. Cimarusti J. Org. Chem., 1982,47 (26), 51605167.

1.2 (3S,4S)-3-Amino-4-methyl-l-(sulfooxy)azetidin-2-one

[00901 Compound 1_2_1 was synthesized according to WO 2007/65288

1.3 (3S,4R)-3-Amino-4-methyl-2-oxoazetidine-l’Sulfonic acid

[0091] Compound 1_3_1 was synthesized according to David M. Floyd, Alan W. Fritz,

1.4 {3S,4R} -3-Amino-4-methyl-l-{sulfooxy)azetidin-2-one

i_4j

L-AHothreonine (Bocjp

PhCHjONUjHC)

EDAC

PhjP, DEAD

THF

P<1C (10%)/EtOH

H,/30 psi

BocNH__/

X o OH

KH jPOyBu.Nl ISO,

Formic acid ! DCM

SOj-Pyridîne compta Pyridinc

[0092] To a solution of potassium hydroxide (2.53 g, 45.1 mmol, in 28 mL of water) at room température was added L-allothreonine (3.0 gm, 25.1 mmol) and the mixture was cooled to

24’C using an ice-bath. A dAtert-butyl dicarbonate solution (Boc₂O,6.02 g in 15 mL of t-BuOH) was then added portïonwïse over 20 minutes to the colorless reaction mixture without cooling to form a white doudy solution. The reaction mixture was then stirred at room température for 5 h until TLC (acetonitrile/acetone/acetic acid, 15:15:1) indicated the absence of any starting material. Obenzyloxyhydroxylamine hydrochloride (6.0 g, 37.6 mmol) was then added In portions over 7 min,

6.0 N HCl (4 mL) was then added in portions maintaining pH 4 (white fumes), l-ethyl-3-(3dimethylamînopropyljcarbodiimide hydrochloride (4.81 g, 25.1 mmol) was then added in portions to the reaction mixture while cooling. The reaction mixture was left stirring at room température ovemïght, saturated with sodium chloride and extracted with ethyl acetate (2 x 200 mL). The organic extracts were combined, dried over MgSO,, filtered, evaporated to dryness and dried under vacuum to afford 1_4_2 (6.5 g, 79.5 %) as viscous oil.

[0093] *H NMR (400 MHz, DMSO-d_e): δ = 1.02 (d, J = 5.8 Hz, 3 H), 1.36 (s, 9 H), 3.49 3.83 (m, 1 H), 3.56 - 3.70 (m, 1 H), 4.70 - 4.81 (m, 2 H), 4.86 (d, J = 4.6 Hz, 1 H), 6.73 (d, J = 8.5 Hz, 1 H), 7.29 - 7.42 (m, 5 H), 11.09 (s, 1 H).

[0094] Diethyl azodicarboxylate (DEAD, 0.51 mL 3.08 mmol) was added dropwise to a solution of compound 1_4_2 (1.0 g, 3.08 mmol) and triphenylphosphine (0.81 g, 3.08 mmol) in THF (40 mL) at room température over 5 min. The reaction mixture was heated at 50’C for 6 h and concentrated to give a viscous oil which was purified by column chromatography eluting with ethyl acetate/hexane (40:60) to give compound 1_4_3 (0.30 g, 31.7 %).

[0095] *H NMR (400 MHz, DMSO-d_s): δ = 1.01 (d, J = 5.8 Hz, 3 H), 1.38 (s, 9 H), 3.87 4.11 (m, 1 H), 4.62 (dd, J = 9.3 and 5.1 Hz, 1 H), 4.78 - 5.02 (m, 2 H), 7.21 - 7.51 (m, 5 H), 7.64 (d, J = 9.3 Hz, 1 H).

[0096] 10 % Pd/C (100 mg, wet) was added to a solution of compound 1_4_3 (1.0 g,

3.26 mmol) in éthanol (100 mL) and the mixture was hydrogenated at 30 psi for 3 h. TLC (1:1, ethyl acetate in hexanes) showed completion of the reaction. The catalyst was removed by filtration through a bed of celîte and was washed with methanol (2 x 50 mL). The filtrate was concentrated under vacuum resulting in compound 1_4_4 as a solid (0.7 g, 99 %) which was used in the next step wîthout further purification.

[0097] *H NMR (400 MHz, DMSO-d₆): δ = 1.05 (d, J = 6.2 Hz, 3 H), 1.37 (s, 9 H), 3.69 4.09 (m, 1 H), 4.60 (dd, J = 8.9 and 5.1 Hz, 1 H), 7.62 (d, J = 9.3 Hz, 1 H), 9.92 -10.40 (m, 1 H).

[0098] Sulfur trioxide-pyridine complex (1.76 g, 11.09 mmol) was added to a solution of compound 1_4_4 (2.0 g, 9.24 mmol) in anhydrous pyridine (20 mL) and the mixture was stirred at room température for 2 h. The mixture was concentrated under vacuum resulting in a foam, vV which was triturated with dichloromethane (10 mL) and hexane (30 mL) to give compound 1_4_5 as a white solid (3.46 g) which was used directly for the next step.

[0099] Compound 1_4_5 (3.46 g, 9.21 mmol) was dissolved in a 0.5 M solution of potassium dihydrogen phosphate (100 mL), extracted with ethyl acetate (2 x 100 mL), and the ethyl acetate extract was discarded. Tetra-n-butyl ammonium sulfate (3.13 g, 9.21 mmol) was added to the aqueous layer in one portion. The mixture was stirred at room température for 1 h and extracted with dichloromethane (2 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum resulting in compound 1_4_6 as a foam (4.0 g) which was used directly for the next step.

[00100] Compound 1_4_6 (4.00 g, 7.41 mmol) was dissolved in 98 % formic acid (16 mL) and the mixture was stirred at room température for 3 h. A white precipitate began to form after few minutes. Dichloromethane (30 mL) was added to the reaction mixture and the mixture was cooled to 0-5*C, and kept overnight in the fridge.The white precipitate formed was isolated by filtration and dried under vacuum to give compound 1_4_7 (1.00 g, 75.8 %}.

[00101] *H NMR (400 MHz, DMSO-d₆): 6 = 1.32 (d, J = 6.2 Hz, 3 H), 4.30 - 4.42 (m, 1 H), 4.50 (d, J = 5.0 Hz, 1 H), 8.31 - 9.20 (m, 3 H). çV—

1.5 (3S)-3-Amino-4,4-dimethyl-l-(sulfooxy)azetidin-2-one

D-Serine

1_5_1

AcCI

MeOH

5 2

CH, (BocJjO TEA/DCM

BocNH

CH₃MgBr

EtjO

BocN

4

TEMPO, NaCIOj NaCIO (cat)

5

BnONHj.HCI DCC, HOBT NaHCO,

DMF

SOj-Pyridine compte* Pyridine / 0*C/2 h

Sodium phosphate Buffer acetonrtnle/water

KjCOj, EtOAc

CT^OBn 1_5_7	Pd/C (5%) Hj/50 psi	BocNH^ 1,	-N. OH 5_8	SO₃-Pyridine Pyridine	-y- o 0 OSOjH 1-5.9	KHjPO, Bu₄NHSO₄
MeOH
BocNH \|			NH-	[
ΓΤ“		Formic acid		— l.wm
Aⁿ.	, ♦			“N.
O OSO,	NBu₄	OCM	o^z	OSO,H
1_5_10			1.	_5_11

[00102] Acetyl chloride (AcCI, 96.0 mL, 1.35 mol) was added dropwise over 15 min to pre-cooled methanol (650 mL) at 0’C. The solution was stirred for an additional 5 min, and then solid D-serine (51.0 g, 0.49 mol) was added in portions. The resulting mixture was heated under reflux for 2 h, then cooted to room température and the solvent was removed under reduced pressure. The solid obtaîned was triturated with 3:1 hexane/ether (300 mL) to give compound 1_5_2 as an off-white solid, which was thoroughly dried overnight in an oven under vacuum to give compound 1_5_2 (87.0 g, 99 %) as a white solid.

[00103] ’H NMR (400 MHz, MethanoK): δ = 3.72 (s, 3H), 3.81 (br. s, 2H), 4.07 (s, IH),

5.6 (br. s, IH), 8.78 (br. s, 2H).

[00104] Triethylamine (TEA, 183 mL, 1.3 mol) was added dropwise to a solution of compound 1_5_2 (94.0 g, 0.605 mol) in THF (3 L) at 0’C. To the resulting thick white suspension a solution of di-tert-butyldicarbonate (135.0 g, 0.65 mol) in THF (500 mL) was added dropwise over a period of 1.5 h at the same température. The reaction mixture was stirred at room température for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between diethyl ether (3 L) and a saturated aqueous sodium bicarbonate solution (3 L).The aqueous layer was extracted with diethyl ether (3x2 L), the organic extracts were combined and dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure to give compound 1_5_3 (134.0 g, 75 %) as a viscous oil.

[00105] ^XH NMR (400 MHz, COCI₃): δ = 1.42 (s, 9H), 3.80 (s, 3H), 3.90 (m, 2H), 4.38 (br. s, 1H), 5.44 (br. S, 1H).

[00106] A 3.0 M solution of MeMgBr in diethyl ether (450 mL, 1.35 mol) was added dropwise to a cooled solution of compound 1_5_3 (50.0 g, 0.23 mol) in diethyl ether (2 L) at -78*C. The reaction mixture was allowed to reach room température, stirred at room température for 1 h, and then poured into a saturated aqueous ammonium chloride solution (2.5 L). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x2 L). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was triturated with diethyl ether/hexane (1:2,500 mL) and cooled In an ice bath. The precipitated solid was isolated by filtration to give compound 1_5_4 (33.0 g, 66 %) as a colorless solid.

[00107] *H NMR (400 MHz, CDCI₃): δ = 1.25 (s, 3 H), 1.35 (s, 3 H), 1.43 -1.48 (m, 9 H), 2.49 (br. s, 1 H), 2.62 (br. s, 1 H), 3.47 (d, J = 8.9 Hz, 1 H), 3.76 - 3.86 (m, 1 H), 3.98 - 4.09 (m, 1 H), 5.37 (br. s, 1 H).

100108] 2,2,6,6-Tetramethylpiperidïne 1-oxyl (TEMPO, 2.3 g, 15 mmol) was added to a mixture of compound 1_5_4 (33.0 g, 150 mmol) in acetonïtrile (750 mL) and sodium phosphate buffer (600 mL, 0.7 M solution, pH 6-7) and the resulting mixture was heated to 35*C. The mixture was then treated by a simultaneous addition of a sodium chlorite solution (34.2 g In 150 mL of water) and 60 drops of a very dilute sodium hypochlorite solution (3 mLof commercial solution in 100 mL of water). The mixture was stirred at 35*C ovemight, cooled to room température, treated with citric acid (~15 g, pH 3), saturated with sodium chloride and extracted with ethyl acetate (3 x 2 L). The organic extracts were combined and concentrated under reduced pressure. The residue was dissolved in 1.5 Lofa 2 M sodium carbonate solution and washed with ethyl acetate (2x2 L). The aqueous layer was cooled to 0*C, the pH was adjusted to 3.0 using a 2 M solution of H₃PO₄and the solution was saturated with sodium chloride. The resulting mixture was extracted with ethyl acetate {3x2 L), the organic phases were combined, dried, filtered and concentrated under reduced pressure to give compound 1_5_5 (28.4 g, 81 %) as a colorless solid.

100109] ^XH NMR (400 MHz, DMSO<): δ = 1.15 (s, 3 H), 1.17 (s, 3 H), 1.39 (s, 9 H), 3.86 (d, J = 8.6 Hz, 1 H) 6.52 (d, J = 8.9 Hz, 1 H).

[00110] Dicyclohexylcarbodiimîde (DCC, 19.5 g, 94.3 mmol) was added to a solution of compound 1_5_5 (20.0 g, 85.7 mmol) in Ν,Ν-dimethylformamide at room température followed by 1-hydroxybenzotrîazole (HOBt, 12.7 g, 94.3 mmol). The resulting mixture was stirred at room température for 30 min, and O-benzylhydroxylamine hydrochloride (15.1 g, 94.3 mmol) was added followed by sodium bicarbonate (18.0 g, 214.3 mmol). The reaction mixture was stirred at room température for 24 h and filtered through a celite bed, washed with ethyl acetate (2 x 50 ml), and concentrated under reduced pressure. The residue was purified by column chromatography eluting with 30-40 % ethyl acetate in hexane to give compound 1_5_6 (24.5 g, 84.5 %) as a colorless solid.

[00111] *H NMR (400 MHz, DMSO-d₆): δ = 1.05 (s, 3 H), 1.08 (s, 3 H), 1.26 (s, 9 H), 3.74 (d, J = 9.3 Hz, 1 H), 4.62 (br. s, 1 H), 4.72 (s, 2 H), 6.42 (d, J = 8.9 Hz, 1 H), 7.26 - 7.47 (m, 5 H), 11.03 (br. s, 1 H).

[00112] Sulfur trioxide-pyridine complex (58.7 g, 0.368 mol) was added to a solution of compound 1_5_6 (96.0 g, 0.283 mol) in pyridine (1 L) at 0*C in portions and the mixture was stirred for 2 h. The pyridine was removed under vacuum and the residue was triturated with diethyl ether/hexanes (1:10,1 L) to remove the major portion of the pyridine. A solution of potassium carbonate (240 g in 1.2 L of water) and 500 mL of ethyl acetate were added to the solid intermediate. The resulting mixture was heated under reflux for 2 h, cooled down to room température and the ethyl acetate layer was separated. The aqueous layer was extracted with ethyl acetate (2 x 200 ml) and the combined ethyl acetate layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatog- nA raphy eluting with 30-40 % ethyl acetate in hexanes. The desired fractions were combined and concentrated. The residue was triturated with 10 % ether in hexane (~400 mL) to give compound 1_5_7 (58.1 g, 64 %} as a colorless solid.

[00113] NMR (400 MHz, CDCI₃):Ô = 1.08 (s, 3H), 1.32 (s, 3H), 1.43 (s, 9H), 4.30 (d, J = 6.8 Hz, 1H), 4.96 (s, 2H), 7.40 (m, 5H).

(001141 5 % Pd/C (6.0 g, wet, ~50 % water) was added to a solution of compound 1_5_7 (30.0 g, 93.6 mmol) in methanol (600 mL) and the mixture was hydrogenated at 50 psi for 1 h. TLC (1:1, ethyl acetate in hexanes) showed completion of the reaction. The catalyst was removed by filtration through a bed of celite and was washed with methanol (2 x 100 mL). The filtrate was concentrated under vacuum and the resulting solid was triturated with 10 % ether in hexanes (100 mL), filtered and dried in vacuum to give compound 1_5_8 (21.9 g, quant.) as a colorless solid.

[001151 *H NMR (400 MHz, DMSO-d₆): 6 = 1.17 (s, 3H), 1.31 (s, 3H), 1.41 (s, 9H), 4.21 (d, J = 6.8 Hz, 1H), 7.71 (d, J = 6.8 Hz, 1H), 10.01 (br. s, 1H).

[00116] Sulfur trioxide-pyridine complex (39.7 g, 0.249 mol) was added to a solution of compound 1_5_8 (50.0 g, 0.217 mol) in pyridine (500 mL) at 0*C. The resulting mixture was stirred at room température for 1.5 h and concentrated under vacuum to give compound 1_5_9 (106.0 g) as a foam, which was dissolved in 4 L of a 0.5 M solution of KH₂PO« and extracted with dichloromethane (2 x 400 mL). The aqueous layer was cooled to O’C and tetra-n-butyl ammonium sulfate (84.8 g, 0.249 mol) was added. The resulting mixture was stirred at 0-5*C for 1 h and extracted with dichloromethane (5 x 500 mL). The combined dichloromethane layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum to give intermediate l_5_10 (115.0 g) as a foam which was dissolved in 96 % formic acid (500 mL) and the resulting mixture was stirred at room température for 4 h. A white precipïtate began to form after few minutes. Dichloromethane (500 mL) was added to the reaction mixture and the mixture was cooled to 0-5*C, and kept In the fridge over the weekend. The white precipïtate was isolated by filtration and dried under vacuum to afford compound 1_5_11 (24.5 g, 53 % over 3 steps) as a colorless solid.

[00117] *H NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 3H), 1.43 (s, 3H), 4.15 (s, IH), 8.80 (br. s, 2 H).

1.6 {[(3S,4S)-3'Amino-4-methyl-2-oxoazetidin-l-yl]oxy}methanesulfonic acid

nh₂

1J5J

BoCjO. NaOH,

THF, H₂O

NHBoc

2

1. NHjOCHjSOjH (1_6_3) ÇH EDC1, KOH THF.HjO

2. Bu.NHSO,

1_6_5

1-MsCt pyridine

2. Bu₄NHSO₄

U OH O

NHBoc

1_6_4

SO,NBu₄

KjCO,

OMsO

ΑγΑ_Ν-Ο^ NHB«J

1_6_6

Actone reflux, 4h

BocNH_K .o	TFA	P
Dowex 50WX4 Yl' Na form N. _w η Λ-Α.	DCM/anisole
0*C/1h	o _u
SOjNa	SOjH
1_6_8		1_6_9

Dowex5CWX4 Na form

BocNH >

O^X so₃nbu₄1_6_7 [00118] Di-tert-butyl dicarbonate (56.7 g, 59.7 mL, 0.23 mol, Aldrich) was added dropwise to a solution of L-threonine 1_6_1 (23.8 g, 0.2 mol) in THF (200 mL) and a 2 N aqueous sodium hydroxide solution (120 mL) at 0’C. The resulting mixture was stirred at 0*C to room température ovemight and concentrated under reduced pressure to remove the solvent. The residue was saturated with solid ammonium chloride, cooled to 0*C, acidified with 1 N hydrochloric acid to pH 3, and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with water (200 mL) and brine (200 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was treated with hexane (300 mL) and filtered to give 1_6_2 (39.7 g, 91 %) as a colorless solid.

[00119] *H NMR (400 MHz, DMSO-d_e): δ = 1.06 (d, J = 6.2 Hz, 3 H), 1.37 (s, 9 H), 3.86 (dd, J = 9.1 and 3.3 Hz, 1 H), 3.98 - 4.08 (m, 1 H), 6.29 (d, J = 9.3 Hz, 1 H).

[00120] (Aminooxy)methanesulfonic acid compound 1_6_3 (5.9 g, 46.4 mmol) was added to a solution of compound 1_6_2 (9.4 g, 42.9 mmol) in THF (50 mL) and water (100 mL) at

0*C, the pH of the mixture was adjusted to 4.5 using a IN aqueous potassium hydroxide solution, and a solution of N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochlorîde (EDCI, 9.3 g, 47.1 mmol) in water (30 mL) was added slowly over 20 min. The resulting mixture was stirred at room température for 3 h while adjusting to pH 4.0-4.5 with lfl sulfuric acid. Tetrabutylammonium hydrogensulfate (14.5 g, 42.9 mmol, Aldrich) was added, the pH was adjusted to 3 using IN sulfuric acid and the mixture was extracted with chloroform (5 x 100 mL). The combined chloroform layers were dried over sodium sulfate and concentrated under reduced pressure to give crude compound 1.6.4 (17.5 g) which was dissolved in water (20 mL) and purified on a Dowex 50WX4 Na form ion exchange resin (200 mL) column eluting with water. The first 400 mL of water fractions were collected and lyophilized to give 1.6.5 (6.93 g, 46 %) as a yellow solid.

[00121 j ^JH NMR (400 MHz, DMSO-d₆): Ô = 1.01 (d, J = 6.2 Hz, 3 H), 1.38 (s, 9 H), 3.72 3.91 (m, 2 H), 4.24 (s, 2 H), 4.85 (br. s, 1 H), 6.37 (d, J = 8.6 Hz, 1 H), 7.40 (s, 1 H), 11.25 (br. s, 1 H).

[00122] Methanesulfonyl chloride (MsCI, 0.72 g, 6.3 mmol) was added dropwise via a syringe to a solution of 1.6.5 (2.0 g, 5.71 mmol) in pyridine (60 mL) at 0*C. The resulting mixture was stirred at room température ovemight and concentrated under reduced pressure. The residue was dissolved In water (10 mL), tetrabutylammonium hydrogensulfate (1.87 g, 5.5 mmol) was added, the pH was adjusted to 3 with IN sulfuric acid, and the mixture was extracted with chloroform (5 x 30 mL). The combined chloroform layers were dried over sodium sulfate and concentrated under reduced pressure to give a light brown solid. MS indicated that the product obtained was a mixture of compound 1.6.6, a N,N,N-tributylbutan-l-amonium sait of compound 1_6_5 and a di-Ms by-product. The mixture was used in the next step without further purification.

[00123] A solution of 1.6.6 (3.1 g, 4.8 mmol) in acetone (10 mL) was added dropwise to a suspension of potassium carbonate (3.0 g, 21.7 mmol) in acetone (90 mL) under reflux. The resulting mixture was kept under reflux for 4 h. After cooling to room température, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure to give crude intermedîate 1.6.7 which was dissolved in a 0.5 M aqueous KH₂PO₄ solution (15 mL), the pH was adjusted to 3 using IN sulfuric acid, and the mixture was extracted with dichloromethane (6 x 50 mLj.The combined dichloromethane layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was dissolved in water (10 mL) and purified on a Dowex

50WX4 Na form ion exchange resin (200 mL) column elutîng with water. The first 500 mL of water fractions were collected and lyophilized to give 1.3 g of crude product as a yellow solid. MS indicated that the product obtained was a mixture of compound 1_6_8 and compound 1_6_5. This mixture was used in the next step without further purification.

[00124] Trifluoroacetic acid (TFA, 10 mL) was added to a suspension of compound

1_6_8 from the previous step as mixture (1.2 g, 3.6 mmol) in dichloromethane (5 mL) and anisole (5 mL) at O’C. The resulting mixture was stirred at 0*C for 1 h and concentrated under reduced pressure. The residue was stirred with benzene (10 mL) and evaporated twice, washed with dichloromethane, and dried in vacuum to give crude compound 1_6_9 (1.6 g, quant, with small amount of residual trifluoroacetic acid). This material was used as 47 % pure in next step without further purification.

[00125] The ’H NMR was complex as the product obtained was a mixture of compound 1_6_9 and compound 1_6_5.

[00126] MS (ES*) m/z: [M-Na]‘ calcd for C_sH₉N₂O_sS: 209.02. Found: 209.11.

1.7 {[(3S)-3-Amino-4,4-dimethyl-2-oxoazetidin-l-yl]oxy}methanesulfonic add

BocHN

KI,K₂COj DMF

r.t

OH

BocH

7 2

BocHN

O O Cl

7_3

AcSH

BocHN

DIPEA DCM -78^oC~r.t

DCM r-t, mCPBA h₂N

7 5 [00127] Chloromethyl methyl sulfîde (1.15 mL 13.8 mmol) was added dropwise to a solution of potassium îodide (2.29 g, 13.8 mmol) in N,N-dimethylformamide (40 mL) at room température. The resulting mixture was stirred at room température forO.Sh, and tert-butyl {(35)4,4-dimethyl-l-hydroxy-2-oxoazetidin-3-yl)carbamate 1_7_1 (1.60 g, 6.94 mmol) was added followed by potassium carbonate (1.90 g, 13.8 mmol). The resulting mixture was stirred at room température ovemight. The mixture was poured into ice water (200 mL) and extracted with ethyl acetate (3 x 30 mL). The combined ethyl acetate layers were washed with water and brine, dried (sodium sulfate) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 6:1 * 3:1 hexane - ethyl acetate to give compound 1_7_2 (1.73 g, 86 %) as a yellow oil.

[OO128I *H NMR (400 MHz, CDCI₃): δ = 1.33 (s, 3 H), 1.45 (s, 9 H), 1.54 (s, 3 H), 2.28 (s, 3 H), 4.39 (d, J = 6.6 Hz, 1 H, 4.96 (s, 2 H), 5.10 (d, J = 6.6 Hz, 1 H).

[00129] Sulfuryl dichloride (0.71 mL 8.78 mmol) was added dropwise to a solution of compound 1_7_2 (1.70 g, 5.85 mmol) in dichloromethane (50 mL) at -78’C. The resulting mixture was stirred at -78’C for 15 min and then at room température for 15 mîn. The reaction mixture was cooled to -78’C and N-ethyldiisopropylamine (DIPEA, 10.1 mL, 58.5 mmol) was added dropwise followed by thioacetic acid (AcSH, 2.1 mL 29.3 mmol). The resulting mixture was stirred at -78’C for 15 min and then at -78’C to room température for 1 hour. The reaction mixture was poured into a saturated aqueous sodium bicarbonate solution (200 mL) and extracted with dichloromethane (3 x 50 mL). The combined dichloromethane layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 6:1 ~ 3:1 hexane - ethyl acetate to give compound 1_7_4 (1.25 g, 67 %) as a yellow solid.

[00130] ’H NMR (400 MHz, CDCI₃): δ = 1.32 (s, 3 H), 1.45 (s, 9 H), 1.52 (s, 3 H), 2.42 (s, 3 H), 4.36 (d, J = 6.6 Hz, 2 H), 5.03 (d, J= 6.6 Hz, 1 H), 5.36 (s, 2H).

[00131] Compound 1_7_4 (1.10 g, 3.45 mmol) was added to a solution of 3chloroperoxybenzoic acid (mCPBA, 4.0 g, 13.8 mmol) in dichloromethane (50 mL). The resulting mixture was stirred at room température ovemight and concentrated under reduced pressure, (//

The residue was treated with fournie acid {96 %, 20 mL) and stirred at room température for 4 h. The solid was fiîtered off and the filtrate was concentrated under reduced pressure. The residue was treated with dichloromethane (S0 mL), stirred at room température for 0.5 h and fiîtered.

The filtrate was concentrated under reduced pressure to give crude compound 1_7_5 (0.9 g, 100 5 %, 0.77 g expected) as a pale yellow solid which was used as it is in the next step.

[00132] *H NMR (400 MHz, DMSO-cfc): δ = 1.46 (s, 3 H), 1.48 (s, 3 H), 4.14 (s, 1 H), 4.42 (AB, J = 8.0 and 32.0 Hz, 2 H), 8.72 (br s, 1 H).

1.8 3-Amino-l-(su IfooxyJ-l-azaspi ro[3.4] octan-2-one

BocHN

l.SO₃-Py.Py

2. Bu,NHSO

3. HCOOH

lUPd-C, MeOH

BocHN

[00133] A mixture of W-(tert-butoxycarbonyl)glycine 1_8_1 (10 g, 57.14 mmol), benzyl chloride (BnCI, 7.30 mL, 62.85 mmol), tetra-n-butylammonium bromide (TBAB, 0.19 g, 0.57 mmol) and potassium bicarbonate (6.87 g, 68.57 mmol) in W,W-dimethylformamîde (100 mL) was stirred at room température for 72 hours and fiîtered. The filtrate was concentrated under vacuum. The residue was treated with water and the solid was colîected and dried to give compound 1_8_2 (10 g, 67%).

[00134] ’H NMR (400 MHz, DMSO-d₆): δ = 1.40 (s, 9H), 3.75 (d, J = 6.8 Hz, 2H), 5.10 (s, 2H), 7.20 (t, J = 6.8 Hz, IH], 7.33 (m, 5H).

[00135] n-Butyl lithium (35.85 mL 1-6 M in hexane) was added to a cooled (-40*C) solution of di-isopropylamine (7.23 mL 51.23 mmol) in THF (40 mL). The mixture was stirred at -40*C for 30 min to form lithium diisopropylamide (LDA). A solution of compound 1_8_2 (5.43 g, 20.49 mmol) in THF (20 ml) was added at -78*C. The mixture was stirred at -78*C for 30 min and cydopentanone (dried over molecular sieves, 2.07 mL 24.59 mmol) was added. The resulting mixture was stirred at -78’C for 20 min, gradually warmed up to -20*C over 30 min and then to 0*C over 20 min, quenched with a solution of acetic acid (2.70 mL 47.13 mmol) in THF (10 mL), poured into water (50 mL), extracted with ethyl acetate (200 mL), dried and concentrated. The residue was purified by column chromatography to give compound 1_8_3 (5.65 g, 79 %).

[00136] ^XH NMR (400 MHz, DMSO-cf₆): δ = 1.40 (s, 9H), 1.50 -1.90 (m, 8H), 2.20 (s, IH), 4.25 (d, J = 7.7 Hz, IH), 5.20 (m, 2H), 5.50 (d, J = 7.7 Hz, IH), 7.40 (m, 5H).

[00137] 10% Pd/C (0.52 g) was added to a degassed solution of compound 1_8_3 (5.65 g, 16.19 mmol) in methanol (100 mL). The mixture was stirred under a hydrogen balloon for 3 h and filtered through a pad of celite. The filtrate was concentrated to give compound 1_8_4 (4.1 g) which was used in the next step without further purification.

[00138] ^ZH NMR (400 MHz, DMSO-d₆): Ô = 1.40 (s, 9H), 1.50 - 2.00 (m, 8H), 4.20 (br. s, IH), 5.95 (br. s, IH).

[00139] 1-Hydroxybenzotriazole (HOBT, 2.19 g, 16.19 mmol) and dicydohexylcarbodiimide (DCC, 3.34 g, 16.19 mmol) was added to a cooled (O’C) solution of compound 1_8_4 (4.1 g) in THF (20 mL). The mixture was stirred at 0*C for 2 hours. A solution of O-benzyl hydroxylamine (made from 7.76 g of its corresponding hydrogen chloride sait and an aqueous sodium hydroxide solution, 47.89 mmol) in THF (10 mL) was added and the mixture was stirred at room température for 5 h and filtered. The filtrate was concentrated and the residue was purified by column chromatography to give compound 1_8_5 (4.7 g, 80 %) [00140] *H NMR (400 MHz, CDCI₃): δ = 1.40 (s, 9H), 1.50 -2.00 (m, 8H), 3.60 (d, J = 7.8

Hz, IH), 3.90 (s, IH), 4.90 (s, 2H), 5.62 (d, J = 7.8 Hz, IH), 7.40 (m, 5H), 9.02 (s, IH).

[00141] A mixture of compound 1_8_5 (4.66 g, 12.80 mmol) and sulfur trioxidepyridine complex (3.71 g, 23.25 mmol) in pyridine (50 mL) was heated at 50-55*C for 2 h and concentrated. The residue was diluted with acetonitrile (20 mL) and concentrated. The residue was dried under high vacuum for 2 h, diluted with ethyl acetate (150 mL) and treated with a solution of potassium carbonate (19.67 g, 143 mmol) in water (54 mL). The resulting mixture was refluxed for 2 h, cooled to room température and the phases were separated. The organic phase was washed with a 5% aqueous sodium hydrogen sulfate solution (20 mL), dried and concentrated. The residue was purified by column chromatography to give compound 1_8_6 (2.5 g, 56 %) as colorless solid.

[00142] ^XH NMR (400 MHz, CDCIj): δ = 1.42 (s, 9H), 1.43 - 2.00 (m, 8H), 4.43 (d, J = 8.0 Hz, IH), 4.90-5.00 (m, 3H), 7.40 (m, 5H).

[00143] 10 % Pd-C (100 mg) was added to a degassed solution of compound 1_8_6 (1.0 g, 2.89 mmol) in methanol (20 mL). The mixture was stirred under a hydrogen balloon for 1 h and filtered through a pad of celite. The filtrate was concentrated to give compound 1_8_7 (0.70 g, 100 %) which was used in the next step without further purification.

[00144] ^XH NMR (400 MHz, DMS0-</₆): Ô = 1.39 (s, 9H), 1.50 - 2.00 (m, 8H), 4.28 (d, J =

7.9 Hz, IH), 7.72 (d, J = 7.9 Hz, IH).

[00145] A mixture of compound 1_8_7 (0.74 g, 2.89 mmol) and sulfur trioxide-pyridine complex (1.43 g, 8.96 mmol) in pyridine (20 mL) was stirred at room température for 2 h, and concentrated. The residue was treated with a 10 % aqueous potassium dihydrogenphosphate solution (10 mL) and the mixture was stirred with tetra-n-butylammonium hydrogensulfate (1.08 g, 3.18 mmol) at 0*C for 30 min. The réaction mixture was extracted with dichloromethane (3 x 50 mL) and the combined organic phases were concentrated. The residue was dissolved in 98 % formic aid (10 mL) and stirred at room température for 4 h, diluted with dichloromethane (30 mL) J/ ‘ and left in the fridge for 16 h. The solid was collected and dried to give compound 1_8_8 (380 mg,

%).

[00146] ^XH NMR (400 MHz, DMS0-tf₆): δ = 1.40 - 2.00 (m, 6H), 2.20 (m, 2H), 4.37 (s,

1H).

1.9 (3S,4S)- 3-Amino-4-(aminocarbonyl)-2-oxo-l-azetidinesulfonic acid

[00147] Compound 1_9_1 was synthesized according to M. Sendai, S. Hashiguchi, M. Tomimoto, S. Kishimoto, T. Matsuo, M. Ochiai; Chemical & Pharmaceutical Bulletin 1985,33 (9), 3798-3810 and EP 73061.

2. Synthesis of amlno-thiazole and amino-thladlazole building blocks

2.1 Oxo[2-(tritylamino)-l,3-thîazol-4-yl]acetic acid

[00148] Compound 2_1_1 was synthesized according to Sakagami, Kenji; Iwamatsu, Katsuyoshi; Atsumi, Kunio; Hatanaka, Minoru; Chemical & Pharmaceutical Bulletin, 1990,38(12), 15 3476-3479.

2.2 {5-[(tert-Butoxycarbonyt)amino]-l,2,4-thIadiazol-3-yl}(oxo}aceticacid

2-2.1 [00149] Compound 2.2.1 was synthesized according to Yamawaki, Kenji; Nomura, Takashi; Yasukata, Tatsuro; Uotani, Koichi; Miwa, Hideaki;Takeda, Kei; Nishitani, Yasuhiro; Bioorgan5 ic & Médicinal Chemistry, 2007,38 (21), 6716-6732.

2.3 [5-Chloro-2-(trityIamino)-l,3-thiazol-4-Yl](oxo)acetic acid

2.3.1 [00150] Compound 2_3_1 was synthesized according to:

a) Sakagami, Kenji; Iwamatsu, Katsuyoshi; Atsumi, Kunio; Hatanaka, Minoru; Chemical &

Pharmaceutical Bulletin, 1990,38(12), 3476 - 3479.

b) Yamawaki, Kenji; Nomura, Takashi; Yasukata, Tatsuro; Uotani, Koichi; Miwa, Hideaki; Takeda, Kei; Nishitani, Yasuhiro; Bioorganic & Médicinal Chemistry, 2007,38(21), 67166732.

3. Synthesis of aryl and heteroaryl amidine si de chalns

3.1

4-[2-(Aminooxy)ethoxy]benzenecarboximidamide

Step 1:4-(2-Bromoethoxy)benzonîtrile (3_1_2) [00151 ] 1,2-Dibromoethane (471 g, 2.52 mol) and potassium carbonate (232 g, 1.68 mol) were added to a solution of 4-hydroxybenzonitrite 3_1_1 (100 g, 0.84 mol) in acetonitrile (4 L). The mixture was refluxed for 18 hours, the solid was removed by filtration and the filtrate was concentrated to give a residue which was purified by chromatography (3:1 hexanes/ethyl acetate) to give compound 3_1_2 (74.4 g, 40 % yield) as a solid.

[00152] NMR (400 MHz, CDCI₃): δ = 3.66 (t, J = 6.0 Hz, 2H), 4.34 (t, J = 6.2 Hz, 2H),

6.97 (d, J = 8.9 Hz, 2H), 7.61 (d, J = 8.9 Hz, 2H).

Step 2:4-(2-[(l,3-Dioxo-l,3-dihydro-2H-isoindol-2-yl)oxy]ethoxy]benzonitrile (3_1_3) [00153] l,8-Diazabicydo[5.4.0]undec-7-ene (49.4 mL, 0.33 mmol) was added slowly over 20 minutes to a solution of compound 3_1_2 (74.3 g, 0.33 mol) and N-hydroxyphtha!imide (Phth-OH, 53.6 g, 0.33 mol) in Ν,Ν-dimethylformamide (470 mL) and the mixture was heated at 15 46*C for 6 hours. After removal of the solvent, the residue was treated with 1N HCl (1 L) which resulted in a precipitate. The precipitate was collected by filtration, washed with water and dried to give compound 3_1_3 (98.0 g, 96 % yield) as a white solid.

[00154] ³H NMR (400 MHz, COCI₃): δ = 4.31 - 4.43 (m, 2H), 4.51 - 4.63 (m, 2H), 6.91 (m, J = 8.5 Hz, 2H), 7.57 (m, J = 8.5 Hz, 2H), 7.75 - 7.87 (m, 4H).

Step 3:4-[2-(Aminooxy)ethoxy]benzonitrile (3_1_4) [00155] Hydrazine hydrate (11.5 mL 0.236 mol) was added to a suspension of compound 3_1_3 (72.7 g, 0.236 mol) in éthanol (800 mL) and the mixture was stirred at 45*C for 14 hours. The solid was removed by filtration and the filtrate was concentrated. The residue was diluted with ethyl acetate (300 mL), the solid was removed by filtration and the filtrate was concentrated to give compound 3_1_4 (40.0 g, 96 % yield) as a white solid.

[00156] ’H NMR (400 MHz, CDCI₃): δ = 4.03 (t, J = 4.8 Hz, 2H), 4.21 (t, J = 4.8 Hz, 2H), 5.58 (s, 2H), 6.98 (d, J = 6.0 Hz, 2H), 7.59 (d, J = 6.0 Hz, 2H).

Step 4: Methyl 4-[2-(aminooxy)ethoxy]benzenecarboximidoate (3_1_5) [00157] Hydrogen chloride gas was bubbled through a solution of compound 3_1_4 (15.0 g, 84.7 mmol) in dry methanol (330 mL) at 0*C for 1 hour and the mixture was stirred at room température for 14 hours (NMR showed 50 % conversion). Hydrogen chloride gas was bubbled through the solution for another 40 minutes at O’C, and the reaction mixture was stirred for 24 hours to give a suspension. Compound 3_1_5 (23.0 g, 96 % yield, hydrochloride sait) was coliected by filtration as a white solid.

[00158] *H NMR (400 MHz, CDCI₃): δ = 3.95 - 4.08 (m, 2H), 4.13-4.25 (m, 2H), 5.55 (br s, 2H), 6.99 (m, J = 8.5 Hz, 2H), 7.26 (s, 1H), 7.59 (m, J = 8.5 Hz, 2H).

Step 5:4-[2-(Aminooxy)ethoxy]benzenecarboximidamide (3_1_6) [00159] Ammonia (7 N in methanol, 53.3 mL) was added to a solution of compound 3_1_5 (11.5 g, 37.3 mmol) in dry methanol (150 mL). The mixture was stirred at 50*C for 2 hours and at room température for 14 hours. After removal of the solvent, the residue was purified by chromatography to give compound 3_1_6 (6.2 g, 85 % yield) as a solid. u* [00160] ‘H NMR (400 MHz, Methanol-dJ: δ = 3.97 - 4.05 (m, 2H), 4.24 - 4.37 (m, 2H),

7.16 (d, J = 8.9 Hz, 2H), 7.79 (d, J = 8.9 Hz, 2H).

[00161] Using the conditions described above under 3.1 the following amidine side chains were prepared:

	starting material	alkylating agent	product
3.2	Y Br	Br'''''-'*	NH Br 3_2_6
3.3	J		HN^.NH₂ ”Ύ ° 3_3_6
3.4	Cl	.Br Br	τ' Z * φ O §· Z
3.5		Βγ^Χ^^/ΒΓ	3_5_6
3.6	Y O X	Br''''-'*	NH NH-CL JÎ. UT I 3_6_6

3.8 tert-Butyl{({4-[2-(amlnooxY)ethoxy]phenyl}amlno)[(tert-butoxycarbonYl)amino]methy· lîdenejcarbamate

Step 1: tert-Butyl [4-(2-bromoethoxy)phenyl]carbamate (3_8_2) [00162] A mixture of tert-butyl (4-hydroxyphenyl)carbamate 3_8_1 (25 g, 119.6 mmol), 1,2-dîbromoethane (41 mL, 478.5 mmol) and potassium carbonate (33 g, 239.2 mmol) in acetonitrile (500 mL) was refluxed for 24 hours (TLC showed 50 % conversion). Addditional 1,210 dibromoethane (20 mL, 239 mmol) and potassium carbonate (16 g, 120 mmol) was added and the mixture was refluxed for another 23 hours. Further potassium carbonate (16 g, 120 mmol) was added and the mixture was refluxed for another 5 hours. The solid was removed by filtration and the filtrate was concentrated to give a residue. The residue was purified by chromatography to give compound 3_8_2 (15.6 g, 41 % yield) as a solid.

[00163] ^JH NMR (CDCI₃): δ = 1.51 (s, 9H), 3.61 (t, J = 6.0 Hz, 2H), 4.26 (t, J = 6.0 Hz, 2H), 4.26 (t, J = 6.0 Hz, 2H), 6.34 (s, IH), 6.85 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.8 Hz, 2H).

Step 2: tert-Butyl (4-{2-[(l,3-dioxo-l,3-dihydro-2H-isoindo1-2-yl)oxy]ethoxy}phenyl)carbamate (3.8.3) [00164] l,8-Diazabicydo[5.4.0]-undec-7-ene (9 mL, 593 mmol) was added to a solution of compound 3_8_2 (15.6 g, 49.4 mmol) and N-hydroxyphalimide (Phth-OH, 12.1 g, 74 mmol) in N,N-dimethylformamide (80 mL) at room température. The mixture was stirred at 45*C for 15 hours, concentrated, extracted with ethyl acetate, washed with a saturated sodium bicarbonate solution, IN hydrochloric acid and brine, dried over sodium sulfate filtered and concentrated. The residue was triturated with hexanes and the solid was collected to give compound 3.8.3 (17.1 g, 86 % yield) as a white solid.

[00165] ^XH NMR (COCI₃): δ = 1.50 (s, 9H), 4.32 (t, J = 6.4 Hz, 2H), 4.56 (t, J = 6.4 Hz, 2H), 6.33 (S, 1H), 6.75 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.8 H, 2H), 7.83 (m, 2H), 7.52 (m, 2H).

Step 3:2-[2-(4-Amînophenoxy)ethoxy]-lH-isoindole-l,3(2H)-dione (3_8_4) [00166] Trifluoroacetic acid (TFA, 143 mL) was added to a solution of compound 3.8.3 (7.4 g, 18.6 mmol) in dichloromethane (150 mL). The mixture was stirred for 2.5 hours at room température, and concentrated. The residue was then triturated with diethyl ether and the solid was collected to give the desired compound 3.8.4 (7.5 g, 97 % yield, trifluoroacetic acid sait) as a pink solid.

[00167] ^XH NMR (MeOH-c/₄): δ = 4.36 (m, 2H), 4.55 (m, 2H), 6.98 (d, J = 8.8 Hz, 2H), 7.26 (d, J = 8.8 Hz, 2H), 7.83 (s, 4H).

Step 4: tert-Butyl ({E)-[(tert-butoxycarbonyl)amino][(4-{2*[(l,3-dioxo-l,3-dihydro-2H-îsoindol-2yl)oxy]ethoxy}phenyl)amino]methylidene}carbamate (3.8.5) [00168] Trifluoroacetic acid (6 mL, 43.2 mmol) was added to a suspension of compound

3.8.4 (7.4 g, 14.1 mmol) in acetonitrile (200 mL), and the mixture was stirred for 30 minutes at room température. Di-tert-butyl [(Z)-lH-pyrazol-l-ylmethylylidene]biscarbamate (3.2 g, 10.8 mmol) was added and the mixture was stirred for 15 hours at room température, concentrated and the residue was extracted with ethyl acetate, washed with brine, filtered and concentrated to give a residue. The residue was purified by chromatography to give compound 3_8_5 (3.82 g, 50 % yield) as a solid.

[00169] ³H NMR (CDC1₃): 5 = 1.49 (s, 9H), 1.53 (s, 9H), 4.32 (t, J = 4.4 Hz, 2H), 4.57 (t, J =

4.4 Hz, 2H), 6.78 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.84 (m, 2H), 7.75 (m, 2H), 10.18 (s, 1H), 11.63 (s, 1H).

Step 5: tert-Butyl {({4-[2-(amînooxy)ethoxy]phenyl}amino)((tert-butoxycarbonyl)amino] methylidenejcarbamate (3_8_6) [001701 Hydrazine hydrate (0.35 mL, 7.1 mmol) was added to a suspension of compound 3_8_5 (3.82 g, 7.1 mmol) in éthanol (200 mL) and the mixture was stirred at 35’C for 18 hours. The solid was removed by filtration and the filtrate was concentrated to give a residue. The residue was purified by chromatography (1:1 ethyl acetate/hexanes) to give a crude product (3.1 g), which was washed with dichloromethane and filtered. The filtrate was concentrated to give pure product 3_8_6 (2.7 g, 97 % yield) as a white solid.

[00171] *H NMR (CDC1₃): 8 = 1.49 (s, 9H), 1.53 (s, 9H), 4.01 (t, J = 4.4 Hz, 2H), 4.14 (t, J =

4.4 Hz, 2H), 5.54 (s, 2H), 6.89 (d, J = 9.2 Hz, 2H), 7.49 (d, J = 9.2 Hz, 2H), 10.19 (s, 1H), 11.64 (s, 1H).

3.9 tert-Butyl {({4-[2-{aminooxy)propoxy]phenyl}amlno)[(tert-butoxycarbonyl)amino]methylidenejca rba mate

[00172] Compound 3_9_6 was prepared using the procedure described above for com pound 3_8_6 using 1,3-dibromopropane instead of 1,2-dibromoethane in step 1. fS

3.10 4-{[2-(Amlnooxy)ethyt]$ulfanyl}benzenecarboxlmidamide

3_10_1

Step 1: 4-[(2-Hydroxyethyl)sulfany1]benzonitrile (3_10_2) [00173] 2-Mercaptoethanol (4.10 g, 0.0525 mmol] and potassium carbonate (7.25 g,

0.0525 mol) was added to a solution of 4-fluorobenzonitrile 3_10_l (4.22 g, 0.035 mol) in acetonitrile (50 mL) and the mixture was stirred at room température for 18 hours. The solid was removed by filtration and the filtrate was concentrated to give a residue, which was purified by column chromatography to give compound 3_10_2 (4.0 g, 64 % yield) as an oil.

[00174] *H NMR (400 MHz, CDCI₃): δ = 1.92 (t, J = 6.1 Hz, 1H), 3.22 (t, J = 5.9 Hz, 2H),

3.86 (q, J = 6.0 Hz, 2H), 7.38 (m, J = 8.6 Hz, 2H), 7.55 (m, J = 8.2 Hz, 2H).

Step 2: 4-{[2-(l,3-Dioxo-l,3-dihydro-2H-isoîndol-2-yl)ethyl]sulfanyl)benzonitrile (3_10_3) [00175] Triphenyl phosphine (5.85 g, 0.0223 mol) was added to a solution of compound 3_10_2 (4.00 g, 0.0223 mol) and N-hydroxyphalimîde (Phth.OH, 3.64 g, 0.223 mol) in tetrahydrofuran (100 mL), followed by diethyl azodicarboxylate (3.66 mL, 0.0223 mol) slowly over 20 minutes. The mixture was stirred at room température for 24 hours then concentrated to give a residue. The residue was purified by column chromatography to afford compound 3_10_3 (4.6 g, 62 % yield). vx/ [00176] ^XH NMR (400 MHz, CDCI₃): Ô = 3.42 (s, 2H), 4.38 (s, 2H,), 7.41 (m, J = 8.2 Hz, 2H), 7.56 (m, J = 8.2 Hz, 2H), 7.79 (d, J = 3.1 Hz, 2H), 7.85 (br s, 2H).

Step 3: 4-{[2-(Aminooxy)ethyl]sulfanyl]benzonitrile (3_10_4) [00177] Hydrazine (0.804 mL, 0.0256 mol) was added to a suspension of compound 3_10_3 (4.6 g, 0.0256 mol) in éthanol (100 mL) and the mixture was stirred at 45’C for 14 hours. The solid was removed by filtration and the filtrate was concentrated. The residue was diluted with dichloromethane (20 mL) and the solid was removed by filtration. The filtrate was concentrated to give compound 3_10_4 (3.5 g, 70 % yield) as an oil.

[00178] ^XH NMR (400 MHz, CDCI₃): δ = 3.25 (t, J = 6.6 Hz, 2H), 3.88 (t, J = 6.6 Hz, 2H), 5.49 (br s., 2H), 7.37 (m, J = 8.2 Hz, 2H), 7.54 (m, J = 8.6 Hz, 2H).

Step 4: 4-{[2-(Aminooxy)ethyl]sulfanyl}benzenecarboximidoate (3_10_5) [00179] Hydrogen chloride gas was bubbled through a solution of compound 3_10_4 (3.5 g, 0.0180 mol) In dry methanol (100 mL) at 0 ²C for 10 minutes. The mixture was stirred at room température for 14 hours to give a suspension. The white solid (3.0 g, 74 % yield, hydrochloride sait) was collected by filtration.

[00180] *H NMR (400 MHz, MeOH-dJ: δ = 3.47 (s, 2H), 4.27-4.40 (m, 5H), 7.57 (d, J = 9.0 Hz, 2H), 7.98 (d, J = 8.6 Hz, 2H).

Step 5: 4-{[2-(Aminooxy)ethyl]sulfanYl]benzenecarboximidamide (3_10_6) [00181] Ammonia (7N in methanol, 10 mL) was added to a solution of compound 3_10_5 (3.0 g, 73.7 mol) in dry methanol (20 mL) and the mixture was heated at 50 ^SC for 2 hours. After removal ofthe solvent, the residue was purified by chromatography to give compound 3_10_6 (1.5 g, 54 % yield) as a solid.

6l [00182] *H NMR (400 MHz, MeOH-d₄): δ = 3.32 (br s, 2H), 3.86 (s, 2H), 7.53 (m, J = 8.6

Hz, 2H) 7.71 (m, J = 8.60 Hz, 2H).

3.11 4-[2-[Aminooxy)ethoxy]-N-(propan-2-yl)benzenecarboximldamide

[00183] Isopropylamine (2 mL) was added dropwise at O’C to a suspension of compound 3_1_5 (1 g, 3.57 mmol) in methanol (10 ml) in a sealed tube and the mixture was heated at 50*C for 16 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (50 mL) and ethyl acetate (50 mL). The aqueous layer was lyophilized to give compound 3_11_6 (1.0 g, 75 % yield) as a yellow foam.

3.12 4-[2-fAminooxv)ethoxy]-N-methylbenzenecarboximidamide

H₂N 3_12_6 [00184] Compound 3_12_6 was prepared using the procedure described above for compound 3_11_6 using methylamine instead of isopropylamîne.

3.13 4-[2-(Aminooxy)ethoxy]-N-(2-hydroxyethyl)benzenecarboxlmldamide

[00185] Compound 3_13_6 was prepared using the procedure described above for compound 3_11_6 using 2-aminoethanol instead of isopropylamine.

3.14 2-{[{4-[2-(Aminooxy)ethoxY]phenyl}(imino)methyl]amino}ethy1 formate

[00186] Compound 3_14_7 was prepared from compound 3_13_6 using a standard literature reported formylation method using formic acid, see e.g. Chem. Commun. 2007, (28), 2977-2979.

3.15 N-(2-(tert-ButoxYcarbonylamIno)ethyl)-4-[2-(aminooxy)ethoxy]benzenecarbox- imldamide

[00187] Compound 3_15_6 was prepared using the procedure described above for compound 3_11_6 using tert-butyl 2-aminoethylcarbamate instead of isopropylamine.

3.16 4-[2-(AmînooxY)ethoxy]-N-(3-{tert-butoxYcarbonylamino)propyl)benzenecarboxi- mldamide sn/

/0

H₂N 3_1β_6 [00188] Compound 3_16_6 was prepared using the procedure described above for compound 3_11_6 using tert-butyl 2-aminopropylcarbamate instead of isopropylamine.

3.17 4-[2-{Aminooxy)ethoxy]-N-(pyridin-2-¥lmethyf)benzenecarboximidamide

[00189] Compound 3_17_6 was prepared using the procedure described above for compound 3_11_6 using 2-aminomethyl pyridine instead of isopropylamine.

3.18 l-{4-[2>(Aminooxy)ethoxY]phenyl}-l*[4-(tert-butoxycarbonylpiperazin-l-Yl)]methanimine

[00190] Compound 3_18_6 was prepared using the procedure described above for compound 3_11_6 using N-Boc protected piperizane instead of isopropylamine.

3.19 4-[2-(Am1nooxy)ethoxy]-N-[2-(dimethylamino)ethyl]benzenecarboximidamide vs

[00191] Compound 3_19_6 was prepared using the procedure described above for compound 3_11_6 using 2-(N,N-dimethylamino)ethylamine instead of isopropylamine.

3.20 N-[{4-[2-(Aminooxy)ethoxy]phenyl}(imino)methy1]glyclne

(00192] Compound 3_20_6 was prepared using the procedure described above for compound 3_11_6 using amino acetic acid instead of isopropylamine.

3.21 4-[2-{AmInooxY)ethoxY]-N-(l,3-di(tert-butoxYCarbonylamÎno)propan-2-yl)benzenecarboximidamide

[00193] Compound 3_21_6 was prepared using the procedure described above for compound 3_11_6 using di-tert-butyl (2-aminopropane-l,3-dryl)biscarbamate instead of isoprop· ylamine.

3.22 N-(l-(tert-butoxYcarbonYlamino)-3-hydroxypropan-2’Ÿl)-4-[2-(amlnooxy)ethoxy]15 benzenecarboximidamlde V-'''

NHBoc /θ

HjN 3_22_β [00194] Compound 3_22_6 was prepared using the procedure described above for compound 3_11_6 using tert-butyl (2-amino-3-{(tert-butyl(dimethyl)silyl]oxy}propyl)carbamate instead of isopropylamine.

3.23 4-(2-Aminooxy-ethoxy)-N-hydroxY-benzamidïne

[00195] Hydroxylamine hydrogen chloride (1.36 g, 19.6 mmol) was added to a mixture of compound 3_1_4 (1 g, 5.61 mmol) and sodium carbonate (1.07 g, 10.1 mmol) in éthanol / water (3 mL : 23 mL). The reaction mixture was stirred at room température for 72 hours, diluted with brine (40 mL), extracted into ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with water, dried over anhydrous sodium sulfate and evaporated. The residue was triturated with dichloromethane, filtered, rinsed with dichloromethane and dried in vacuum to give compound 3_23_5 (0.3 g, 25 % yield) as a white powder.

[00196] ^XH NMR (400 MHz, DMSO-<f₆): δ = 3.82 (br s, 2H), 4.11 (br s, 2H), 5.69 (s, 2H),

6.08 (s, 2H), 6.91 (d, J = 8.99 Hz, 2H), 7.57 (d, J = 8.99 Hz, 2H), 9.42 (s, IH).

[00197] MS: m/z (ES*, %) 212 (M+H, 100), 179 (5), 153 (10), 124 (15), 103 (25).

3.24 4-[(AmÎnooxy)methy I] benze necarboximidamlde

3_24_4 3_24_5

Step 1: 4-(((1,3-Dioxo-l,3-dihydro-2H-isoindol-2-yl)oxy]methyl}benzonitrile (3_24_2) [00198] N-Hydroxyphthalimide (PhthOH, 7.12 g, 55 mmol), triphenylphosphine (14.41 g, 55 mmol) and dïethyl azodicarboxylate (DEAD, 9 mL, 55 mmol) were slowly added to a solution of 4-hydroxymethyl benzonitrile 3_24_1 (8.15 g, 50 mmol) in tetrahydrofuran (100 mL). The mixture was stirred at room température for 15 hours. The solid was collected by filtration, 10 washed with tetrahydrofuran and dried to give compound 3_24_2 (10 g, 72 % yield) as a solid.

Step 2; 4-[(Aminooxy)methyl]benzonitrile (3_24_3) [00199] Hydrazine hydrate (0.336 g, 6.2 mmol) was added to a suspension of compound 3_24_2 (1.55 g, 5.6 mmol) in éthanol (20 mL) and the mixture was stirred at room température for 15 hours. The solid was removed by filtration and the filtrate was concentrated. The residue was diluted with dichloromethane (30 mL), the solid was removed by filtration and the filtrate was concentrated to give compound 3_24_3 (0.88 g, 100 % yield) as a solid.

Step 3: Methyl 4-[(aminooxy)methyl]benzenecarboximidoate (3_24_4) [00200] Hydrogen chloride gas was bubbled through a solution of compound 3_24_3 (0.88 g, 5.6 mmol) in methanol (30 mL) at 0 SC for 5 minutes and the mixture was stirred at room température for 20 hours. The solid was colîected by filtration, washed with methanol and dried to give compound 3_24_4 (0.54 g, 38 % yield) as a white solid.

Step4: 4-[(Aminooxy)methyl]benzenecarboximidamide (3_24_5) [00201] Compound 3_24_4 (0.54 g, 2.13 mmol) in methanol (5 ml) was added slowly to a solution of ammonia (7 N in methanol, 7 mL, 21 mmol) in methanol (10 mL) and the mixture was stirred at room température for 18 hours. After removal of the solvent, the residue was diluted with dichloromethane (30 mL), and the solid was colîected by filtration to give compound 3_24_5 (0.42 g, 83 % yield) as a white solid.

3.25 4-{[2-(AminooxY)ethyl]amlno}ben2enecarboxlmidamide

Step 1: 4-[{2-Hydroxyethyl)amino]benzonitri1e (3_25_2) [00202] 2-Aminoethanol (3.0 mU 49.48 mmol) and potassium carbonate (6.84 g, 49.48 mmol) were added to a solution of 4-fluorobenzonitrHe 3_25_1 (5.0 g, 41.24 mmol) in dimethyl sulfoxide (30 mL). The mixture was stirred at 100*C for 18 hours, poured onto ice-water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined extracts were washed with brine (50 mL), dried over magnésium sulfate, and concentrated to give a residue which was purified by column chromatography to give compound 3_25_2 (3.0 g, 45 % yield) as an oil.

[00203] ^XH NMR (400 MHz, CDCI₃): δ = 1.80 (t, J = 53 Hz, 1H), 3.34 (q, J = 5.5 Hz, 2H), 3.87 (q, J = 5.2 Hz, 2H), 4.61 (br s., 1H), 6.60 (d, J = 8.6 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H).

Step 2: 4-((2-((1,3-Dioxo-l,3-dihydro-2H-isoindo!-2-yl)oxy]ethyl)amino)benzonitrile (3_25_3) [00204] Triphenylphosphine (1.61 g, 6.16 mmol) was added to a solution of compound 3_25_2 (1.00 g, 6.16 mmol) and N-hydroxyphthalimide (Phth-OH, 1.05 g, 6.16 mmol) in tetrahydrofuran (100 mL), followed by the slow addition of diethyl azodicarboxylate (1.02 mL, 6.16 mmol) over 20 minutes. The mixture was stirred at room température for 24 hours and concentrated to yield a residue which was purified by column chromatography to afford compound 3.25.3 (1.1 g, 58 % yield).

[00205] ^XH NMR (400 MHz, DMSO-d₆): δ = 3.50 (d, J = 5.5 Hz, 2H), 4.29 (t, J = 5.47 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 6.79 (s, 1H), 7.47 (d, J = 8.6 Hz, 2H), 7.86 (s, 4H).

Step 3: 4-{[2-(Aminooxy)ethyl]amino}benzonitrile (3.25.4) [00206] Hydrazine hydrate (0.255 mL, 10.90 mmol) was added to a suspension of compound 3.25.3 (335 g, 10.90 mmol) in éthanol (80 mL) and the mixture was stirred at 45’C for 14 hours. The solid was removed by filtration and the filtrate was concentrated. The residue was diluted with dichloromethane (20 mL). The solid was removed by filtration and the filtrate was concentrated to give compound 3.25.4 (1.9 g, 97 % yield) as an oil.

[00207] ^XH NMR (400 MHz, DMSO-d₆): Ô = 3.27 (d, J = 5.7 Hz, 2H), 3.58-3.71 (m, 2H), 6.04 (s, 2H), 6.66 (d, J = 8. Hz, 3H), 7.43 (d, J = 8.9 Hz, 2H).

Step 4: 4-{[2-(Aminooxy)ethyl]amino]benzenecarboximidoate (3.25.5) χ/V— [0020S] Hydrogen chloride gas was bubbled through a solution of compound 3.25.4 (1.9 g, 10.72 mmol) in dry methanol (50 mL) at 0 ®C for 10 minutes. The mixture was stined at room température for 14 hours to give compound 3.25.5 as a white solid (1.0 g, 45 % yield, hydrochloride sait) which was collected by filtration.

[00209] ^JH NMR (400 MHz, MeOH-d₄): δ = 3.60 (s, 2H), 4.18-4.30 (m, 5H), 6.79 (d, J =

8.9 Hz, 2H), 7.86 (d, J = 8.9 Hz, 2H).

Step 5: 4-{[2-(Aminooxy)ethyl]amino}benzenecarboximidamîde (3.25.6) [00210] Ammonia (7N in methanol, 5 mL) was added to a solution of compound 3.25.5 (1.0 g, 4.78 mmol) in dry methanol (10 mL) and the mixture was heated at 50⁵C for 2 hours. After removal of the solvent, the obtained product (930 mg, 100 % yield) was used without further purification.

[0021 ï] *H NMR (400 MHz, MeOH-d₄): δ = δ 3.40 (t, J = 5.5 Hz, 2H), 3.82 (t, J = 5.5 Hz, 2H), 6.74 (d, J = 9.0 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H).

3.26 5-{[2-(Aminooxy)ethoxy]methyl)thiophene-3-carboxÎmidamlde

Step 1: (4-Bromothiophen-2-yl)methanol (3.26.2):

[00212] Sodium borohydride (5.20 g, 0.137 mol) was added to a solution of 4-bromothiophene-2-carba!dehyde 3.26.1 (25.0 g, 0.131 mol) in anhydrous tetrahydrofuran {400 mL) at

room température and the resulting mixture was stirred at room température for 1.5 hours. The reaction was quenched by carefully adding a saturated ammonium chloride solution (100 mL) at room température. The mixture was extracted into ethyl acetate and the extract was washed with brine, dried over sodium sulfate, and concentrated to give the product (25.02 g, 99% yield) which was used in the next step without further purification.

[00213] *H NMR (400 MHz, CDCI₃): δ = 1.93 (br. s., 1H), 4.79 (s, 2H), 6.93 (s, 1H), 7.18 (d, J = 1.5 Hz, 1H).

Step 2: 5-(HydroxYmethyl)thîophene-3-carbonitrile (3_26_3) [00214] Zinc cyanide (15.2 g, 0.129 mmol) was added to a solution of (4-bromothïophen-2-yl)-methanol 3_26_2 (25.0 g, 0.129 mol) in N,N-dimethylformamide (150 mL). After degassing for 10 minutes, tetrakis(triphenylphosphine)palladîum(0) (7.48g, 6.47 mmol) was added and the reaction mixture was stirred at 80*C for 4 hours. After cooling to room température, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography to give the desired product (13.67 g, 76 % yield).

[00215] *H NMR (400 MHz, CDCIj): δ = 1.98 (t, 1H), 4.86 (d, J = 6.1 Hz, 2H), 7.17 (d, J = 1.2 Hz, 1H), 7.88 (d, J = 1.2 Hz, 1H).

Step 3: 5-(Bromomethyl)thiophene-3-carbonitrile (3_26_4) [00216] Triphenylphosphine (9.9 g, 37.7 mmol) and carbon tetrabromide (12.59 g, 37.7 mmol) were added to a solution of 5-hydroxymethyl-thiophene-3-carbonitrile 3_26_3 (5.0 g, 35.9 mmol) in tetrahydrofuran (150 mL), at room température. After stirring for 4 hours, the mixture was concentrated to dryness. The residue was purified by column chromatography to give the desired product (4.85 g, 67 % yield) as a colorless oil.

Step 4: 5-[(2-Hydroxyethoxy)methyl]thiophene-3-carbonitrile (3_26_5) [002171 Sodium (0.824 g, 3S.8 mmol) was added to a solution of ethylene glycol (14.8 g, 0.239 mol) in tetrahydrofuran (20 mL) at room température. After ail the sodium was consumed, 5-bromomethyl-thiophene-3-carbonitrife 3_26_4 (4.83 g, 23.9 mmol) in tetrahydrofuran (20 mL) was added at -10*C and the reaction mixture was stirred at room température for 9.5 hours. The reaction mixture was neutralized to pH 7 using diluted hydrochloric acid at 0*C and the mixture was extracted with ethyl acetate and the extract was washed with brine, dried over sodium sulfate and concentrated to dryness to give the product (4.12 g, 9 % yield) as a colorless oil.

[00218] ’H NMR (400 MHz, CDCIj): δ = 1.90 (t, 1H), 3.58 - 3.65 (m, 2H), 3.73 - 3.88 (m, 2H), 4.62 - 4.81 (m, 2H), 7.18 (d, J = 1.2 Hz, 1H), 7.90 (d, J = 1.5 Hz, 1H).

[002191 MS (ES*) m/z: [M+H]* calcd for C₈H₁₀NO₂S: 184.23. Found: 184.93.

[00220] Following the procedures as described under 3_24 and using 5-(2-hydroxyethoxymethy!)-thiophene-3-carbonitrile (3_26_5) in place of 4-hydroxymethyl benzonitrile (3_24_1), compound 3_26_6 was prepared.

3.27 5-[(Aminooxy)methyl]thiophene-3-carboximldamide

[00221] Following the procedures as described under 3_24 and using 5(hydroxymethyl)-thiophene-3-carbonitrile (3_26_3) in place of 4-hydroxymethyl benzonitrile (3_24_1), compound 3_27_6 was prepared.

3.28 3-Amlno-4-(2-am1nooxy-ethoxy)-benzamidine Vv^

Step 1: 4-(2-Hydroxy-ethoxy)-3-nitro-benzonitrile (3_28_2) [00222] Sodium (1.038 g, 45.2 mmol) was added to a mixture of ethylene glycol (28.03 g, 0.451 mol) in tetrahydrofuran (20 mL) at room température. After ait sodium was consumed, 4fluoro-3-nitro-benzonitrile 3_28_1 (5.0 g, 30.1 mmol) in tetrahydrofuran (10 mL) was added at 10*C and the reaction mixture was stirred at room température for 3 hours. The reaction mixture was quenched by adding ice-water and neutralized to pH 7 using dîlute hydrochloric acid at 0*C. The mixture was extracted with ethyl acetate and the extract was washed with brine, dried over sodium sulfate and concentrated to dryness. The residue was purified by crystallization from ethyl acetate/hexanes to give the desired product (4.45 g, 71 % yield) as a light yellow solid.

[00223] ^lH NMR (400 MHz, DMSO-d₆): 5 = 3.60-3.79 (m, 2H), 4.17-4.37 (m, 2H), 4.94 (t, J = 5.3 Hz, IH), 7.56 (d, J = 8.8 Hz, IH), 8.09 (dd, J = 8.9, 2.2 Hz, IH), 8.45 (d, J = 2.0 Hz, IH).

[00224] MS (ES·) m/z: [M-H]‘ calcd for qH₇N₂O₄:207.18. Found: 206.90.

Step 2: 3-Amino-4-(2-hydroxy-ethoxy)-benzonitrile (3_28_3) <7 [00225] Palladium on charcoal (10 %, 0.4g) was added to a solution of 4-(2*hydroxyethoxy)-3-nitro-benzonitrile 3_28_2 (2.7 g, 12.97 mmol) in éthanol (40 mL) and tetrahydrofuran (40 mL). The mixture was hydrogenated on a Parr Shaker apparatus at room température for 3 hours. After filtration, the filtrate was concentrated and the residue was purified by flash column chromatography to give the desired product (1.50 g, 65 % yield) as a white solid.

[00226] 'H NMR (400 MHz, DMSO-d₆): δ = 3.71 (m, 2H), 3.98 (t, J = 4.7 Hz, 2H), 4.93 (t, J = 6.3 Hz, 1H), 5.30 (s, 2H), 6.77 - 6.98 (m, 3H).

[00227] MS (ES*) m/z: [M+H]⁺ calcd for CgHuNîOî: 179.19. Found: 178.99.

Step 3: 3-Amino-4-[2-(l,3-dioxo-l,3-dihydro-isoindol-2-yloxy)-ethoxy]-benzonitrile (3_28_4) [00228] N-Hydroxyphthalimide (Phth-OH, 1.44 g, 8.83 mmol) and triphenylphosphine (2.53 g, 9.63 mmol) were added to a solution of 3-amino-4-(2-hydroxy-ethoxy)-benzonitrile 3_28_3 (1.43 g, 8.02 mmol) in anhydrous tetrahydrofuran (40 mL) at room température. Diethyl azodicarboxylate (1.68 g, 9.63 mmol) was added dropwise to the resulting solution at 20C and the resulting mixture was stirred at room température ovemight. After the évaporation of the tetrahydrofuran, the residue was dissolved in acetone (25 ml) and diluted with hexanes (33 mL). The white precipïtate was collected and washed with a miminum amount of acetone to give the desired product (1.91 g, 74 % yield) as a white solid.

[00229] *H NMR (400 MHz, DMSO-d₆): δ = 4.34 (m, 2H), 4.54 (ddd, J = 3.9,2.2,2.0 Hz, 2H), 5.21 (s, 2H), 6.83 - 7.03 (m, 3H), 7.86 (s, 4H).

Step 4: 3-Amlno-4-(2-aminooxy-ethoxy)-benzonitrile (3_28_5) [00230] Hydrazine monohydrate (0.338 g, 6.76 mmol) was added to a solution of 3amino-4-[2-(l,3-dioxo-l,3-dihydro-isoindol-2-yloxy)-ethoxy]-benzonitrile 3_28_4 (1.90 g, 5.88 mmol) in anhydrous éthanol (15 mL) and tetrahydrofuran (30 mL) at O'C and the resulting mixture was stirred at room température for 6.5 hours. After concentration, the residue was stirred with ether (40 mL) for 1 hour and filtered. The filtrate was concentrated to give crude compound

3_28_5 (1.31 g, crude) as a white solid.

[002311 ^XH NMR (400 MHz, DMS0-</₆): δ = 3.77-3.91 (m, 2H), 4.12-4.22 (m, 2H), 5.13 (s, 2H), 6.09 (br s., 2H), 6.82-7.00 (m, 3H).

Step 5: 3-Amino-4-(2-aminooxy-ethoxY)-benzimidic acid methyl ester dihydrochloric acid sait (3_28_6) [00232] Hydrogen chloride gas was introduced into a solution of 3-amino-4-(2aminooxy-ethoxyj-benzonitrile 3_28_5 (1.30 g, 6.73 mmol) in anhydrous methanol (200 mL) at 0*C for 15 minutes and the resulting mixture was stirred at room température overnight. After concentration, the residue was stirred with ether (60 mL) for 0.5 hour and the precipitate was collected and dried to give the desired product (1.33 g, 66 % yield) as a white solid.

[00233] *H NMR (400 MHz, DMSO-<f₆): δ = 4.23 (s, 3H), 4.34-4.51 (m, 8H), 7.12 (d, J = 8.8 Hz, IH), 7.43 (d, J = 1.5 Hz, IH), 7.61 (br s., IH), 8.05 (br s., IH).

Step 6: 3-Amino-4-(2-aminooxy-ethoxy)-benzamidine (3_28_7) [00234] Ammonia (7 N in methanol, 9.6 mL, 66.9 mol) was added to a suspension of 3amino-4-(2-aminooxy-ethoxy)-benzÎmidic acid methyl ester dihydrochloric acid sait 3_28_6 (1.33 g, 4.46 mmol) in anhydrous methanol (35 mL) at 0*C and the resulting mixture was stirred at 50 ®C for 3 hours. After concentration, the residue was stirred with éthanol for 1 hour. After filtration, the filtrate was concentrated to dryness to afford the desired product (1.2 g, >100% yield) as a white solid, which was used without further purification.

3.29 4-[2-(Aminooxy)ethoxy]-3-(hydroxymethyl)benzenecarboximidamlde

Step 1: 3-Formyl-4-hydroxybenzonitrile (3_29_2) [00235] Hexamethylenetetramine (HMTA, 117.6 g, 840 mmol) was added to a cooled (0*C) solution of 4-cyanophenol 3_29_1 (50 g, 420 mmol) in trifluoroacetic acid (TFA, 340 mL). After the addition, the mixture was heated at 100*C for 16 hours, cooled to room température, quenched with 50 % sulfuric acid (210 mL) and water (1260 mL), extracted with ethyl acetate, dried and concentrated. The residue was purified by chromatography to give compound 3_29_2 10 (12 g, 19 % yield) as an off-white solid.

Step 2: 4-(2-Bromoethoxy)-3-formylbenzonîtrile (3_29_3) [00236] A mixture of compound 3_29_2 (0.5 g, 3.4 mmol), 1,2-dibromoethane (0.85 mL, 10.20 mmol) and K₂CO₃ (2.35 g, 17 mmol) in acetonitrile was refluxed for 2 h, cooled to RT, filtered and concentrated. The residue was purified by chromatography to give compound 3_29_3 15 (650 mg, 76 % yield) as a colorless oil.

Step 3: 4-(2-Bromoethoxy)-3-(hydroxymethyl)benzonitrile (3_29_4) [00237] Sodium borohydride (67 mg, 1.77 mmo!) was added in portions to a cooled (0*C) solution of compound 3_29_3 (224 mg, 0.89 mmol) in methanol (5 mL). Afterthe addition, the mixture was stirred at O’C for 40 minutes, quenched with a saturated ammonium chloride solution, diluted with ethyl acetate (30 mL), washed with water (5 mL), dried over sodium sulfate 5 and concentrated to give compound 3_29_4 (170 mg, 7S % yield) as a gum.

[00238] Following the procedures as described under 3_1 and using 4-(2bromoethoxy)-3-{hydroxymethyl)benzonitrile (3_29_4) instead of 4-(2-bromoethoxy)benzonitrile (3_1_2), compound 3_29_5 was prepared.

3.30 tert-Butyl [{6{2-(aminooxy)ethoxy]pyridazir>3-ylXimino)methy!]carbamate

Step 1: 6-(2-Hydroxyethoxy)pyridazine-3-carboximîdic acid 2-hydroxy-ethyl ester (3_30_2) [00239] Sodium (0.593 g, 0.0258 mmol) was added to a flask containing ethylene glycol (13.34 g, 0.215 mol) at 0*C. After ail sodium was consumed, 6-fluoro-pyridazine-3-carbonitrile 3_30_l (3.0 g, 0.0215 mmol) in tetrahydrofuran (10 mL) was added at O’C and the reaction mixture was stirred at room température ovemight. The reaction mixture was filtered and the filter cake was washed with cold tetrahydrofuran and dried to afford the desired product 3_30_2 (4.32 g, 88 % yield) as a white solid.

[00240] ^JH NMR (400 MHz, DMSO-d₆): δ = 3.65-3.86 (m, 4H), 4.23-4.34 (m, 2H), 4.47 4.57 (m, 2H), 4.82-5.03 (m, 2H), 7.37 (d, J = 9.0 Hz, IH), 8.04 (d, J = 9.0 Hz, IH), 9.23 (s, IH).

[00241] MS (ES*) m/z: [M+H]* calcd for CsHmNjO*: 228.22. Found: 228.07.

Step 2: 6-(2-Hydroxyethoxy)pyrîdazine-3-carboxamidine (3_30_3) [00242] Ammonium chloride (0.899 g, 16.8 mmol) was added to a mixture of 6-(2hydroxy-ethoxy)-pyridazine-3-carboximidic acid 2-hydroxy-ethyl ester 3_30_2 (3.185 g, 14.0 mmol) in methanol (120 mL). The mixture was refluxed ovemight and then concentrated to dryness. The residue was dissolved in water, neutralized to pH 9 using a saturated sodium bicarbonate solution and lyophilized to give the crude product. The matériel was purified by flash column chromatography to give the desired product (2.1 g, 82 % yield) as a white solid.

[00243] *H NMR (400 MHz, DMSO-d₆): δ = 3.78 (m, 2H), 4.41 - 4.57 (m, 2H), 4.88-4.99 (m, IH), 6.87 (br. s., 3H), 7.29 (d, J = 9.1 Hz, IH), 8.24 (d, J = 9.4 Hz, IH).

Step 3: tert-Butyl {[6-(2-hydroxyethoxy)pyridazin-3-yt](imino)methyl}carbamate (3_30_4) [00244] A saturated sodium bicarbonate solution (8 mL) and a solution of di-tertbutyldicarbonate (BOCjO,2.753 g, 12.6 mmol) in 1,4-dioxane (10 mL) were added to a solution of 6-(2-hydroxy-ethoxy)-pyridazine-3-carboxamidine 3_30_3 (1.915 g, 10.5 mmol) in water (10 mL) at room température. After stirring at room température ovemight, more dî-tertbutyldicarbonate (1.0 g) was added and the mixture was stirred for another 16 hours. The resulting mixture was concentrated and the white solid was collected, washed with water and dried to give the desired product (1.29 g, 44 % yield) as an off-white solid.

[00245] *H NMR (400 MHz, DMSO-d₆): δ = 1.45 (s, 9H), 3.68 - 3.89 (m, 2H), 4.41 - 4.61 (m, 2H), 4.95 (t, J = 5.4 Hz, 1H), 7.32 (d, J = 9.4 Hz, 1H), 8.22 (d, J = 9.1 Hz, 1H), 9.03 (br s., 2H).

[00246] MS (ES*) m/z: [M+H]* calcd for C12H19N4O4:283.30 Found: 283.25.

Step 4: tert-Butyl [(6-{2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)oxy]ethoxy]pyridazin-3-yl)(imino) methyljcarbamate (3_30_5) [00247] N-Hydroxyphthalîmide (Phth-OH, 0.814 g, 4.99 mmol) and triphenylphosphine (1.427 g, 5.44 mmol) were added to a solution of {[6-(2-hydroxy-ethoxy)-pyridazin-3-yl]-iminomethy!}-carbamic acid tert-butyl ester 3_30_4 (1.28 g, 4.53 mmol) in anhydrous tetrahydrofuran (40 ml) at room température and a solution of diethyl azodîcarboxylate (0.948 g, 5.44 mmol) in tetrahydrofuran (20 mL) was added dropwise to the resulting solution at 20*C. The resulting mixture was stirred at room température for 2 hours. After évaporation of half ofthe tetrahydrofuran, the white precipitate was collected, washed with a small volume of cold tetrahydrofuran and dried to afford the product 3_30_5 (1.412 g, 73 % yield) as a white solid.

[00248] ’H NMR (400 MHz, DMSO-d₆): δ = 1.53 (s, 9H), 4.50 - 4.66 (m, 2H), 4.73-4.89 (m, 2H), 7.29 (d, J = 9.1 Hz, 1H), 7.86 (s, 4H), 8.23 (d, J = 9.1 Hz, 1H), 9.03 (br s., 2H).

[00249] MS (ES*) m/z: [M+H]* calcd for C_MH₂₂N₅O₆:428.42. Found: 428.22.

Step 5: tert-Butyl [(6-[2-(aminooxy)ethoxy]pyridazin-3-yl](imino)methy!]carbamate (3_30_6) [00250] Hydrazine monohydrate (0.178 g, 3.55 mmol) was added to a solution of ({6-[2(l,3-dioxo-l,3-dihydro-isoindol-2-yloxY)-ethoxY]-pyridazin-3-yl}-imino-methyl)-carbamic acid tertbutyl ester 3_30_5 (1.381 g, 3.23 mmol) in anhydrous éthanol (20 mL) and tetrahydrofuran (20 mL) at 0‘C and the resulting mixture was stirred at room température for 2.5 hours. After concen- — tration, the residue was purified by flash column chromatography to give compound 3_30_6 (0.960 g, 100 %) as a white solid.

[00251] *H NMR (400 MHz, DMSO-d₆): δ = 1.44 (s, 9H), 3.80-3.96 (m, 2H), 4.58-4.70 (m, 2H), 6.12 (s, 2H), 7.31 (d, J = 9.4 Hz, 1H), 8.19 (d, J = 9.1 Hz, 1H).

[00252] MS (ES*) m/z: [M+Hf calcd for CuHmNsO,: 298.32. Found: 298.27.

3.31 tert-Butyl [{5-[2-tAminooxY)ethoxy]pyrazine-2-yl}(imlno)methyl]carbamate

[00253] Using the procedure as described under 3.30 but using 5-chloro-pyrazine-2carbonitrile (3_31_1) instead of 6-fluoro-pyridazine-3-carbonitrile (3_30_l), compound 3_31_6 was prepared.

3.32 5-[2-fAminooxv)ethoxy]pyridine-2-carboximidamlde

Step 1: 5-(2-(1,3-Dioxo-l,3-dihydro-lsoindol-2-y!oxy)-ethoxy]-pyridine-2-carbonitrile (3_32_2) [00254] Triphenylphosphine (4.36 g, 16.65 mmol) was added to a solution of N-{25 hydroxyethoxyjphthalimide (3.45 g, 16.65mmol) and 2-cyano-5-hydroxypyridîne 3_32_1 (2.0 g,

16.65 mmol) in tetrahydrofuran (200 mL), followed by the slow addition of diethyl azodicarboxylate (2.73 mL, 16.65 mmol) over 20 minutes and the mixture was stirred at room température for 24 hours. After removal of the solvent, the residue was purified by crystallization from tetrahydrofuran to afford compound 3_32_2 (3.0 g, 58 % yield).

[00255] NMR (400 MHz, DMSO-d₆): δ = 4.51 (dd, J = 17.5,5.7 Hz, 4H), 7.60 (dd, J =

8.9,2.9 Hz, 1H), 7.87 (s, 4H), 8.02 (d, J = 8.9 Hz, 1H), 8.39 (d, J = 2.9 Hz, 1H).

Step 2: 5-(2-Aminooxy-ethoxy)-pyridine-2-carbonitrile (3_32_3) [00256] Hydrazine hydrate (0.310 mL, 9.69 mmol) was added to a suspension of compound 3_32_2 (3.0 g, 9.69 mmol) in éthanol (100 mL) and the mixture was stirred at 45*C for 14 hours. The solid was removed by filtration and the filtrate was concentrated. The residue was diluted with dichloromethane (20 mL), the solid was removed by filtration and the filtrate was concentrated to give compound 3_32_3 (1.3 g, 75 % yield) as an oil.

[00257] *H NMR (400 MHz, DMSO-d_fi): δ = 3.80-3.90 (m, 2H), 4.24-4.34 (m, 2H), 6.13 (s, 2H), 7.61 (dd, J = 8.7,3.0 Hz, IH), 8.00 (d, J = 8.6 Hz, IH), 8.45 (d, J = 2.5 Hz, IH).

Step 3: 5-(2-Aminooxy-ethoxy)-pyridine-2-carboximidicacid methyl ester (3_32_4) [00258] Sodium methoxide (23 mg, 0.418 mmol) was added to a solution of compound

3_32_3 (150 mg, 0.837 mmol) in 5 mL of dry MeOH. The mixture was stirred at room température for 16 hours, and the solvent was evaporated to give compound 3_32_4 as a white solid (0.176 mg, 100% yield).

[00259] ’H NMR (400 MHz, MeOH-d₄): δ = 3.94 (s, 3 H), 3.93-4.03 (m, 2H), 4.19-4.38 (m, 2H), 7.45 (dd, J = 8.6,2.74Hz, 1H),7.84 (d, J = 8.6 Hz, IH), 8.35 (d, J = 2.7 Hz, IH).

Step 4: 5-(2-Aminooxy-ethoxy)-pyridine-2-carboxamidine (3_32_5) [00260] Ammonium chloride (31 mg, 0.568 mmol) was added to a solution of 3_32_4 (100 mg, 0.437 mmol) in methanol (5 mL) and the mixture was stirred at room température for 6 hours. After the removal of the solvent, the residue was washed with tert-butyl methyl ether (10 mL), and stirred with ammonia (6N in methanol, 1 mL) for 1 hour. The solvents were then evapo15 rated to give compound 3_32_5 (0.10 g, crude) as a solid.

[00261] ^XH NMR (400 MHz, DMSO-d₆): δ = 4.31 (b. s., 2H), 4.35-4.43 (m, H), 6.01 (br. s., 2H), 7.42-7.51 (m, IH), 7.74-7.82 (m, IH), 8.30 (br s., IH).

3.33 tert-Butyl (2-{[{5-[2-{aminooxy)ethoxy]pyridin-2-yl}(imino)methyl]amino}ethyl)carbamate

[00262] Following the procedure described under 3.32 but using N-Boc-diethylamine instead of ammonium chloride compound 3_33_5 was prepared.

3.34 6-[2-{AminooxY)ethoxy]pyridine-3-carboximidamlde

{00263] Following the procedure described under 3.32 but using 5-cyano-2hydroxypyridine instead of 2-cyano-5-hydroxypyridine (3_32_1) compound 3_34_5 was prepared.

3.35 tert-Butyl2-[{5-[2-{aminooxy)ethoxy]pheny!}(imlno)methyl]hydrazinecarboxylate

Step 1: 4-Hydroxy benzenecarboximidoate (3_35_2) [002641 A suspension of 4-cyanophenol 3_35_1 (20.0 g, 167.9 mmol) in methanol (300 mL) was cooled to O’C and a stream of hydrogen chloride gas was passed through until the solution became saturated. The reaction mixture was stirred ovemight at room température and the solid was collected by filtration to obtain compound 3_35_2 (28.6 g, 90 % yield, hydrochloride sait) as a white solid.

[00265] *H NMR (400 MHz, DMSO<): δ = 4.22 (s, 3H), 6.99 (d, J = 8.6 Hz, 2H), 8.02 (d, J = 9.0 Hz, 2H), 11.18 (br s, 1H), 11.68 (br s, 1H).

[00266] MS (ES*) m/z: [M+H]* calcd for C₈H₁₀NO₂:152.07; found: 152.13.

Step 2: tert-Butyl 2-[(5-hydroxyphenyl)(imino)methyl]hydrazînecarboxylate (3_35_3) [00267] Triethylamine (5.42 g, 53.3 mmol) was added to a suspension of compound 3_35_2 (10.0 g, 53.3 mmol) in methanol (200 mL) followed by tert-butyl hydrazinecarboxylate (Boc-Hydrazine, 14.1 g, 106.6 mmol). The resulting dear solution was heated at 40*C for 2 hours, it was then evaporated and purified by column chromatography to obtain compound 3_35_3 (9.2 g, 69 % yield) as a white solid.

[00268] ^XH NMR (400 MHz, DMS0-d_s): δ = 1.42 (s, 9H), 6.08 (br s, 2H), 6.71 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 8.80 (br s, 1H), 9.60 (s, 1H).

[00269] MS (ES*) m/z: [M+H]* calcd for C_UH_UN₃O₃:252.13; found: 252.17.

Step 3: tert-Butyl 2-[{5-{2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)oxY]ethoxy}phenyl)(imino)methyl]hydrazinecarboxylate(3_35_4) [00270] To a suspension of compound 3_35_3 (3.2 g, 12.8 mmol), triphenylphosphine (3.7 g, 14.1 mmol), and W-(2’hydroxyethoxy)phthalimide (2.9 g, 14.1 mmol) in tetrahydrofuran (20 mL) was added diisopropyl azodicarboxylate (2.8 g, 14.1 mmol) dropwise with sonication in an vA ultra sonie bath. The mixture was sonicated for an additional 15 minutes, stirred ovemight at room température, evaporated and purified by column chromatography to obtain compound 3_35_4 {4.4 g, 79 % yield) as a white solid.

[002711 ^XH NMR (400 MHz, DMSO-d₆): δ = 1.43 (s, 9H), 4.18-4.37 (m, 2H), 4.37-4.57 (m, 2H), 6.15 (s, 2H), 6.81 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 9.0 Hz, 2H), 7.85 (s, 4H), 8.86 (br s, IH).

[00272] MS (ES*) m/z: [M+H]* calcd for C₂₂H₂5N«O₆:441.18; found: 441.20.

Step 4: tert-Butyl 2-[{5-[2-(aminooxy)ethoxy]phenyl)(imino)methy1]hydrazinecarboxylate (3_35_5) [00273] Hydrazine hydrate (0.68 g, 20.2 mmol) was added to a suspension of compound 3_35_4 (4.5 g, 10.1 mmol) in éthanol and the resulting mixture was slowly heated to 45*C with vigorous stirring until a precipitate formed. The slurry was allowed to cool to room température and stirred for 4 hours. After the solid was removed by filtration, the filtrate was evaporated and purified by column chromatography to obtain compound 3_35_5 (2.7 g, 87 % yield).

[00274] *H NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 3.82 (d, J = 4.44 Hz, 2H), 4.11 (d, J = 4.8 Hz, 2H), 6.08 (s, 2H), 6.15 (br s, 2H), 6.90 (d, J = 8.9 Hz, 2H), 7.64 ( d, J =8.9 Hz, 2H), 8.86 (br s, IH).

3.36 4-f2-Amlnooxy-2-methyl-propoxy]-ben2amidine

O step 1 o step 2 q

3_36_¹ ° 3_3β_2 3_36_3 step 6

BoCjO step 3

LAH.THF step 4

HQ. MeOH

3_36_7 O_x

7N NHj, MeOH step 7

BocHN._Qù<^,OH

3_36_S

HA₀X^°

3_36_8

Step 1: 2-(l,3-Dioxo-l,3-dihydro-isoindol-2-yloxy)-2-methyl-propionic acid ethyl ester (3_36_2) [00275] N-Hydroxyphthalimide (8.36 g, 51.27 mmol) was added dropwise to a solution of compound 3_36_1 (10.0 g, 51.26 mmol) in dry N,N-dimethylformamide (70 mL) followed by l,8-diazabicyclo[5.4.0]undec-7-ene (7.7 mL, 51.27 mmol) during 20 minutes. The mixture was stirred at 35’C for 3 days, concentrated under vacuum and the residue was suspended in ethyl acetate (200 mL) and washed successively with cold 0.5 M hydrochloric acid, water and brine. The organic extract was dried over anhydrous sodium sulfate and evaporated to afford the title compound 3_36_2 (14.0 g, 98 % yield), which was used in the next step without further purification.

(00276) ’H NMR (400 MHz, DMSO-d₆): δ = 1.21 (t, J = 7.0 Hz, 3H), 1.50 (s, 6H), 4.12 (d, J = 7.0 Hz, 2H), 7.86 (s,4H).

[00277] MS: m/z (ES* %) 278 (M+H, 35) 204 (100), 186 (20), 164 (35), 115 (45).

Step 2: 2-Aminooxy-2-methyl-propionic acid ethyl ester (3_36_3) [00278] Hydrazine hydrate (1.01 mL, 18.7 mmol) was added to a suspension of compound 3_36_2 (4.95 g, 17.8 mmol) in absolute éthanol (50 mL) and the mixture was stirred at 40‘C for 2 hours. The suspension was cooled to 20’C, filtered, washed with éthanol and the filtrate was evaporated. The residue obtained was triturated with ethyl acetate (50 ml) and filtered. The filtrate was concentrated to obtain compound 3_36_3 (1.9 g, 73 % yield) as a white solid.

[002791 *H NMR (400 MHz, DMSO-d₆): δ = 1.18 (t, J = 7.1 Hz, 3H), 1.25 (s, 6H), 4.06 (q, J = 70 Hz,2H),5.81 (brs,2H).

[00280] MS: m/z (ES*, %) 148 (M+H, 100)

Step 3: N-Boc-2-Aminooxy-2-methyl-propionic acid ethyl ester (3_36_4) [00281] Di-tert-butyldicarbonate (BOC₂0,2.82g, 12.92 mmol) was added to a solution of compound 3_36_3 (1.9 g, 12.92 mmol) in dry tetrahydrofuran (25 mL) and the mixture was stirred at room température for 16 hours and evaporated under vacuum. The residue obtained was purified by chromatography to obtain compound 3_36_4 (2.3 g, 72 % yield) as a clear thick oil.

[00282] *H NMR (400 MHz, DMSO-d₆): δ = 1.10-1.29 (m, 3H), 1.32 (s, 3H), 1.39 (s, 3H), 1.47 (s, 9H), 3.96-4.19 (m, 2H), 9.55 (s, IH).

[00283] MS: m/z (ES*, %) 248 (M+H, 60), 192 (100), 175 (8), 115 (18).

Step 4: N-Boc-2-Aminooxy-2-methyl-propan-l-ol (3_36_5) [00284] Lithium aluminium hydride (LAH, IM in tetrahydrofuran, 13.45 mL, 11.33 mmol) was added dropwise to a cold (0*C) solution of compound 3_36_4 (1.9 g, 7.68 mmol) in dry diethyl ether (35 mL) over 15 minutes. The reaction mixture was stirred at 0*C for 5 hours and quenched by pouring into a cold (0*C) saturated ammonium chloride solution. The aqueous phase was extracted with ethyl acetate (2 χ 75 mL) and the combined organic extracts were filtered through Celite, washed with water, brine, dried over anhydrous sodium sulfate and evaporated to yield compound 3_36_5 (1.1 g, 70 % yield) as a solid. (χΤ-17341 [00285] *H NMR (400 MHz, DMSO-d_s): δ = 1.05 (s, 6H), 1.40 (s, 9H), 3.21 (d, J = 6.6 Hz, 2H), 4.43 (t, J = 6.6 Hz, 2H), 9.58 (d, J = 3.9 Hz, 1H).

Step 5: N-Boc-4-(2-Aminooxy-2-methyl-propoxy)-benzonitrile (3_36_6) [00286] Sodium hydride (60 % in minerai oil, 0.41g, 10.24 mmol} was added in portions to a cold (10*C) solution of compound 3_36_5 (0.7 g, 3.41 mmol) In dry tetrahydrofuran (9 mL) under a nitrogen atmosphère. After stirring for 15 minutes 4-fluorobenzonitrile (0.496 g, 4.09 mmol) was added dropwise and the mixture was refluxed for 3 hours, stirred at 50’C for 16 hours, cooled to room température, poured into cold water, acidified with acetic acid (1.5 mL) and extracted into ethyl acetate (3 * 75 mL). The combined organic extracts were filtered through Celite, washed with water and brine, dried over anhydrous sodium sulfate, evaporated and the residue was purified by column chromatography to obtain compound 3.36.6 (0.75 g, 72 % yield) as an off-white solid.

[00287] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.23 (s, 6H), 1.37 (s, 9H), 3.94 (s, 2H), 7.09 (m, J = 8.9 Hz, 2H), 7.76 (m, J = 8.9 Hz, 2H), 9.55 (s, 1H).

[00288] MS: m/z (ES, %) 305 (M+H, 98), 218 (100), 204 (8).

Step 6: 4-(2-Aminooxy-2-methyl-propoxy)-benzimidic acid methyl ester hydrochloride sait (3.36.7) [00289] A solution of compound 3_36_6 (0.75 g, 2.45 mmol) in anhydrous methanol (20 mL) in a pressure reaction vessel (100 mL) at -10*C was saturated with dry hydrogen gas and the sealed vessel was stirred at room température for 18 hours. The réaction mixture was concentrated to half the volume, diluted with diethyl ether (75 mL), stirred, filtered, washed with diethyl ether and dried under vacuum to obtain compound 3_36_7 (0.7 g, 70 % yield) as a white powder, which was used in the next step without purification.

[00290] ^XH NMR (400 MHz, DMSO-d_s): δ = 1.44 (s, 6H), 4.14 (br s, 3H), 4.22-4.38 (m, 2H), 7.24 (m, J = 8.9 Hz, 2H), 8.16 (m, J = 8.9 Hz, 2H), 11.08 (br s, 3H).

[00291] MS: m/z (ES* %) 239 (M*H, 45), 206 (100), 174 (15), 152 (90), 104 (30)

Step 7: 4-(2-Aminooxy-2-methy1-propoxy)-benzamidine (3_36_8) [00292] Ammonia (7W in methanol, 3.0 mL) was added to a suspension of compound 3_36_7 (0.70 g, 2.55 mmol) in anhydrous methanol (10 mL) at 20*C and the mixture was stirred at 5 room température for 1 hour. The reaction mixture was concentrated and the residue was triturated with hexanes/ether (1:1,50 ml), fiîtered, washed with hexanes/ether (1:1) and dried under vacuum to obtain the title compound 3_36_8 (0.55g, quant.) as a white powder.

[00293] ’H NMR (400 MHz, DMSO-d₆): δ = 1.17 (s, 6H), 3.99 (s, 2H), 7.15 (d, J = 9.0 Hz, 2H), 7.82 (d, J = 9.0 Hz, 2H), 8.96 (br s, 2H), 9.19 (br s, 1H).

[00294] MS: m/z (ES* %) 224 (M*H, 100), 199 (74), 191 (82), 137 (7).

3.37 4-(2-Aminooxy-l,l-dimethyl-ethoxy)-benzam ldi ne

N-Hydroxyphthalimide

DIAD, PPhj, THF

Irydrazine hydrate step

HO, MeOH

HCI

Η,Ν-Ο^Κ?

step 5

3_37_6

7N NHj, MeOH step 6

3_37_7

Step 1: 2-(4-Cyano-phenoxy)-2-methyl-propionic acid ethyl ester (3_37_2) [00295] Potassium carbonate (14.16 g. 102.5 mmol) was added to a solution of compound 3_37_1 (10.0 g, 51.27 mmol) în dry N,N-dimethylformamîde (70 ml) followed by 4cyanophenol (6.7 g, 61.52 mmol) at room température and the reaction mixture was heated at 60*C for 16 hours. The reaction mixture was cooled to room température, filtered, washed with N,fl-dimethylformamide and the filtrate was concentrated under vacuum. The residue was dissolved in ethyl acetate (300 ml), washed with a cold, aqueous 0.5 M sodium hydroxide solution (3 χ 30 mL), water and brine, dried over anhydrous sodium sulfate and evaporated. The crude product was purified by column chromatography to afford compound 3_37_2 (3.1 g, 26 % yield) as a clear liquid.

[002961 *H NMR (400 MHz, DMSO-d₆): δ = 1.12 (t, J = 7.03 Hz, 3H), 1.58 (s, 6H), 4.15 (d, J = 7.0 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 7.73 (d, J = 9.0 Hz, 2H).

Step 2: 4-(2-Hydroxy-l,l-dimethyl-ethoxy)-benzonitrile (3_37_3) [00297] Sodium borohydride (2.3 g, 60.76 mmol) was added in portions to a cold (5*C) solution of compound 3_37_2 (4.7 g, 20.17 mmol) in anhydrous methanol (50 mL) over 10 minutes. The mixture was stirred at room température for 16 hours and the suspension was concentrated to remove most of the methanol. The residue was partitioned between a cold saturated ammonium chloride solution and ethyl acetate (150 mL each). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (50 mL). The combined organic extracts were washed with water and brine, dried over anhydrous sodium sulfate and evaporated. The crude product obtained was purified by column chromatography to give compound 3_37_3 (3.2 g, 79 % yield) as a colorless liquid.

[00298] *H NMR (400 MHz, DMSO-d₆): δ = 1.26 (s, 6H), 3.41 (d, J = 5.86 Hz, 2H), 5.00 (t, 1H), 7.16 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 Hz, 2H).

Step 3: 4-[2-(l,3-Dioxo-l,3-dihydro-isoindol-2-yloxy)-l,l-dimethyl-ethoxy]-benzonitrile (3_37_4) [002991 Triphenylphosphine (2.31 g, 8.79 mmol) was added to a mixture of compound 3_37_3 (1.6 g, 8.37 mmol) and N-hydroxyphthalimide (1.43 g, 8.79 mmol) in tetrahydrofuran (20 mL), and the mixture was sonicated for 20 minutes, and treated with diisopropyl azodicarboxylate (DIAD, 1.73 mL, 8.79 mmol). The reaction mixture was stirred at room température for 20 hours, concentrated and the residue was purified by column chromatography to give compound 3_37_4 (1.6 g, 57 % yield) as an off-white solid, which was used in the next step without further purification.

Step 4: 4-(2-Aminooxy-l,l-dimethyl-ethoxy)-benzonitrile (3_37_5) [00300] Hydrazine hydrate (0.24 mL, 4.99 mmol) was added to a solution of compound 3_37_4 (1.6 g, 4.75 mmol) in absolute éthanol (30 mL) and the mixture was stirred at 35*C for 2 hours. The resulting suspension was cooled to 20’C, filtered, washed with éthanol and evaporated. The residue was triturated in ethyl acetate (50 mL), filtered and the filtrate was evaporated to obtain compound 3_37_5 (1.0 g, 100% yield), which was used in the next step without purification.

[00301] ’H NMR (400 MHz, DMSO-d₆): δ = 1.29 (s, 6H), 3.61 (s, 2H), 6.17 (s, 2H), 7.16 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 Hz, 2H).

Step 5: 4-(2-Aminooxy-l,l-dimethyl-ethoxy)-benzimidic acid methyl ester (3_37_6) [00302] A solution of compound 3_37_5 (1.6 g, 4.85 mmol) in anhydrous methanol (20 mL) at -10*C was saturated with dry hydrogen chloride gas and the sealed vessel was stirred at room température for 18 hours. The reaction mixture was concentrated to half the volume, diluted with diethyl ether (75 mL), stirred, filtered, washed with diethyl ether and dried under vacuum to obtain compound 3_37_6 (1.6 g, >100% yield) as a white powder, which was used in the next step without purification.

[00303] *H NMR (400 MHz, DMSO-d₆): δ = 1.37 (s, 6H), 4.13 (s, 2H), 4.24 (s, 3H), 7.27 (d, J = 8.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H).

Step 6: 4-(2-Aminooxy-l,l-dimethyl-ethoxy)-benzamidine (3_37_7) [003041 Ammonîa (7 N in methanol (7.5 mL, 52.5 mmol) was added to a suspension of compound 3_37_6 (1.6 g, 4.85 mmol) in anhydrous methanol (150 mL) at 20’C and the mixture was stirred at 35*C for 1.5 hours and concentrated. The residue was triturated in a mixture of hexanes/ether (50 mL, 1:1), filtered, washed with hexanes/ether (1:1) and dried under vacuum to afford compound 3_37_7 (1.0 g, 93 % yield) as a white powder.

3.38 tert-8utyl [{2-[2-{aminooxY)ethoxy]-l,3-thiazol-4-yl}(imino)methyl]carbamate step 1

CONH.

THP-O step 4 step 7

POClyTEA

THP-O'^^x~^x°^Na ______THP-O

N-Ov^-o

PhjP.DEAD step 9

O 3_38_10

THP-O

1. CtCO₂Et, TEA

2. aqNH

NH-Boc H/JNHj

Ethytene glycol step 5

Boc-0

HQ, MeOH

NH-Boc

NH-Boc step 10

Step 1: 2-[2-{Tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxylicacid ethyl ester (3_38_2) [00305] Sodium hydride (60 % dispersion in oil, 1.69 g, 42.4 mmol) was added to a solution of 2-(tetrahydro-pyran-2-yloxy)-ethanol (6.19 g, 42.4 mmol) in N.N-dimethylformamide (20 mL). After stirring at 0’C for 1 hour, 2-bromo-thiazole-4-carboxylic acid ethyl ester 3_38_1 (10.0 g, 42.4 mmol) in N,N-dimethylformamide (10 mL) was added at 0*C and the resulting mixture was stirred at 0*C for 2.5 hours. The reaction mixture was neutralized to pH 7 using acetic acid at 0’C, diluted with ethyl acetate (150 mL) and washed with brine. The organic layer was dried over m/ sodium sulfate and concentrated. The residue was purified by column chromatography to give the desired product (99.4 g, 73 % yield) as a white solid.

[00306] *H NMR (400 MHz, DMSO-d₆): δ = 1.28 (t, J = 7.2 Hz, 3H), 1.37 -1.53 (m, 4H), 1.56-1.78 (m, 2 H), 3.38-3.48 (m, 1H), 3.66-3.80 (m, 2H), 3.85 - 3.98 (m, 1H), 4.26 (q, J = 7.0 Hz, 2H), 4.37 - 4.46 (m, 1H), 4.52 - 4.59 (m, 1H), 4.64 (br s, 1H), 7.93 (s, 1H).

Step 2: 2-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxylic acid (3_38_3) [00307] A solution of lithium hydroxide (1.26 g, 52.6 mmol) in water (35 mL) was added to a solution of 2-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxylic acid ethyl ester 3_38_2 (3.17 g, 10.5 mmol) in tetrahydrofuran (45 mL). After stirring at room température for 2 hours, the reaction mixture was neutralized to pH 7 using dilute hydrochloric acid at 0*C, diluted with ethyl acetate (150 mL) and washed with brine. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by column chromatography to give the desired product (2.9 g, 100 % yield) as a white solid.

[00308] *H NMR (400 MHz, DMSO-d₆): δ = 1.35-1.54 (m, 4H), 1.57-1.76 (m, 2H), 3.393.47 (m, 1H), 3.67-3.81 (m, 2H), 3.90-3.98 (m, 1H), 4.50-4.58 (m, 2H), 4.64 (br s, 1H), 7.85 (s, 1H).

Step 3: 2-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxylic acid amide (3_38_4) [00309] Triethylamine (TEA, 1.22 g, 12.07 mmol) was added to a solution of 2-[2(tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxylic acid 3_38_3 (3.0 g, 11.0 mmol) in tetrahydrofuran (60 mL), followed by ethyl chloroformate (1.31 g, 12.07 mmol) slowly at -10*C. After stirring at room température for 1.5 hour, concentrated ammonium hydroxide (0.80 g, 13.17 mmol) was slowly added to the reaction mixture at O’C and the resulting mixture was stirred at room température for 1 hour. The reaction mixture was concentrated, diluted with ethyl acetate (150 mL) and washed with brine. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by column chromatography to give the desired product (1.76 g, 59 % yield) as a white solid.

[00310] *H NMR (400 MHz, DMSO<): δ = 1.33-1.53 (m, 4H), 1.55-1.79 (m, 2H), 3.383.51 (m, 1H), 3.66-3.82 (m, 2H), 3.87-4.00 (m, 1H), 4.43-4.74 (m, 3H), 7.44-7.57 (m, 2H}, 7.62 (s, 1H).

[00311] MS (ES*) m/z: [M+H]* calcd for CnHpNjC^S: 273.33. Found: 273.24.

Step 4: 2-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carbonïtrile (3_38_5) [00312] Triethylamîne (ΊΈΑ, 7.625 g, 75.3 mmol) was added to a solution of 2-[2(tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxylic acid amide 3_38_4 (1.71 g, 6.28 mmol) in dïchloromethane (50 mL) at O’C. Phosphores oxychloride (2.407 g, 15.70 mmol) was slowly added to the reaction mixture at O'C and the resulting mixture was stirred at room température for 1 hour. The reaction was quenched with ice-water (20 mL), extracted with ethyl acetate and the extract was washed with brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel column to give the desired product (1.42 g, 88.9 %) as a white solid.

[00313] ’H NMR (400 MHz, DMSO-t/₆): S = 1.38-1.55 (m, 4H), 1.57-1.79 (m, 2H), 3.383.51 (m, 1H), 3.67-3.79 (m, 2H), 3.87-4.00 (m, 1H), 4.49-4.71 (m, 3H), 8.25 (s, 1H).

[00314] MS (ES*) m/z: [M+H]* calcd for CnH^N^S: 255.31. Found: 255.20.

Step 5: 2-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboximidic acid 2-hydroxy-ethyl ester (3_38_6) [00315] Sodium (0.036 g, 1.56 mmol) was added to a flask containing ethylene glycol (1.33 g, 5.23 mmol) at room température. After ail sodium was consumed, 2-[2-(tetrahydropyran-2-yloxy)-ethoxy]-thiazole-4-carbonitrile 3_38_5 (1.33 g, 5.23 mmol) in tetrahydrofuran (10 mL) was added at O’C and the reaction mixture was stirred at room température ovemight. The reaction mixture was neutralized to pH 7 using acetic acid and diluted with ethyl acetate. The mixture was washed with brine, dried and concentrated to afford the desired product (1.52 g, 92% yield) as a white solid, which was used without purification.

[00316] ²H NMR (400 MHz, DMSO-cf₆): δ = 1.35-1.53 (m, 4H), 1.58-1.76 (m, 2H), 3.413.48 (m, IH), 3.66-3.79 (m, 4H), 3.89-3.98 (m, IH), 4.19 (t, J = 5.0 Hz, 2H), 4.54-4.61 (m, 3H), 4.64 (d, J = 2.9 Hz, 2H), 7.48 (s, IH), 8.31 (br s, IH).

[00317] MS (ES*) m/z: [M+H]* calcd for C₁₃H₂₁N₂O₅S: 317.38. Found: 317.27.

Step 6: 2-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxamidine (3_38_7) [00318] Ammonium chloride (0.302 g, 5.65 mmol) was added to a mixture of 2-[2(tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboximîdic acid 2-hydroxy-ethyl ester 3_38_6 (1.49 g, 4.71 mmol) in methanol (40 mL) and the mixture was refluxed for 6.5 hours and concentrated to dryness to afford the crude product which was purified by column chromatography to give the desired product (1.35 g, 100 %) as a white solid.

[00319] ^:H NMR (400 MHz, DMS0-d₆): δ = 1.44 (m, 4H), 1.54-1.79 (m, 2H), 3.38-3.48 (m, H), 3.66-3.80 (m. H), 3.85-4.00 (m, IH), 4.54-4.73 (m, 3H), 8.39 (s, IH), 9.20 (br s, 4H).

[00320] MS (ES*) m/z: [M+H]* calcd for CnH^N^OjS: 272.34. Found: 272.23.

Step 7: 2-(2-Hydroxy-ethoxy)-thiazole-4-carboxamidine hydrochloric acid (3_38_8) [00321] Concentrated hydrochloric acid (0.1 mL) was added to a mixture of 2-[2(tetrahydro-pyran-2-yloxy)-ethoxy]-thiazole-4-carboxamidine 3_38_7 (1.25 g, 4.61 mmol) in methanol (10 mL) and the mixture was stirred at room température for 1 hour and concentrated to dryness to afford compound 3_38_8 as crude product (0.92 g, 91 % yield) as a white solid.

[00322] ’H NMR (400 MHz, DMSO-d₆): δ = 3.67-3.77 (m, 2H), 4.43-4.53 (m, 2H), 8.40 (s, IH), 9.14 (s. H), 9.24 (s, 2H).

[00323] MS (ES*) m/z: [M+HJ* calcd for CeHioNjOjS: 188.22. Found: 188.20. vK

Step 8: {[2-(2-Hydroxy-ethoxy)-thiazol-4-yl]-imino-methyl}-carbamic acid tert-butyl ester (3.38.9) [00324] A saturated sodium bicarbonate solution (15 mL) and a solution of di-tertbutyldicarbonate (BOC₂O,1.346 g, 6.17 mmol) in 1,4-dioxane (10 mL) were added to a solution of 2-(2-hydroxy-ethoxy)-thiazole-4-carboxamidine hydrochloric acid 3_38_8 (0.92 g, 4.11 mmol) in water (5 mL) at room température. After stirring at room température ovemight, the resulting mixture was concentrated and the residue was extracted with ethyl acetate. The extract was washed with brine, dried over sodium sulfate and concentrated to dryness. The crude product was purified by column chromatography to give the desired product (0.68 g, 58 % yield) as a white solid.

[00325] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 3.6S-3.78 (m, 2H), 4.47 (t, J = 4.7 Hz, 2H), 4.96 (t, J = 5.4 Hz, 1H), 7.79 (s, 1H), 8.32 (br s, 1H), 9.09 (br s, 1H).

[00326] MS (ES*) m/z: [M+H]* calcd for CnH₁₈N_îO₄S: 288.34. Found: 288.20.

Step 9: ({2-[2-(l,3-Dioxo-l,3-dihydro-isoindol-2-yloxy}-ethoxy]-thiazol-4-yl}-iniino-methyl)carbamic acid tert-butyl ester (3.38.10) [00327] N-Hydroxyphthalimide (0.393 g, 2.41 mmol) and triphenylphosphine (0.690 g, 2.63 mmol) were added to a solution of {[2-(2-hydroxy-ethoxy)-thiazol-4-yl]-imino-methy1]carbamic acid tert-butyl ester 3.38.9 (0.63 g, 2.19 mmol) in anhydrous tetrahydrofuran (40 mL) at room température. A solution of diethyl azodicarboxylate (DEAD, 0.458 g, 2.63 mmol) in tetrahydrofuran (20 mL) was added dropwise to the resulting solution at 20*C and the resulting mixture was stirred at room température ovemight. After évaporation of the tetrahydrofuran, the crude product was purified by column chromatography to give the desired product (1.02 g, 100 % yield) as a white solid.

[00328] *H NMR (400 MHz, DMSO-d₆): δ = 1.41 (s, 9 H), 4.53-4.65 (m, 2 H), 4.70 - 4.83 (m, 2 H), 7.81 {s, 1 H), 7.85 (s, 4 H).

[00329] MS (ES*) m/z: [M+H]* calcd for C₁₉H₂₁N₄O₆S: 433.46. Found: 433.34.

Step 10:3.38. tert-Butyl [{2-[2-(aminooxy)ethoxy]-l,3-thiazol-4-yl}(imino)methyl]carbamate (3_38_11) [00330] Hydrazine monohydrate (0.127 g, 2.54 mmol) was added to a solution of ({2-[2(l,3-dioxo-l,3-dihydro-isoîndol-2-yloxy)-ethoxy]-thiazol-4-yl}-imino-methyl)-carbamicacid tert5 butyl ester 3_38_10 (1.0 g, 2.31 mmol) in anhydrous éthanol (15 ml) and tetrahydrofuran (10 mL) at 0*C and the resulting mixture was stined at room température for 2.5 hours. After concentration, the residue was stirred with ethyl acetate/hexanes (2:1,20 mL) and filtered. The filtrate was concentrated to afford the desired product (0.6 g, 86 % yield) as a white solid.

[00331] ^XH NMR (400 MHz, DMSO-tf₆): δ = 1.42 (s, 9H), 3.78 - 3.89 (m, 2H), 4.57-4.64 (m, 2H), 6.12 (s, 2H), 7.79 (s, 1H), 8.36 (br s, 1H), 9.09 (br s, 1H).

339 te rt-Butyl [{5-[2-(a mInooxy)ethoxy)-l,3,4-thiadiazol-2-yl}(imi no)methyl]ca rba mate n

3-39,1 step 1

CuBr, t-BuONO

3_39_2

1. NaOMe. MeOH

2. nh₄q

THPO^O^S^*^CN ^S'^ep4 3-39-5

TF AA. TEA (BocJ^O J N NH —T step 7 NHBoc

3.39.8 step 2

HQ. MeOH step 5 step 6 step 8

ΝΗ.ΟΗ

N-hydroxyphthallmide

tep3 NH,

NHBoc step 9

I^nh ho^o^as^ NH.

3_39 7

TH PO-/^-'o^_S

3_39 8

3_39_4

NH

NHBoc

3_39_10

Step 1: 5-Bromo-[l,3,4]thiadiazole-2<arboxylic acid ethyl ester (3_39_2) [00332] CuBr₂ (18.06 g, 80.1 mmol) was added to a suspension ofS-amino[l,3,4]thiadiazo!e-2-carboxylic acid ethyl ester 3_39_1 (7 g, 40.5 mmol) In 150 mL of acetonitrile, the mixture was stirred for 15 min, t-BuONO (9.6 mL, 80.1 mmol) was added over 20 min., and the mixture was heated at 60’C for 0.5 h. Water and ethyl acetate were added, the mixture was stirred untîl the dark color disappeared and filtered through celite, and the organic layer was y' washed with brine, dried over Na₂SO₄, filtrated and concentrated to give compound 3_39_2 (7.56 g, 79 % yield) as a yellow solid.

[00333] ’H NMR (400 MHz, DMSO-d_fi): δ = 1.32 (t, J = 7.14 Hz, 3 H), 4.41 (q, J = 7.30 Hz, 2 H);

Step 2: 5-Bromo-(l,3,4]thiadiazole-2-carboxvlic acid amide (3_39_3) [00334] NH«OH (50 % aq solution, 6.45 ml) was added to a solution of compound 3_39_2 (7.56 g, 31.8 mol) in 70 mL of tetra hydrofuran, and the mixture was stined at room température for 16 h and concentrated to give a solid, which was triturated with ether, filtered, and dried to give compound 3_39_3 (6.5 g, 98 % yield) as a yellow solid.

[00335] ’H NMR (400 MHz, DMSO-d₆): δ = 8.26 (br. s., 1 H), 8.64 (br. s., 1 H).

Step 3: 5-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-[l,3,4] thiadiazole-2-carboxylic acid amide (3_39_4) [00336] NaH (1.6 g, 40.2 mmol) was added to a solution of compound 3_39_3 (4.16 g, 20.1 mmol) in 20 mLof Ν,Ν-dimethylformamide, and the mixture was stirred at room température for 20 min. 2-(Tetrahydro-pyran-2-yloxy)-ethanol (3.81 mL, 26.1 mmol) was added, and the mixture was heated at 50-60’C for 3 h, concentrated, diluted with ethyl acetate, washed with brine, dried over Na₂SO₄, filtered and concentrated to give a residue, which was purified by column chromatography to give compound 3_39_4 (2.15 g, 40 % yield) as a gum.

[00337] ’H NMR (400 MHz, CDCIj): δ = 1.45 -1.70 (m, 4 H), 1.69 -1.92 (m, 2 H), 3.54 (m, 1 H), 3.79 - 3.94 (m, 2 H), 4.05 - 4.15 (m, 1 H), 4.68 (t, J = 3.49 Hz, 1 H), 4.77 (dt, J = 6.03,3.01 Hz, 2 H), 5.90 (br. s., 1 H), 7.08 (br. s., 1 H).

Step 4: 5-(2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-[l,3,4]thiadiazole-2-carbonitrile (3_39_5) [00338] Trifluoroacetic anhydride (TFAA, 1.13 mL, 8.46 mmol) was added to a solution of compound 3_39_4 (2.1 g, 7.69 mmol) and triethylamine (TEA, 1.13 mL, 8.64 mmol) in tetrahydrofuran (20 mL) at 0⁵C, and the mixture was warmed to room température, and stirred for 1 hour. Additional 0.4 mL of trifluoroacetic anhydride and 3 mL of triethylamine were added and the mixture was stirred at room température for 16 h, diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution and brine, dried over Na₂SO₄, Altered, and concentrated to give a residue. The residue was purified by column chromatography to give compound 3_39_5 (1.3 g, 68 % yield) as a yellow oil.

[00339] *H NMR (400 MHz, CDCI₃): δ = 1.48 -1.66 (m, 4 H), 1.68 -1.88 (m, 2 H), 3.55 (t, J = 5.39 Hz, 1 H), 3.81 - 3.91 (m, 2H), 4.06 - 4.17 (m, 1 H), 4.67 (t, J = 2.86 Hz, 1 H), 4.78 - 4.93 (m, 2 H).

Step 5: 5-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-[l,3,4]thiadiazole-2-carboxamidine (3_39_6) [00340] NaOMe (0.08 g, 1.5 mmol) was added to solution of compound 3_39_5 (0.77 g, 3.02 mmol) in 15 mL of dry MeOH, and the mixture was stirred at room température for 0.5 h. NH₄CI (7.6 g, 30.1 mmol) was added, and the réaction mixture was refluxed for 20 h, concentrated, diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution and brine, dried over Na₂SO₄, filtered and concentrated to give compound 3_39_6 (0.41 g 50 % yield) as a brown gum.

[00341] ^XH NMR (400 MHz, DMSO-d₆ with one drop of trifluroacetic acid): δ = 1.32 1.52 (m, 4 H), 1.53 -1.72 (m, 2 H), 3.42 (m, 1 H), 3.67 - 3.87 (m, 2 H), 3.93 - 4.04 (m, 1 H), 4.59 4.69 (m, 1 H), 4.75 (m, 2 H), 9.66 (br. s., 2 H), 9.87 (br. s., 2 H).

Step 6: 5-(2-Hydroxy-ethoxy)-[l,3,4]thiadiazole-2-carboxamidine (3_39_7) [00342] 3 mL of IN HCl were added to a solution of compound 3_39_6 (0.41 g, 1.5 mmol) in 15 mL of MeOH at 0 ®C, and the mixture was stirred at 20 ^SC for 2 h, concentrated and lyophilized to give crude compound 3_39_7 (0.51 g, >100% yield) as a solid, which was used in the next step without purification, [00343] *H NMR (400 MHz, DMSO-de with one drop of trifluroacetic acid): δ = 3.77 (d, J = 4.12 Hz, 2 H), 4.59 (t, J = 4.44 Hz, 2 H), 9.64 (br. s., 2 H), 9.88 (br. s., 2 H).

Step 7: {[5-(2-Hydroxy-ethoxy)-[l,3,4]thiadiazol-2-yl]-imino-methyl}-cart)amic acid tert-butyl ester (3_39_8) [00344] Di-tert-butyldicarbonate (Boc₂O,0.5 g, 2.25 mmol) was added to a solution of compound 3_39_7 (0.5 g crude as obtained above) in 3 mLof a saturated sodium bicarbonate solution, 5 mL of dioxane and 2.5 mL of water, and the mixture was stirred for 16 h at room température, concentrated, diluted with ethyl acetate, washed with brine, dried over Na₂SO₄, filtered, and concentrated to give compound 3_39_8 (0.3 g, 69 % yield over two steps) as a brown oil.

[00345] ^JH NMR (400 MHz, DMSO-<f₆): δ = 1.42 (s, 9 H), 3.75 (d, J = 4.12 Hz, 2 H), 4.52 (d, J = 4.12 Hz, 2 H), 5.06 (s, 1 H).

Step 8: ({5-[2-(l,3-Dioxo-l,3-dihydro-isoindol-2-yloxy)-ethoxy]-[l,3,4]thiadiazol-2-yl}-iminomethylj-carbamic acid tert-butyl ester (3_39_9) [00346] Triphenylphosphine (0.37 g, 1.5 mmol) and diisopropyl azodicarboxylate (0.3 mL, 1.5 mmol) were added to a solution of compound 3_39_8 (0.3 g, 1 mmol) and Nhydroxyphalimide (0.17 g, 1 mmol) in 10 mL of tetrahydrofuran, at 0 ^SC, and the mixture was stirred at room température for 1.5 h, diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution and brine, dried over Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by column chromatography to give compound 3_39_9 (0.4 g, 92 % yield).

[00347] *H NMR (400 MHz, CDCI₃): δ = 1.55 (s, 9 H), 4.55 - 4.67 (m, 2 H), 4.88 - 5.00 (m, 2 H), 7.70 - 7.91 (m, 4 H).

Step 9: tert-Butyl [{5-[2-(aminooxy)ethoxy]-l,3,4-thiadiazol-2-yl](imino)methyl]carbamate (3-39-10)

100 [00348] Hydrazine hydrate (0.1 mL, 2 mmol) was added to a suspension of compound 3_39_9 (1.5 g, 2 mmol) in 6 mL of EtOH, and the mixture was stirred at room température for 4 h. The solid was removed by filtration, and the filtrate was concentrated to give a residue. The residue was dissolved in dichloromethane, filtered to remove the solid, and the filtrate was concentrated to give compound 3_39_10 (0.43 g, 71 % yield) as an oil.

[003491 ’H NMR (400 MHz, CDCI₃): δ = 1.54 (s, 9 H), 4.04 (d, J = 4.44 Hz, 2 H), 4.79 (d, J = 4.12 Hz, 2 H), 6.34 (br. s., 2 H).

3.40 tert-Butyl[(3-[2-(aminooxy)ethoxy]-l,2-oxazol-5-yl}(imino)methyl]carbamate

[00350] Following the procedure as described above under 3.38 but using ethyl 3bromo-isoxazole-5-carboxylate instead of ethyl 2-bromo-thiazole-4-carboxylate 3_38_1 compound 3_40_10 was prepared.

3.41 tert-Butyl [{3-[2-{aminooxy)ethoxy]-l-methyl-lH-pyrazo1-5-yl}(imino)methyl]carbamate

ΙΟΙ

NH₂NHMe

H^SO, step 1

_ho^^othp

PPhjDIAD.THF step 2

41 3 ο^ότηρ

MeO₂C—=—CO₂Me

3_41_1

4110

Step 1: Methyl 3-hydroxy-l-methyl-lH-pyrazole-5-carboxylate (3_41_2) [OO35I] Triethylamine (66 mL 474.4 mmol) was added to a solution of methylhydrazine sulfuric acid sait (30.4 g, 211 mmol) in water (150 ml) and methanol (300 mL) at room température. The mixture was stirred for 0.5 hour at room température, but-2-ynedioic acid dimethyl ester (30 g, 211 mmol) was added and the mixture was stirred for 18 hours at 70*C. The reaction mixture was kept at room température for two days and the solid was collected by filtration and dried to give 12 g of the desired compound. The filtrate was concentrated, treated with ice and the solid was collected by filtration, and dried to give an additional 5 g of the desired compound 3_41_2 (17 g, 52 % yield) as a yellow solid.

[00352] NMR (400 MHz, DMSO-d₆): δ = 3.79 (s, 3H), 3.88 (s, 3H), 6.01 (s, IH), 10.05 (S, IH).

Step 2:2-Methyl-5-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-2H-pyrazole-3-carboxylic acid ethyl ester (3_41_3) [00353] Diisopropyl azodicarboxylate (DIAD, 41.6 mL, 205.8 mmol) was added to a solution of 3_41_2 (10.7 g, 68.6 mmol), 2-(tetrahydro-pyran-2-yloxy)-ethanol (17 mL 102.9 mmol) and triphenylphosphine (53.9 g, 205.8 mmol) at O’C, and the mixture was stirred at room température for 16 hours. The reaction mixture was heated at 80’C for 16 hours, more 2(tetrahydro-pyran-2-yloxy)-ethanol (3.75 mL), triphenylphosphine (5.3 g) and diisopropyl azodicarboxylate (3 mL) were added, and the reaction mixture was refluxed for 16 hours, concentrated

102 and treated with diethyl ether and hexanes (2:3,500 ml) to give a precipitate, which was removed by filtration. The filtrate was concentrated and the residue obtained was purified by column chromatography to give compound 3_41_3 (26.6 g, >100 % yield, conta mïnated with dîisopropyl azodicarboxylate) as a yellow oil.

[00354] ^XH NMR (400 MHz, CDCI₃): δ = 1.45-1.90 (m, 6H), 3.52 (d, J=11.4 Hz, IH), 3.793.92 (m, 5H), 3.95-4.10 (m, 5H), 4.31 (t, J=4.9 Hz, 2H), 4.69 (t, J=35 Hz, IH), 6.21 (s, IH).

[00355] Following the procedure as described above under 3.38 intermediate 3_41_3 was converted to compound 3_41_10.

3.42 tert-Butyl [{5-[2-(aminooxy)ethoxy]-l-methyi-lH-pyrazol-3-yl}(imino)rnethy1]carbamate

as described for 3_41_10 and 3_38_t0

NHBoc

3_42_10 [00356] Using ethyl 5-hydroxY-l-methyl-lH-pyra2ole-3-carboxyiate 3_42_1 (EP

1990336,2008) as the starting material and following the conditions described under 3.41 and

3.38 compound 3_42_10 was prepared.

3.43 4-[2-fAminooxy}ethoxy]-5-methYl-l,3-thiazole-2-carboxImidamide

43 1

Step 1: 5-Hydroxy-l-methyl-lH-pyrazole-3-carboxYlic acid ethyl ester (3_43_2) tV''^-’

103 [00357] Pyridine (2 mL) was slowly added to a mixture of 2-mercaptopropionic acid (10 g, 94 mmol) and nitriloacetic acid ethyl ester 3_43_1 (8.77 g, 94 mmol) at 0*C, and the mixture was stirred for 1 hour and then heated at 100’C for 2 hours. After cooling, éthanol (100 mL) was added and the reaction mixture was stined at room température for 1 hour to give a suspension, which was collected by filtration, washed with diethyl ether, and dried to give compound 3_43_2 (104 g, 60 % yield) as a white solid.

[00358] ’H NMR (400 MHz, DMSO-d₆): δ = 1.27 (td, J = 7.2,1.9 Hz, 3H), 2.23 (d, J = 1.9 Hz, 3H), 4.29 (dd, J = 7.0,1.9 Hz, 2H).

[00359] Following the conditions as described under 3.41 and 3.38 the intermediate

3_43_2 was converted to compound 3_43_10.

3.44 4-[2-(Amlnooxy)ethoxy]-2-hydroxybenzenecarboximidamlde

HO, EtOH step 3

H₂N

as for prevnus examples

Step 1: 2-Fluoro-4-(2-hydroxy-ethoxy)-benzonitrile (3_44_2) [00360] Anhydrous potassium carbonate (10.0 g, 72.4 mmol) was added to a solution of 2-fluoro-4-hydroxy-benzonitrile 3_44_1 (5.0 g, 36.5 mmol) in N,N-dîemthylformamide (50 mL). The resulting mixture was stirred at room température for 10 minutes, and 2-bromoethano! (13.5 g, 7.7 mL, 108.0 mmol) was added dropwise over 15 minutes. The resulting mixture was stirred at room température for 3 days. TLC showed the reaction was incomplète. Additional 2

104 bromoethanol (3 mL) was added and the reaction mixture was stirred for another day, poured into water (300 mL) and extracted with ethyl acetate (3 x 50 mL). The combined ethyl acetate layers were washed with a saturated sodium bicarbonate solution, water and brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to give compound 3_44_2 (5.0 g, 76 % yield) as a white solid.

[00361] *H NMR (CDCIj, 400 MHz): δ = E3.99 - 4.01 (m, 2H), 4.02 - 4.14 (m, 2H), 6.73 6.81 (m, 2H), 7.51 - 7.55 (m, 12H).

Step 2 and 3: 2-(3-Amino-benzo[d]isoxazo!-6-yloxy)-ethanol (3_44_4) [00362] Potassium tert-butoxide (6.5 g, 58.0 mmol) was added in portions to a solution of acetone acetone oxime (4.2 g, 58.05 mmol) in W,W-dimethylformamide (100 mL). The resulting mixture was stirred at room température for 1 hour, and a solution of compound 3_44_2 (S.O g, 27.6 mmol) in Ν,Ν-diemthylformamide (20 mL) was added dropwise. The resulting mixture was stirred at room température for 3 hours. The reaction mixture was poured into a saturated ammonium chloride solution (600 mL) and extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate layers were washed with water and brine, dried over sodium sulfate and concentrated under reduced pressure to give crude intermediate 3_44_3 (5.3 g, yellow oil). The intermediate 3_44_3 was dissolved in éthanol (100 mL) and 2N hydrochloric acid solution (100 mL) and heated under reflux for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (200 ml), and washed with a saturated sodium bicarbonate solution, water and brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to give 3_44_4 (1.9 g, 35 % yield) as a white solid.

[00363] ’H NMR (MeOH-d«, 400 MHz): δ = B3.90 (t, J = 4.8 Hz, 2H), 4.11 (t, J = 4.8 Hz, 2H), 6.87 - 6.93 (m, 2H), 7.45 (d, J = 8.4 Hz, 1H).

Step 4: 2-Hydroxy-4-(2*hydroxy-ethoxy)-benzamîdine (3_44_5) v*-*·'

105 [00364] Palladium on charcoal (5 % wet, 1.5 g, ~50 % water) was added to a solution of compound 3_44_4 (1.9 g, 7.7 mmol) in methanol (100 mL) and the mixture was hydrogenated at 1 atmosphère with a balloon for 31 hours. TLC showed completion ofthe reaction. The catalyst was removed by filtration through a bed of celite and washed with methanol (2 x 10 mL). The filtrate was concentrated under reduced pressure to give compound 3_44_5 (1.4 g, 73 % yield) as an offwhite solid which was used without further purification.

[00365] ^XH NMR (MeOH-d₄,400 MHz): δ = 133.84 (t, J = 4.8 Hz, 2H), 4.03 (t, J = 4.8 Hz 2H), 6.14 - 6.19 (m, 2H), 7.45 (d, J = 8.8 Hz, 1H).

[00366] MS: m/z (ES*, %) 197 (M**H, 100).

[00367] Following the conditions described in the previous examples intermediate 3_44_5 was converted via a Mitsunobu reaction with N-hydroxyphthalimide and consecutive phthalimide deprotection to compound 3_44_6.

106

3.45 Diphenylmethyl 2-iaminooxy)-3-{4-[N-(tert-butoxYcarbonyl)carbamimidoyl]phenoxy}- propanoate

HO—CN EtOjC'^

3_45_1 step 1

EtO₂C f \

HO O

3_45_2

HO, MeOH

MeO₂C

HO O step 2

3_45_3

Na OH

HO _NH NHyMeOH

OMe step 3 ,NH step 4

NHBoc

N-hydroxy- θ Ρθ^ΗΡΛϊ

MeOX /\ /=\z.^NH ^H0

MeO.C bocjO ¹

HO O

3_45_5

,NH

NHBoc

3_45_» step 5

HOÆ

HO O

3_45_6 hydrazine hydrate ,NH

NHBoc

NHBoc ^5,6,38 Π^'θ °“

3_4S_9

,NH

NHBoc

Step 1: 3-(4-Cyano-phenoxy)-2-hydroxy-propionic acid ethyl ester (3_45_2) [00368] Potassium carbonate (10.705 g, 77.5 mmol), lithium perchlorate (5.497 g, 51.7 mmol) and ethyl 2,3-epoxypropanoate (3.0 g, 25.8 mmol) were added to a solution of 4hydroxybenzonïtrile 3_45_1 (12.31 g, 0.103 mmol) in acetonitrile (100 mL). After refluxing for 4 hours, the resulting mixture was cooled and filtered. The filtrate was diluted with ice-water and neutralized to pH 7 using dilute hydrochloric acid and extracted with ethyl acetate. The extract was washed with brine, dried over sodium sulfate and concentrated. The residue was purified by column chromatography to give the desired compound 3_45_2 (2.92 g, 48 % yield) as a thick colorless oil.

[00369] *H NMR (400 MHz, DMSO-d₆): δ = 1.18 (t, J = 1.7 Hz, 3H), 4.03-4.19 (m, 2H),

4.25 (d, J = 4.4 Hz, 2H), 4.38-4.51 (m, 1H), 5.89 (d, J = 5.9 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H).

[00370] MS (ES*) m/z: [M+HJ* calcd for C₁₂H₁₄NO₄: 236.24. Found: 236.16.

Step 2: 2-Hydroxy-3-(4-methoxycarbonimidoyl-phenoxy)-propionic acid methyl ester hydrochloric acid sait (3_45_3)

107 [00371] Hydrogen chloride gas was întroduced into a solution of 3-(4-cyano-phenoxy)2-hydroxy-propionic acid ethyl ester 3_45_2 (2.10 g, 8.93 mmol) in anhydrous methanol (70 mL) at O*C for 10 minutes and the resulting mixture was stirred at room température ovemight. After concentration, the residue was stirred with diethyl ether (20 mL) for 0.5 hour and the precipitate was collected and dried to give the desired product (2.43 g, 94 % yield) as a white solid.

[00372] *H NMR (400 MHz, DMSO-d₆): δ = 3.66 (s, 3H), 4.24 (s, 3H), 4.27-4.30 (m, 2H), 4.48 (t, J = 4.4 Hz, 1H), 7.16 (d, J = 9.1 Hz, 2H), 8.09 (d, J = 9.1 Hz, 2H).

Step 3: 3-(4-Carbamimidoyl-phenoxy)-2-hydroxy-propionic acid methyl ester (3_45_4) [00373] Ammonia (7N in methanol, 3.0 mL, 20.97 mmol) was added to a mixture of 2hydroxy-3-(4-methoxycarbonimidoyl-phenoxy)-propionic acid methyl ester hydrochloric acid sait 3_45_3 (2.43 g, 8.39 mmol) in anhydrous methanol (30 mL) at 0*C and the resulting mixture was stirred at 40*C for 5 hours. The reaction mixture was concentrated to dryness to give the crude product of compound 3_45_4 (2.39 g, >100% yield) as a white solid which was used without purification.

[00374] ‘H NMR (400 MHz, DMSO-d₆): δ = 3.65 (s, 3H), 4.22-4.31 (m, 2H), 4.47 (q, J = 4.7 Hz, 1H), 5.99 (d, J = 5.9 Hz, 1H), 7.13 (d, J = 8.9 Hz, 2H), 7.85 (d, J = 8.9 Hz, 2H), 9.16 (br. s., 3H).

[00375] MS (ES*) m/z: [M+H]* calcd for CnH^N^: 239.25. Found: 239.23.

Step 4: 3-[4-(tert-Butoxycarbonylamino-imino-methy1)-phenoxy]-2-hydroxy-propionic acid methyl ester (3_45_S) [00376] A saturated sodium carbonate solution (lOmL) and di-tert-butyldicarbonate (BOCjO, 2.197 g, 10.07 mmol) were added to a solution of 3-(4-carbamimidoyl-phenoxy)-2hydroxy-propionic acid methyl ester 3_45_4 (2.35 g, crude material from previous step, 8.39 mmol) in tetrahydrofuran (30 mL) at room température. After stirring at room température for 3.5 hours, the resulting mixture was extracted with ethyl acetate. The extract was washed with

108 brine, dried and concentrated. The residue was purified by column chromatography to give the desired product (2.0 g, 66 % yield) as a white solid.

[00377] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 3.66 (s, 3H), 4.14-4.25 (m, 2H),

4.45 (t, J = 4.4 Hz, 1H), 5.88 (s, 1H), 6.98 (d, J = 8.8 Hz, 2H), 7.92 (d, J = 8.8 Hz, 2H).

Step 5: 3-[4-(tert-Butoxycarbonylamino-imino-methyl)-phenoxy]-2-hydroxy-propïonic acid (3_45_6) [00378] A solution of sodium hydroxide (0.189 g, 4.73 mmol) in water (4 mL) was added to a solution of 3-[4-(tert-butoxycarbonylamino-imino-methyl)-phenoxy]-2-hydroxy-propionic acid methyl ester 3_45_5 (0.8 g, 2.36 mmol) in tetrahydrofuran (10 mL) at 0*C. After stirring at this température for 15 minutes, the reaction mixture was neutralized to pH 7 using acetic acid and concentrated to dryness to afford the crude desired product (1.12 g) as a white solid.

[00379] ^XH NMR (400 MHz, DMSO-d₆): δ = 3.77-3.79 (m, 2H), 3.84-3.95 (m, 1H), 4.134.29 (m, 1H), 6.94 (d, J = 7.9 Hz, 2H), 7.90 (d, J = 8.2 Hz, 2H).

[00380] MS (ES*) m/z: [M+H]* calcd for CisH₂₁N₂O₆: 325.34. Found: 325.22.

Step 6: 3-[4-(tert-Butoxycarbonylamino-imino-methyl)-phenoxy]-2-hydroxy-propionic acid benzhydryl ester (3_45_7) [00381] A solution of diazo(diphenyl)methane (0.459 g, 2.36 mmol) was slowly added to a solution of 3-[4-(tert-butoxycarbonylamino-imino-methyl)-phenoxy]-2-hydroxy-propionicacid 3_45_6 (1.12 g, crude, 2.36 mmol) in methanol (10 mL).The resulting mixture was stirred at room température ovemight and concentrated to dryness. The residue was purified by column chromatography to give the desired product (0.571 g, 49 % yield) as a white solid.

[00382] ^XH NMR (400 MHz, DMS0-d₆): δ = 1.42 (s, 9H), 4.20-4.30 (m, 1Η), 4.30-4.43 (m, 1H), 4.61 (d, J = 4.4 Hz, 1H), 6.00 (d, J = 4.4 Hz, 1H), 6.85 (s, 1H), 6.95 (d, J = 9.1 Hz, 2H), 7.20-7.45 (m, 10H), 7.93 (d, J = 8.8 Hz, 2H). x/A

109 [00383] MS (ES*) m/z: [M+H]* calcd for C₃bH₃₁N₂O₆: 491.56. Found: 491.23.

Step 7: 3-[4-(tert-Butoxycarbonylamino-imino-methyl)-phenoxy]-2-(l,3-dioxo-l,3-dihydroisoindol-2-yloxy)-propionic acid benzhydryl ester (3_45_8) [00384] N-Hydroxyphthalimîde (0.205 g, 1.26 mmol) and triphenylphosphine (0.359 g, 1.37 mmol) were added to a solution of 3-[4-(tert-butoxycarbonylamino-imino-methyl)-phenoxy]2-hydroxy-propionicacid benzhydryl ester 3_45_7 (0.56 g, 1.14 mmol) in anhydrous tetrahydrofuran (10 mL) at room température. A solution of diethyl azodicarboxylate (0.238 g, 1.37 mmol) in tetrahydrofuran (5 mL) was added dropwise to the resulting solution at 20*Cand the resulting mixture was stirred at room température ovemight. After évaporation of the tetrahydrofuran, the crude product was purified by column chromatography to give the desired product (0.79 g, 88 % yield) as a white solid.

[00385] ’H NMR (400 MHz, DMSO-d₆): δ = 1.43 (s, 9H), 4.51-4.66 (m, 2H), 5.43 (t, J = 3.2 Hz, 1H), 6.92 (s, 1H), 6.95 (d, J = 2.6 Hz, 2H), 7.19-7.46 (m, 10H), 7.85 (s, 4H), 7.94 (d, J = 8.8 Hz, 2H), 8.98 (brs,2H).

[00386] MS (ES*) m/z: [M+H]* calcd for C^Hj^Og: 366.68. Found: 366.34.

Step 8: Diphenylmethyl 2-(aminooxy)-3-(4-[N-(tert-butoxycarbonyl)carbamimidoyl]phenoxy}propanoate (3_45_9) [00387] Hydrazine monohydrate (0.067 g, 1.35 mmol) was added to a solution of 3-[4(tert-butoxycarbonylamino-imino-methyl)-phenoxy]-2-(l,3-dioxo-l,3-dihydro-isoindol-2-yloxy)propionic acid benzhydryl ester 3_45_8 (0.78 g, 1.23 mmol) in anhydrous éthanol (15 mL) and tetrahydrofuran (10 mL) at 0*C and the resulting mixture was stirred at room température for 2 hours. After concentration, the residue was stirred with dichloromethane (10 mL) and filtered. The filtrate was concentrated to afford the desired product (0.76 g, >100% yield) as a white solid, which was used without purification.

no [00388] ^XH NMR (400 MHz, DMSO-d₅): δ = 1.42 (s, 9H), 4.28-4.46 (m, 2H), 4.60 (t, J = 4.1 Hz, 1H), 6.43 (s, 2H), 6.89 (s, 1H), 6.94 (d, J = 8.5 Hz, 2H), 7.19-7.47 (m, 10H], 7.92 (d, J = 8.8 Hz, 2H), 8.98 (brs, 2H).

3.46 4-[2-(Aminooxy)ethoxy]-2-methylbenzenecarboximidamide

46 1 ^HO'-^'ONa step 1

as for previous examples

Step 1: 4-(2-Hydroxyethoxy)-2-methylbenzonitrile (3_46_2) [00389] Sodium hydride (60 %, 0.62 g, 40.8 mmol) was added slowly to ethylene glycol (40 mL) and the resulting mixture was stirred at room température for 0.5 hour. 4-Bromo-2methylbenzonitrile 3_46_1 (2.0 g, 10.2 mmol) was then added followed by copper(l) bromide 10 (0.44 g, 3.06 mmol) and the reaction mixture was heated at 120’C for 2 hours, cooled to room température, poured into water (300 mL), and extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate layers were washed with water (2 x 200 mL) and brine (1 x 200 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to give compound 3_46_2 (1.6 g, 88 % yield) as a pale yellow solid.

[00390] ^JH NMR (400 MHz, CDCIj): δ = 2.51 (s, 3H), 3.94-4.04 (m, 2H), 4.07-4.15 (m,

2H), 6.74-6.87 (m, 2H), 7.53 (d, J = 8.6 Hz, 1H).

[00391] Using intermediate 3_46_2 and following the conditions as described in the previous examples, compound 3_46_3 was prepared. 4J

111

3.47 tert-Butyl [{4-[2-(aminooxy)ethoxy]pyridin-2-yl}(imIno)methyl]carbamate

ά	’-_Na0—^OTHP 2. HCl. MeOH	in	1. Na, MeOH 2. NH₄CI 3. BoCjO	A	N-hydroxyphthalîmide
	step 1		step 2	\^Z\^NHBOC	step 3
3_47_1		3_47_2		NH
				3_47_3

Step 1: 4-(2-Hydroxyethoxy)-pyridine-2-carbonitrile (3_47_2) [00392] 2-(Tetrahydropyran-2-yloxy)ethanol (3.50 g, 22 mmol) was added dropwise to a cooled (0*C) suspension of sodium hydride (530 mg, 60 % in minerai oil, 21 mmol) in N,Ndimethylformamide. After the addition was over, the mixture was stirred at room température for · 10 minutes. The reaction mixture was cooled to O’C and 4-chloro-pyridine-2-carbonitrile 3_47_1 (2.77 g, 20 mmol) was added in one portion. The resulting mixture was stirred at room tempera10 ture for 2 hours and the mixture was quenched with a saturated aqueous ammonium chloride solution, extracted with ethyl acetate, washed with water, dried and concentrated. The residue was dissolved in methanol (30 mL) and treated with a IN hydrochloric acid solution (10 mL) at 0*C. The mixture was stirred at room température for 2 hours, extracted with ethyl acetate (150 mL), dried and concentrated. The residue was purified by column chromatography to give 3_47_2 (2.04 g, 62 % yield) as a white solid.

[00393] ’H NMR (CDCIj,400MHz): δ = 8.60 (d, 1H), 7.25 (s, 1H), 7.03 (d, 1H), 4.27 (m,

2H), 4.00 (m, 2H), 2.00 (t, 1H).

Step 2: {[4-{2-Hydroxyethoxy)-pyridin-2-yl]-iminomethyl)carbamic acid tert-butyl ester (3_47_3) vt/~~

112 [00394] A solution of compound 3_47_2 (1.0 g, 6.10 mmol) in methanol (10 mL) was added to a freshly prepared solution of sodium methoxide (0.28 g of sodium in methanol (10 mL) at 0‘C and the reaction mixture was stirred at room température for 90 minutes. Ammonium chloride (1.30 g, 24.4 mmol) was added and the reaction mixture was heated at reflux for 16 hours. A saturated aqueous sodium bicarbonate solution (20 mL) and di-tert-butyl dicarbonate (Boc₂0,4.17 g, 18.3 mmol) were added to the cooled (0*C) mixture. The resulting mixture was stirred at room température for 16 hours, extracted with ethyl acetate (150 mL), dried and concentrated. The residue was purified by column chromatography to give compound 3_47_3 (1.53 g, 90 % yield) as viscous oil.

[00395] ’H NMR (COCI₃, 400MHz): δ = 9.40 (br S, 1H), 8.44 (d, 2H), 8.00 (s, 1H), 7.00 (d, 1H), 4.30 (d, 2H), 4.00 (m, 2H), 2.00 (br s, 1H), 1.60 (s, 9H).

Step 3: ((4-[2-(l,3-Dioxo-l,3-dihydro-isoindol-2-yloxy)-ethoxy]-pyridin-2-yl}-iminomethyljcarbamîc acid tert-butyl ester (3_47_4) [00396] Diisopropyl azodicarboxylate (1.28 mL, 6.53 mmol) was added dropwise to a cooled mixture of compound 3_47_3 (1.53 g, 5.44 mmol), N-hydroxyphthalimide (0.98 g, 5.98 mmol) and triphenylphosphine (1.71 g, 6.53 mmol) in tetrahydrofuran. After the addition, the mixture was stirred at room température for 16 hours and concentrated. The residue was purified by column chromatography to give compound 3_47_4 (1.66 g, 72 % yield) as a white solid.

[00397] ’H NMR (CDCI₃, 400MHz): δ = 9.40 (br s, 1H), 8.37 (d, 2H), 7.91 (s, 1H), 7.85 (m, 2H), 7.78 (m, 2H), 6.91 (d, 1H), 4.90 (m, 2H), 4.49 (m, 2H).

Step 4: tert-Butyl [{4-[2-(aminooxy)ethoxy]pyridin-2-yl}(imino)methyl]carbamate (3_47_5) [00398] Ammonia (2.5 mL, 2N in methanol) was added to a solution of compound 3_47_4 (210 mg, 0.5 mmol) in methanol (1 mL). The mixture was stirred for 16 hours, filtered and the filtrate was concentrated. The residue was diluted with dichloromethane and filtered. The filtrate was concentrated to give compound 3_47_5 (160 mg, >100 % yield) which was used in the next step without further purification.

113 [00399] ^XH NMR (CDCL 400 MHz): δ = 9.30 (br s, 1H), 8.40 (m, 2H), 8.00 (s, 1H), 7.00 (d,

1H), 5.60 (s, 2H), 4.40 (m, H), 4.10 (m, 2H), 1.60 (s, 9H).

3.48 tert-Butyl [{2-[Z-[aminooxY)ethoxy]pyridin-4-yl}(imIno)methyl]carbamate

NHBoc [00400] Following the procedure as described under 3.47 but using 2-chloro-4-cyanopyridine 3.48.1 as the starting material instead of 4-chloro-2-cyano-pyridine 3.47.1 compound 3.48.5 was prepared.

3.49 tert-Butyl [{5-[2-(aminooxy)ethoxyl-3-hydroxypyridin-2-yl}(imino)methYl]carbamate

49 1

HO. MeOH

49 3

Hï, Pd-C step 3

3.49 2 step 2

NH

H/INH, r^V^NHBoc step 6

3_49_7

Step 1: 3,5-Bis-isopropylideneaminooxy-pyridine-2-carbonitrile (3.49.2) [00401] Sodium hydride (0.875 g, 21.89 mmol, 60 % in minerai oil) was added to a solution of acetone acetone oxime (1.60 g, 9.95 mmol) in Ν,Ν-dimethylformamïde (30 mL) at O’C and the resulting mixture was stirred at room température for 1 hour. A solution of 5-bromo-3-fluoro15 pyridine-2-carbonîtrile 3.49.1 (2.0 g, 9.95 mmol) in Ν,Ν-dimethylformamide (10 mL) was added

114 at O’C and the reaction mixture was stirred at room température ovemight. After the removal of most of the Ν,Ν-dimethylformamide, the mixture was cooled to 0*C and water (40 mL) was added and the mixture was stirred for 0.5 hour. The white precipitate was collected, washed with cold water and dried to give the desired product (2.55 g, 100 % yield) as a white solid.

[00402] *H NMR (400 MHz, DMSO-d₆): δ = 2.05 (s, 3H), 2.06 (s, 3H), 2.09 (s, 3H), 2.13 (s, 3H), 7.69 (d, J = 23 Hz, 1H), 8.21 (d, J = 2.3 Hz, 1H).

[00403] MS (ES*) m/z: [M+H]* calcd for C_UH₁₅N₄O₂:247.27. Found: 247.12.

Step 2; Propan-2-one 0-(3-amino-isoxazolo[4,5-b]pyridin-6-yl)-oxime (3_49_3) [00404] Conc. hydrochloric acid (1:1,32 mL) was added to a mixture of 3,5-bisisopropylideneaminooxy-pyridine-2-carbonitrile 3_49_2 (4.8 g, 19.49 mmol) in methanol (80 mL) and the resulting mixture was stirred at 60*C for 4 hours. After cooling to room température, the white precipitate was collected, washed with water, and dried to give the desired product (3.50 g, 87 % yield) as a white solid.

[00405] *H NMR (400 MHz, CDCI₃): δ = 2.01-2.04 (m, 3H), 2.06-2.09 (m, 3H), 6.42 (s, 2H), 7.63 (d, J = 2.0 Hz, 1H), 8.40 (d, J = 2.0 Hz, 1H).

[00406] MS (ES*) m/z: [M+H]* calcd for CsH^N^: 207.21. Found: 207.11.

Step 3: 3,5-Dihydroxy-pyridine-2-carboxamidine (3_49_4) [00407] Palladium on carbon (2.0 g, 10 wt. %, wet) was added to a solution of propan2-one 0-(3-amino-isoxazolo[4,5-b]pyridin-6-yl)-oxime 3_49_3 (3.67 g, 17.80 mmol) in anhydrous tetrahydrofuran (30 mL), methanol (30 mL) and Ν,Ν-dimethylformamide (150 mL) and the resulting mixture was hydrogenated under 1 atmosphère at room température for 3 hours. The reaction mixture was filtered and the filtrate was concentrated to dryness to afford the crude compound 3_49_4 (4.08 g, >100 % yield) as a white solid, which was used in the next step without purification. /J ’

115 [00408] *H NMR (400 MHz, DMSO-d₆): δ = 6 6.08 (d, J = 23 Hz, IH), 7.23 (d, J - 2.3 Hz, IH), 7.53 (brs, 2H).

[00409] MS (ES*) m/z: [M+H]* calcd for CeHgNjOj: 154.14. Found: 154.15.

Step 4: [(3,5-Dihydroxy-pyridin-2-y!)-ïmîno-methyl]-carbamic acid tert-butyl ester (3_49_5) [00410] Di-tert-butyl dicarbonate (BocjO, 5.826 g, 26.70 mmo!) was added to a suspension of 3,5-dihydroxy-pyridine-2-carboxamidine 3_49_4 (4.08 g, crude, 17.8 mmol), in methanol (40 mL) and tetrahydrofuran (60 mL) followed by sodium carbonate (3.77 g, 35.61 mmo!) in water (20 mL) at room température. After stirring at room température overnight, the resulting mixture was filtered and the filtrate was concentrated, dituted with ethyl acetate, washed with a saturated aqueous ammonium chloride solution and brine, dried and concentrated to give the desired product (2.90 g, 64 % yield) as a white solid.

[00411] *H NMR (400 MHz, DMSO-d₆): δ = 1.48 (s, 9H), 6.55 (d, J = 2.3 Hz, IH), 7.40 (d, J = 2.3 Hz, IH), 7.85 (brs,2H).

[00412] MS (ES*) m/z: [M+H]* calcd for CuH_MN₃O₄:252.26. Found: 252.19.

Step 5: ({5-[2-(l,3-Dioxo-l,3-dihydro-isoîndol-2-yloxy}-ethoxy]-3-hydroxy-pyridin-2-yl}-iminomethyl)-carbamic acid tert-butyl ester (3_49_6) [00413] Triethylamine (1.465 g, 14.47 mmol) was added to a solution of N-{2hydroxyethoxyjphthalimide (2.0 g, 9.65 mmol) in dichloromethane (20 mL) at 0’C. Methanesulfonyl chloride (1.657 g, 14.47 mmol) was slowly added to the reaction mixture at 0’C. After stirring at room température for 3 hours, the reaction mixture was washed with brine, dried over sodium sulfate and concentrated to dryness to give methanesulfonic acid 2-(l,3-dioxo-l,3dihydro-isoindol-2-yloxy)-ethyl ester (2.46 g, 89 % yield) as a white solid.

[00414] Potassium carbonate (0.994 g, 7.19 mmol) was added to a solution of [(3,5dihydroxy-pyridin-2-yl)-imino-methyl]-carbamîc acid tert-butyl ester 3_49_5 (0.911 g, 3.60 mmol)

116 in Ν,Ν-dimethylformamide (20 mL). After stirring at 60*C for 15 minutes, a solution of methanesulfonic acîd 2-(l,3-dioxo-l,3-dïhydro-isoindol-2-yloxy)-ethyl ester (1.026 g, 3.60 mmol) in N,N-dimethylformamide (30 mL) was slowly added at 60*C and the mixture was stirred at 60’C for 4 hours before it was neutralized to pH 7 using dilute hydrochloric acid and diluted with cold water. The precipitate was collected and purified by column chromatography to give the desired product (0.243 g, 15 % yield) as a white solid.

[00415] ^XH NMR (400 MHz, DMSO-d₆): δ = 01.49 (s, 9H),4.39 (brs, 2H),4.44-4.57 (m, 2H), 6.76 (br s, 1H), 7.67 (br s, 1H), 7.87 (s, 4H), 9.03 (br s, 2H).

[00416] MS (ES*) m/z: [M+Hf calcd for C₂₁H₂₃N«O₇:443.43. Found: 443.11.

Step 6: tert-Butyl [{5-[2-(aminooxy)ethoxy]-3-hydroxypyridin-2-yl)(imino)methyl]carbamate (3_49_7) [00417] Hydrazine monohydrate (0.0445 g, 0.890 mmol) was slowly added to a solution of ({5-[2-(l,3-dioxo-l,3-dihydro-îsoindol-2-y!oxy)-ethoxy]-3-hydroxy-pyridin-2-yl}-imino-methyl)carbamic acid tert-butyl ester 3_49_6 (0.358 g, 0.809 mmol) in tetrahydrofuran (3 mL) and éthanol (5 mL). The resulting mixture was stirred at room température for 1 hour and concentrated. The resulting solid was stirred with dichloromethane (25 mL) for 15 minutes and filtered. The filtrate was concentrated to give the desired product (0.320 g, >100 % yield) as a white solid, which was used for the next step without further purification.

[00418] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.49 (s, 9H), 3.77-3.91 (m, 2H), 4.10-4.26 (m, 2H), 6.12 (s, 2H), 6.79 (br s, 1H), 7.80 (br s, 1H).

[00419] MS (ES*) m/z: [M+H]* calcd for C_uH_2lN₄O₅:313.33. Found: 313.13.

117

3.50 2-{4-[2-{AminooxY)ethoxY]phenyl}-4,5-dihydro-lH-imidazole

step 2 ethylened'iamine

Step 1: tert-Butyl [2-{4-cyanophenoxy)ethoxy]carbamate (3_50_2) [00420] A mixture of 4-[2-(aminooxy)ethoxy]benzonitrile 3_50_l (5.0 g, 28.0 mmol), ditert-butyl dicarbonate (Boc₂O,6.1 g, 28.0 mmol) and triethyl amine (2.8 g, 28.0 mmol) in dichloromethane (300 mL) was stirred ovemight at room température. The mixture was evaporated and the residue suspended in ether (200 mL). The resulting white precipitate was collected to obtain compound 3_50_2 (7.1 g, 91 % yield).

[00421] ’H NMR (400 MHz, DMSO-d₆): Ô = 136 (s, 9H), 4.02 (dd, J=5.2,3.0 Hz, 2H), 4.21 (dd, J=5.2,3.3 Hz, 2H), 7.10 (d, J=8.9 Hz, 2H), 7.7S (d, J=8.9 Hz, 2H), 10.08 (br s, IH) [00422] MS (ES*) m/z: [M+H]* calcd for C₁₄H₁₉N₂O₄:279.13; found: 279.12.

Step 2: tert-Butyl (2-[4'{4,5-dihydro-lH-imidazol-2-yl)phenoxy]ethoxy}carbamate (3_50_3) [00423] Sodium hydrogen sulfide (0.16 g, 2.16 mmol) was added to a suspension of tert-butyl [2-(4-cyanophenoxy)ethoxy]carbamate 3_50_2 (6.0 g, 21.6 mmol) and ethylenediamîne (20 mL). The resulting mixture was heated at 120*C for 2 hours, cooled to room température and poured into crushed ice to form a white solid. The solid was collected and dried under vacuum to obtain compound 3_50_3 (3.8 g, 55 %) as a white solid.

118

100424] *H NMR (400 MHz, DMSO-d₆): δ = 1.14-1.67 (m, 9H), 3.55 (s, 4H), 3.91-4.10 (m,

2H), 4.08-4.29 (m, 2H), 6.79-7.09 (m, 3H), 7.54-7.87 (m, 3H) [00425] MS (ES*) m/z: [M+H]* calcd for C₁₆H₂₄N₃O₄:322.18; found: 322.15

Step 3: 2-{4-[2-(Aminooxy)ethoxy]phenyl)-4,5-dihydro-lH-imidazole (3_50_4) [00426] A solution of tert-butyl (2-(4-(4,5-dihydro-lH-imidazol-2yl)phenoxy]ethoxy}carbamate 3_50_3 (3.8 g, 12.0 mmol) in dichloromethane (50 mL) was treated with trifluoroacetic acid (TFA, 3.8 mL). The resulting solution was stirred ovemight at room température, evaporated to remove excess trifluoroacetic acid and diluted with dichloromethane (200 mL). The solution was washed with an aqueous sodium bicarbonate solution (10 ml), dried and evaporated to obtain compound 3_50_4 (2.17 g, 81 % yield) as a gum.

[00427] ’H NMR (400 MHz, DMSO-d6): δ = 3.69 (s, 4H), 3.77 - 3.94 (m, 2H), 4.10-4.30 (m, 2H), 6.11 (brs, 2H), 6,90-7.17 (m, 2H),759-7.96 (m, 3H).

[00428] MS (ES*) m/z: [M+H]* calcd for C_uHi6N₃O₂: 222.12; found: 222.14.

3.51 tert-Butyl4-([{4-[2-(amlnooxY)ethoxy]phenYl}(imlno)methYl](tert-butoxYcarbonyl)15 amlno)plperldine-l-carboxylate

119

Step 1: tert-Butyl 4-{[(4-hydroxyphenyl)(imino)methyl]amino}piperidine-l-carboxylate (3_51_2) [004291 A suspension of compound 3_S1_1 (1.0 g, 4.46 mmol) in methanol (10.0 mL) was treated with triethylamîne (1.20 ml, 0.86 mmol) at O’C to give a clear yellow solution. The solution was treated with tert-butyl 4-aminopiperidine-l-carboxylate (0.90 g, 4.46 mmol) in methanol (2.0 mL) and stirred at room température overnight. The mixture was concentrated in vacuo to a yellow foam. The foam was purified by column chromatography to afford compound 3_51_2 (1.20 g, 85 % yield) as an off-white solid.

[004301 ’H NMR (400 MHz, DMSO-d₆): δ = 1.22 (t, J = 7.03 Hz, 2H), 1.42 (s, 9H), 1.461.55 (m, 2H), 1.88-1.93 (m, 2H), 3.05-3.10 (m, 1H), 3.80-4.11 (m, 2H), 6.95 (d, J = 8.99 Hz, 2H), 7.61 (d, J = 8.99 Hz, 2H), 9.02 (br s, 1H), 10.53 (br s, 1H).

[00431] MS (ES*) m/z: [M+H]* caicd for C₁₇H₂₆N₃O₃:320.20. Found: 320.21.

Step 2: tert-Butyl 4-{(tert-butoxycarbonyl)[{4-[(tert-butoxycarbony1)oxy]phenyl}(imino)methyl]amino)piperidine-l-carboxy!ate(3_51_3) [00432] A solution of compound 3_S1_2 (2.40 g, 7.51 mmol) in 1,4-dioxane (100 mL) was treated with a saturated sodium carbonate solution (100 mL) followed by di-tert-butyl dicarbonate (Boc₂0,8.20 g, 37.57 mmol) at O’C. The mixture was stirred at room température overnight and then extracted with ethyl acetate. The organic extracts were fiîtered through a short plug of silica gel and the pad was rinsed with ethyl acetate. The filtrate was concentrated to afford compound 3_51_3 (2.40 g, 62 % yield) as a white solid.

[00433] ’H NMR (400 MHz, DMSO-d₆): 5 = 1.18 (s, 9H), 1.24-1.40 (m, 2H), 1.40 (s, 9H),

1.49 (S, 9H), 1.84-1.89 (m, 2H), 2.67-2.90 (m, 2H), 3.81-3.90 (m, 3H), 7.26 (d, J = 8.60 Hz, 2H), 7.38 (d, J = 8.60 Hz, 2H), 7.75 (d, J = 6.25 Hz, 1H).

[00434] MS (ES*) m/z: [M+H]* calcd for C₂₇H₄₂N₃O₇:520.30. Found: 520.30.

120

Step 3: tert-Butyl 4-{(tert-butoxycarbonyl)[(4-hydroxyphenyl)(imino)methyl]amino}piperidine-lcarboxylate (3_51_4) [00435] A colorless solution of compound 3_51_3 (2.40 g, 4.62 mmol) in tetrahydrofuran (50 mL) and methanol (50 mL) was treated with lithium hydroxide monohydrate (0.58 g, 13.86 mmol) in water (5.0 mL) at 0*C. The mixture was stirred at room température for 2 hours and concentrated in vacuo to remove organic solvents. The residue was diluted with water and extracted with ethyl acetate. The extracts were dried over sodium sulfate, filtered and concentrated in vacuo to provide a white solid which was purified by column chromatography to give compound 3_51_4 (1.70 g, 88 % yield) as a white solid.

[004361 ^XH NMR (400 MHz, DMSO-d_e): δ =01.19 (s, 9H), 1.21-1.31 (m, 2H), 1.38 (s, 9H), 1.78-1.84 (m, 2H), 2.70-2.80 (m, 2H), 3.80-3.95 (m, 3H), 6.74 (d, J = 8.60 Hz, 2H), 7.17 (d, J = 8.60 Hz, 2H), 7.40-7.50 (m, IH).

[004371 MS (ES*) m/z: [M+Hf calcd for C_nH_uN₃0_s: 420.25. Found: 420.25.

[00438] Using the intermediate 3_51_4, compound 3_51_5 was prepared using the conditions as described in the previously cited examples.

352 tert-Butyl 4-{[{4-[(3S)-3-{amlnooxy)ethoxy]phenyl}(imino)methyl](tert-butoxYcarbonyl)amino)pyrrolidine-l-carboxylate

H.

,NBoc

3_52_5 [00439] Using conditions as described under 3.51 but using tert-butyl (35)-3aminopyrrolidine-l-carboxylate instead of tert-butyl 4-aminopiperidine-l-carboxylate, compound 3_S2_5 was prepared.

121

3.53 tert-Butyl (2S,4S)-4-{[{4-[2-(Aminooxy)ethoxY]phenyl}(imino}methyl](tertbutoxycarbonyl)a mino}-N,N -d i methyl-prolina mlde-l-carboxylate

		C) VNMe₂
il	ι^Η f	NBoc
	Boc
3_53.	.5

[004401 Using conditions as described under 3.51 but using tert-butyl (2S,4S)-4-amino5 2-(dimethylcarbamoyl)pyrro!idine-l-carboxYlate instead of tert-butyl 4-aminopiperidine-lcarboxylate, compound 3_53_5 was prepared.

3.54 !-(2-{[{4-[2-(Aminooxy)ethoxy]phenyl}(imino)methyl]amÎno}ethyl)-l-methylpyrrolidinium trifluoroacetate

54 1

BoCjO step 1

BocHN

3_54_2

HCl	“ 0	as described for3_11_6
step 3	H,N	--
² Cl
	3_54_4

Mel step 2

Q

BocNH ^x '

3_54_3

Step 1: (2-Pyrrolidin-l-yl-ethyl)-carbamic acid tert-butyl ester (3_54_2) [00441] A solution of di-tert-butyldicarbonate (Boc₂O,10.512 g, 48.2 mol) în tetrahydrofuran (20 mL) was added to a solution of 2-pyrrolidin-l-yl-ethylamine 3_54_1 (5.0 g, 43.8 mol) in tetrahydrofuran (40 mL) at O’C. After stirring at room température ovemight, the resulting mixture was concentrated to give the desired product (9.45 g, 100% yield) as a colorless oil, which 15 was used in the next step without purification.

122 [00442] ^XH NMR (400 MHz, CDCI₃): 5 = 1.45 (s, 9H), 1.74 - 78 (m, 4H), 2.48-2.58 (m, 6H), 3.22-3.26 (3,2H), 5.08 (brs, IH).

Step 2: l-(2-tert-Butoxycarbonylamino-ethyl)-l-methyl-pyrrolidinium iodide (3_54_3) [00443] lodomethane (20 mL) was added to a solution of compound 3_54_2 (9.45 g, crude, 43.8 mmol) in dichloromethame (30 mL) at -10*C. The resulting solution was sealed, stirred at 60 ovemight and concentrated to give the desired product (16.79 g, >100 % yield) as a light yellow sticky solid, which was used in the next step without purification.

[00444] *H NMR (400 MHz, DMSO-d₆): Ô = 1.38 (s, 9H), 2.06 (br s, 4H), 2.98 (s, 3H), 3.34-3.37 (m, 4H), 3.42-3.46 (m, 2H), 3.47-3.54 (m, 2H), 7.18 (br s, IH).

Step 3: l-(2-Amino-ethyl)-l-methyl-pyrrolidinium chloride hydrochloride sait (3_54_4) [00445] Hydrogen chloride gas was introduced into a solution of compound 3_54_3 (16.79 g, crude, 47.1 mmol) in dichloromethane (100 mL) at 0*C for 10 minutes. After stirring at room température for 1 hour, the resulting solid was filtered off, washed with dichloromethane and then dissolved in methanol (10 mL). Ether (30 mL) was added to the solution and the precipitate was collected and dried to give the desired product (10.1 g, 100 % yield) as an off-white solid.

[00446] ^lH NMR (400 MHz, DMSO-d₆): δ = 2.06-2.11 (m, 4H), 3.05 (s, 3H), 3.27-3.33 (m, 2H), 3.48-3.56 (m, 2H), 3.57-3.65 (m, 4H), 8.60 (br s, 2H).

[00447] Using the intermediate 3_54_4 and following the procedure as described under 3.11 compound 3_54_5 was prepared.

123

3.55 tert-Butyl 2-{4-[2-(aminooxy)ethoxyJpheny1}-l-tert-butoxycarbonyl-l_l4,5,6tetrahydropyrimidin-5-carbamate

as In previous examples /—\

HyPd-C	/=\
	^H0“Cr	J	H NHBoc
step 3
	3_55_4	Boc

HjN-O O

NHBoc

55 5 ⁶⁰⁰

Step 1: tert-Butyl {2-[4-(benzyloxy)phenyl]-l,4,5,6-tetrahydropyrimidin-5-yl)carbamate (3_55_2) [00448] 4-(Benzyloxy)benzaldehyde 3_55_1 (1.00 g, 4.71 mmol) was treated with tertbutyl (l,3-diaminopropan-2-yl)carbamate (0.94 g, 4.97 mmol) in dichloromethane (47.0 mL). The mixture was stirred at room température for 7 h, cooled to 0*C, and treated with Nbromosuccinimide (0.88 g, 4.94 mmol). The suspension was stirred at 0*C to room température ovemight, and quenched with a saturated sodium metabisulfite solution and a IN sodium hydroxide solution. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to give a yellow oil. The oil was purified by column chromatography to afford compound 3_55_2 (1.05 g, 59 % yield) as a light yellow solid.

[00449] ¹H NMR (400 MHz, CD₃OD): δ =01.45 (s, 9H), 3.42 (dd, J = 13.3,5.1 Hz, 2H),

3.65 (dd, J = 12.9,3.9 Hz, 2H), 4.05-4.09 (m, 1H), 5.18 (s, 2H), 7.15 (d, J = 8.6 Hz, 2H), 7.30-7.75 (m,

5H), 7.66 (d,J = 9.0 Hz, 2H).

Step 2: tert-Butyl 2-[4-(benzyloxy)phenyl]-5-[(tert-butoxycarbonyl)amino]-5,6-dihydropyrimidinel(4H)-carboxylate (3_55_3) w/

124 [00450] A solution of compound 3_55_2 (1.05 g, 2.75 mmol) in a mixture of dioxane/methanol/tetrahydrofuran (1.0 mL/2.0mL/53.0 mL) and a saturated sodium carbonate solution (50.0 mL) was cooled to 0*C, and treated with di-tert-butyl dicarbonate (Boc₂O,2.86 g, 13.1 mmol) in portions. The suspension was stirred at room température ovemight, concentrated in vacuo to remove the organic solvents, and diluted with ethyl acetate. The extracts were dried over sodium sulfate, filtered and concentrated to give a yellow oil. The oil was purified by column chromatography to afford compound 3_55_3 (1.10 g, 87 % yield) as a yellow solid.

[00451] NMR (400 MHz, CDjOD): δ =131.08 (s, 9H), 1.43 (s, 9H), 3.37 (dd, J = 16.0, 5.9 Hz, IH), 3.68-3.81 (m, 3H), 3.84-3.37 (m, IH), 5.15 (s, 2H), 7.00 (d, J = 9.0 Hz, 2H), 7.25-7.45 (m, 7H).

Step 3: tert-Butyl 5-[{tert-butoxycarbonyl)amino]-2-(4-hydroxyphenyl)-5,6-dihydropyrimidinel(4H)-carboxylate (3_55_4) [00452] A solution of compound 3_55_3 (2.50 g, 5.19 mmol) in methanol was treated with palladium on carbon (10 % wet, 0.25 g), and hydrogenated at 15 psi of hydrogen gas for 3 hours. The mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo to give a yellow oil. The oil was purified by column chromatography to afford compound 3_55_4 (1.50 g, 74 % yield) as a white solid.

[00453] ^JH NMR (400 MHz, DMSO-d₆): δ = 1.09 (s, 9H), 1.39 (s, 9H), 3.25-3.39 (m, 2H), 3.64-3.73 (m, 3H), 6.73 (d, J = 9.0 Hz, 2H), 7.00-7.04 (m, IH), 7.27 (d, J = 9.0 Hz, 2H), 9.67 (br s, IH).

[00454] The above intermediate 3_55_4 was used to préparé compound 3_55_5 by following the conditions as described before.

3.56 tert-Butyl l-(2-{4-[2-(Amlnooxy)ethoxY]phenyl}-l-tert-butoxycarbonyl-4,5-dihYdro-lHlmidazol-5-yl)methancarbamate ιΎ

125

NHBoc [00455] Using the conditions as described under 3.55 but using tert-butyl (2,3diaminopropan-l-yl)carbamate in place of tert-butyl (l,3-diaminopropan-2-yl)carbamate, compound 3_56_5 was prepared.

3.57 Di-tert-butyl4-([{4-[2-(aminooxy)ethoxY]pheny1}{imino)methyl]amino}pyrazolidine-l,2- dicarboxylate

step 1

TBDMSCI, imidazole

OTBDMS

3-57.2 .NHBoc BocHhT step 2

Boc Boc

OTBDMS

TB AF step 3

3_57 3

Msd step 4

57 5

3_57_6

Hj, Pd-C step 6

Boc Boc

NH₂3_57_7 as for

1 6

Boc Boc ç OH

3_57_4

Step 1: tert-Butyl[(l,3-dibromopropan-2-yl}oxy]dimethy!silane (3_57_2) [00456] Imidazole (19.69 g, 289 mmol) was added in portions to an ice-cold solution of l,3-dibromopropan-2-ol 3_57_1 (25.2 g, 115 mmol) and tert-butyldimethylsilyl chloride (TBDM17341

126

SCI, 20.92 g, 138 mmol) in N,N-dimethylformamide (116 mL) and the resulting solution was stined at room température for 18 hours. The mixture was diluted with ethyl acetate, and washed with water and brine. The organic phase was dried and concentrated under reduced pressure. Vacuum distillation afforded compound 3_57_2 (27.6 g, 72 % yield).

Step 2: Di-tert-butyl 4-{[tert-butyl(dimethyl)silyl]oxy}pyrazolidine-l,2-dicarboxylate (3_57_3) [00457] A solution of di-tert-butyl hydrazine-l,2-dicarboxylate (BocNH-NHBoc, 1.51 g, 6.492 mmol) In N,N-dimethylformamlde (32 mL) was treated with sodium hydride (60 % in minerai oil, 0.262 g, 6.446 mmol) to give a yellow slurry. The mixture was stined for 1.75 hours, treated with compound 3_57_2 (2.135 g, 6.428 mmol) and stined for another 1.75 hours. Another portion of sodium hydride (60 % in minerai oil, 0.270 g, 8.484 mmol) was added and the mixture was heated at 90*C for 2 hours. The mixture was cooled to room température, another portion of sodium hydride was added (60 %, in minerai oil, 0.103 g, 2.57 mmol) and the mixture was heated at 90*C for 1 hour. The solvent was removed under reduced pressure, and the mixture was quenched with methanol and extracted with ethyl acetate. The organic extract was washed with water and brine, dried and concentrated under vacuum to afford crude compound 3_57_3 (2.1 g, 80% yield) as an oil.

Step 3: Di-tert-butyl 4-hydroxypyrazolidine-l,2-dicarboxylate (3_57_4) [00458] A solution of compound 3_57_3 (9.05 g, 22.48 mmol) in tetrahydrofuran (225 mL) was cooled to 0‘C, then treated with glacial acetic acid (3.87 mL, 67.46 mmol) followed by the addition of tetra-n-butylammonium fluoride (TBAF, IN in tetrahydrofuran, 47.6 mL, 47.6 mmol). The mixture was heated at 50*C for 4.5 hours, cooled to room température and extracted with ethyl acetate. The extract was washed with a saturated sodium bicarbonate solution, dried and concentrated in vacuo to afford the crude compound 3_57_4 (6.48 g, 100 % yield), which was used without purification.

Step 4: Di-tert-butyl 4-[(methylsulfonyl)oxy]pyrazolïdine-l,2-dicarboxylate (3_57_5) -V

127 [00459] A solution of compound 3_57_4 (6.48 g, 22.48 mmol) in dichloromethane (112 mL) at 0*C was treated with triethylamine (1ΈΑ, 6.27 mL, 44.96 mmol) followed by methanesulfonyl chloride (MsCI, 2.62 mL, 11.24 mmol). The resulting mixture was stirred for 1.5 hours, washed with a saturated sodium bicarbonate solution, water and brine. The extract was dried and concentrated in vacuo to afford the crude compound 3_57_5 (8.24 g, 100 % yield).

Step 5: Di-tert-butyl 4-azidopyrazolidine-l,2-dicarboxylate (3_57_6) [00460] A solution of compound 3_57_5 (8.24 g, 22.48 mmol) in N,Ndimethylformamide was treated with sodium azide (4.38 g, 67.44 mmol). The resulting mixture was heated at 50*C for 20 hours, then extracted with ethyl acetate (225 mL) and washed with water and brine. The extract was dried and concentrated In vacuo to afford the crude compound

3_57_6 (7.02 g, 100 % yield).

Step 6: Di-tert-butyl 4-aminopyra2olidine-l,2-dicarboxylate (3_57_7) [00461] A solution of compound 3_57_6 (0.125 g, 0.40 mmol) and palladium on charcoal (5 %, 0.10 g) in methanol (6 mL) was hydrogenated at 42 psi of hydrogen for 4.5 hours. The mixture was filtered through a bed of Celite and the filtrate was concentrated in vacuo to afford crude compound 3_57_7 (0.103 g, 90 % yield).

[00462] Treating the intermediate 3_1_5 with the above compound 3_57_7 instead of ammonia as described under 3.1 gave the desîred compound 3_57_8.

I28

3.S8 tert-Butyl [(4-{[2-(aminooxy)-4-hydroxybutan-l-yl]oxy}phenyl)(imlno}methyl]carbamate

OH OH

TBSCI step 2

step 3

N-hydroxyphthaümide

3_58_2

Step 1: 3,4-Dihydroxybutyl acetate (3_58_2) [00463] A mixture of compound 3_58_1 (W02005/70874, 30 g, 159.6 mmol) in acetic acid (150 mL) and water (100 mL) was heated at 60 *C for 2.5 hours and concentrated to dryness to give crude compound 3_58_2 (25 g, >100 % yield) as an oil, which was used in the next step without further purification.

[00464] ’H NMR (400 MHz, CDCI₃): δ = 1.78 (m, 2H), 1.97-2.18 (m, 5H), 3.45 (m, 1H),

3.67 (dd, J=11.3,3.1 Hz, 1H), 3.80 (tt, J=8.0,3.7 Hz, 1H), 4.03-4.25 (m, 1H), 4.38 (m, 1H).

Step 2: 4-{[tert-Butyl(dimethyl)silyl]oxy}-3-hydroxybutyl acetate (3_58_3) [00465] Tert-butyldimethylchlorosilane (TBSCI, 24 g, 152.0 mmol) was added portionwise to a solution of compound 3_58_2 (crude 25 g), triethylamîne (32.7 g, 235.2 mmol) and 4-dimethylaminopyridine (1.2 g, 9.8 mmol) in dichloromethane (250 mL). The reaction mixture was stirred at room température overnight, fiîtered and the filtrate was concentrated.

The residue was dissolved in ethyl acetate, fiîtered again to remove the solid and the filtrate was μ/'

129 concentrated to give a residue, which was purified by column chromatography to give compound 3_58_3 (13 g, 30 % yield) as an oil.

[004661 *H NMR (400 MHz, CDCIj): δ = 0.01 (s, 6H), 0.82 (s, 9H), 1.70 (m, 2H), 1.98 (s, 3H), 2.41 (d, J = 3.6 Hz, 1H), 3.38 (m, 1H), 3.54 (m, 1H), 3.63 (m, 1H), 4.16 (m, 1H)B

Step 3: 4-{[tert-Butyl(dimethyl)silyl]oxy}-3-[(l,3-dioxo-l,3-dihydro-2H-isoindo!-2-yl)oxy]butyl acetate (3_58_4) [00467] Triphenylphosphine (16.4 g, 62.8 mmol) was added to a solution of compound 3_58_3 (13 g, 48.3 mmol) and N-hydroxyphthalîmide (11 g, 67.6 mmol) in tetrahydrofuran (200 mL), and diisopropyl azodicarboxylate (14.6 mL, 72.5 mmol) at O*C, and the mixture was stirred at room température for 3 hours and concentrated to give a residue, which was purified by column chromatography to give compound 3_58_4 (20 g, 99 % yield) as a yellow solid.

[00468] *H NMR (400 MHz, CDCI₃): δ = 0.02 (s, 6H), 0.80 (s, 9H), 2.10 (m, 5H), 3.81 (m, 1H), 3.96 (m, 1H), 4.42 (m, 3H), 7.78 (m, 2H), 7.82 (m, 2H).

Step 4: 3-[(l,3-Dioxo-l,3-dihydro-2H-isoindol-2-yl)oxy]-4-hydroxybutyl acetate (3_58_5) [00469] Hydrogen fluoride-pyridine complex (HF-pyridine, 5 ml) was added to a solution of compound 3_58_4 (10 g, 24.1 mmol) in tetrahydrofuran (100 mL) under cooling, and the mixture was stirred at room température for 16 hours, and concentrated to give a residue, which was purified by column chromatography to give compound 3_58_5 (6.4 g, 91 % yield) as a yellow solid.

[00470] *H NMR (400 MHz, CDCI₃): δ = 1.96 (m, 1H), 2.04 (s, 3H), 2.30 (m, 1H), 3.51 (m, 1H), 3.60 (m, 1H), 3.80 (m, 1H), 4.31 (m, 2H), 4.45 (m, 1H), 7.79 (m, 2H), 7.86 (m, 2H).

Step 5: 4-{4-[N-(tert-Butoxvcarbonyl)carbamimidoyl]phenoxy}-3-[(l,3-dioxo-l,3-dihydro-2Hisoindol-2-yl)oxy]butyl acetate (3_58_6)

130 [00471] Diisopropyl azodicarboxylate (5.93 mL, 29.4 mmol) was added to a solution of compound 3_58_5 (5.74 g, 19.58 mmol), tert-butyl-N-l^-hydroxyphenylJiminomethyn-carbamate (4.64 g, 19.58 mmol) and triphenylphosphine (6.1 g, 23.49 mmol) in tetrahydrofuran (100 mL) at 0*C and the mixture was stirred at room température for 16 hours and concentrated to give a residue, which was purified by column chromatography to give compound 3_58_6 (8.76 g, 78 % yield) asa gum.

[00472] ^XH NMR (400 MHz, CDCI₃): δ = 1.54 (s, 9H), 2.210(s, 3H), 2.27 (m, 2H), 4.25 (m, IH), 4.38 (m, 2H), 4.52 (m, IH), 4.70 (m, IH), 6.78 (d, J = 6.4 Hz, 2H), 7.81 (m, 6H).

Step 6: 3-(Aminooxy)-4-{4-[N’(tert-butoxycarbonyl)carbamimidoyl]phenoxy}butyl acetate (3_58_7) [00473] Hydrazine monohydrate (0.13 g, 2.6 mmol) was added to a solution of compound 3_58_6 (1.4 g, 2.73 mmol) in anhydrous éthanol (15 mL) under cooling. The resulting mixture was stirred at room température for 16 hours, filtered and the filtrate was concentrated to afford crude compound 3_58_7 (1 g, 96 % yield) as a white solid.

[00474] ^XH NMR (400 MHz, CDCIj): δ = 1.54 (s, 9H), 1.98 (m, 2H), 2.28 (s, 3H), 4.00 (m, IH), 4.15 (m, 2H), 4.23 (m, 2H), 5.42 (br s, 2H), 6.85 (d, J = 6.4 Hz, 2H), 7.81 (d, J = 6.4 Hz, 2H).

Step 7: tert-Butyl [{4-[2-(aminooxy)-4-hydroxybutoxy]phenyl](imino)methy1]carbamate (3_58_8) [00475] Potassium carbonate (0.13 g, 2.6 mmol) was added to a solution of compound 3_58_7 (1 g, 2.62 mmol) in anhydrous methanol (30 mL) under cooling, and the mixture was stirred at room température for 1 hour. The resulting mixture was concentrated, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography to give compound 3_58_8 (0.18 g, 20 % yield) asa gum.*^

131 [00476] *H NMR (400 MHz, DMSO-d₆): 8 = 1.42 (s, 9H), 1.43 (m, IH), 1.78 (m, IH), 3.50 (m, IH), 3.80 (m, IH), 4.16 (m, 2H), 4.42 (m, IH), 5.95 (s, 2H), 7.22 (d, J=6.4 Hz, 2H), 7.96 (d, J=6.4 Hz, 2H).

3.59 Dlphenylmethyl 2-(amInooxy)-3-{4-[N-{tert-butoxycarbonyl)-N-{2-[(tert butoxycarbonyl)amino]ethyl}carbamlmidoyl]phenoxy}propanoate

Step 1: 3-[4-[N-(2-tert-Butoxycarbonylamino-ethyl)-carbamimidoyl]-phenoxy}-2-hydroxypropionic acid methyl ester (3_59_1) [00477] Triethylamine (1.295 g, 12.8 mmol) and (2-amino-ethyl)-carbamic acid tert10 butyl ester (1.76 g, 11.0 mmol) were added to a mixture of compound 3_45_3 (3.09 g, 10.7 mmol) in anhydrous methanol (50 ml) at 0*C and the resulting mixture was stirred at room température ovemight. The reaction mixture was concentrated to dryness and the residue was purified by column chromatography to give the desired product (3.09 g, 76 % yield) as a white solid.

[00478] ^XH NMR(400 MHz, DMSO-d₆): 8 = 1.35 (s, 9H), 3.18-3.27 (m, 2H), 3.38-3.47 (m,

2H), 3.65 (S, 3H), 4.23 - 4.28 (m, 2H), 4.44-4.50 (m, IH), 5.95 (d, J = 6.2 Hz, IH), 7.12 (d, J = 9.1 Hz,

2H), 7.72 (d, J = 8.8 Hz, 2H), 8.96 (br. s., IH), 9.36 (br s, IH), 9.55 (br s, IH).

Step 2: 3-(4-{[tert-Butoxycarbonyl-(2-tert-butoxycarbonylamino-ethyl)-amino]-imino-methyl)phenoxy)-2-hydroxy-propionic acid methyl ester (3_59_2) w—

132 [00479] A saturated solution of sodium carbonate (20 mL) and di-tert-butyldicarbonate (Boc₂O, 3.519 g, 16.1 mmol) in 1,4-dïoxane (25 mL) were added to a solution of compound 3_59_1 (2.05 g, 5.37 mmol) in water (30 mL) at 0 ®C. After stirring at room température for 4.5 hours, the resulting mixture was extracted with ethyl acetate and the extract was washed with brine, dried and concentrated. The residue was purified by column chromatography to give the desired product (0.66 g, 26% yield) as a white solid.

[00480] ²H NMR (400 MHz, DMSO-d₆): δ = 1.21 (s, 9H), 1.37 (s, 9H), 3.05-3.14 (m, 2H), 3.17-3.25 (m, 2H), 3.64 (s, 3H), 4.13-4.19 (m, 2H), 4.44 (m, 1H), 5.87 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 7.31 (d, J =8.8 Hz, 2 H).

[00481] Using compound 3_59_1 and following the procedure as described under 3.45 compound 3_59_3 was prepared.

3.60 Diphenylmethy!2-(aminooxy)-3-[(6-{tert-butoxycarbonyl-carbamimidoyl}pyridin-3yl)oxy]propanoate

OH		OBn
n	BnBr	A	LHMDS
	step 1		Step 2
CN		CN
3_6OJI		3_60_2

OBn		OBn
ΙίΊ	BoCjO		Hj.Pd-0
V^N	step 3	Un	step 4
HN^NHj		HN^NHBoc
3_β0-3		3 60 4

as descnbed for

3_45_9

3_60_5

60 β

NHBoc

3_60 7

Step 1: 5-Benzyloxy-pyridine-2-carbonitrile (3_60_2) [00482] A mixture of 5-hydroxy-pyridine-2-carbonitrile 3_60_l (14 g, 116 mmol) and potassium carbonate (32.2 g, 233 mmol) in N,N-dimethylformamide (140 mL) was heated at 60*C for 0.5 hours. Benzylbromide (13.9 g, 116 mmol) was added and the mixture was stirred at 66’C —

133 for 1 hour, and filtered and the filtrate was concentrated, extracted with ethyl acetate, washed with brine, dried over sodium sulfate and concentrated. The residue was triturated with diethyl ether and hexanes to give a precipitate, which was collected to give compound 3_60_2 (21 g, 85 % yield) as a solid.

[00483] ’H NMR (400 MHz, DMSO-d₆): δ = 5.27 (s, 2H), 7.33-7.50 (m, 5H), 7.65 (dd, J=8.8,2.9 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 8.50 (d, J = 3.2 Hz, 1H).

Step 2: 5-Benzyloxy-pyridine-2-carboxamÎdine (3.60.3) [00484] Butyllithium (1.6N in hexane, 168 mL 269 mmol) was added to a solution of hexamethyldisilazane (56.5 mL, 269 mmol) in tetrahydrofuran (250 mL) at 0*C, and stirred at 0*C for 1 hour to form lithium hexamethyldisilazide (LHMDS). A solution of compound 3.60.2 (22.6 g, 107.6 mmol) in tetrahydrofuran (250 mL) was added slowly at 0*C, and the mixture was warmed to room température slowly and stirred for 16 hours at room température. A IN hydrochloric acid solution (300 mL) was added to the reaction mixture to give a precipitate which was collected to give pure compound 3.60.3 (17 g, 70 % yield). From the mother liquor an additional amount of crude compound 3.60.3 (10 g) was obtained as a gum.

[00485] ^XH NMR (400 MHz, DMS0-d₆): δ = 5.32 (s, 2H), 7.32-7.52 (m, 5H), 7.78 (dd, J = 8.8,2.9 Hz, 1H), 8.25 (d, J = 8.6 Hz, 1H), 8.54 (d, J = 2.7 Hz, 1H), 9.18 (s, 2H), 9.32 (s, 2H).

Step 3: Amino-(5-benzyloxy-pyridin-2-yl)-methy!ene]-carbamic acid tert-butyl ester (3.60.4)

100486] Sodium bicarbonate (7.78 g, 92.5 mmol) was added to a suspension of compound 3.60.3 (14 g, 61.67 mmol) in a mixture of dioxane (200 mL) and water (200 mL) at room température, and the mixture was stirred at room température for 20 minutes. Di-tert-butyl dicarbonate (Boc₂O,13.4 g, 61.44 mmol) was added, and the mixture was stirred for 16 hours at room température to give a precipitate. The precipitate was collected, dissolved in ethyl acetate and washed with brine, dried over sodium sulfate and concentrated to give pure compound 3.60.4 (5 g, 25 % yield). The filtrate was concentrated to remove dioxane, extracted with ethyl y/^-

134 acetate, washed with brine, dried over sodium sulfate and concentrated to give a solid, which was triturated with diethyl ether to give further compound 3.60.4 (6.2 g, 31 % yield) as a yellow solid.

[00487] *H NMR (400 MHz, CDCI₃): δ = 1.56 (d, J = 5.1 Hz, 9H), 7.31 (dd, J = 8.8,2.9 Hz, 1H), 7.34-7.46 (m, 5H), 8.32 (d, J = 2.7 Hz, 1H), 8.40 (d, J = 9.0 Hz, 1H), 9.33 (br s, 1H).

Step 4: Amino-(5-hydroxy-pyridin-2-yl)-methy!ene]-carbamtc acid tert-butyl ester (3.60.5) [00488] A mixture of compound 3.60.4 (5 g, 15.3 mmol) and palladium on charcoal (10 %, wet, 1 g) in a mixture of methanol (80 mL) and ethyl acetate (10 mL) was hydrogenated at room température under 35 psi for 3 hours. The reaction mixture was filtered and concentrated to give compound 3.60.5 (3.4 g, 97 % yield) as a brown solid.

[00489] *H NMR (400 MHz, CDCI₃): δ = 1.57 (s, 9H), 5.15 (s, 2H), 7.51 (dd, J = 8.8,2.5 Hz, 1H), 8.27 (d, J = 2.7 Hz, 1H), 8.73 (d, J = 9.0 Hz, 1H).

Step 5: 3-[6-(tert-Butoxycarbonylamino-imino-methyl)-pyridin-3-yloxY]-2-hydroxy-propionic acid ethyl ester (3.60.6) [00490] Potassium carbonate (5.46 g, 39.6 mmol) was added to a solution of compound

3.60.5 (3 g, 13.2 mmol) in acetonitrile (50 mL) and the mixture was heated at 93*C for 0.5 hours. Ethyl 2,3-epoxypropanoate (4.6 g, 39.6 mmol) was added to the reaction mixture. After refluxing for 48 hours, the resulting mixture was cooled and filtered and the filtrate was concentrated to give a residue which was purified by column chromatography to give compound 3.60.6 (2 g, 21 % yield) as a brown solid.

[00491] *H NMR (400 MHz, DMSO-d₆): δ = 1.18 (t, J = 7.0 Hz, 3H), 1.45 (m, 9H), 4.15 (dd, J = 7.0,1.5 Hz, 2H), 4.29-4.37 (m, 2H), 4.48 (q, J = 4.7 Hz, 1H), 5.92 (d, J = 5.9 Hz, 1H), 7.55 (dd, J = 8.8,2.9 Hz, 1H), 8.19 (d, J = 9.0 Hz, 1H), 8.35 (d, J = 2.7 Hz, 1H), 8.75 (br. s., 1H), 9.02 (br. s, 1H).

[00492] Using the above alcohol 3.60.6 and following the procedure as described under 3.45 compound 3.60.7 was prepared.

135

136

3.61 tert-Butyl (l-{4-[2-(amtnooxy)-3-{tert-butyl-dimethyl-sIlanyloxY)-propoxy]-phenyl}iminomethyl)-ca rba mate

Ha, MeOH step 2

NHBoc step 4

HO O

3_61_4

NH

OMe NHj.MeOH

TBDMS-a step 3

step 5

TBDMS

NHBoc

Step 1: 4-(2,2-Dimethyl-[l,3]dioxo!an-4-ylmethoxY)-benzonitrile (3_61_2) [00493] 2,2-Dimethyl-l,3-dioxolane-4-methanol (3.66 g, 27.7 mmol) and triphenylphosphine (7.93 g, 30.2 mmol) were added to a solution of 4-hydroxybenzonitrile 3_61_1 (3.0 g, 25.2 mmmol) in anhydrous tetra hydrofuran (80 mL) at room température. Diethyl azodicarboxylate (5.26 g, 30.2 mmol) was added dropwise to the resulting solution at 20*C and the resulting mixture was stirred at room température ovemight. After évaporation of the tetrahydrofuran, the crude product was purified by column chromatography to give the desired product (5.65 g, 96 % yield) as a white solid.

[00494] ’H NMR (400 MHz, DMSO-d₆): δ = 131.28 (s, 3H), 1.33 (s, 3H), 3.69-3.79 (m, 1H), 3.99-4.18 (m, 3H), 4.33-4.47 (m, 1H), 7,11 (d, J = 8.8 Hz, 2H), 7.75 (d, J = 8.8 Hz, 2H).

Step 2: 4-(2,3-Dihydroxy-propoxy)-benzimidic acid methyl ester hydrochloric acid sait (3_61_3) [00495] Hydrogen chloride gas was introduced into a solution of compound 3_61_2 (3.02 g, 12.9 mmol) in anhydrous methanol (80 mL) at 0*C for 10 minutes and the resulting ,__

137 mixture was stirred at room température overnight. After concentration, the residue was stirred with diethyl ether (60 mL) for 0.5 hours and the precipitate was collected and dried to give the desired product (3.26 g, 97 % yield) as a white solid.

[00496] ^XH NMR (400 MHz, DMSO-d_fi): δ = E3.37-3.48 (m, 2H), 3.75-3.84 (m, H), 4.00 (dd, J = 10.1,6.3 Hz, 1H), 4.13 (dd, J = 10.3,3.8 Hz, 1H), 4.23 (s, 3H), 7.14-7.19 (m, 2H), 8.06 (d, J = 8.8 Hz, 2H).

Step 3: 4-(2,3-Dihydroxy-propoxy)-benzamidine (3_61_4) [00497] Ammonia (27 mL, 7N in methanol, 0.187 mol) was added to a solution of compound 3_61_3 (3.26 g, 12.5 mmol) in anhydrous methanol (20 mL) at 0*C and the resulting mixture was stirred at 40 ®C for 3 hours. The reaction mixture was concentrated to dryness to give the crude desired product (2.92 g, >100 % yield) as a white solid, which was used without purification.

[00498] ^XH NMR (400 MHz, DMSO-d₆): δ = B3.45 (br s, 2H), 3.81 (br. s, 1H), 3.99 (dd, J = 10.3, 6.2 Hz, 1H), 4.12 (dd, J = 10.1,4.0 Hz, 1H), 4.74 (br. s, 1H), 5.04 (d, J = 4.7 Hz, 1H), 7.12-7.19 (m, 2H), 7.79-7.86 (m, 2H), 8.90 (s, 2H), 9.19 (s, 2H).

Step 4: ([4-(2,3-Dihydroxy-propoxy)-pheny!]-imino-methyl}-carbamic acid tert-butyl ester (3_61_5) [00499] A saturated sodium carbonate solution (8mL) and di-tert-butyldicarbonate (Boc₂0,6.52 g, 30 mmol) were added to a solution of compound 3_61_4 (3.70 g, crude, 12.5 mmol) in methanol (30 mL) and tetrahydrofuran (20 mL) at 0 ®C. After stirring at room température overnight, the resulting mixture was extracted with ethyl acetate and the extract was washed with brine, dried and concentrated. The residue was washed with a small volume of cold ethyl acetate to give the desired product (3.10 g, 80 % yield) as a white solid.

138 [00500] ’H NMR (400 MHz, DMSO-d₆): δ = 01.44 (s, 9H), 3.41-3.48 (m, 2H), 3.80 (d, J = 5.0 Hz, 1H), 3.93 (dd, J = 9.8,6.3 Hz, 1H), 3.99-4.11 (m, 1H), 4.70 (t, J = 5.7 Hz, 1H), 4.99 (d, J = 5.0 Hz, 1H), 7.00 (d, J = 9.1 Hz, 2H), 7.94 (d, J = 9.1 Hz, 2H).

Step 5: ((4-[3-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxy-propoxy]-phenyl}-imino-methyl)5 carbamic acid tert-butyl ester (3_61_6) [OO5OI] Imidazole (1.44 g, 21.1 mmol) and tert-butyldïmethylsilyl chloride (TBDMS-CI,

1.592 g, 10.6 mmol) were added to a solution of compound 3_61_5 (2.98 g, 9.60 mmol) in N,Ndimethylformamide (15 mL) at 0 ²C. After stirring at room température ovemight, the reaction mixture was quenched by adding ice-water (30 mL) and extracted with ethyl acetate. The extract 10 was washed with brine, dried over sodium sulfate and concentrated to dryness to afford the crude desired product (4.81 g, >100 % yield) as an off-white sticky solid, which was used without purification.

[00502] ’H NMR (400 MHz, DMSO-d₆): δ = 00.05-0.14 (m, 6H), 0.87-0.92 (m, 9H), 1.48 (S, 9H), 3.68 (d, J = 5.9 Hz, 2H), 3.82-3.91 (m, 1H), 3.95-4.04 (m, 1H), 4.05-4.14 (m, 1H), 5.11 (d, J = 15 5.0 HZ, 1H), 6.99-7.07 (m, 2H), 7.94-8.01 (m, 2H).

[00503] Using the above alcohol 3_61_6 and following the procedure as described under 3.45 compound 3_61_7 was prepared.

3.62 tert-Butyl4-{[(4-{[(2S)-2-(aminooxy)-3-(dipheny!methoxy)-3-oxopropyl]oxy}phenYl)(lmIno)methYlJamino)plperidine-l-carboxylate

139

NH

EtO_aC

HO C

HO. MeOH :n * step 2

ΜβΟ,Ο

HO C

HQ

HjN-^JMSoc

NH

3_β2_3

OMe steP 3 s””⁵ HO '0

3_β2_β

N+iydroxyphthallmide

NH step 6

3_β2_7 hydraztne OCHPhj |i .— hydrate Os/ ^Boc step⁷ HjN-O^Z—''o'^^%'^

3_62_β

Step 1: (R)-3-(4-Cyano-phenoxy)-2-hydroxy-propionic acid ethyl ester (3_62_2) [00504] A mixture of a Co(I!l)-catalyst (0.26 g, 0.31 mmol, ref: J. Am. Chem. Soc. 1999,

121,6086-6087), and 4Â molecular sieves (2 g) was treated with 4-hydroxybenzonitrile 3_62_1 (1.0 g, 8.4 mmol) and ethyl oxirane-2-carboxylate (2.0 g, 17 mmol) followed by tert-butyl methyl ether (3.0 mL) under a stream of nitrogen. The suspension was stirred at room température overnight and filtered through a pad of Celite. The filtrate was concentrated to give a dark brown liquid. The liquid was purified by column chromatography to afford compound 3_62_2 (1.9 g, 96 10 % yield) as a brown oîl.

[00505] ^JH NMR (400 MHz, DMSO-d_fi): δ = 1.18 (t, J = 1.7 Hz, 3H), 4.03 - 4.19 (m, 2H), 4.25 (d, J = 4.4 Hz, 2H), 4.38-4.51 (m, IH), 5.89 (d, J = 5.9 Hz, IH), 7.11 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H).

Step 2: (R)-2-Hydroxy-3-(4-methoxycarbonimidoyl-phenoxy)-propionic acid methyl ester hydrochloric acid sait (3_62_3) [00506] A mixture of compound 3_62_2 (1.1 g, 4,7 mmol) in methanol (50 mL) was cooled to 0’C in a sealed vessel. Anhydrous hydrogen chloride gas was bubbled through the solution until the mixture was saturated. The flask was sealed and stirred at 0*C to room tempera

140 ture ovemight. The mixture was concentrated in vacuo and diluted with diethyl ether to give a suspension. The suspension was stirred for 15 minutes and compound 3_62_3 (1.1 g, 81 % yield) as a white solid was collected after drying under high vacuum.

[00507] ^XH NMR (400 MHz, DMSO-d₆): δ = 3.66 (s, 3H), 4.24 (s, 3H), 4.27-4.30 (m, 2H), 4.48 (t, J = 4.4 Hz, 1H), 7.16 (d, J = 9.1 Hz, 2H), 8.09 (d, J = 9.1 Hz, 2H).

Step 3: (R)-tert-Butyl 4-(4-(2-hydroxy-3-methoxy-3-oxopropoxy)benzimidamido)pîperidine-lcarboxylate (3_62_4) [00508] Triethylamine (1.537 g, 15.2 mmol) and tert-butyl 4-aminopiperidine-lcarboxylate (2.765 g, 13.8 mmol) were added to a mixture of compound 3_62_3 (4.0 g, 13.8 mmol) in anhydrous methanol (50 mL) at 0*C and the resulting mixture was stirred at room température overnîght. The reaction mixture was concentrated to dryness to give the crude desired product (7.81 g, >100 % yield) as a white foam, which was used without purification.

[00509] ’H NMR(400 MHz, DMSO-d₆₁: Ô = 1.38 (s, 9H), 1.54-1.43 (m, 2H), 1.82-1.93 (m, 2H), 2.60-2.90 (m, 2H), 3.64 (s, 3H), 3.90-4.00 (m, 3H), 4.12-4.28 (m, 2H), 4.44-4.50 (m, 1H), 5.98 (s, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H).

Step 4: (R)-3-(4-(N-(l-(tert-Butoxycarbonyl)piperidin-4-yl)carbamimidoyl)phenoxy)-2-hydroxypropanoïc acid (3_62_5) [00510] A solution of sodium hydroxide (0.552 g, 13.8 mmol) in water (20 mL) was added to a solution of compound 3_62_4 (3.905 g, crude, 6.90 mmol) in tetrahydrofuran (50 mL) at 0*C. After stirring at this température for 90 minutes, the reaction mixture was neutralized to pH 7 using AN hydrogen chloride in dioxane. The mixture was concentrated and dried to afford the crude desired product (5.20 g, >100 % yield) as a white solid, which was used in the next step without purification.

Step 5: (R)-tert-Butyl 4-(4-(3-(benzhydryloxy)-2-hydroxy-3-oxopropoxy)benzÎmidamido)piperidine-l-carboxylate (3_62_6)

141 [00511] A solution of diazo(diphenyl)methane (Ph₂CN₂,2.00 g, 10.35 mmol) in methanol (15 mL] was slowly added to a solution of compound 3_62_5 (5.20 g, crude, 6.90 mmol) in methanol (100 mL). The resulting mixture was stirred at room température ovemight and concentrated to dryness. The residue was purified by column chromatography to give the desired product (1.8 g, 46 % yield) as a white solid.

[00512] *H NMR (400 MHz, DMSO-d₆): δ « 1.39 (s, 9H), 1.42-1.52 (m, 2H), 1.87-1.92 (m, 2H), 2.82 (br. s, 2H), 3.90-4.00 (m, 3H), 4.30-4.42 (m, 2H), 4.62-4.65 (m, 1H), 6.48 (d, J = 7.6 Hz ,1H), 6.84 (s, 1H), 7.09 (d, J = 8.8 Hz, 2H), 7.22-7.41 (m, 10H), 7.69 (d, J = 8.8 Hz, 2H), 9.10 (br. s, 1H), 9.38 (br. s, 1H).

[00513] MS: 574.14 (M+l).

Step 6: (S)-tert-Butyl 4-(4-(3-(benzhydryloxy)-2-((l,3-dioxoisoindolin-2-yl)oxy)-3-oxopropoxy)benzimidamido)piperidine-l-carboxylate (3_62_7) [00514] W-Hydroxyphthalimide (0.573 g, 3.51 mmol) and triphenylphosphine (1.005 g, 3.83 mmol) were added to a solution of compound 3_62_6 (1.831 g, 3.19 mmol) in anhydrous tetrahydrofuran (60 mL) at room température. A solution of diethyl azodicarboxylate (0.667 g, 3.83 mmol) in tetrahydrofuran (5 mL) was added dropwise to the resulting solution at 20*C. The resulting mixture was stirred at room température for 2.5 hours. After évaporation of the tetrahydrofuran, the crude product was purified by column chromatography to give the desired product (1.5 g, 65 % yield) as a white soîid.

[00515] ^JH NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 1.44-1.53 (m, 2H), 1.92-1.96 (m, 2H), 2.82 (br. s, 2H), 3.92-4.16 (m, 3H), 4.68 (br. s, 2H), 5.48 (br m., 1H), 6.98 (s, 1H), 7.11 (d, J = 8.6 Hz, 2H), 7.26-7.48 (m, 10H), 7.75 (d, J = 8.6 Hz, 2H), 7.86 (s, 4H), 9.24 (br. s, 1H), 9.40 (b. s, 1H).

[00516] MS: 719.18 (M+l).

142

Step 7: 2-Aminooxy-3-(4-{[tert-butoxycarbonyl-(2-tert-butoxycarbonYlamino-ethyl)-amîno]-iminomethyl}-phenoxy)-propionic acid benzhydryl ester (3_62_8) [00517] Hydrazine monohydrate (0.114 g, 2.28 mmol) was added to a solution of compound 3_62_7 (1.49 g, 2.07 mmol) in anhydrous éthanol (35 mL) and tetrahydrofuran (20 mL) at

0*C and the resulting mixture was stirred at room température for 2 hours. The mixture was concentrated to dryness and the residue was stirred with dichloromethane (10 mL) at room température for 15 minutes and filtered. The filtrate was concentrated to afford the crude desired product (1.4 g, >100 % yield) as an off-white foam, which was used in the next step without purification.

[00518] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 1.44-1.53 (m, 2H), 1.89-1.94 (m, 2H), 2.85 (br. s, 2H), 3.92-4.02 (m, 3H), 4.36-4.47 (m, 2H), 4.62-4.66 (m, IH), 6.45 (s, 2H), 6.91 (S, IH), 7.09 (d, J = 8.8 Hz, 2H), 7.26-7.45 (m, 10H), 7.72 (d, J = 8.8 Hz, 2H), 9.25 (br. s, 2H).

[00519] Following the procedure detailed above under 3.62 but using the amines R-NH₂shown in the table below instead of tert-butyl 4-aminopiperidine-l-carboxylate in step 3 of the 15 synthesis, compounds 3_63_8 to 3_79_8 were prepared.

as described for3_62_8

NH

H₂N''° 3_63_8 - 3_79_8

	amine (R-NH₂)	product
3.63	A H,N NHBOC (cis)	NH A ? u Ph-^o^r^-o·⁴^ H _N.° 3-63.8

vv—

143

3.64	Γ~ΝΒοο	jyçXr⁰*· Η/Γ⁰ 3_64_8
3.65	1 Boc	Ph O f^iÿiV^N^^xN'Boc ΛYoV ^H Η,Ν'θ 3.65-8
3.66	h/>	Ph ο ^N-⁰ 3_66_8
3.67	Γ NBoc	r⁰ rZrf^CNB“ ^0 3.67.8
3.68	F^N	Η,Ν·^{0 3}-“^J
3.69		ivx/inr· HjN*⁰ 3_69-8
3.70	.NHBoc	nh r*³” Η,Ν-⁰ 3-70-8

144

3.71	Ύ	HJT⁰ 3.71.8
3.72		NH χυΰΫ'' ^0 3.72.8
3.73		V ⁰ lÀV^®’’ ph-Yo^'-f^oA^ H,rr° ³-”-⁸
3.74	_HjNX?NBoo R/S	NH O a V X/À^NBKpAoY<Y H,N° ³-⁷⁴-⁸
3.75	·» _pocΗ,Ν-'-φ	NH Boc x^h 3 oLcû Ph^AO^AfO^ H₂N'° 3.75.8
3.76	hJ>~	- - γΛ°· PtAAf'^O'LJ H/T⁰ ^-⁶
3.77	B oc H N JJ'NBoc h₂n^ R/S	BocHN NH Y^_kl„ Il 1 NBoc Ph o Aîr n^⁷ ï JJ _Λ JL J H R/S ριΛοΎΧι-^Υ ^o s.TT.s

145

3.78	FUS Boc	NH fVS Boc Ph 9 n^Y^Ni ayA ^h A η/γ° W
3.79		Η,Ν-θ ³-⁷⁹-⁸

[00520] Following the procedure detailed above under 3.62 but using the enantiomer of 3_62_3 and amines R-NHj shown in the table below instead of tert-butyl 4-aminopiperidine-lcarboxylate in step 3 of the synthesis, compounds 3_80_8 to 3_82_8 were prepared.

MeO_zC,

H HO O

HCl

as described for 3 62 8

ent 3_62_3

	amine (R-NH₂)	product
3.80	.NHBoc	nh r®** Ηί,ΝΓ⁰ 3_80_8
3.81		NH _H HjN'⁰ 3_81_8

146

3.82
		H^⁰ 3-82-8

3.83 tert-Butyl [{4-[3-amlno-2-(amlnooxy)-3-oxopropoxy]phenYl}(imino)methyl]carbamate

Step 1: Methyl 3-[4-[N-(tert-butoxycarbonyl)carbamimidoyl]phenoxy)-2-[(l,3-dioxo-l,3-dihydro5 2H-isoindol-2-yl)oxy]propanoate (3_83_1) [00521] Dilsopropyl azodicarboxylate (0.39 g, 2.41 mmol) was added dropwise to a mixture of methyl 3-{4-[N-(tert-butoxycarbony1)carbamimidoyl]phenoxy}-2-hydroxypropanoate 3_45_5 (0.68 g, 2.01 mmol), N-hydroxy-phthalimide (PhthN-OH, 0.68g, 2.01 mmol) and triphenylphosphine (0.63 g, 2.41 mmol) in tetrahydrofuran. After the addition was complété, the mixture was stirred at room température for 16 hours and concentrated. The residue was purified by column chromatography to give compound 3_83_1 (1.0 g, 100 % yield) as yellow foam.

[00522] *H NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 3.77 (s, 3H), 4.45 (m, 1H), 4.58 (m, 1H), 5.22 (m, 1H), 6.97 (d, J = 8.2 Hz, 2H), 7.85 9s, 4H), 7.92 (d, J = 8.2 Hz, 2H).

[00523] MS (m/z, ES*): 484.17

147

Step 2: tert-Butyl [{4-[3-amino-2-(aminooxy)-3-oxopropoxy]phenyl)(imino)methy!]carbamate (3-.83-2) [00524] Compound 3_83_1 (1.0 g, 4.29 mmol) was dissolved in a methanolic solution of 7N ammonia (10 ml), stirred at room température for 24 hours and filtered. The filtrate was concentrated to give compound 3_83_2 (0.7 g, 100 % yield), which was used in the next step without further purification.

[00525] NMR (400 MHz, DMSO-d₆): δ = 1.42 (s, 9H), 4.20-<50(m, 3H), 6.40 (br. s, 2H), 6.97 (d, J = 8.2 Hz, 2H), 7.85 (s, 4H), 7.92 (d, J = 8.2 Hz, 2H).

[00526] MS (m/z, ES+): 339.11

3.84 tert-Butyl [(4-{[l-(aminooxy)-3-hydroxypropan-2-Yl]oxy}phenYl)(imino)methyl]' carbamate

OAc tbsq

OH OH step 1

3_84_1

PtittiN-OH

TBSO ÔH

84 2

NHBoc

K.CO, step 6 step 5

NHBoc

NHBoc hydrazme hydrate

TBAF HO step 3

NHBoc

Step 1:3-{[tert-Butyl(dimethyl)silyl]oxy}-2-hydroxypropyl acetate (3_84_2) [00527] Tert-butyldimethylchlorosilane (TBSCI, 28.2 g, 180.1 mmol) was added portion wise to a mixture of compound 3_84_1 (27 g, 189.6 mmol; ref.: J. Med. Chem. 1989,2104-2110), triethylamine (36.9 mL, 265.4 mmol) and 4-dimethylaminopyridine (1.38 g, 11.4 mmol) in dichloromethane (250 mL). The reaction mixture was stirred at room température overnight, filtered and the filtrate was concentrated. The residue was dissolved in EtOAc, filtered again to w

148 remove any solid, and the filtrate was concentrated to give a residue, which was purified by column chromatography eluting with 30% EtOAc in hexane to give compound 3_84_2 (22 g, 46 % yield) as an oil.

[005281 ^XH NMR (400 MHz, CDC1₃): δ = 0.07 (s, 6 H), 0.89 (s, 9 H), 2.08 (s, 3 H), 2.49 (d, J=5.5 Hz, 1 H), 3.57 - 3.65 (m, 1 H), 3.65 - 3.73 (m, 1 H), 3.82 - 3.93 (m, 1 H), 4.04 - 4.21 (m, 2 H).

Step 2: 2-{4-[N-(tert-Butoxycarbonyl)carbamimidoyl]phenoxy)-3-{[tert-butyl(dimethyl)silyl]oxy}propyl acetate (3_84_3) [00529] Triphenylphosphine (4.33 g, 16.53 mmol) was added to a mixture of compound 3_84_2 (3.5 g, 14.11 mmol) and tert-butyl [(4-hydroxyphenyl)(imino)methyl]carbamate (3.26 g, 13.78 mmol) în tetrahydrofuran (100 mL), and diisopropyl azodicarboxylate (4.17 mL, 20.67 mmol) at 0 ^SC, and the mixture was stirred at room température for 16 h. The mixture was concentrated to give a residue, which was purified by column chromatography eluting with 30% EtOAc in hexane to give compound 3_84_3 (6.5 g, 99 % yield) as a yellow solid.

[005301 *H NMR (400 MHz, CDCI₃): δ = 0.09 (m, 6 H), 0.87 (s, 9 H), 1.55 (s, 9 H), 2.04 (s, 3 H), 3.75 - 3.86 (m, 2 H), 425 - 4.41 (m, 2 H), 4.51 - 4.64 (m, 1 H), 6.98 (d, J = 9.0 Hz, 2 H), 7.83 (d, J = 9.0 Hz, 2 H).

Step 3: 2-{4-[N-(tert-Butoxycarbonyl)carbamimidoyl]phenoxy}-3-hydroxYpropyl acetate (3_84_4) [00531] Tetra-n-butylammonïum fluoride (TBAF, IN in tetrahydrofuran, 39.9 mL, 39.9 mmol) was added to a solution of compound 3_84_3 (9.3 g, 19.9 mmol) in tetrahydrofuran (100 mL) under cooling, and the mixture was stirred at room température for 2 h and concentrated to give a residue, which was purified by column chromatography to give compound 3_84_4 (3.6 g, 51 % yield) as a gum.

[00532] ^XH NMR (400 MHz, CDCI₃): Ô = 1.55 (s, 9 H), 2.06 (s, 3 H), 3.85 (dd, J = 5.1,2.3 Hz, 2 H), 4.24 - 4.32 (m, 1 H), 435 - 4.45 (m, 1 H), 4.62 (t, J = 5.1 Hz, 1 H), 7.01 (d, J = 9.0 Hz, 2 H), 7.84 (d, J = 9.0 Hz, 2 H).

149

Step 4: 2-{4-[N-(tert-Butoxycarbonyl)carbamimidoy!]phenoxy}-3-[(L3-dioxo-l,3-dihydro-2Hi$oindol-2-y!)oxy]propyl acetate (3_84_5) [00533] Diisopropyl azodicarboxylate (3.11 mL, 15.42 mmol) was added to a solution of compound 3_84_4 (3.62 g, 10.28 mmol), N-hydroxyphthalimide (PhthN-OH, 2.34 g, 14.39 mmol) and trîphenylphosphine (3.50 g, 13.36 mmol) in tetrahydrofuran (100 mL) at 0C, and the mixture was stirred at room température for 4 h. The mixture was concentrated, extracted with EtOAc, washed with a saturated sodium bicarbonate solution and brine, dried over sodium sulfate and concentrated to give a residue, which was purified by column chromatography to give compound 3_84_5 (3.4 g, 66 % yield) as a white solid.

[00534] ^XH NMR (400 MHz, CDCI₃): δ = 1.54 (s, 9 H), 2.08 (s, 3 H), 4.41 - 4.50 (m, 4 H),

4.91 - 5.00 (m, 1 H), 6.98 (d, J = 9.0 Hz, 2 H), 7.70 - 7.86 (m, 6 H).

Step 5: 3-(Aminooxy)-2-{4-[N-(tert-butoxycarbonyl)carbamimidoyl]phenoxy}propyl acetate (3_84_6) [00535] Hydrazine monohydrate (0.34 g, 6.84 mmol) was added to a solution of 3_84_S (3.4 g, 6.84 mmol) in anhydrous éthanol (40 mL) under cooling and the resulting mixture was stirred at room température for 5 h and filtered and the filtrate was concentrated to afford crude compound 3_84_6 (2.4 g, 96 % yield) as a solid, which was used without purification.

[00536] ^XH NMR (400 MHz, CDCIj): δ = 1.55 (s, 9 H), 2.05 (s, 3 H), 3.81 - 3.94 (m, 2 H),

4.26 - 4.37 (m, 2 H), 4.82 - 4.87 (m, 1 H), 7.04 (d, J = 9.0 Hz, 2 H), 7.83 (d, J = 9.0 Hz, 2 H).

Step 6: tert-Butyl [(4-{[l-(aminooxy)-3-hydroxypropan-2-yl]oxy}phenyl)(imino)methyl]carbamate (3-84.7) [00537] Potassium carbonate (0.9 g, 6.53 mmol) was added to a solution of compound 3_84-6 (2.4 g, 6.53 mmol) in anhydrous methanol (40 mL) under cooling and the resulting mixture was stirred for 1 h, concentrated, extracted with EtOAc, washed with brine, dried over anhydrous \J^

150 sodium sulfate, and filtered and the filtrate was concentrated to give compound 3_84_7 (1.57 g, 74 % yield) as a gum, which was used without further purification.

[00538] ^XH NMR (400 MHz, DMSO-d₆): δ - E1.42 (s, 9 H), 3.56 (m, 2 H), 3.72 (m, 2 H),

4.62 (t, J = 5.2 Hz, 1 H), 4.90 (s, 1 H), 6.10 (s, 2 H}, 7.02 (d, J = 8.4 Hz, 2 H), 7.90 (d, J = 8.4 Hz, 2 H).

3.85 Dipheny1methyl2-(aminooxy)-3-{3-hydroxy-4-[N-(tert-butoxycarbonyl)carbamimidoYl] phenoxyj-propanoate

Step 1: 2-Fluoro-4-(tetrahydro-2H-pyran-2-yloxy)benzonitrile (3_85_2) vt/^-

151 [00539] 3,4-Dihydro-2H-pyran (DHP, 7.20 mL, 79.12 mmol) was added to a mixture of 2-fluoro-4-hydroxy-benzonitri!e (5.42 g, 39.56 mmol) and pyridium p-toluenesulfonate (PPTS, 170 mg, 0.68 mmol) in dry dichloromethane (100 mL) and the mixture was stirred at room température for 16 hours and concentrated. The residue was purified by column chromatography to give compound 3_85_2 (8.9 g, 100 % yield) as a dear oil.

Step 2: 6-(Tetrahydro-pyran-2-yloxy)-benzo[d]isoxazol-3-ylamine (3_85_3) [00540] Potassium tert-butoxide (8.96 g, 80 mmol) was added in portions to a solution of N-hydroxy acetamide (6.00 g, 80 mmol) in N,N-dimethylformamide (40 mL). After the addition was complété, the resulting mixture was stirred at room température for 1 hour. A solution of 2fluoro-4-(tetrahydro-2H-pyran-2-yloxy)benzonitrile 3_85_2 (8.90 g, 40 mmol) in N,Ndimethylformamide (20 mL) was added and the resulting mixture was stirred at room température for 24 hours and concentrated. The residue was diluted with ethyl acetate (200 mL), washed with water (20 mL) and brine (20 mL), dried and concentrated. The residue was purified by column chromatography to give compound 3_85_3 (6.5 g, 69 % yield).

Step 3: 3-Amino-l,2-benzoxazol-6-ol (3_85_4) [00541] IN hydrochloric acid solution (10 mL) was added to a solution of 6-(tetrahydropyran-2-yloxy)-benzo[d]isoxazol-3-ylamine 3_85_3 (6.5 g, 27.77 mmol) in methanol (30 mL) and the mixture was stirred at room température for 1 hour and concentrated. The residue was purified by column chromatography to give compound 3_85_4 (4.10 g, 100 % yield) as a white solid.

[00542] ^JH NMR (400 MHz, DMSO-d₆): δ = 6.20 (br. s, 2H), 6.70 (m, 2H), 7.59 (d, J = 9.4 Hz, IH), 10.05 (br. s, IH).

Step 4: 3-[(3-Amino-l,2-benzoxazol-6-yl)oxy]-2-hydroxypropanoate (3_85_5) [00543] A mixture of 3_85_4 (7.31 g, 63 mmol) and potassium carbonate (11.60 g, 84 mmol) in dry acetonitrile (40 mL) was refluxed for 5 hours and filtered. The filtrate was concen17341

152 trated and purified by column chromatography to give compound 3_85_5 (1.43 g, 26 % yield) as a sticky gum.

[00544] ^XH NMR (400 MHz, COCI₃): 6 = 1.27 (t, J = 9.5 Hz, 3H), 3.20 (d, J = 2 Hz, 1H), 4.20-4.40 (m, 4H, 439 (m, 1H), 6.83 (d, J = 8.6 Hz, 1H), 7.28 (s, 1H), 7.40 (d, J = 8.6 Hz, 1H).

Step 5: 3-(4-Carbamimidoyl-3-hydroxyphenoxy)-2-hydroxypropanoate (3_85_6) [00545] 5% palladium on charcoal (140 mg) was added to a degassed solution of

3_85_5 (330 mg, 1.24 mmol) in methanol (30 ml). The mixture was stirred under hydrogen with a balloon for 2 hours and filtered through a pad of Celite. The filtrate was concentrated to give compound 3_85_6 (310 mg, 93 % yield).

[00546] ^XH NMR (400 MHz, COjOD): δ = 1.23 (t, J « 8.8 Hz, 3H), 4.20-4.30 (m, 4H), 4.50 (m, 1H), 6.15 (d, J = 9.2 Hz, 1H), 6.20 (s, 1H), 7.43 (d, J = 9.2 Hz, 1H).

[00547] MS (ES*): 269.10 (Calcd: 268.11} [00548] Following the same procedure as described above under 3.45 but using intermediate 3_85_6 instead of3_45_4 compound 3_85_7 was obtained. (K*

153

4. Oxime formation, coupîing reaction and de-protection

[00549] Ketoacid 2_x (1.7 mmol) was added to a solution of compound 3_x (1.7 mmol) in anhydrous éthanol (30 mL) and chloroform (10 mL) and the resulting mixture was stirred at room température ovemight and concentrated under reduced pressure. The residue was recrystallized from éthanol or purified by column chromatography to afford compound 4_3 (24 % 91% yield) as a yellow solid.

[00550] Dicydohexylcarbodiimide (DCC, 0.29 g, 1.41 mmol) and 1-hydroxybenzotriazole (HOBT, 0.14 g, 1.41 mmol) were added to a solution of compound 4_3 (0.706 mmol) in N.N10 dimethylformamide (15 mL) at room température. After stirring at room température for 30 minutes, 3-amino-azetidin-2-one l_x (1.06 mmol) was added followed by sodium bicarbonate (0.23 g, 2.8 mmol). The resulting mixture was stirred at room température ovemight and concentrated under reduced pressure at40’C.The residue was purified by column chromatography eluting with 5-10 % methanol in dichloromethane to give compound 4_5 (8 % - 90 % yield) as a yellow solid.

[00551] A solution of compound 4_5 (0.42 mmol) in 90 % formic acid (15 mL) or trifluoroacetic acid / dichloromethane (1:1,10 mL) was stirred at 40*C for 40 min. After concentratîng to dryness under reduced pressure, the residue was stirred with water (20 mL) for 20 min.

154

After filtration, the filtrate was lyophilized to give the crude product which was purified by prepHPLC to afford compound 4_6 (S % - 78 % yield) as formate or TFA sait as a colorless solid.

[00552] The compounds 4_6 of Examples 1-111 were prepared according to the procedures detailed above. The compound of Example 38 was prepared by treating the compound of Example 24 with isopropyl formimidate hydrochloride In the presence of potassium carbonate (conditions see e.g. US 2009/0012054). The compound of Example 43 was prepared by treating the compound of Example 39 with ethanimidoate hydrochloride in the presence of potassium carbonate (conditions see e.g. US 2009/0012054). The compound of Example 46 was prepared by oxidizing the compound of Example 81 with Jones reagent (conditions see e.g. Kenneth Bowden, I. M. Heilbron, E. R. H. Jones and B. G L Weedon, J. Chem. Soc., 1946,39-45). The compounds of Example 87 were prepared by oxidizing the compound of Example 112 with Jones reagent (conditions see e.g. Kenneth Bowden, I. M. Heilbron, E. R. H. Jones and B. C. L Weedon, J. Chem. Soc., 1946,39-45) followed by a standard de-protection and HPLC séparation.

[00553] The compound of Example 78 was prepared by treating the compound of Example 24 with dîisopropylethylamine followed by di-tert-butyl [(Z)-lH-pyrazol-l-yl-methylylidene]biscarbamate at room température for 15 hours (conditions see e.g. WO 2009/49028 Al). The compound of Example 60 was prepared by treating the compound of Example 59 with formic acid as formylating agent. The compound of Example 63 was prepared by treating the compound of Example 64 with formic acid as formylating agent.

[00554] For the convenience of the reader the structures of the final compounds as well as used building blocks (l_x, 2_x and 3_x) are provided in table 3, which is followed by analytical data for ail examples.

Table 3. Structures of final compounds and used building blocks

Example

Structure

BB 1 (1_x) BB 2 (2_x) BB 3 (3_x)

I55

1	OH NH o	1_5_11	2_1_1	3_44_6
2	TT ⁰ Ά n nu	1_1_1	2_1_1	3_44_6
3	u un A ^AV„₀ 0 A 0 OH	1_1_1	211	3_32_5
4	NH .“-CjrJ'Vt' » ^S 0 O—jj—OH O	1_5_11	2_1_1	3_32_5
5	r/-* /A'o'V •h/ïV.» o A 0 OH	1_1_1	2_1_1	3_34_5
6	. 6· v_	1_1_1	2_1_1	3_10_6

156

2_1_1 3_10_6

211 3 25 6

11 3 01 6

211 3 01 6

2_1_1 3016

11 3 01 6

157

ο

1_5_11 2_1_1 3_46_3

1_1_1 2_1_1 3_46_3

1_5_11 2_1_1 3_47_5

211 3 01 6

2_1_1 3_37_7

211 3 36 8

158

ο

1_5_11	2_1_1	3_48_5
1_5_11	2_1_1	3_51_5

	2 11	3_15_6

159

2_1_1 3_50_4

26A

111 211 3 45 9

1_1_1 2_1_1 3_45_9

27A

5 11 211 3 45 9

27B

EpinwA

1511 211 3 45 9

1_1_1 2_1_1 3_30_6

160

5 11 211 3 30 6

1_1_1 2_1_1 3_31_6

111 211 3 38 11

1_1_1 2_1_1 3_27_6

1511 211 3 49 7

34A xxS .οΛ

1_5_11 2JI_1 3_85_7

EptwA

161

211 3_85_7

1_1_1 2_1_1 3_28_7

36A

Ephwr A

1511 211 3 60 7

36B

1_5_11 2_1_1 3 60 7

1_1_1 2_1_1 3_07_6

from example 24

162

5 11 211 3 52 5

1_5_11 2_1_1 3196

1_5_11 2_1_1 3_01_6

1_5_11 2_1_1 3_53_5

EptatA from example 39

1_5_11 2_1_1 3_59_3

163

5 11 2 1 1 3 59 3

44B

45A

45B

5 11 211 3 61 7

Epimer B

from example 81 (mixture of epimers)

1_2_1 2_1_1 3_01_6

1_3_1 2_1_1 3_07_6

164

1_1_1 2_1_1 3_02_6

1_1_1 2_1_1 3_08_6

1_1_1 2_1_1 3_09_6

1_1_1	2_2_1	3_01_6
1-V1	2_1_1 '	3_03_6

1-1-1	2_1_1	3_11_6

165

1_1_1	2_1_1	3_26_5
1_5_11	2_1_1	3_24_5

1_5_11	2_1_1	3_07_6

1_1_1	2_1_1	3_29_5

from example 59

166

from example 64

1_1_1 2_1_1 3_35_5

u/—

167

1_1_1	2_1_1	3_40_10

1_1_1	2_1_1	3_12_6

1_1_1	2_1_1	3_13_6

1_1_1 2_1_1 3_42_10

1_1_1 2_1_1 3_41_10

168

5 11 2 1 1 3 20 6

5 11 2 1 1 3 43 10

1_5_11 2_1_1 3_83_2

o o

from example 24

169

81A

81B

EpinwA

Ο

Ep™· B

1_5.11	2_1_1	3_18_6

1_5_11	2_1_1	3_58_8

1-5_11	2_1_1	3_58_8

1_5_11	2_1_1	3_33_5

170

5 11 211

3_21_6

1_5_11 2_1_1

5 11 211 from example 112 from example 112

1_5_11 2_1_1 3_72_8

I71

1_5_11	211	3_57_8 3_66_8
2_1,	_1

	2_1.	_1	3 69 8

172

5 11 2 1 1 3 65 8

1_5_11 2_1_1 3_67_8

5 11 211 3 74 8

1_5_11 2_1_1 3_75_8

2_1_1 3_78_8

173

5 11 211

101

100 A

100B

63 8

5 11

76 8

102

103

5 11

70 8

80 8

71 8

104

174

1_5_11 2_1_1 3_81_8

105

1_5_11 2_1_1 3_77_8

1.	_5J1	2_1_1	3_64_8
1.	_5_11	2_1_1	3_62_8

1.	_5_11	2_1_1	3_68_8

1.	_5_11	2_1JI	3_79_8

[00555] Analytical data for examples 1-112 (structures shown above):

Example 1 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoyl-3-hydroxyphenoxy)ethoxy]imino}-N5 [{3S)-2,2-dïmethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00556] ’H NMR (400 MHz, DMSO-d₆): δ = 1.23 (s, 3 H), 1.40 (s, 3 H), 4.19 (m, 2H), 4.38 (m, 2H), 4.59 (d, J = 8.0 Hz, 1H), 6.49 (s, 1 H), 6.57 (d, J= 8.8 Hz, 1H,), 6.76 (s, 1 H), 7.21 (br s, 2 H), 7.57 (d, J = 8.8 Hz, 1H), 9.49 (d, J = 8.0 Hz, 1H).

[00557] MS (ES*) m/r. [M+H]* calcd for CjgH^NyOgS;: 558.11. Found: 558.14.

[00558] HPLC: 98.63%

Example 2 (2S,3S)-3-{[(2Z)-2-(2-Amino-l,3-thîazol-4-yl)-2-{[2-(4-carbamimidoy1-3hydroxyphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid aY

176 [00559] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.33 (d, J = 6.2 Hz, 3 H), 3.67 (m., 1 H), 4.22 (m, 2H), 4.35 (m, 2H), 4.41 (m, 1H), 6.45 (br. s, 1H,), 6.52 (m, 1H), 6.79 (s, 1 H), 7.22 (m, 2H), 7.56 (d, J = 8.8 Hz, 1H), 9.32 (m, 1H).

[00560] MS (ES*) m/z: [M-H]' calcd for C₁₈H₂₀N7O₈S₂:526.08. Found: 526.13.

[00561] HPLC: 91.43 %

Example 3 (2S,3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-y!)-2-({2-[(6-carbamimidoylpyridin-3yl)oxy]ethoxy}imrno)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonîc acid [00562] *H NMR (400 MHz, DMSO-<f₆): δ = 1.35 (d, J = 6.2 Hz, 3 H), 3.66 (dd, J = 6.0 and 2.5 Hz, 1 H}, 4.26 - 4.57 (m, 5 H), 6.78 (s, 1 H), 7.76 (dd, J = 8.9 and 2.7 Hz, 1 H), 8.26 (d, J = 8.9 Hz, 1 H), 8.52 (d, J = 2.3 Hz, 1 H}, 8.95 (s, 2 H), 9.21 - 9.49 (m, 3 H).

[00563] MS (ES^-) m/r. [M-H]* calcd for Ci₇H_MN_aO₇S₂:512.09. Found: 512.53.

[00564] HPLC: 96.60 %

Example 4 (2Z)-2-(2-AmÎno-l,3-thiazol-4-yl)-2-({2-[(6-carbamimidoylpyridin-3-yl)oxy]ethoxy}imïno)-N-[(3S)-

2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00565] *H NMR (400 MHz, DMS0-d₆): δ = 1.23 (s, 3 H), 1.40 (s, 3 H), 3.77 (d, J = 3.9 Hz, 1 H), 4.42 (d, J = 4.6 Hz, 3 H), 4.59 (d, J = 7.8 Hz, 1 H), 7.21 (s, 2 H), 7.74 (dd, J = 8.7 and 2.9 Hz, 1 H), 8.12 - 8.40 (m, 2 H), 8.49 (d, J = 2.7 Hz, 1 H), 9.44 (d, J = 8.2 Hz, 3 H).

100566] MS (ES·) m/r. [M-H]’ calcd for C^HaNgOjS/ 541.09. Found: 541.23.

[00567] HPLC: 88.45 %

177

Example 5 (25.35) -3-([(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(5-carbamimidoylpyridîn-2-yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-su!fonic acid [005681 *H NMR (400 MHz, DMSO-d₆): δ = 1.33 (d, J = 6.2 Hz, 3 H), 3.61 (dd, J = 6.0 and 2.5 Hz, 1 H), 4.35 - 4.49 (m, 3 H), 4.49 - 4.71 (m, 2 H), 6.79 (s, 1 H), 7.12 (d, J = 8.9 Hz, 1 H), 8.10 (dd, J = 8.7 and 2.5 Hz, 1 H), 8.64 (d, J = 1.9 Hz, 1 H), 8.86 (s, 4 H), 9.12 - 9.43 (m, 2 H).

[00569] MS (ES ) m/z: [M-H]' calcd for C₁₇H₁₉N₈O₇S₂:511.08. Found: 511.13.

[005701 HPLC: 96.6 %

Example 6 (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(4-carbamimidoylphenyl)suïfanyl]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid [00571] *H NMR (400 MHz, DMS0-d₆): δ = 1.40 (d, J = 5.8 Hz, 3 H), 3.28 - 3.40 (m, 2 H), 3.73 (dd, J = 6.0 and 2.5 Hz, 1 H), 4.25 (t, J = 6.2 Hz, 2 H), 4.44 (dd, J = 7.8 and 2.3 Hz, 1 H), 6.78 and 8.16 (2s, 1 H), 7.22 (br. s, 2 H), 7.57 (m, 2 H), 7.76 (m, 2 H), 8.85 (br. s, 2 H), 9.26 (s, 2 H), 9.21 (s, 1 H).

[00572] MS (ES*) m/r. [M+H]* calcd for C^H^O^: 528.08. Found: 527.97.

[00573] HPLC: 98.3 %

Example 7 (2Z)-2-(2-Amino-l,3-thia2ol-4-yl)-2-({2-[(4-carbamimidoylphenyl)sulfanyl]ethoxy)imino)-N-[(3S)'

2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide

178 [00574] ^JH NMR (400 MHz, DMSO-d₆): δ = 1.29 (s, 3 H), 1.43 (s, 3 H), 3.38 (t, J = 6.6 Hz, 2 H), 4.25 (t, J = 6.6 Hz, 2 H), 4.61 (d, J = 7.8 Hz, 1 H), 6.82 (s, 1 H), 7.5 (br. s, 2H), 7.55 (d, J = 8.6 Hz, 2 H), 7.75 (d, J = 8.6 Hz, 2 H), 8.82 (s, 2 H), 9.23 (s, 2 H), 9.46 (d, J = 7.8 Hz, 1 H).

[00575] MS (ES*} m/r. [M+H]* calcd for C₁₉H₂₄N₇O₇S₃:558.09. Found: 558.09.

[00576] HPLC: 92.85%

Example 8 (25.35) -3-{[{2Z)-2-(2-Amino-l,3-thïazol-4-Yl}-2-((2-[(4-carbamimidoylphenyl)amino]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-su!fonic acid [00577] ^XH NMR (400 MHz, DMSO-dg): δ = 136 (d, J = 6.2 Hz, 3 H), 3.45 (t, J = 4.8 Hz, 2 H), 3.66 (dd, J = 6.2 and 2.3 Hz, 1 H), 4.20 (t, J = 5.0 Hz, 2 H), 4.45 (dd, J = 8.0 and 2.S Hz, 1 H), 6.66 - 6.86 (m, 3 H), 7.65 (d, J = 8.9 Hz, 2 H), 8.28 (br. s, 2 H), 8.77 (s, 2 H), 9.27 (d, J = 7.8 Hz, 1 H).

[00578] MS (ES*) m/r. [M+H]* calcd for C^NgOeS^ 511.12. Found: 510.96.

[00579] HPLC: 95.40%

Example 9 (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid [00580] 'H NMR (400 MHz, DMS0-d₆): δ = 1.33 (d, J = 6.3 Hz, 3 H), 3.64 (dd, J = 6.1 and 2.7 Hz, 2 H), 4.34 (d, J = 5.3 Hz, 2 H), 4.36 - 4.49 (m, 3 H), 6.78 (s, 1 H), 7.21 (d, J = 8.8 Hz, 2 H), 7.80 (d, J = 8.8 Hz, 2 H), 8.67 (s, 2 H}, 9.13 (s, 2 H), 9.31 (d, J = 9.2 Hz, 1 H).

[00581] MS (ES*) m/r. [M+H]* calcd for 512.09. Found: 512.13.

[00582] HPLC: 99.00%

179

Example 10 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[(2R,3S)-2methyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00583] ^XH NMR {400 MHz, DMSO-d_e): δ = 1.11 (d, J = 6.2 Hz, 3 H), 4.20 - 4.44 (m, 5 H), 5 4.85 - 5.04 (m, 1 H), 6.79 (s, 1 H), 7.18 (d, J = 8.2 Hz, 3 H}, 7.80 (d, J = 8.9 Hz, 2 H), 8.67 (s, 2 H),

9.15 (s, 2 H), 9.34 (d, J = 8.6 Hz, 1 H).

[00584] MS (ES*) m/r. [M+H]* calcd for C^NtO^: 528.10. Found: 527.90.

[00585] HPLC: 92.10%

Example 11 (2R,3S)-3-{[(2Z)-2-{2-Amino-l,3-thiazol-4-yl)’2-{[2-{4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyM-oxoazetidine-l-sulfonic acid [00586] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.33 (d, J = 6.2 Hz, 3 H), 3.64 (dd, J = 6.0 and 2.1 Hz, 1 H), 4.33 (br. s, 2 H), 4.35 - 4.47 (m, 3 H), 6.76 (s, 1 H), 7.15 - 7.27 (m, 4 H), 7.80 (d, J = 8.5 Hz, 2 H), 8.65 (br. s, 2 H), 9.12 (br. s, 2 H), 9.29 (d, J = 8.2 Hz, 1 H).

[00587] MS (ES) m/z: [M-H] calcd for CUH20N7O7SJ: 510.09. Found: 510.02.

[00588] HPLC: 95.60 %

Example 12 {[(2S,3S)-3-([(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-([2-(4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidin-l-yl]oxY)methanesulfonicacÎd —17341

180 [00589] *H NMR (400 MHz, DMSO<): δ = 1.30 (d, J = 7.8,1 H), 3.96 (dd, J = 6.2 and 1.9 Hz, 1 H), 4.25 - 4.35 (m, 2 H), 4.35 - 4.47 (m, 4 H), 6.76 (s, 1 H), 7.11 - 7.29 (m, 4 H), 7.82 (d, J = 8.9 Hz, 2 H), 9.03 (br. s, 4 H), 9.25 (d, J = 7.8 Hz, 1 H).

[005901 MS (ES! m/z: [M-H]’ calcd for Ci₉H₂₂N₇O₈S₂: 540.10. Found: 540.10.

[00591] HPLQ 98.51 %

Example 13 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoyl-3-methylphenoxy)ethoxy]imino]-N-[{3S)-

2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00592] *H NMR (400 MHz, DMS0-d₆): δ = 1.23 (s, 3 H), 1.41 (s, 3 H), 2.37 (s, 3 H), 4.20 4.31 (m, 2 H), 4.40 (t, J = 4.3 Hz, 2 H), 4.59 (d, J = 7.8 Hz, 1 H), 6.79 (s, 1 H), 6.89 7.06 (m, 1 H),

7.40 (d, J = 8.6 Hz, 1 H), 8.85 (s, 2 H), 9.11 (s, 2 H), 9.48 (d, J = 7.8 Hz, 1 H).

[00593] MS (ES*) m/z: [M-H]’ calcd for C₂₀H₂₄N₇O₈S₂:554.11. Found: 554.14.

[00594] HPLC: 97.18%

Example 14 (2S,3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamtmidoyl-3-methylphenoxy)ethoxy]imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00595] *H NMR (400 MHz, DMS0<): δ = 1.34 (d, J = 6.2 Hz, 3 H), 2.36 (s, 3 H,) 3.60 (dd, J = 6.0 and 2.5 Hz, 1 H), 4.24 - 4.31 (m, 2 H), 4.35 - 4.40 (m, 2 H), 4.43 (dd, J = 8.2 and 2.7 Hz, 1 H), 6.75 (s, 1 H), 6.92 - 7.05 (m, 2 H), 7.21 (s, 2 H), 7.39 (d, J = 8.6 Hz, 1 H), 8.90 (br. s, 2 H), 9.09 (br. s, 2 H), 9.27 (d, J = 8.2 Hz, 1 H).

[00596] MS (ES*) m/z: [M-H]' calcd for C^H^N^S/ 524.10. Found: 524.06. yv—

181 [00597] HPLC: 96.56%

Example 15 (2Z)-2-(2-Amino-l,3-thiazo1-4-yl)-2-({2-[(2-carbamimidoy1pyridin-4-y1)oxy]etboxy}imino)-N-[(3S)-

2,2-dimethyl-4-oxo-l-{sulfooxy)azetidin-3-yl]ethanamide [00598] ’H NMR (400MHz, DMSO<f₆): δ = 1.22 (s, 3H), 1.40 (s, 3H), 4.36 - 4.44 (m,4H), 4.57 (d, J = 2.3 Hz, 1H), 6.76 (s, 1H), 7.19 (s, 2H), 7.36 (m, 1H), 7.86 (s, 1H), 8.61 (m, 1H), 9.20 -

9.40 (br. s, 2H), 9.45 (m, J = 8.2 Hz, 1H).

[00599] MS (ES*) m/r. [M+H]* calcd for (WMA: 543.11. Found: 543.08.

[00600] HPLC: 98.52 %

Example 16 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-([2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[2-oxo-l($ulfooxy)-l-aza$piro[3.4]oct-3-yl]ethanamide [00601] ’H NMR (400 MHz, DMS0<): δ = 1.20 -1.60 (m, 4H), 1.70 -1.90 (m, 3H), 2.10 - 2.20 (m, 1H), 4.30 (br. s, 2H), 4.40 (br. s, 2H), 4.65 (d, J = 8.3 Hz, 1H), 6.96 (s, 1H), 7.20 (m, 4H), 7.80 (d, J = 9.2 Hz, 2H), 8.80 (br. s, 2H), 9.10 (br. s, 2H), 9.48 (d, J = 8.3 Hz, 1H).

[00602] MS (ES*) m/r. [M+H]* calcd for C^H^NtC^: 568.13. Found: 568.17.

[00603] HPLC: 97.04 %

Example 17 (2S,35)-3-{[(22j-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy}-2-methylpropoxy]imino}acetyl]amino}-2-methyM-oxoazetidine-l-sulfonic acid fjj17341

182 [00604] *H NMR (400 MHz, DMSO-tf₆): δ = 1.24 -1.47 (d, 3H), 3.71 (br. s, 1H), 4.15 (s, 2H), 4.44 (br. s, 1H), 6.74 (s, 1H), 7.25 (d, J = 8.5 Hz, 2H), 7.22 (br. s, 2H), 7.77 (d, J = 8.5 Hz, 2H,) 8.96 (br. s, 1H), 9.36 (br. s, 1H).

[00605] MS (ES*) m/r. [M+H]* calcd for Ο^Ν/^: 540.13. Found: 540.17.

[00606] HPLC 92.38 %

Example 18 (25.35) -3-{[[2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({[l-(4-carbamimidoylphenoxy)-2-methy!propan-2yl]oxy}imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00607] ¹H NMR (400 MHz, DMSO-d₆): δ = 1.28 -1.46 (m, 9H), 3.66 (dd, J = 6.1 and 2.3 Hz, 1H), 4.10 (d, J = 1.9 Hz, 2H), 4.44 (dd, J = 7.9 and 2.5 Hz, 1H), 6.72 (s, 1H), 7.09 - 7.31 (m, 4H), 7.80 (d, J = 8.8 Hz, 2H), 8.65 (br. s, 2H), 8.98 - 9.20 (m, 3H).

[00608] MS (ES*) m/z: (M+H]* calcd for Οκ^ΝτΟ^: 540.13. Found: 540.08.

[00609] HPLC: 97.8%

Example 19 (25.35) -3-(I(2Z}-2-(2-Amino-l,3-thïazol-4-yl}-2-{[2-(4-carbamimidoy!-2-fluorophenoxy)ethoxy]imino]acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00610] *H NMR (400 MHz, DMSO-d₆): δ = 1.34 (d, J = 6.0 Hz, 3H), 4.27 - 4.52 (m, 4H), 6.77 (S, 1H), 7.40 - 7.54 (m, 1H), 7.78 (d, J = 2.5 Hz, 1H), 7.75 (s, 1 H), 8.80 (br. s, 2H), 9.19 (br. s, 2H), 9.31 (S, 1H).

[00611] MS (ES) m/z: [M-H]' calcd for C^H^N^S/ 528.08. Found: 528.06.

183 [00612] HPLC: 97.7 %

Example 20 (25.35) -3-([(22)-2-(2-Amino-l,3-thiazol-4-yl}-2-{[2-(4-carbamimidoyl-2chlorophenoxy)ethoxy]îmino]acetyl]amino)-2-methyl-4-oxoazetidine-l-sulfonic acid [00613] ^XH NMR (400 MHz, DMSO-d_fi): δ = 1.35 (d, J = 5.8 Hz, 3H), 3.66 (dd, J = 6.0 and 2.5 Hz, IH), 4.44 (s, 4H), 6.76 (s, IH), 7.22 (s, 2H), 7.41 (d, J = 8.6 Hz, IH), 7.69 - 7.89 (m, IH), 7.96 (d, J = 1.9 Hz, IH), 9.28 (d, J = 7.4 Hz, 4H).

[00614] MS (ES*) m/r. [M+H]* calcd for CjsHnCINzO^: 546.06. Found: 546.15.

[00615] HPLC: 99.0%

Example 21 (25.35) -3 -(((22)-2-(2 -Amîno-l,3-thiazol-4-yl)-2-({2-[4-(N-hydroxyca rba m ïm idoyl) p henoxy]ethoxy)imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00616] ^XH NMR (400 MHz, DMS0-d₆): δ = 1.33 (d, J = 6.0 Hz, 3H), 3.64 (m, IH), 4.25 (m, 2H), 4.40-4.42 (m, 3H), 6.78 (s, IH), 7.20 (d, J = 8.8 Hz, 2H), 7.40 (br. s, 2H), 7.68 (d, J = 9.2 Hz, 2H), 8.85 (br. s, IH), 9.20 (br. s, IH) 9.31 (d, J = 7.6 Hz, 2H), 10.97 (s, IH).

[00617] MS (ES*) m/r. (M+H]* calcd for C₁₈H₂₂N₇O₈S₂: 528.10. Found: 528.15.

[00618] HPLC: 95.6 %

Example 22 (22)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(4-carbamimidoylpyridin-2-y1)oxyîethoxy}îmino)-N-[{3S)-

2,2-dimethyl-4-oxo-l-(sulfooxy)azetidîn-3-yl]ethanamide H/

184 [00619] *H NMR (400 MHz, DMSO-d₆): 6 = 1.23 (s, 3H), 1.40 (s, 3H), 4.38 - 4.41 (m, 2H),

4.50 - 4.54 (m, 2H), 4.58 (d, J = 7.8 Hz, 1H), 6.75 (s, 1H), 7.20 (s, 2H), 7.22 (s, 1H), 7.32 (d, J = 5.0 Hz, 1H), 8.40 (d, J = 5.4 Hz, 1H), 9.30 (br. s, 1H), 9.45 (d, J = 8.2 Hz, 1H).

[00620] MS (ES*} m/z: [M+H]* calcd for CuHjjNsOgS^ 543.11. Found: 542.98.

[00621] HPLC: 91.72 %

Example 23 ( 2Z)-2-(2-Am ino-l,3-thiazo l-4-yl)-N-[(3S)-2,2-di m et hy1-4-oxo-l-( sulfooxy )a zetidi n-3-y l]-2-[(2-{4-[N(piperidin-4-yl)carbamimidoy!]phenoxy}ethoxy)imino]ethanamide [00622] ^XH NMR (400 MHz, DMSO-4₆): δ « 1.21 (s, 3H), 1.39 (s, 3H), 1.51 -1.57 (m, 2H), 1.82 -1.90 (m, 2H), 2.52 - 2.68 (m, 2H), 3.04 - 3.13 (m, 2H), 3.66 - 3.79 (m, 1H), 4.26 - 4.32 (m, 2H),

4.40 - 4.43 (m, 2H), 4.58 (d, J = 7.8 Hz, 1H), 6.77 (S, 1H), 7.16 (d, J = 8.9 Hz, 2H), 7.21 (s, 2H), 7.70 (d, J = 8.6 Hz, 2H), 9.44 (d, J = 8.2 Hz, 1H).

[00623] MS (ES') m/z: [M-HJ* calcd for C₂₄H₃iN₈O₈S₂: 623.17. Found: 622.94.

[00624] HPLC: 96.71 %

Example 24 (2Z)-2-[(2-{4-[N-(2-Aminoethyl)carbamimïdoyl]phenoxy}ethoxy)imino]-2-(2-amino-l,3-thiazol'4yl)-N-[(3S}-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00625] ^XH NMR (400 MHz, DMSO-d₆+TFA): δ = 1.18 (s, 3H), 1.38 (s, 3H), 2.48 (t, J = 1.7 Hz, 2H), 3.95 (S, 4H), 4.29 - 4.45 (m, 2H), 4.44 - 4.58 (m, 2H), 4.59 (d, J = 7.8 Hz, 1H), 6.96 (s, 1H), 6.97 (s, 1H), 7.08 (s, 1H), 7.14 - 7.27 (m, 4H), 7.89 (d, J = 8.9 Hz, 2H), 9.68 (d, J = 7.8 Hz, 1H), 10.27 (s, 1H).

[00626] MS (ES·) m/z: [M-H]' calcd for C₂₁H₂₇N₈O₈S₂:583.14. Found: 583.14

185 [00627] HPLC: 98.64%

Example 25 (2Z)’2-(2-Amino-l,3-thiazol-4-y1)-2-({2-[4-(4,5-dihydro-lH-imidazo!-2-yl)phenoxy]ethoxy)imino}-N[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00628] *H NMR (400 MHz, DMSO-d₆+TFA): δ = 1.19 (s, 3H), 1.38 (s, 3H), 3.94 (s, 4H),

4.33 - 4.43 (m, 2H), 4.47 - 4.56 (m, 2H), 4.60 (d, J = 7.8 Hz, 1H}, 6.98 (s, 1H), 7.18 (d, J = 8.6 Hz, 2H), 7.89 (d, J = 8.6 Hz, 2H), 9.69 (d, J = 7.4 Hz, 1H), 10.26 (s, 1H), 12.05 -12.49 (m, 3H).

[00629] MS (ES*) m/z: [M-H]calcd for C₂₁H₂₄N₇O₈S₂: 566.11: Found: 566.16 [00630] HPLC: 98.64 %

Example 26 (2S and 2R)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(2S, 3S)-2-methyl-4-oxo-l-sulfoazetidin-3yl]amino}-2-oxoethylidene]amino}oxy}-3-(4-carbamidinoyl-phenoxy)propanoicacid

Eplmer A [00631] *H NMR (400 MHz, DMS0-d₆): δ = 1.29 (d, J = 6.2 Hz, 3H), 3.61 (dd, J = 5.7 and

2.8 Hz, 1H), 4.31 - 4.55 (m, 3H), 4.82 (br. s., 1H), 6.53 (s, 1H), 6.79 (s, 1H), 7.11 - 7.30 (m, 4H), 7.78 (d, J = 9.1 Hz, 2H), 8.85 (br. s., 2H), 9.08 (br. s., 2H], [00632] MS (ES ) m/z: [M-H]' calcd for ^,ΗμΝ/^: 554.08. Found: 554.20.

[00633] HPLC: 99.59 % (RT: 11.050 min).

Epimer B

186 [00634] ’H NMR (400 MHz, DMSO-d_s): Ô = 1.33 (d, J = 6.2 Hz, 3H), 3.75 (br. s.» IH), 4.33 - 4.58 (m, 3H), 4.85 (br. s., IH), 6.51 (s, IH), 6.82 (s, IH), 7.15 - 7.29 (m, 4H), 7.78 (d, J = 9.1 Hz, 2H), 8.75 - 8.91 (m, 2H), 9.09 (s, 2H).

[00635] MS (ES·) m/z: [M-H] calcd for C^H^O^: 554.08. Found: 554.20.

100636] HPLC: 98.82 % (RT: 11.168 min).

Example 27 (2S and2/ï)-2’({[(lZ}-l-(2-Amino-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin3-yl]amino]-2-oxoethylidene]amino}oxy}-3-(4-carbamimidoylphenoxy)propanoicacÎd

187

Epinier A [00637) ’H NMR (400 MHz, DMSO-c/₆): δ = 1.10 (s, 3H) 1.40 (s, 3H), 4.40 (m, 2H), 4.60 (d, J = 6.6 Hz, 1H), 5.0 (m, 1H), 6.80 (s, 1H), 7.17 (d, J = 8.8 Hz, 2H), 7.24 (br. s, 2H), 7.80 (d, J = 8.8 Hz, 2H), 8.60 (s, 2H), 9.27 (s, 2H), 9.40 (d, J = 6.6 Hz, 1H). ” F NMR: - 74.

[00638] MS (ES·) m/r. [M-H]* calcd for ^Η^ΝτΟ^: 584.09. Found: S84.08.

[00639] HPLC: 97.15%.

Epimer B [00640] ’H NMR (400 MHz, DMSO-d₆): δ = 1.24 (s, 3H) 1.420 (s, 3H), 4.45 (m, 2H), 4.60 (d, J = 6.6 Hz, 1H), 5.0 (m, 1H), 6.80 (s, 1H), 7.20 (d, J = 8.8 Hz, 2H), 7.24 (br. s, 2H), 7.80 (d, J = 8.8 Hz, 2H), 8.64 (s, 2H), 9.18 (s, 2H), 9.40 (d, J = 6.6 Hz, 1H). ” F NMR: - 74.

[00641] MS (ES*) m/r. [M-H]' calcd for CmHjjNjOmSj: 584.09. Found: 584.08.

[00642] HPLC: 97.08 %.

Example 28 (2S,3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazof-4-yl)-2-({2-I(6-carbamimidoy1pyridazin-3yl)oxY]ethoxy}imino)acety!]amino}-2-methyl-4-oxoazetidine-l-sulfonÎcacid [00643] ‘H NMR (400 MHz, DMS0-d₆): δ = 1.35 (d, J = 6.2 Hz, 3H), 3.62 (dd, J = 6.3 and 2.8 Hz, 1H), 4.42 (dd, J = 7.9 and 2.6 Hz, 1H), 4.48 (t, J = 4.4 Hz, 2H), 4.69 - 4.85 (m, 2H), 6.76 (s, 1H), 7.22 (s, 2H), 7.64 (d, J = 9.4 Hz, 1H), 8.31 (d, J = 9.4 Hz, 1H), 9.26 (d, J = 7.9 Hz, 1H).

[00644] MS (ES ) m/r. [M-H]' calcd for Ci₆H₁₈N₉O₇S₂:512.51. Found: 512.08.

[00645] HPLC: 92.31 %. vxx

188

Example 29 (2Z)-2-(2-Amino-l,3-thîazol-4-yl)-2-({2-[(6-carbamimidoylpyridazin-3-yl)oxyJ-ethoxy}imino)-N[{3S)-2,2-dimethyl-4-oxo-l-{sulfooxy)azetidin-3-yl]ethanamide [00646] ’H NMR (400 MHz, DMSO-d_fi): δ = 1.24 (s, 3H), 1.40 (s, 3H), 4.45 - 4.52 (m, 2H), 5 4.56 (d, J = 7.6 Hz, 1H), 4.68 - 4.84 (m, 2H), 6.79 (s, 1H), 7.62 (d, J = 9.4 Hz, 1H), 8.31 (d, J = 9.4 Hz,

1H), 9.23 (br. s., 2H), 9.46 (br. s, 1H), 9.69 (br. s, 2H).

[00647] MS (ES] m/r. [M-H]' calcd for C₁₇H_MN₉O₈S₂:542.54. Found: 542.13.

[00648] HPLC: 91.40%.

Example 30 (25,35)-3-{[{2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-((2-[{5-carbamimidoylpyrazin-2-yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid [00649] ’H NMR (400 MHz, DMSO-d₆): δ = 1.36 (d, J = 6.2 Hz, 3H), 3.64 (dd, J = 6.3 and 2.5 Hz, 1H), 4.32 - 4.54 (m, 3H), 4.60 - 4.77 (m, 2H), 6.80 (s, 1H), 8.58 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 1.2 Hz, 1H), 9.11 (S, 2H), 9.31 (d, J = 7.9 Hz, 1H), 9.47 (s, 2H).

[00650] MS (ES] m/z: [M-H]’ calcd for C₁₆Hi8N₉O₇S₂:512.51. Found: 512.20.

[00651] HPLC: 95.45 %.

Example 31 (25,3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-((2-[(4-carbamimidoyl-l,3-thiazo!-2yl)oxy]ethoxy}îmino)acetyl]amîno}-2-methyl-4-oxoazetidine-l-$ulfonicactd vL·^-

189 [00652] ‘H NMR (400 MHz, DMSO-d₆): δ = 1.37 (d, J = 6.2 Hz, 3H), 3.58 - 3.72 (m, IH), 4.36 - 4.55 (m, 3H), 4.64 - 4.76 (m, 2H), 6.79 (s, 1 H), 8.26 (s, IH), 8.91 (s, 2H), 9.14 (s, 2H), 9.33 (d, J = 7.9 Hz, IH).

[00653] MS (ES') m/z: [M-H]’ calcd for C^H₁₇N_aO₇S₃:517.55. Found: 517.23.

[00654] HPLC: 98.78 %.

Example 32 (2S,3S)-3-{[(7Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{2-[(4-carbamimÎdoylthiophen-2yl)methoxy]imino)acetyl]amino]-2-methyl-4-oxoazetidine-l-sulfonÎcacid [00655] ¹H NMR (400 MHz, DMSO-d₆): δ =01.38 (d, J = 6.2 Hz, 3 H), 3.68 (dd, J = 6.2 and 2.6 Hz, IH), 4.42 (dd, J = 7.9 and 2.6 Hz, IH), 5.29 (s, 2H), 6.79 (s, IH), 7.23 (s, 2H), 7.61 (s, IH), 8.49 (d, J = 1.5 Hz, IH), 8.66 (s, 2H], 9.17 (s, 2H), 9.34 (d, J = 7.6 Hz, IH).

[00656] MS (ES*) m/z: [M+H]* calcd for C₁₅H₁₈N₇O₆S₃:488.54. Found: 488.00.

[00657] HPLC: 95.07 %.

Example 33 (2Z)-2-(2-Amino-l,3-thiazol-4-yl}-2-({2’[(6-carbamimÎdoyl-5-hydroxypyridin-3yl)oxy]ethoxy)imino)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy}azetidin-3-yl]ethanamlde [00658] ^JH NMR (400 MHz, DMSO-d₆): δ = 1.23 (s, 3H), 1.40 (s, 3H), 4.34 (t, J = 4.4 Hz, 2H), 4.44 (t, J = 4.1 Hz, 2H), 4.60 (d, J = 8.2 Hz, IH), 6.79 (s, 1 H), 6.97 (d, J = 2.6 Hz, IH), 8.04 (d, J = 2.3 Hz, IH), 8.61 (s, 2H), 8.84 (s, 2H), 9.45 (d, J = 7.9 Hz, IH).

[00659] MS (ES*) m/z: [M-H]‘ calcd for CuHjiNeOA: 557.55. Found: 557.08.

[00660] HPLC: 94.21 %. 0/^

190

Example 34 (2S and 2R)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dîmethyl-4-oxo-l-($u1fooxy)azetidin3-yl]amino}-2-oxoethylidene]amino}oxY)-3-(4-carbamimidoyl-3-hydroxyphenoxy)propanoicacid

EpimerA [00661] *H NMR (400 MHz, DMSO-d₆): δ « 1.19 (s, 3H), 1.41 (s, 3H), 4.30-4.40 (m, 2H), 4.60 (d, J = 8.4 Hz, 1H), 4.95 (m, 1H), 6.51 (s, 1H), 6.60 (m, 1H), 6.80 (s, 1H), 7.25 (br s, 2H), 7.57 (d, J = 9.2 Hz, 1H ), 8.48 (s, 2H), 8.82 (s, 2H), 9.40 (d, J = 8.4 Hz, 1H), 11.29 (s, 1H).¹⁹ F NMR: - 74 ppm.

[00662] MS (ES*) m/z: [M-H]* calcd for C_MH₂₂N₇0iiS₂:600.08. Found: 600.06.

[00663] HPLC: 91.6 %.

Epimer B [00664] *H NMR (400 MHz, DMS0-d₆): δ = 1.24 (s, 3H) 1.420 (s, 3H), 4.45 (m, 2H), 4.60 (d, J = 6.6 Hz, 1H), 5.0 (m, 1H), 6.80 (s, 1H), 7.20 (d, J = 8.8 Hz, 2H), 7.24 (br s, 2H), 7.80 (d, J = 8.8 Hz, 2H), 8.64 (s, 2H), 9.18 (s, 2H), 9.40 (d, J = 6.6 Hz, 1H).

¹⁹F NMR:-74 ppm.

[00665] MS (ES*) m/z: [M-H]' calcd for C₂₀H₂₂N₇O_uS₂: 600.08. Found: 600.06.

[00666] HPLC: 95.4 %.

Example 35 (25,3S)-3-([(2Z)-2-{[2-(2-Amino-4-carbamimidoylphenoxy)ethoxy]imino}-2-(2-amino-l,3-thiazoMyl)acetyl]amino]-2-methy!-4-oxoazetÎdine-l-sulfonicacid [00667] ^XH NMR(400 MHz, DMSO-d₆): δ = 1.32 (d, J = 6.4 Hz, 3H), 3.52 - 3.69 (m, 1H), 4.25 - 4.35 (m, 2H), 4.37 - 4.50 (m, 3H), 6.79 (s, 1H), 6.92 - 7.12 (m, 3H), 8.56 (s, 2H), 8.99 (s, 2H), 9.32 (d, J = 7.3 Hz, 1H). W—

191 [006681 MS (ES ) m/z: [M-H]' calcd for ^ΗηΙ^ΟΛ: 525.55. Found: 525.16.

[00669] HPLC: 98.17%.

Example 36 (2S and 2R)-2-({[{lZ)-l-(2-AmÎno-l,3-thiazol-4-yl)-2-{((3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin5 3-yl]amino}-2-oxoethylidene]amino}oxy)-3-[(6-carbamimidoylpyridin-3-yl)oxyÎpropanoicacid

Eplmer A [00670] *H NMR (400 MHz, DMSO-d₆): δ =131.21 (s, 3H), 1.42 (s, 3H), 4.56 (m, 2H), 4.66 (d, J = 8.6 Hz, IH), 4.76 - 4.98 (br, IH), 6.54 (s, lH)s, 6.81 (s, IH), 7.19 (s, IH), 7.78 (dd, J = 8.8 and 2.9 Hz, 2H), 8.25 (d, J = 8.6 Hz, IH), 8.53 (s, J = 2.3 Hz, IH), 9.09 (br. s, 2H), 9.34 (br. s, 2H).

[00671] MS (ES) m/z: [M-H]' calcd for ^Η^ΝΑΑ: 585.10. Found: 585.15.

[00672] HPLC: 92.9 %.

Eplmer B [00673] *H NMR (400 MHz, DMSO-<f₆): δ = 1.28 (s, 3H), 1.42 (s, 3H), 4.35 - 4.49 (m, IH), 4.59 (d, J = 8.2 Hz, 2H), 4.72 - 4.91 (m, IH), 6.54 (s, IH), 6.84 (s, IH), 7.19 (s, 2H), 7.80 (d, J = 2.7

Hz, IH), 8.25 (d, J = 9.0 Hz, IH], 8.51 (d, J = 2.3 Hz, IH), 9.13 (br. s, 2H), 9.33 (br. s, 2H).

[00674] MS (ES) m/z: [M-H]’ calcd for C₁₉H₂₂N₈O_loS2:585.10, Found: 585.15.

[00675] HPLC: 91.5 %. çix

192

Example 37 (2S, 3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-I{3-(4-carbamimidoylphenoxy)propoxy]imino}acetyl]amino]-2-methy!-4-oxoazetidine-l-sulfonicacîd [00676] *H NMR (400 MHz, DMSO-d₆): δ = 1.27 (d, J = 8.20 Hz, 3H), 2.01 - 2.11 (m, 2H), 3.58 - 3.68 (m, 1H), 4.10 - 4.17 (m, 2H), 4.22 (t, J = 5.66 Hz, 2H), 4.43 (dd, J = 8.20,2.73 Hz, 1H), 6.75 (s, 1H), 7.14 (d, J = 8.98 Hz, 2H), 7.78 (d, J = 8.59 Hz, 2H), 8.66 (br. s., 2H), 9.07 (br. s., 2H), 9.33 (d, J =8.20 Hz, 1H).

[00677] MS (ES*) m/r. [M+H]* calcd for Ο^ΝτΟ^: 525.57. Found: 526.27.

[00678] HPIC: 98.74%

Example 38 (2Z)-2-{2-Amino-l,3-thiazol-4-y!)-W-[(3S)-l-hydroxy-2,2-dimethyl-4-oxoazetidin-3-yl]-2-({2-[4-(/V{2-[(iminomethyl)amîno]ethyl}carbamimidoyl}phenoxy]ethoxy}Îmino}ethanamide [00679] ^JH NMR (400 MHz, DMSO-d₆ + TFA): δ = 1.18 (s, 3H), 1.38 (s, 3H), 3.56 (br s, 4H), 4.340 - 4.37 (m, 2H), 4.50-4.52 (m, 2H), 4.60 (d, J = 7.6 Hz, 1H), 6.98 (s, 1H), 7.15 - 7.18 (m, 2H), 7.71 - 7.73 (m, 2H), 7.96 - 7.98 (m, 1H), 8.11 (s, 1H), 9.00 - 9.10 (m, 2H), 9.32 - 9.53 (m, 2H), 9.61-9.69 (m,2H).

[00680] MS (ES*) m/z: [M+H]* calcd for CuHaoNgOgSî: 612.17. Found: 612.01.

[00681] HPLC: 90.08%

Example 39 [22)-2-(2-Amîno-l,3-thiazol-4-yl)-W-[{3S)-2,2’dimethyl-4-oxo-l-(sulfooxy)azetidin-3-y!]-2-{[2-{4-{W[(3S)-pyrrolidin-3-yl]carbamimidoyl)phenoxy}ethoxy]imino}ethanamide yS

193 [00682] ’H NMR (400 MHz, DMSO-d₆): δ = 1.21 ($, 3H), 1.39 (s, 3H), 1.79 -1.97 (m, 1H), 2.12 - 2.20 (m, 1H), 2.80 - 2.97 (m, 1H), 3.00 - 3.15 (m, 3H), 4.14 -4.20 (m, 1H), 4.26 - 4.30 (m, 2H), 4.38 - 4.42 (m, 2H), 4.58 (d, J = 7.82 Hz, 1H), 6.77 (s, 1H), 7.14 (d, J = 9.0 Hz, 2H), 7.21 (s, 1H), 7.71 (d, J = 9.0 Hz, 2H), 9.44 (d, J = 7.8 Hz, 1H).

[00683] MS (ES*) m/r. [M-H]' calcd for C₂₃H₂₉N₈O₈S₂:609.16. Found: 609.00.

[00684] HPLC: 91.82 %

Example 40 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-{N-[2-(dîmethylamino)ethyl]carbamimidoyl}phenoxy)ethoxy]îmino}-W-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidîn-3-yl]ethanamide [00685] ’H NMR (400 MHz, DMS0-d₆): 5 = 1.19 (s, 3H), 1.39 (s, 3H), 2.50 (s, 6H), 3.34 3.53 (m, 2H), 3.68 - 3.84 (m, 2H), 4.21 - 4.37 (m, 2H), 4.37 - 4.50 (m, 2H), 4.59 (d, J = 7.8 Hz, 1H), 6.81 (s, 1H), 7.19 (d, J = 8.99 Hz, 2H), 7.53 (br. s, 1H), 7.79 (d, J = 8.9 Hz, 2H), 9.10 (s, 1H), 9.48 (d, J = 7.8 Hz, 1H), 9.57 (br. s, 2H), 9.84 (br. s, 1H).

(006861 MS (ES·) m/r. [M-H]‘ calcd for C₂₃H₃₃N₈O₈S₂:611.17. Found: 611.01 [00687] HPLC: 97.87 %

Example 41 {2Z)-2-(2-Amino-l,3-thîazol-4-yl}-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[{3$)-2,2dîmethyl-4-oxo-l-(sulfooxy)azetidin-3-yI]ethanamide [006881 ’H NMR (400 MHz, DMS0-d₆): δ =01.21 (s, 3H) 1.39 (s, 3H) 4.19 - 4.50 (m, 4H) 4.59 (d, J = 7.8 Hz, 1H) 6.79 (s, 1H) 7.06 - 7.31 (m, 2H) 7.81 (d, J = 8.9 Hz, 2H) 8.67 (s, 2H) 9.14 (s, 2H)9.47 (d, J = 7.8 Hz, 1H).

[006891 MS (ES*) m/r. [M+HJ* calcd for C₁₉H₂₃N₇O₈S₂: 542.10. Found: 542.01.

194

100690] HPLC: 92.4 %.

Example 42 (4S)-4-{[{4-[2-({[(lZ)-l-(2-Amîno-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin3-yl]amino}-2-oxoethylidene]amino}oxy)ethoxy]phenyl}{imÎno)methyl]amino}-/V,N-dimethy1-Lprolinamide [00691] ’H NMR (400 MHz, DMS0-d_s): δ = 1.19 (s, 3H), 1.38 (s, 3H), 2.03-2.10 (m, IH), 2.40-2.50 (m, IH), 2.80-3.10 (m, 2H), 2.94 (s, 3H), 3.00 (s, 3H), 4.27-4.32 (m, 2H), 4.404.43 (m, 2H), 4.44-4.53 (m,lH], 4.57 (d, J = 8.2 Hz, IH), 4.65-4.75 (m, IH), 6.78 (s, IH), 7.20 (d, J = 8.2 Hz, 2H), 7.20-7.39 (m, IH), 7.73 (d, J = 8.2 Hz, 2H), 8.71-8.85 (m, IH], 9.18 (br. s, IH), 9.35-9.47 (m, 2H), 9.59 (br. s, IH}, 9.89-10.01 (m, IH).

[00692] MS (ES) m/z: [M-H]’ calcd for C^H^N^S/ 680.19. Found: 680.05.

[00693] HPLC: 91.92 %

Example 43 (22)-2-(2-Amîno-l,3-thiazol-4-Yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]-2-{[2-(4-(N[(3S)-l-ethanimidoylpyrrondîn-3-yl]carbamimidoyl}phenoxy}ethoxy]imino)ethanamide [00694] ’H NMR (400 MHz, DMS0-d₆): S = 1.19 (s, 3H), 1.39 (s, 3H), 2.25 (d, J = 5.4 Hz, 3H), 3.49-3.65 (m, 2H), 3.69-3.83 (m, 3H), 3.85-3.98 (m, IH), 4.28-1.30 (m, 2H), 4.404.42 (m, 2H), 4.47-4.49 (m, IH), 4.57 (d, J = 8.2 Hz, IH), 6.78 (s, IH), 7.18 (d, J = 9.0 Hz, 2H), 7.24-7.40 (m, IH), 7.72 (d, J = 8.2 Hz, 2H), 8.45 (s, IH), 9.15-9.35 (m, 2H), 9.44 (d, J = 7.4 Hz, IH), 9.45-9.55 (m, IH), 9.61-9.70 (m, IH).

[00695] MS (ES*) m/z: [M+H]* calcd for CkH^NsOsSï: 652.20. Found: 651.92.

[00696] HPLC: 86.7 % \TV^

I95

Example 44 (2Rand2S)-3-{4-[N-(2-Aminoethyl)carbamimidoyl]phenoxyF2-(([(lZ)-l-(2-amino-l,3-thiazol-4-yl)2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetîdin-3-yl]amino}-2-oxoethylidene]amino}oxy)propanoic acid

Epi mer A [00697] ’H NMR (400 MHz, DMSO-d₆): 5 = 1.26 (s, 3H), 1.35 (s, 3H), 3.14 - 3.21 (m, 2H), 3.57 - 3.62 (m, 2H), 4.37 - 4.46 (m, 2H), 4.57 (d, J = 8.0 Hz, 1H), 4.95 - 4.96 (m, 1H), 6.51 (br. s, 1H), 6.78 (s, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.23 (br. S, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.87 (br. s, 3H), 8.98 (br. s, 1H), 9.38 (d, J = 73 Hz, 1H), 9.48 (br. s, 2H).

[00698] MS (ES*) m/z: [M-H]' calcd for ΟυΗ^ΟκΑ: 627.13. Found: 626.99.

[00699] HPLC: 97.08 % (RT: 8.435 min).

EpfrnerB [00700] *H NMR (400 MHz, DMSO-cf₆): δ = 1.22 (s, 3H), 1.37 (s, 3H), 3.15 - 3.22 (m, 2H), 3.57 - 3.62 (m, 2H), 4.42 - 4.44 (m, 2H), 4.56 (d, J = 7.6 Hz, 1H), 4.95 - 4.99 (m, 1H), 6.50 (br. s, 1H), 6.80 (s, 1H), 7.18 -7.22 (m, 4H), 7.80 (d, J = 8.8 Hz, 2H), 7.84 (br. s, 3H), 8.98 (br. s, 1H), 9.35 (d, J = 73 Hz, 1H), 9.43-9.47 (br. s, 2H).

[00701] MS (ES) m/z: [M-H]’ calcd for C₂₂H₂₇N₈O₁₀S₂: 627.13. Found: 626.99.

[00702] HPLC: 97.02 % (RT: 8.793 min).

Example 45 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({[(2R and 2S)-l-(4-carbamimidoylphenoxy)-3-hydroxypropa n2-yl]oxy}imîno)-/V-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide

EpImerA

196 [00703] ^JH NMR (400 MHz, DMSO-d₆): 5 = 1.20 (s, 3H), 1.40 (s, 3H), 3.59 - 3.77 (m, 2H), 4.21 - 4.29 (m, 2H), 4.38 - 4.44 (m, 1H), 4.56 (d, J = 7.6 Hz, 1H}, 6.78 (s, 1H], 7.18 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 9.1 Hz, 2H), 8.66 (s, 2H), 9.14 (s, 2H), 9.37 (d, J = 7.6 Hz, 1H).

[00704] MS (ES*) m/z: [M-H]' calcd for CjoHmN^A: 570.11. Found: 570.08.

[00705] HPLC: 87.39 % (RT: 2.210 min).

Epimer B [00706] *H NMR (400 MHz, DMSO-d₆): δ = 1.21 (s, 3H), 1.36 (s, 3H), 3.65 - 3.72 (m, 2H),

4.15 - 4.22 (m, 1H), 4.24 - 4.30 (m, 1H), 4.38 - 4.44 (m, 1H), 4.56 (d, J = 7.6 Hz, 1H), 6.78 (s, 1H),

7.16 (d, J = 9.1 Hz, 2H), 7.79 (d, J = 9.1 Hz, 2H), 8.64 (s, 2H), 9.12 (s, 2H), 9.34 (d, J - 7.6 Hz, 1H).

[00707] MS (ES*) m/z: [M-H]' calcd for C₂₀H₂₄N₇O₉S₂:570.11. Found: 570.08.

[00708] HPLC: 92.48 % (RT: 2.317 min).

Example 46

3-({[(lZ)-l-{2-Amino-l,3-thïazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amino}2-oxoethylidene]amino}oxy)-4-(4-carbamimidoylphenoxy)butanoic acid [00709] Ή NMR (400 MHz, DMSO-d₆): δ = 1.24 (d, 3H), 1.40 (s, 3H), 2.65 - 2.76 (m, 2H), 4.26 (d, J = 5.5 Hz, 2H), 4.57 (dd, J = 7.6 and 3.7 Hz, 1H,) 4.77 (br. s, 1H), 6.79 (s, 1H), 7.18 (dd, J = 9.0 and 3.1 Hz, 2H), 7.23 - 7.32 (br. s, 2H), 7.81 (d, J = 7.4 Hz, 2H), 8.70 (br. s, 2H), 9.13 (s, 2H), 9.36 (m, 1H).

[00710] MS (ES*) m/r. [M+H]* calcd for CjiHbNtOmSj: 600.11. Found: 599.98.

[00711] HPLC: 95.2%.

Example 47

197 (2Z)-2-(2-Amino-l,3-thia2ol-4-yl)-2’([2-{4<arbamimidoylphenoxy)ethoxy]imino}-N-[(2S,3S)-2methyl-4-oxo-l-(sulfooxy)a2etidin-3-yl]ethanamide [00712] ’H NMR (400 MHz, DMSO-d₆): δ = 1.32 (d, J = 6.2 Hz, 3H), 3.90 (m, 1H), 4.28 4.48 (m, 2H), 4.40 - 4.48 (m, 3H), 6.78 (s, 1H), 7.28 -7.32 (m, 3H), 7.80 (d, J = 8.9 Hz, 2H), 8.67 (s, 2H), 9.15 (s, 2H>, 9.44 (d, J = 8.6 Hz, 1H).

100713] MS (ES*) m/r. (M+H)* calcd for 528.10. Found: 528.10 (007141 HPLC: 92.75%.

Example 48 (2R,3S)-3-([(2Z)-2-(2-Amino-l,3-thiazol-4-yl)'2-{[3-{4-carbamimidoylphenoxy)propoxy]imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid [00715] 'H NMR (400 MHz, DMSO-d_Ê): δ = 1.30 (d, J = 6.2 Hz, 3H), 2.08 (m, 2H), 3.17 4.25 (m, 5H), 4.44 (dd, J = 2.4 and 7.8 Hz, 1H), 6.77 (s, 1H), 7.11 (d, J = 9.0 Hz, 2H), 7.80 (d, J = 9.0 Hz, 2H), 8.68 (S, 2H), 9.09 (s, 2H), 9.35 (d, J = 8.2 Hz, 1H).

[00716] MS (ES*) m/r. [M+H]* calcd for C_l9H₂₄N₇O₇S₂: 526.12. Found: 526.08.

[00717) HPLC: 94.79%.

Example 49 (2S,3S)-3-{[{2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(2-bromo-4-carbamimidoylphenoxy)ethoxy]imino)acetyl]amino)-2-methyl-4-oxoazetidine-l-sulfonic acid [00718] ^JH NMR (400 MHz, DMSO-d₆): δ = 1.36 (d, J = 6.2 Hz, 3H), 3.67 (dd, J = 2.7 and 5.8 Hz, 1H), 4.36 - 4.52 (m, 5H), 6.79 (s, 1H), 7.37 (d, J = 8.9 Hz, 1H), 7.86 (d, J = 1.9 Hz, 1H), 8.10 (d, J = 2.3 Hz, 1H), 8.80 (br. s., 2H), 9.20 (br. s, 2H), 9.30 (br. s, 1H).

198 [00719] MS (EST) m/z: [M-H]' calcd for CuHajBrNTOjSj: 590.00; found: 589.88.

[00720] HPLC: 93.93 %.

Example 50 (25.35) -3-([(2Z)-2-(2-AmÎno-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidamidophenoxy}eth- oxy]imino}acetyl]amino}-2-methyM-oxoazetidine-l-sulfonic acid [00721] ’H NMR (400 MHz, DMS0-d₆): δ = 1.35 (d, J = 6.4 Hz, 2H), 3.64 (m, IH), 4.24 (m, 2H), 4.42 (m, 2H), 4.44 (m, IH), 6.80 (s, IH), 7.03 (d, J = 8.4 Hz, 2H}, 7.17 (s, 6H), 9.34 (s, IH), 9.36 (s, IH).

[00722] MS (ES*) m/r. [M+H]* calcd for CuH^NgO^: 527.10. Found: 527.02.

[00723] HPLC: 93.93%.

Example 51 (25.35) '3’{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[3-(4-carbamimidamidophenoxy)propoxy]imino}acetyl]amino}-2-methy1-4-oxoazetidine-l-$ulfonic acid [00724] ’H NMR (400 MHz, DMSO-d₆): δ = 1.35 (d, J = 6.0 Hz, 2H,), 2.07 (m, 2H), 3.65 (m, IH), 4.06 (t, J = 6.0 Hz, 2H), 4.23 (t, J = 6.0 Hz, 2H), 4.50 (m, IH), 6.78 (s, IH), 7.01 (d, J = 8.8 Hz,

2H), 7.16 (br. s, 6H), 9.33 (s, IH), 9.36 (d, J =8.8 Hz, IH).

[00725] MS (ES*) m/r. [M+H]* calcd for C₁₉H₂₄N₈O₇S₂:541.12. Found: 541.01.

[00726] HPLC: 95.00%.

Example 52

199 (2Z)-2-(5-Amino-l,2,4-thiadiazo!-3-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[(2S,3S)-l-hydroxy-2-methyl-4-oxoazetidin-3-yl]ethanamÎde [007271 *H NMR (400 MHz, DMSO-d_fi): δ = 1.32 (d, J = 6.0 Hz, 3H), 3.57 (m, 2H), 4.34 (m, 2H), 4.40 (dd, J = 2.4 and 7.6 Hz, 2H), 4.49 (m, 2H), 7.21 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H),

8.16 (s, 2H), 8.67 (s, 2H), 9.13 (s, 2H), 9.33 (s, 2H).

[007281 MS (ES*) m/z: [M+H]* calcd for C₁₇H₂₀N_gO₇S₂: 512.09. Found: 512.85.

[00729] HPLC: 91.20 %.

Example 53 (25.35) -3-{[(2Z)-2-(2’Amino-l,3’thiazol-4-yl}-2-{[2-(3-carbamimidoylphenoxy)eth' oxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00730] *H NMR (400 MHz, DMS0-d₆): δ = 1.33 (d, J = 6.0 Hz, 3H), 3.66 (qd, J= 2.5 and 6.0 Hz, 1H), 4.26 - 4.36 (m, 2H), 4.36 - 4.51 (m, 3H), 6.82 (s, 1H), 7.30 - 7.41 (m, 3H), 7.51 (t, J = 8.0 Hz, 1H), 8.94 (br. s, 2H), 9.25 (br. s, 2H], 9.37 (d, J = 7.9 Hz, 1H).

[00731] MS (ES·) m/z: [M-H]' calcd for C^NtO^: 512.09. Found: 511.97.

[00732] HPLC: 90.81 %.

Example 54 (25.35) -3-(((2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-[(2-{4-[N-(propan-2-yl)carbamimidoyl]phenoxy}ethoxy)imino]acetyl}amîno)-2-methyl-4-oxoazetidine-l-sulfonic acid [007331 *H NMR (400 MHz, DMSO-<f₆): δ = 1.23 (d, J = 6.4 Hz, 6H), 1.31 (d, J = 6.4 Hz, 3H), 3.6 (m, 1H), 3.9 (m, 1H), 4.29 (d, J = 4.0 Hz, 2H), 4.39 (m, 3H), 6.73 ($, 1H), 7.17 (m, 4H), 7.65 (d, J = 8.8 Hz, 2H), 8.68 (s, 2H), 9.06 (br. s, 1H), 9.26 (d, J = 8.0 Hz, 1H).

200 [00734] MS (ES) m/z: [M-H]' calcd for 552.13. Found: 551.90.

[00735] HPLC: 94.27 %.

Example 55 (2S,3$)-3-{[(2Z)-2-{2-Amino-l,3-thîazol-4-yl)-2-{[(4-carbaniimidoylbenzy!)oxy]inriino}acetyl]amino}5 2-methyl-4-oxoazetidine-l-sulfonic acid [00736] ³H NMR (400 MHz, DMS0-d₆): δ = 1.38 (d, J = 6.4 Hz, 3H), 3.65 (dd, J = 2.5 and 6.0 Ηζ,ΙΗ), 4.45 (dd, J = 2.9 and 7.9 Ηζ,ΙΗ), 5.26 (s, 1H), 6.78 (s, 1H], 7.28 (br. s, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H), 8.86 (s, 2H), 9.24 (s, 1H), 9.44 (d, J = 7.9 Hz, 1H).

[00737] MS (ES*) m/z: [M+H]* calcd for C₁₇H₂₀N7O₆S₂:482.09. Found: 481.93.

[00738] HPLC: 96.47%.

201

Example 56 (2S,3S)-3’{[(2Z)-2-(2-Amîno-l,3-thiazol-4-yl)-2-({2-[(4-carbamimidoylthiophen-2-yl)methoxy]ethoxy}imino}acetyl]amino]-2-methyl-4-oxoazetidine-l-sulfonicacid [00739] ’H NMR (400 MHz, DMSO-d₆): δ = 1.36 (d, 3H}, 3.61 - 3.80 (m, 3H), 4.16 - 4.28 5 (m, 2H), 4.41 (dd, J = 7.9,2.6 Hz, 1H), 4.71 (s, 2H), 6.72 (s, 1 H), 7.20 (s, 2H), 7.55 (s, 1H), 8.45 (d, J = 1.5 Hz, 1H), 8.70 (br. s, 2H), 9.10 (br. s, 2H), 9.28 (d, J = 7.6 Hz, 1H).

[00740] MS (ES) m/z: [M-H]' calcd for CnH^N^Sj:530.59. Found: 530.07.

[00741] HPLC: 97.62%.

Example 57 (2Z)-2-(2-Amino*l,3-thiazol-4-yl)-2-{[{4-carbamimÎdoylbenzyl)oxy]imino)-N-[{3S)-2,2-dimethyl-4oxo-l*(sulfooxy)azetidin-3-yl]ethanamide [00742] *H NMR (400 MHz, DMSO-d₆): δ = 1.22 (s, 3H), 1.43 ($, 3H), 4.60 - 4.66 (m, 1H), 5.25 (s, 2H), 6.75 (s, 1H), 7.20 (s, 2H), 7.59 (d, J = 8.6 Hz, 2H), 7.78 (d, J = 8.6 Hz, 2H), 8.22 (s, 1H), 9.07 - 9.17 (m, 2H), 9.19 - 9.27 (m, 1H), 9.59 (d, J = 7.9 Hz, 1H).

[00743] MS (ES^-) m/z: [M-H]’ calcd for Ο^Η^Ν,Ο^: 510.08. Found: 510.16.

[00744] HPLC: 99.75 %.

Example 58 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[3-(4-carbamimidoylphenoxy)propoxy]imino}-/V-[(35)-2,2dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide 17341

202 [00745] *H NMR (400 MHz, DMSO-d_fi): δ = 1.23 (s, 3H), 1.39 (s, 3H), 2.03 - 2.13 (m, 2H),

4.17 (t, J = 8.0 Hz, 2H), 4.23 (t, J = 8.0 Hz, 2H), 4.60 (d, J = 7.9 Hz, IH), 6.76 (s, IH), 7.16 (d, J = 9.2 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 8.67 (s, 2 H), 9.12 (s, 2H), 9.49 (d, J = 7.9 Hz, IH).

[00746] MS (ES*) m/r. [M+H]* calcd for C_MH_2SN7O_eS₂:556.12. Found: 556.14.

[00747] HPLC: 98.10%.

203

Example 59 (25,35)-3-{[(2Z)-2-(2-Amino-l, 3-thiazol-4-yl)-2-({2-[4-€arbamimidoyl-2-(hydroxymethyl) phenoxy]ethoxy)imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid (00748] ’H NMR (400 MHz, METHANOL-d»): δ = 1.45 (d, J = 8.0 Hz, 2H), 3.82 (dd, J = 2.7 5 and 6.1 Hz, 1H), 4.39 - 4.49 (m, 1H), 450 - 4.62 (m, 2H), 4.66 - 4.81 (m, 2H), 6.85 (s, 1H), 7.19 (d, J = 8.5 Hz, 1H), 7.74 (dd, J = 2.3 and 8.7 Hz, 1H), 7.85 (d, J = 1.9 Hz, 1H).

[00749] MS (ES ) m/r. [M-H]’ calcd for CwHjîNtObSj: 540.1. Found: 540.1.

[00750] HPLC: 86.90%.

Example 60 (25,3S)-3-({(22}-2-(2-Amino-l,3-thiazol-4-yl)-2-[(2-{4-carbamimidoyl-2-[(formyloxy)methyl]phenoxy]ethoxy)imino]acetyl}amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00751 ] ’H NMR (400 MHz, DMS0<): δ = 1.33 (d, 1 = 6.2 Hz, 3H), 3.62 (dd, J = 2.5 and 6.0 Hz, 1H), 4.27 - 4.50 (m, 3H), 5.23 (s, 2H), 6.75 (s, 2H), 7.21 (s, OH), 7.31 (d, J = 8.9 Hz, 1H), 7.65 7.93 (m, 3H), 8.27 - 8.43 (m, 2H), 9.11 (br. s, 1H), 9.28 (d, 2H).

[00752] MS (ES') m/r. [M-H]' calcd for C₂₀H₂₂N₂OgS2: 568.09. Found: 568.09.

[00753] HPLC: 86.60%.

Example 61 (25,35}-3-{[(2Z)-2-(2-Amino-5-ch!oro-l,3-thiazol-4-y1)-2-{[2-(4-carbamimidoylphenoxY)ethoxy]imino)acetyl]amino}-2-methYl-4-oxoazetidine-l-sulfonicacid

204 [00754] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.31 (d, J = 6.3 Hz, 3H), 3.60 (m, IH), 4.38 (m, 2H), 4.40 (m, IH), 4.42 (m, 2H), 7.21 (d, J = 8.9 Hz, 2 H), 7.80 (d, J = 9.2 Hz, 2H), 8.66 (s, 2H), 9.12 (s,2H), 9.30 (d, J =8.4 Hz, IH).

[00755] MS (ES*) m/r. [M-Hf calcd for C₁₈H_MCIN7O₇S₂: 544.05. Found: 544.14.

[00756] HPLC: 97.10 %.

205

Example 62 (25.35) -3-([(2Z)-2-({2-[4-(2-Amino-2-iminoethyl)phenoxy]ethoxy)imino)-2-(2-amino-l,3-thiazol-4yl)acetyl]amîno)-2-methyl-4-oxoazetidine-l-sulfonicacÎd [00757] ^JH NMR (400 MHz, DMSO-dJ: δ = 1.23 -1.46 (m, 3H), 2.49 (br. s., 1H),, 3.56 5 3.75 (m, 2H), 4.09 - 4.27 (m, 2H), 4.27 - 4.52 (m, 2H), 6.56 - 6.83 (m, 1H), 6.86 - 7.04 (m, 2H), 7.17 7.43 (m, 3H), 8.32 - 8.53 (m, 2H), 8.82 - 9.10 (m, 2H), 9.26 (s, 1 H).

[00758] MS (ES*) m/r. [M+Hf calcd for C₁₉H₂₄N₇O₇S₂: 526.12. Found: 526.13.

[00759] HPLC: 95.50%.

Example 63 (2S,3S)-3-({(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-[{2-{4-[(2-formylhydrazinyl)(imino)methyl]phenoxy)ethoxy)imino]acetyl}amtno)-2-methyl-4-oxoazetidine-l-sulfonic acid [00760] *H NMR (400 MHz, DMSO-<f₆): δ = 1.34 (d, J = 6.2 Hz, 3H), 3.44 (br. s., 2H), 3.61 • 3.73 (m, 1H), 4.30 - 4.38 (m, 2H), 4.38 - 4.48 (m, 3H), 6.78 (s, 1H), 7.25 (d, J = 8.9 Hz, 2H), 7.78 (d, J= 8.9 Hz, 2H), 8.23 (s, 1H), 9.32 (d, J = 7.8 Hz, 1H), 9.41 (br. s, 1H), 9.80 (br. s, 1H), 10.73 (s, 1H).

[00761] MS (ES*) m/z: [M+H]* calcd for C₁₉H₂₃N_aO_aS₂: 555.56. Found: 555.23.

[00762] HPLC: 92.05 %.

Example 64 (25.35) -3-(((22)-2-(2-Amino-l,3-thiazol-4-yl)-2-[(2-{4-[hydrazinyl(imino)methyl]phenoxy)ethoxy)imino]acetyl}amino}-2-methyl-4-oxoazetidïne-l-sulfonicacid

206 [OO7G31 ^XH NMR (400 MHz, DMSO-d₆): δ = 1.40 (d, J = 6.2 Hz, 3H), 3.58 - 3.71 (m, 1H), 4.26 - 4.36 (m, 2H), 4.35 - 4.51 (m, 3H), 5.13 - 5.31 (m, 1H), 6.73 (s, 1H), 7.28 (br. s, 2H), 7.69 (d, 2H), 7.78 (d, J = 8.9 Hz, 2H), 8.72 (br. s, 1H), 9.26 (br. s, 2H), 10.75 (br. s, 1H).

[00764] MS (ES·) m/z: [M-H]' calcd for 525.54. Found: 525.31.

[00765] HPLC: 96.80%.

207

Example 65 (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazo!-4-yl)-2-({2-[(5-carbamimidoyl-l,3,4-thiadiazol-2yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetïdine-l-sulfonicacid [00766] *H NMR (400 MHz, DMSO-d₆): δ = 1.39 (d, 1=6.25 Hz, 3H), 3.64 (dd, J = 6.1 and 2.5 Hz, IH), 4.38 - 4.52 (m, 3H), 4.81 (d, J = 4.7 Hz, 2H), 6.78 (s, IH), 9.29 (d, J = 8.2 Hz, IH), 9.42 (s, 2H), 9.78 (S, 2H).

[00767] MS (ES*) m/z: [M+H]’ calcd for C₁₄H₁₇N₉O₇S₃:518.04. Found: 518.17.

[00768] HPLC: 94.0%.

Example 66 (2S,3S}-3-{[(2Z}-2-(2-Amino-l,3-thiazol-4-yl)-2-{(2-(4-carbamimîdoy!phenoxy)ethoxy]imino]acetyl]amino]-2-carbamoyl-4-oxoazetidine-l-sulfonicacÎd [00769] *H NMR (400 MHz, DMS0-d₆): δ = 4.35 (m, 4H), 5.26 - 5.43 (m, IH), 6.97 (s, IH), 7.19 - 7.24 (m, 2H), 7.85 (m, 2H), 8.55 - 8.82 (m, 2H), 9.05 - 9.33 (m, 2H}.

[00770] MS (ES*) m/z: [M+H]* calcd for C_uH₂₁N_aO₈S₂: 541.09. Found: 541.23.

[00771] HPLC: 91.2 %.

Example 67 (25.35) -3-([(2Z)-2-(2'Amino-l,3-thiazol-4-y!)-2-({2-[(3-carbamimidoyl-l,2-oxazol-5yl)oxy]ethoxy]imino)acetyl]amino]-2-methyl-4-oxoazetidtne-l-sulfonicacid [00772] ’H NMR (400 MHz, DMS0-d₆): δ = 1.38 (d, J = 6.2 Hz, 3H), 3.67 (d, J = 2.3 Hz, IH), 4.32 - 4.51 (m, 5H), 6.76 (s, IH), 6.87 (s, IH), 7.23 (s, 3H), 8.32 (s, 2H), 9.31 (d, J = 8.2 Hz, IH).

208

[00773]	MS (ES*) m/z: [M+Hf calcd for C₁₅H₁₈N₈O₈S₂:503.06. Found: 503.20.
[00774]	HPLC: 91.9

209

Example 68 (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[4-(N-methylcarbamimidoyl)phenoxy]ethoxy}imîno)acetyl]amino)-2-methyl-4-oxoazetidine-l-sulfonicacid [00775] ^XH NMR (400 MHz, DMSO-</₆): δ = 1.33 (d, J = 6.2 Hz, 3H), 2.97 (s, 3H), 3.61 5 3.67 (m, IH), 4.29 - 4.35 (m, 2H), 4.38 - 4.42 (m, 2H), 4.43 (d, J - 2.7 Hz, IH), 6.75 (s, IH), 7,20 (d, J = 8.9 Hz, 2H), 7.21 (s, 2H), 7.72 (d, J = 8.9 Hz, 2H), 8.41 - 8.47 (m, IH), 9.28 (d, J = 8.2 Hz, IH).

[00776] MS (ES ) m/z: [M-H]‘ calcd for 524.55. Found: 524.25.

[00777] HPLC: 97.51%.

Example 69 (2S,3S)-3-({(2Z)-2-(2-Amino-l,3-thîazol-4-yl)-2-[(2-{4-[N-{2-hydroxyethYl)carbamimidoyl]phenoxy}ethoxY)imîno]acetyl}amîno)-2-methyM-oxoazetidine-l-sulfonic acid [00778] ^lH NMR (400 MHz, DMS0-d₆): δ = 1.32 (d, J = 6.2 Hz, 3H), 3.42 - 3.48 (m, 2H),

3.56 - 3.71 (m, 2H), 4.22 - 4.36 (m, 3H), 4.36 - 4.51 (m, 4H), 6.74 (s, IH), 7.11 - 7.26 (m, 4H), 7.71 (d, J = 8.6 Hz, 2H), 8.30 (s, IH), 9.27 (d, J = 7.8 Hz, IH).

[00779] MS (ES^-) m/z: [M-H]' calcd for C_MH₂₄N₇O₈S₂:554.58. Found: 554.26.

[00780] HPLC: 97.00%.

Example 70 (25.35) -3-(](2Z)-2-(2-Amino-l,3-thiazol-4-yl}'2-{[2-(4-(N-[2-(formyloxy)ethyl]carbamimidoyl}phenoxy)ethoxy]imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid

210 [00781] ’H NMR (400 MHz, DMSO-d₆): δ = 1.31 (d, J = 6.2 Hz, 3H), 3.40 - 3.42 (m, 2H), 3.58 - 3.71 (m, 2H), 4.26 - 4.36 (m, 4H), 4.36 - 4.44 (m, 3H), 6.74 (s, 1H), 7.15 - 7.24 (m, 4H), 7.68 (d, J = 8.9 Hz, 2H), 8.26 (s, 1H), 8.31 (s, 1H), 9.27 (d, J = 7.8 Hz, 1H).

[00782] MS (ES*) m/z: [M-H]' calcd for CaH^NA^:582.59. Found: 582.27.

[00783] HPLC: 91.79 %.

21I

Example 71 (25,35)-3-{[(2Ζ)-2-(2-Απΐϊηο-1,3-ΐΗΐ3ΖθΙ-4-γΙ)-2-{{2-[(3οήΐ3ΓηίΓπΐΰογΙ-1-ΓηβΙήγΙ-1Η·ργΓ3ζοΙ-5yl)oxy]ethoxy)imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid [00784] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.37 (d, J = 5.8 Hz, 3H), 3.65 - 3.68 (m, IH), 5 3.71 (s, 3H), 4.30 - 4.37 (m, 2H), 4.41 (m, 3H), 6.50 (s, IH), 6.76 (s, IH), 7.21 (s, IH), 8.36 (br. s.,

IH), 9.34 (d, J =8.0 Ηζ,ΙΗ).

[00785] MS (ES*) m/r. [M+H]* calcd for C₁₆H₂iN₉O76S₂:516.10. Found: 516.10.

[00786] HPLC: 96.30%.

Example 72 (25,35)-34I(22)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(5-carbamimidoyl-l-methyl-lH-pyrazol-3yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid [00787] ^XH NMR (400 MHz, DMS0-d₆): δ = 1.35 (d, J = 6.2 Hz, 3H), 3.53 - 3.72 (m, IH), 3.80 (S, 3H), 4.34 (d, J = 5.5 Hz, 4H), 4.38-4.51 (m, IH), 6.32 (s, IH), 6.75 (s, IH), 7.21 (br. s., 2H),

8.17 (s, IH), 9.27 (d, J = 8.0 Hz, IH).

[00788] MS (ES*) m/r. [M-H]’ calcd for C₁₆H₂₁N₉O₇S₂:514.10, Found: 514.16.

[00789] HPLC: 97.70 %.

Example 73

N-[(4-[2-({[{lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy}azetidin-3yl]amino]-2-oxoethylidene]amino}oxy)ethoxy]phenyl}(imino)methyl]glycine sA'''

212 [00790] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.22 (s, 3H), 1.38 (s, 3H), 2.31 (dt, J = 1.9 and 3.6 Hz, 1H], 2.61 - 2.68 (m, 2H), 4.24 - 4.31 (m, 2H), 4.35 - 4.41 (m, 2H), 6.58 (s, 2H), 6.75 (s, 1H), 7.14 (d, J = 8.9 Hz, 2H), 7.19 (s, 2H}, 7.71 (d, J = 8.9 Hz, 2H), 8.42 (br. s., 1H), 9.43 (d, J = 8.2 Hz, 1H).

[00791] MS (ES') m/z: [M-H]‘ calcd for Cj^N/)^: 598.59, Found: 598.12.

[00792] HPLC: 84.19 %.

213

Example 74 (2Z)-2-(2-Amino-l,3-thÎazol-4-yl)-2-({2-[(2-carbamimÎdoyl-5-methy!-l,3-thïazol-4yl)oxy]ethoxy)imino)-W-[(3S)-2,2-dimethyl-4-oxo-l-{sulfooxy)azetidin*3-yl]ethanamide [007931 1H NMR (400 MHz, DMSO-d₆): δ = 1.22 (s, 3H), 1.40 (s, 3H), 2.34 (s, 3H), 4.38 (d, J = 4.7 Hz, 2H), 4.54 (q, J = 4.4 Hz, 2H), 4.57 (d, J = 7.8 Hz, 1H), 6.74 (s, 1H), 7.19 (s, 2H), 8.17 (s, 1H), 9.45 (d, J = 7.8 Hz, 1H).

[007941 MS (ES*) m/r. [M+HJ* calcd for CnH^NsOgSj: 563.07. Found: 563.09.

1007951 HPLC: 98.60%.

Example 75

2-{{[(lZ)-l-(2-Amïno-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amino}2-oxoethylidene]amino}oxy}-3-(4-carbamimidoylphenoxy)propanamide [00796] *H NMR (400 MHz, DMSO-d₆): δ = 1.15 ($, 3H), 1.34(s, 3H), 4.33 - 4.47 (m, 1H),

4.56 - 4.66 (m, 2H), 4.80 - 4.91 (m, 1H), 6.82 (s, 1H), 7.12 - 7.23 (m, 2H), 7.74 - 7.90 (m, 2H), 8.74 (S, 1H), 9.20 (S, 1H), 9.70 (s, 1H).

[00797] MS (ES) m/z: [M-H]' calcd for CjoHnNgOaSj: 583.10. Found: 582.90.

[00798] HPLC: 75.70%.

Example 76 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-W-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxY)azetidin-3-yl]-2-[(2-{4-[W(pyridin-2-ylmethyl)carbamîmïdoyl]phenoxy]ethoxy)imino]ethanamide [00799] ’H NMR (400 MHz, DMSO-d₆): δ = 1.22 (s, 3H), 1.40 (s, 3H), 4.29 (br. s., 2H),

4.41 (d, J = 4.6 Hz, 2H), 4.59 (d, J = 8.2 Hz, 1H), 4.74 (s, 2H), 6.77 (s, 1H), 7.11 - 7.25 (m, 4H), 7.36 —

214 (d, J = 4.6 Hz, IH), 7.47 (d, J = 7.8 Hz, IH), 7.71 - 7.92 (m, 3H), 8.38 (s, IH), 8.58 (d, J = 3.9 Hz, IH), 9.45 (d, J = 7.8 Hz, IH).

100800] MS (ES·) m/z: [M-H]' calcd for C₂₅H₂₇N₈O₈S₂: 631.66. Found: 631.06.

(008011 HPLC: 95.66%.

Example 77 {[(2S,3S)-3-{[(2Z)-2-[{2-(4-[N-(2-AmÎnoethyl)carbamimidoyl]phenoxy}ethoxy)imino]-2-(2-aminol,3-thiazol-4-yl)acetyl]amino)-2-methyl-4-oxoazetidin-l-yl]oxy}methanesulfonic acid [00802] ’H NMR (400 MHz, DMSO-d₆): δ = 1.37 (d, J = 5.8 Hz, 3H), 3.17 - 3.31 (m, 2H), 3.64 - 3.76 (m, 2H), 3.96 - 4.06 (m, IH), 4.33 - 4.53 (m, 6 H), 4.60 (d, J = 4.6 Hz, IH), 7.10 (s, IH),

7.17 (s, IH), 7.26 (d, J = 8.6 Hz, 2H), 7.82 - 7.92 (m, 2H), 8.00 (br. s, 2H), 9.08 (br. s, IH), 9.46 - 9.64 (m, 3H).

[00803] MS (ES ) m/z: [M-H]' calcd for C₂₁H₂₇N₈O₈S₂:583.14. Found: 582.75.

[00804] HPLC: 87.53 %.

Example 78 {2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-[(2-{4-[N-(2-carbamimidamidoethyl)carbamimidoyl]phenoxy}ethoxy)Îmino]-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00805] ’H NMR (400 MHz, DMS0-d₆): δ = 1.19 (s, 3H), 1.39 (s, 3H), 3.35 - 3.41 (m, 2H), 3.47 - 3.53 (m, 4H), 4.25 - 4.35 (m, 2H), 4.36 - 4.46 (m, 2H), 4.58 (d, J = 7.8 Hz, IH), 6.78 (s, IH),

7.18 (d, J = 8.9 Hz, 2H), 7.25 (br. s, 2H), 7.71 - 7.77 (m, 3H), 8.96 (s, IH), 9.41 (br. s, IH), 9.44 (d, J = 7.8 Hz, IH), 9.57 (t, J = 5.0 Hz, IH).

[00806] MS (ES*) m/z: [M+H]* calcd for C₂₂H₃₁N₁₀O₈S₂:627.18. Found: 626.92. —

215 [00807] HPLC: 91.16%.

Example 79 l-(2-{[[4-[2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-[[{3S)-2,2-dimethyl-4-oxo-l-(su1fooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)ethoxy]pheny!}{imino)-methyl]amino}ethyl)-lmethylpyrrolidinium chloride [00808] *H NMR (400 MHz, DMS0-d_fi): δ = 1.17 (s, 3H), 1.38 (s, 3H), 2.13 (br. s, 4H), 3.49 - 3.56 (m, 2H), 3.59 - 3.63 (m, 2H), 3.67 -3.71 (m, 2H), 3.87 - 3.89 (m, 2H), 4.31 -4.33 (m, 2H), 4.41 -4.43 (m, 2H), 4.57 (d, J = 8.0 Hz, IH), 6.78 (s, IH), 7.21 (d, J = 8.8 Hz, 2H), 7.26 (br.s, 2H), 7.73 (d, J = 8.8 Hz, 2H), 9.14 (br. s, IH), 9.43 (d, J = 7.6 Hz, IH), 9.60 - 9.63 (m, 2H).

[00809] MS (ES*) m/z: M* calcd for C₂₆H₃₇N₈O_gS₂:653.22. Found: 653.05.

[00810] HPLC: 96.65%.

Example 80 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-N-[(3S)-2,2-dimethy!-4-oxo-l-(sulfooxy)azetidin-3-yl]'2-[(2-{4[imino(piperazin-l-yl)methyl]phenoxy}ethoxy)imino]ethanamide [00811] ^XH NMR (400 MHz, DMSO-d₆): S = 1.16 (s, 3H), 1.38 (s, 3H), 3.26 (br. s., 2H}, 3.59 (br. s., 2H), 3.88 (br. s., 2H), 4.30 (br. s., 2H), 4.42 (d, J = 4.6 Hz, 2H), 4.57 (d, J = 7.8 Hz, IH), 6.77 (s, IH), 7.19 (d, J = 8.9 Hz, 2H), 7.24 (s, IH), 7.26 - 7.33 (m, IH), 7.60 (d, J = 8.5 Hz, 2H), 9.09 (br. s., 2H), 9.32 (br. s., IH), 9.44 (d, J = 7.8 Hz, IH), 9.64 (s, IH).

[00812] MS (ES ) m/z: [M-H]‘ calcd for C₂₃H₂₉N_gO₈S₂: 609.15. Found: 609.13.

[00813] HPLC: 89.11%.

Example 81

216 (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({[l-(4-carbamimidoylphenoxy)-4-hydroxybutan-2yl]oxy}imino)-N-[(3S)-2,2-dimethyl-4-oxo-l-($ulfooxy)azetidin-3-yl]ethanamide

EpimerA

100814] ¹H NMR (400 MHz, DMSO-d₆): δ = 1.27 (s, 3H), 1.41 (s, 3H), 1.84 (m, 1H), 1.91 (m, 1H), 3.54 (m, 2H), 4.21 (m, 2H), 4.55 (m, 1H), 4.58 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 7.14 (, J = 8.8 Hz, 2H), 7.21 (s, 2H), 7.79 (d, J = 8.8 Hz, 2H), 8.46 (br. s, 4H), 9.42 (d, J = 7.2 Hz, 1H).

(00815] MS (ES ) m/z: [M-H]' calcd for C₂₁H₂₇N ASj: 584.13. Found: 584.01.

[00816] HPLC: 95.20%.

Epîmer B [00817] *H NMR (400 MHz, DMSO-<f₆): δ = 1.23 (s, 3H], 1.42 (s, 3H), 1.86 (m, 1H), 2.51 (m, 1H), 3.54 (m, 2H), 4.22 (m, 2H), 4.55 (m, 1H), 4.60 (d, J = 8.8 Hz, 1H), 6.74 (s, 1H), 7.14 (, J = 8.8 Hz, 2H), 7.221 (s, 2H), 7.79 (d, J = 8.8 Hz, 2H), 8.49 (br. s, 4H), 9.38 (d, J = 7.2 Hz, 1H}.

[00818] MS (ES) m/z: [M-H]' calcd for C₂₂H₂₇N A>S₂: 584.13. Found: 584.01.

[00819] HPLC: 92.70%.

Example 82 (22)-2-{[2-({6-[N-(2-Aminoethyl)carbamimidoyl]pyridin-3-yl]oxY)ethoxy]imino}-2-(2-amînO'l,3' thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidîn-3-yl]ethanamide [00820] ^XH NMR (400 MHz, DMSO-d₆): δ = 3.15 (dd, J = 4.1 and 10.4 Hz, 2Η), 3.69 (dd, J = 5.9 and 12.1 Hz, 2H), 4.41 - 4.45 (m, 4H), 4.58 (d, J = 7.8 Hz, 1H), 6.78 (s, 1H), 7.20 - 7.26 (m, 2H), 7.76 - 7.86 (m, 4H), 8.25 (d,J = 9.0 Hz, 1H), 8.51 (d, J = 2.7 Hz, 1H), 9.25 (br. s, 1H), 9.43 (d, J = 7.8 Hz, 1H), 9.72 (br. s, 1 H), 9.80 (s, 1H).

217 [008211 MS (ES*) m/r. [M+H]* calcd. for C_MH₂₈N₉O₈S₂:586.15. Found: 586.14.

[008221 HPLC: 94.78 %.

Example 83 {2Z}-2-[(2-{4-[/V-(3-Aminopropyl)carbamimidoyl]phenoxy}ethoxy)imïno]-2-(2-amino-l,3'thiazol-4yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-{sulfooxy)azetidin-3-yl]ethanamîde [00823] ’H NMR (400 MHz, DMS0<): δ = 1.20 (s, 3H), 1.39 (s, 3H), 1.81 -1.98 (m, 2H), 2.80 - 3.00 (m, 2H), 3.41 - 3.48 (m, 2H), 4.24 - 4.36 (m, 2H), 4.37 - 4.47 (m, 2H), 4.58 (d, J = 7.8 Hz, 1H), 6.78 (s, 1H), 7.02 (s, 1H), 7.18 (d, J = 8.9 Hz, 2H), 7.27 (s, 1H), 7.73 (d, J = 8.9 Hz, 2H), 7.76 7.89 (m, 2H), 8.92 (br. s., 1H), 9.37 (br. s., 1H), 9.46 (d, J = 7.8 Hz, 1H), 9.59 (br. s., 1H).

[008241 MS (ES*) m/r. [M+H]* calcd for C₂₂H_îiN₈O₈S₂: 599.17, Found: 599.23.

[00825] HPLC: 90.78%.

Example 84 (2Z)-2-(2-Amino-l,3'thiazo!-4-yl)-2-[(2-{4-[N-(l,3-diaminopropan-2-yl)carbamimid' oyl]phenoxy}ethoxy)imino]-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00826] ’H NMR (400 MHz, DMS0-d₆): δ = 1.17 (s, 3H), 1.39 (s, 3H), 3.10 - 3.32 (m, 4H),

3.57 - 3.64 (m, 4H), 4.25 - 4.37 (m, 2H), 4.37 - 4.47 (m, 2H), 4.58 (d, J = 7.8 Hz, 1H), 6.79 (s, 1H), 7.22 (d, J = 8.9 Hz, 2H), 7.23 - 7.33 (m, 1H), 7.89 (d, J = 8.9 Hz, 2H), 8.09 (br. s, 2H), 9.03 (br. s, 1H), 9.32 (d, J = 7.0 Hz, 1H), 9.44 (d, J = 7.8 Hz, 1H), 9.76 (br. s, 1H).

[00827] MS (ES) m/r. ]M-H]' calcd for C₂₂H3oN_g0₈S₂:612.17. Found: 612.20.

[00828] HPLC: 90.51%.

Example 85

218 (2Z)-2-{[2-{4-{W-[(2R)-l-Amino-3-hydroxypropan-2-yl]carbamimidoy!}phenoxy)ethoxy]imÎno}-2-(2amino-l,3-thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [008291 *H NMR (400 MHz, DMSO-d₆): δ = 1.22 (s, 3H), 1.42 (s, 3H), 3.20 (m, 2H), 4.10 (m, 1H), 4.30 (m, 2H), 4.40 (m, 2H), 4.60 (d, J = 8.8 Hz, 1H), 6.80 (s, 1H), 7.20 (d, J = 8.8 Hz, 2H), 7.22 (s, 2H), 7.79 (d, J = 8.8 Hz, 2H), 8.00 (br. s., 3H), 9.00 (s, 1H), 9.38 (d, J = 7.2 Hz, 1H), 9.50 (m, 2H).

[00830] MS (ES) m/r. [M-Hf calcd for C₂₂H₂₉N₈O_sS₂: 613.15. Found: 613.10.

[00831] HPLC:92.70%.

Example 86 {2Z)-2-({2-[4-(5-Amino-l,4,5,6-tetrahydropyrimidin-2-yl)phenoxy]ethoxy)imino)-2-(2-amino-l,3thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide [00832] ^XH NMR (400 MHz, DMSO-<f₆): δ = 1.16 (s, 3Η), 1.38 (s, 3H), 3.50-3.57 (m, 2H), 3.72-3.79 (m, 2H), 3.98-4.04 (m, 1H), 4.28-432 (m, 2H), 4.41-4.45 (m, 2H), 4.57 (d, J = 7.8 Hz, 1H), 6.79 (s, 1H), 7.22 (d, J = 8.6 Hz, 2H), 7.22-7.44 (m, 1H), 7.70 (d, J = 8.6 Hz, 2H), 8.22-8.42 (br. m, 3H), 9.44 (d, J = 7.8 Hz, 1H), 10.00 (br. s, 2H).

[00833] MS (ES ) m/z: [M-H]' calcd for C₂₂H₂₇N_gO₈S₂: 595.14. Found: 595.09.

[00834] HPLC: 93.67 %.

Example 87

3-(([(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyM-oxo-l-(su!fooxy)azetidin-3-yl]amino}2-oxoethylidene]amrno}oxy)-2-(4-carbamimidoy!phenoxy)propanoic acid

EpimerA

219 [00835] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.20 (s, 3H), 1.37 (s, 3H), 4.4-4.5 (m, 2H),

4.57 (d, J = 8.0 Hz, 1H), 5.02 (m, 1H), 6.76 (s, 1H), 7.05 (d, J = 9.0 Hz, 2H), 7.2 (s, 2H), 7.8 (d, J = 9.0 Hz, 2H), 8.9 (s, 2H), 9.1 (s, 2H}, 9.43 (d, J = 8.0 Hz, 1H).

[00836] MS (ES*) m/z: [M+H]* calcd for C^H^N^cS/ 584.09. Found: 584.13.

[00837] HPLC: 87.90 %.

Epimer B [00838] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.20 (s, 3H), 1.39 (s, 3H), 4.37 - 4.52 (m, 2H), 4.56 (d, J = 8.2 Hz, 1H), 4.90 - 5.09 (m, 1H), 6.76 (s, 1H), 7.06 (d, J = 9.0 Hz, 2H), 7.22 (s, 2H), 7.75 (d, J = 9.0 Hz, 2H), 8.87 (s, 2H), 9.08 (s, 2H), 9.47 (d, J = 7.2 Hz, 1H).

[00839] MS (ES·) m/z: [M-H]' calcd for C₂₀H₂₃N₇O₁₀S₂:584.09. Found: 584.13.

[00840] HPLC: 91.10%.

Example 88 (2S)-2-([[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-{N-[(3ff)-piperidîn-3-yl]carbamimidoyl}phenoxy)propanoic acid [00841] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.24 (s, 3H), 1.44 (s, 3H), 1.64 -1.76 (m, 2H), 1.90 - 2.04 (m, 2H), 2.84 - 2.98 (m, 2H), 3.06 - 3.16 (m, 1H), 3.86 (br. s, 1H), 4.19 (d, 7=10.55 Hz, 1H), 4.35 - 4.46 (m, 1H), 4.69 - 4.77 (m, 2H), 6.84 (s, 1H), 7.08 (d,7=8.99 Hz, 2H), 7.19 (br. s, 2H), 7.61 (d, 7=8.60 Hz, 2H), 8.17 (s, 2H), 8.97 (br. s, 1H), 9.24 - 9.82 (m, 3H), 10.59 (br. s, 1H).

[00842] MS (ES) m/z: [M-H]' calcd C_2SH32N₈OioS₂:668.17. Found: 667.05.

[00843] HPLC: 98.6 % tA7—

220

Example 89 (2R)-2-({[(12)-l-(2-Amîno-l,3-thiazol-4-yl)-2-([(3S)-2,2-dimethyl-4-oxo-l-(su!fooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-{N-[(3/ï)-piperidin-3-yl]carbamimidoyl}phenoxy)propanoic acid [00844] ’H NMR (400 MHz, DMSO-d₆): 5 = 1.22 (s, 3H), 1.40 (s, 3H), 1.52 (s, 3H], 1.69 (br. s, 2H), 1.71 -1.83 (m, 2H), 1.83 - 2.00 (m, 2H), 2.74 - 2.88 (m, 2H), 2.87 - 3.03 (m, 2H), 3.81 3.95 (m, 2H), 3.95 - 4.08 (m, 1H) 4.18 - 4.36 (m, 1H}, 4.67 (d, 7=859 Hz, 2H), 6.82 (s, 1H), 7.09 (d, 7=8.98 Hz, 2H), 7.16 (br. s, 1H), 7.71 (d, 7=8.98 Hz, 2H), 8.14 (s, 1H).

[00845] MS (ES) m/z: [M-H]' calcd C₂₅H₃₂N_aO₁₀S₂:668.17. Found: 667.05.

[00846] HPLC: 98.0 %

Example 90 {[{3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-y1)-2-{[{4-carbamimidoylbenzyl)oxy]imino}acetyl]amino}2,2-dimethyl-4-oxoazetidin-l-yl]oxy)methanesulfonicacid [00847] ’H NMR (400 MHz, DMSO-d₆): δ = 1.16 (s, 3H), 1.41 (s, 3H), 4.22 - 4.32 (m, 3H), 4.37 - 4.43 (m, 3H), 4.54 (d, 7 = 7.6 Hz, 1H), 6.79 (s, 1H), 7.15 (d, 7 = 8.0 Hz, 2H), 7.80 (d, J = 8.0 Hz, 2H), 8.66 (br. s, 2H), 9.13 (br. s, 2H), 9.39 (d,7 = 7.6 Hz, 1H).

[00848] MS (ES*) m/z: [M+H]* calcd for C_MH_2eN A₈S₂: 555.13. Found: 556.06.

[00849] HPLC: 98.76%.

Example 91 (22)-2-[(2-{4-[5-(Aminomethyl)-4,5-dihydro-lH-imidazo1-2-yl]phenoxy}ethoxy)imino]-2-(2-aminol,3-thiazol-4-yl)’N'[{3S)-2,2-dimethyl-4-oxO’l’(sulfooxy)azetidin-3-yl]ethanamide

221 [00850] *H NMR (400 MHz, DMSO-tf₆): δ = 1.16 (s, 3H), 1.37 (s, 3H), 3.16 (t, J = 5.0 Hz, 2H), 3.44 (br. s, 2 H), 3.87 (dd, J = 7.2 and 11.5 Hz, 1H), 4.13 (t, J = 11.7 Hz, 1H), 4.29 - 4.36 (m, 2H), 4.39 - 4.45 (m, 2H), 4.57 (d, J = 7.8 Hz, 1H), 6.78 (s, 1H), 7.26 (d, J = 8.9 Hz, 2Η), 7.91 (d, J = 9.3 Hz, 2H), 8.03 (br. s, 2H], 9.43 (d, J = 8.2 Hz, 1H), 10.37 (br. s, 1H), 10.55 (br. s, 1H).

[00851] MS (ES*) m/z: [M-H]‘ calcd for C_aH_I7N₈O_aS₂:595.14. Found: 595.22.

[00852] HPLC: 93.28%.

Example 92 (3S)-3'(((2Z)-2-(2-Amino-l,3-thiazol'4-yl)-2-[{2-{4-[N-(pyrazolidin-4-yl)carbamimidoyl]phenoxy]ethoxy)imÎno]acetyl]amino)-2,2-dimethyl-4-oxoazetidine-l-sulfonÎcacid [00853] *H NMR (400 MHz, DMS0-d₆): δ = 1.17 (s, 3H), 1.36 (s, 3H), 3.00-3.80 (4H, masked by H₂O), 4.26-4.48 (m, 5H), 4.56 (d, J = 7.4 Hz, 1H), 6.77 (s, 1H), 7.12 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 9.03 (d, J = 2.3 Hz, 1H), 9.34 - 9.45 (m, 3H).

[00854] MS (ES) m/z: [M-H]' calcd for C₂₂H₂₉N₉O_gS₂:610.16. Found: 610.19.

[00855] HPLC: 90.14 %.

Example 93 (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazo1-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-sulfoazetidîn-3-yl)amino}2-oxoethylidene]amino}oxy)-3-(4-{N-[(35)-pyrrolidin-3-yl]carbamimidoyl}phenoxy)propanoie acid [00856] ^XH NMR (400 MHz, DMS0-d₆): δ = 1.08 (s, 3H), 1.37 (s, 3H), 2.08 - 2.36 (m, 2H), 3.17 - 3.62 (m, 4H), 4.35 - 4.48 (m, 3H), 4.60 (d, J = 7.8 Hz, 1H), 4.88 - 5.04 (m, 1H), 6.81 (s, 1H), 7.20 (d, J = 8.9 Hz, 2H), 7.35 (br. s, 1H), 7.76 (d, J = 8.9 Hz, 2H), 8.82 - 9.10 (m, 1H), 9.15 (br. s, 1H), 9.45 (d, J= 8.2 Hz, 1H), 9.57 (br. s, 2H).

[00857] MS (ES*) m/z: [M-H]’ calcd. for C^H^NgOioS/ 653.15. Found: 652.99.

222 [00858] HPLC: 94.26 %.

Example 94 (2S}-3-{4-[N-(2-Amino-2-methylpropyl)carbamimidoyl]phenoxy}-2-({[(lZ}-l-(2-amino-l,3-thÎazol· 4-yl)-2-[[(3S}-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amino}-2oxoethylidene]amino]oxy)propanoie acid [00859] ^XH NMR (400 MHz, DMSO-<f_fi): δ = 1.09 (s, 3H), 1.33 (s, 6H), 1.37 (s, 3H), 3.58 (d, J = 6.3 Hz, 2H), 4.37-4.42 (m, 1H), 4.44-4.50 (m, 1 H), 4.60 (d, J = 7.8 Hz, 1H), 4.95-5.01 (m, 1H), 6.82 (s, 1H), 7.21 (d, J = 9.0 Hz, 2H), 7.39 (br. s, 1H), 7.85 (d, J = 9.0 Hz, 2H), 8.00 (br. s, 2H), 9.09 (br. s, 1H), 9.46 (d, J = 7.8 Hz, 1H), 9.55 (br. s, 1H), 9.61 (br. s, 1H).

[00860] MS (ES) m/z: [M-H]' calcd for C₂4H₃₁N₈O₁₀S₂: 655.16. Found: 654.93.

[00861] HPLC: 94.85 %.

Example 95 (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazo!-4-y!)-2-{[(3S)-2,2-dimethy1-4-oxo-l-(sulfooxY)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-{A/-[2-(methylamino)ethyl]carbamimidoyl)phenoxy)propanoïc acid [00862] *H NMR (400 MHz, DMSO-d₆): δ = 1.20 (s, 3H), 1.40 (s, 3H), 2.35 (s, 1H), 3.653.75 (m, 3H), 3.60-3.80 (m, 2H), 4.30 - 4.50 (m, 2H), 4.60 (d, J = 7.8 Hz, 1H), 4.95-5.00 (m, 1H), 6.80 ($, 1H), 7.18 (d, J = 8.9 Hz, 2H), 7.27 (br.s, 2H), 7.80 (d, J = 8.9 Hz, 2H), 8.45 (br. s, 2H), 9.05 (br. s, 1H), 9.40-9.60 (m, 3H).

[00863] MS (ES*) m/r. [M+H]* calcd for C₂₃H₃iN₈O₁₀S₂: 643.16. Found: 643.02.

[00864] HPLC: 95.18%.

Example 96

223 (25)-2-(([(lZ)-l-{2-Amino-l,3-thiazoM-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-sulfoazetidin-3-yl]amino}2-oxoethytidene]amino}oxy)-3-(4-{N-[(3/ï)-pyrrolidin-3-yl]carbamimidoyl}phenoxy)propanoie acid [00865] ^XH NMR (400 MHz, DMSOO: δ = 1.24 (s, 3H}, 1.43 (s, 3H), 2.17 (m, IH), 2.23 2.34 (m, IH), 3.19 - 3.27 (m, 2H), 3.54 (d, J = 1.6 Hz, 2H), 4.05 (d, J = 11.6 Hz, IH), 4.20 - 4.29 (m,

IH), 4.48 (br. s, IH), 4.66 (d, J = 7.8 Hz, IH), 4.71 (dd, J = 2.0 and 8.6 Hz, IH), 6.84 (s, IH), 7.07 (d, J = 8.6 Hz, 2H), 7.19 (br. s, 2H), 7.76 (d, J = 9.0 Hz, 2H), 10.51 (br. s, IH).

[00866] MS (EST) m/r. [M-Η]' calcd for 653.15. Found: 653.02.

[00867] HPLC: 97.20%.

Example 97 (25)-2-(([(lZ)-l-(2-Amîno-l,3-thiazol-4-yl)-2-{[(3S}-2,2-dimethyl-4-oxo-l-{sulfooxy)azetidin-3yl]amino)-2-oxoethylidene]amino)oxy)-3-{4-[N-(piperidin-3-yl)carbamimidoyl]phenoxy}propanoic acid [00868] *H NMR (400 MHz, DMSO-d₆): δ = 1.08 (s, 3H), 1.36 (s, 3H), 1.53 - 2.11 (m, 4H), 2.77 - 3.54 (m, 4H), 3.94 (br. s, IH), 4.41 - 4.57 (m, 2H), 4.62 (dd, J = 1.5 and 7.8 Hz, IH), 5.08 (d, J 15 =1.9 Hz, IH), 6.93 - 7.26 (m, 3H), 7.71 (br. s, 2H), 8.02 (d, J = 16.7 Hz, IH), 8.56 (br. s, IH), 8.84 (br.

s, IH), 9.13 (br. s, 1 H), 9.33 - 9.57 (m, 2H), 9.57 - 9.76 (m, IH).

[00869] MS (ES/) m/r. [M-H] calcd for C₂₅H₃₁N₈0iqS₂: 667.16. Found: 667.02.

[00870] HPLC: 96.60%.

224

Example 98 (2S)-2-({[(lZ}T-(2-Amino-l,3-thiazol-4-yl)-2-{[(35)-2,2~dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino)-2-oxoethylidene]amino}oxy)-3-{4-[N-(pyrrolidin-2-ylmethyl}carbamimidoyljphenoxyîpropanoîc acid [00871] *H NMR (400 MHz, DMSO-d₆): δ = 1.24 (d, 3H), 1.43 (s, 3H), 1.52 -1.67 (m, 1H), 1.77 -1.98 (m, 2H), 2.05 - 2.17 (m, 1H), 3.08 - 3.25 (m, 2H), 3.46 - 3.76 (m, 2H), 3.77 - 3.90 (m, 1H), 4.17 (m, 1H), 4.26 - 4.39 (m, 1H), 4.64 - 4.75 (m, 2H), 6.82 - 6.87 (m, 1H), 7.05 (d, J = 8.7 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 7.20 (br. s, 2H), 7.26 - 7.26 (m, 1H), 7.72 - 7.80 (m, 2H).

[00872] MS (ES·) m/r. [M-H]' calcd for C_2SH₃₁N₈O_loS₂.667.16. Found; 667.02.

[00873] HPLC: 89.04%.

Example 99 (2S)-2-(([(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-([(3S}-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethy!idene]amino}oxy)-3-(4-[N-(piperidin-2-ylmethyl}carbamimidoyl]phenoxy]propanoic acid [00874] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.08 (s, 3H), 1.37 (s, 3H), 1.36-1.62 (m, 3H), 1.62-1.81 (m, 2H), 1.90-2.00 (m, 1H), 2.85-3.00 (m, 1H), 3.30-3.42 (m, 2H}, 3.42-3.61 (m, 2H), 4.384.49 (m, 2H), 4.60 (d, J = 7.8 Hz, 1H), 4.96-5.00 (m, 1H), 6.81 (s, 1H), 7.21 (d, J = 8.6 Hz, 2H), 7.217.40 (br. s, 2H), 7.83 (d, J = 9.0 Hz, 2H}, 8.40-8.60 (br. s, 2H), 9.05 (br. s, 1H), 9.41 (d, J = 7.8 Hz, 1H), 9.56 (br. s, 2H).

[00875] MS (ES*) m/r. (M+H)* calcd for C₂₆H₃₃N_eO_l0S₂:681.18. Found: 681.05.

[00876] HPLC: 96.45 %.

Example 100 —

225 (2S)-3-(4-[N-(trans-2-Aminocyclopropyl)carbamimidoyl]phenoxy}-2-({[(lZ)-l-(2-amino-l,3-thiazol4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amino}-2oxoethylidene]amino)oxy)propanoic acid

Antl EpimerA [00877] *H NMR (400 MHz, DMSO-d₆): δ = 1.07 (s, 3H), 1.37 (s, 3H), 1.37-1.42 (m, 2H), 2.90-3.07 (m, 1H), 3.08-3.17 (m, 1H), 4.35-4.42 (m, 1H), 4.42-4.49 (m, 1H), 4.59 (d, J = 7.8 Hz, 1H), 4.96-5.00 (m, 1H), 6.83 (s, 1H), 7.19 (d, J = 8.9 Hz, 2H), 7.73 (d, J = 9.0 Hz, 2H), 8.29 (br. s, 3H), 9.04 (br. s, 1H), 9.45 (d, J = 7.8 Hz, 1H), 9.67 (br. s, 1H}, 9.78 (br. s, 1H).

[00878] MS (ES*) m/z: [M+H]* calcd for C₂₃H₂₇N₈OioS₂: 639.13. Found: 639.08.

[00879] HPLC: 96.02 %.

Anti Epimer B [00880] ^XH NMR (400 MHz, DMSO-d₆): δ = 1.23 (s, 3H), 1.39 (s, 3H), 1.37-1.43 (m, 2H), 2.90-3.07 (m, 1H), 3.08-3.17 (m, 1H), 4.43-4.48 (m, 2H), 4.58 (d, J = 7.4 Hz, 1H), 4.97-5.02 (m, 1H), 6.84 (s, 1H), 7.19 (d, J = 8.9 Hz, 2H), 7.73 (d, J = 9.0 Hz, 2H), 8.31 (br. s, 3H), 9.05 (br. s, 1H), 9.43 (d, J = 7.8 Hz, 1H), 9.68 (br. s, 1H), 9.79 (br. s, 1H).

[00881] MS (ES*) m/z: [M+H]* calcd for C₂₃H₂₇N₈O_1OS₂:639.13. Found: 639.01.

[00882] HPLC: 93.77 %.

Example 101 f2S)-2-(([(12)-l-(2-Amino-l,3-thiazol-4-yl)-2-([(3S)-2,2-dimethyl-4-oxo-l-sulfoazetidin-3-yl]amino}2-oxoethylidene]amino)oxy)-3-(4-{N-[(3S)-l-methylpyrrolidin-3-yl]carbamimidoyl}phenoxy)propanoicacid /z-*'

226 [00883] *H NMR (400 MHz, DMSO-d₆): δ = 1.07 (s, 3H), 1.36 (s, 3H), 2.16 - 2.33 (m, 1H), 2.65 (br. s, 1H), 2.90 (br. s, 3H), 3.39 (br. s, 6H), 3.75 (br. s, 1H), 4.30 - 4.54 (m, 3H), 4.58 (d, J = 7.8 Hz, 1H), 4.96 (t, J = 3.7 Hz, 1H), 6.78 (s, 1H), 7.18 (d, J = 8.6 Hz, 2H), 7.23 (br. s, 2H), 7.75 (d, J = 7.8 Hz, 2H), 9.12 (br. s, 1H), 9.38 (d, J= 7.4 Hz, 1H), 9.55 (br. s, 1H).

[00884] MS (ES) m/z: [M-H]' calcd CsHaNeOioS* 667.17. Found: 666.99.

[00885] HPLC: 97.10%.

Example 102 (2S)-2-(([(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{I(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-{4-[N-(l,3-diaminopropan-2yl)carbamimidoyl]phenoxy)propanoie acid [00886] *H NMR (400 MHz, DMSO-d₆): 6 = 1.04 (s, 3H), 1.37 (s, 3H), 2.29 - 2.36 (m, 1H), 2.64 - 2.71 (m, 1H), 3.08 - 3.29 (m, 4H), 4.22 - 4.35 (m, 1H), 4.35 - 4.54 (m, 2H), 4.60 (d, J = 7.8 Hz, 1H), 4.93 - 5.02 (m, 1H), 6.55 (s, 1H), 6.81 (s, 1H), 7.24 (d, 1 = 7.8 Hz, 2H), 7.28 (br. s, 1H), 7.90 (d, J = 8-9 Hz, 2H), 8.01 (br. s, 2H), 8.86 - 9.10 (m, 1H), 9.32 (d, J = 9.7 Hz, 1H), 9.42 (d, J = 7.4 Hz, 1H), 9.71-9.82 (m, 1H).

[00887] MS (ES*) m/r. [M+H]* calcd for CnHjjNeOwSj: 658.17. Found: 657.94.

[00888] HPLC: 81.08 %.

Example 103 (2/î)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyM-oxo-l-(sulfooxy)azetidin-3yl]amîno}-2-0xoethylidene]amino}oxy)-3-{4-[N-(l,3-diaminopropan-2yl)carbamimidoyl]phenoxy}propanoic acid [00889] ^XH NMR (400 MHz, DMSO-d₆): 6 = 1.23 (s, 3H), 1.39 (s, 3 H), 2.25 - 2.39 (m, 3H), 2.64 - 2.73 (m, 2H), 3.56 - 3.79 (m, 2H), 4.47 (br. s, 3H), 4.59 (d, J = 7.4 Hz, 1H), 4.98 (br. s, 1H),

227

6.58 (br. s, 2H), 6.82 (s, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.28 (br. s, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.97 (br. s, 2H), 8.20 (br. s, 1H), 8.93 - 9.18 (m, 1H), 9.42 (br. s, 1H), 9.69 (br. s, 1H).

[00890] MS (ES ) m/z: [M-H] calcd for C₂₃H3oN₉0₁₀S₂:656.16. Found: 656.06. [00891] HPLC: 83.70 %.

Example 104 (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino]-2-oxoethy!idene]amînoîoxy)-3-{4-[N-(lH-imidazol-2-ylmethyl)carbamimidoyl]phenoxy}propanoicacîd [00892] ’H NMR (400 MHz, DMSO-d₆): Ô = 1.28 (s, 3H), 1.38 (s, 3H), 4.39 - 4.42 (m, 2H),

4.49 -4.55 (m, 4H), 6.58 (s, 1H), 6.81 (s, 1H), 7.0S (s, 2H), 7.18 (s, 2H), 7.22 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.8 Hz, 2H), 8.18 (br. s, 1H).

[00893] MS (ES) m/z: ]M-H] calcd for C₂₄H₂₆N₉O₁₀S₂: 664.12. Found; 663.95.

[00894] HPLC: 92.00 %.

Example 105 (2R)-2-({[{lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-([(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethYlidene]amino}oxy)-3-{4-[N-(lW-imidazol-2-ylmethyl)carbamimidoyl]phenoxy}propanoic acid [00895] ’H NMR (400 MHz, DMS0-d₆): δ = 1.25 (s, 3H), 1.36 (s, 3H), 4.18 (m, 1H), 4.45 4.65 (m, 5H), 6.62 (br. s, 1H), 6.85 (s, 1H), 7.05 (br. s, 2H), 7.18 (s, 2H), 7.22 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.8 Hz, 2H), 8.18 (br. s, 1H).

228 [00896] MS (ES] m/r. [M-H]' calcd for C₂₄H_2BN₉O₁₀S₂: 664.12. Found: 664.01.

[00897] HPLC: 80.60%.

Example 106 (2S}-3-{4-[N-(4-AminopyrrolidÎn-3-yl)carbamimidoyl]phenoxy}-2-({[(12)-l-(2-amino-l,3-thiazol-4yl)’2-{[(3S)-2_f2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amîno}-2-oxoethylidene]amino}oxy)propanoic acid [00898] ^XH NMR (400 MHz, DMS0-d₆): δ = 1.03 (s, 3H), 1.38 (s, 3H), 3.00 (m, 2H), 3.65 3.83 (m, IH), 4.08 - 4.22 (m, IH), 4.38 - 4.68 (m, 4H), 5.01 (m, IH), 6.78 (s, IH), 7.19 - 7.38 (m, 3H), 7.80 (m, 2H), 8.40 (m, IH), 9.38 - 9.48 (m, IH), 9.60 (m, IH), 9.70 (m, IH).

[00899] MS (ES-) m/r. [M-H]- calcd for C₂₄HîoN₉OioS₂: 668.16. Found: 668.05.

[00900] HPLC: 92.04 %.

Example 107 (2S)-2-{{UlZ)-l-(2-Amino-l,3-thiazol-4-Yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino)-2-oxoethylidene]amino}oxy)-3-{4-[N-(azetidin-3-yl)carbamimidoyl)phenoxy}propanoic acid [00901] *H NMR (400 MHz, DMSO<): δ = 1.06 (s, 3H), 1.35 (s, 3H), 4.14 - 4.33 (m, 4H), 4.35 - 4.51 (m, 2H), 4.57 (d, J = 7.8 Hz, IH), 4.63 - 4.80 (m, IH), 4.97 (m, IH), 6.79 (s, IH), 7.20 (d, J = 8.9 Hz, 2H), 7.25 (br. s, 2H), 7.76 (d, J = 8.9 Hz, 2H), 8.85 - 9.03 (br. s, 2H), 9.02 (s, IH), 9.39 (d, J = 7.8 Hz, IH), 9.61 (br. s, IH), 10.11 (d, J = 7.8 Hz, IH).

[00902] MS (ES) m/r. [M-H]‘ calcd for C₂₃H₂₇N_eO₁₀S₂: 639.13. Found: 638.92.

[00903] HPLC: 95.07%.

229

Example 108 (2S}-2-({[{lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dîmethyl-4-oxo-l-{sulfooxy}azetidin’3yl]amino}-2-oxoethylîdene]amîno]oxy)-3-{4-[/V-(piperidin-4-yl)carbamimidoyl]phenoxy}propanoic acid [00904] ‘H NMR (400 MHz, DMSO-d₆): δ = H1.27 (s, 3H), 1.44 (s, 3H], 1.71 (br. s, 2H), 1.98 (br. s, 2H), 2.78 (br. s, 2H), 3.23 (br. s, 2H), 3.83 (br. s, IH), 4.43 (m, 2H), 4.65 - 4.75 (m, 2H), 6.84 (s, IH), 7.15 (br. s, 2H), 7.20 (d, J = 8.7 Hz, 2H), 7.70 (d, J = 8.7 Hz, 2H)0.

[00905] MS (ES ) m/z: ]M-H]' calcd for CsHjjNjOmS,: 667.16. Found: 666.93.

[00906] HPLC: 95.80%.

Example 109 (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethytidene]amino}oxy)-3-{4-[N-(a2etidin-3-yl)carbamimidoyl]phenoxy}propanoic acid [00907] *H NMR (400 MHz, DMSO-d₆): δ = 1.04 (s, 3H), 1.36 (s, 4H), 2.68 (t, J = 4.6 Hz, 4H), 3.27 (d, J = 11.7 Hz, 4H), 3.77 - 4.00 (m, 3H), 4.15 (t, J = 11.7 Hz, 3H), 4.31 · 4.81 (m, 8H), 4.99 (br. s, 2H), 6.80 (s, IH), 7.27 (d, J = 8.6 Hz, 5H), 7.92 (d, J = 8.9 Hz, 3H), 8.63 (br. s, 2H), 9.38 (d, J = 7.8 Hz, IH), 10.37 (br. s, IH), 10.62 (br. s, IH).

[00908] MS (EST) m/z: [M-H]’ calcd ίοιΐ^Η^Οκ^: 653.15. Found: 652.96.

[00909] HPLC: 91.44 %.

Example 110

230 (2S)-2-({[{lZ)-l-(2’Amino-l,3-thiazol-4-yl)-2-([(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylîdene]amino}oxy)-3-(4-{/V-I2-(pyrimidin-2-ylamino}ethyl]carbamimidoyl}phenoxy)propanoie acid [00910] ’H NMR (400 MHz, DMSO-d₆): δ = 1.09 (s, 3H), 1.36 (s, 3H), 3.30 - 3.60 (m, 4H), 4.59 - 4.35 (m, 2H}, 4.95 (d, J = 11.2 Hz, 1H), 4.96 (br.s, 1H), 6.61 (t, J = 4.8 Hz, 1H), 6.79 (s, 1H), 7.25 (d, J = 9.2 Hz, 2H), ), 7.36 (br. s, 2H), 7.68 (d, J = 9.2 Hz, 2H), 8.28 (d, J = 4.8 Hz, 2H), 8.91 (br. s, 2H), 9.32 (br. s, 1H), 9.42 (d, J= 11.2 Hz, 1H), 9.60 (br. s, 1H).

[00911] MS (ES) m/z: [M-H]‘ calcd C^HæNwOuS;:706.72. Found: 705.14.

[00912] HPLC: 96.03 %

Example 111 (2K)-2-{{[(12)-l-(2-Amino-l,3-thiazo!-4-yl}-2-{[(3S)-2,2-dimethy1-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-{N-[2-(pyrimidin-2-ylamino)ethyl]carbamimidoyl}phenoxy)propanoic acid [00913] ’H NMR (400 MHz, DMSO-d₆): δ = 1.39 (s, 3H), 2.50 (s, 3H), 3.57-3.51 (m, 4H), 4.45 -4.43 (m, 2H}, 4.60 (d, J = 7.6 Hz, 1H), 5.00 - 4.97 (m, 1H}, 6.64 (t, J = 4.4 Hz, 1H), 6.82 (s, 1H}, 7.18 (d, J = 8.8 Hz, 2H), 7.40 (br. s, 2H], 7.70 (d, J = 8.8 Hz, 2H), 8.30 (d, J = 4.4 Hz, 2H), 8.95 (br. s, 2H}, 9.35 (br. s, 1H), 9.43 (d, J = 7.6 Hz, 1H), 9.62 (br. s, 1H).

[00914] MS (ES) m/z: [M-H]‘ calcd C₂₆HjoN₁₀0₁₍₎S₂: 706.72. Found: 705.14.

[00915] HPLC: 79.11%

Example 112 tert-Butyl {[4-({l’[({(lZ)-2-{[(3S)-2,2-dimethyM-oxo-l-{sulfooxy)azetidin-3-yl]amino}-2-oxo-l-(2(tritylamino}-l,3-thiazo1-4-yl]ethylidene}amino)oxy]’3-hydroxypropan-2-yl}oxy}phenyl](imino)methyljca rbamate t^X~

231 [009161 *H (400 MHz, DMSO-d_fi): S = 1.16 (s, 1.5H), 1.17 (s, 1.5H), 1.27 (s, 3H), 1.5 (s, 9H), 3.6 - 3.7 (m, 2H), 4.2 - 4.3 (m, 2H), 4.5 (t, J = 7.6 Hz, IH), 4.7 (br. s., IH), 5.0 (br. s., IH), 6.7 (s, IH), 7.1 (d, J = 9.0 Hz, 2H), 7.2 - 7.4 (m, 16H), 7.8 (d, J = 9.0 Hz, 2H), 9.35(d, J = 7.6,0.5H), 9.38(d, J = 7.6,0.5H).

[00917] MS (ES*) m/z: [M-H]' calcd (WWW 837.93. Found: 836.44.

[00918] HPLC: 90.05%

Pharmacological Methods

Abbreviatlons

MIC: minimum inhibitory concentration

CFU: colony forming units

ED100:100% protectîve dose [009191 The antimicrobial activity of the compounds of this invention against a sélection of different bacteria may be evaluated by a number of assays, including the in-vitro détermination of the minimum inhibitory concentration (MIC) or the détermination ofthe in-vivo efficacy in mouse infection models.

Minimum Inhibitory Concentration (MIC) Détermination [00920] Compounds of this invention were tested for antimicrobial activity by determining minimum inhibitory concentrations (MICs, in pg/mL) using the broth microdilution method according to the guidelines ofthe Clinical Laboratories and Standards Institute (Methods for Dilution Antimicrobial Susceptibilïty Tests for Bacteria that Grow Aerobically, Approved standard, 7th ed., Clinical and Laboratory Standards Institute (CLSI) Document M7-A8, Wayne, P a., USA, 2009.). Test compounds were dissolved in DMSO. The compounds were then diluted in microbial growth medium (Mueller Hinton Broth II, cation adjusted) resulting in a final concentration range of 0.063-32 pg/mL in serial two-fold dilution. In ail cases the final DMSO concentration was less iA'-'*

232 than 0.5%. Bacteria were added to 96-well microtitre plates containing the serial two-fold dilutions of the compounds; the final cell density was approxîmately 5*10⁵ colony forming units/mL (CFU/mL). Plates were incubated at 37*C for 18-24 hours and read visually. The MIC, i.e. the lowest concentration of the test compound that inhibited visible growth of the bacteria, was recorded. The same assay conditions were used when the compounds of this invention were tested in combination with /Mactamase inhibitors. While the compounds of this invention were serially diluted as described above, a constant concentration of the /Mactamase inhibitors of 4 pg/mL was used.

[00921] Bacterial strains that were used to evaluate the antimîcrobial acitivity using the 10 MIC détermination induded but were not limited to E. coliATCC25922, K. pneumoniae 60, E.

doacae 34654, C freundii K21/3034, M. morganii 126/3048, P. aeruginosa PAO1, P. aeruginosa 2297 (AmpC wt), P. aeruginosa 2297-con (AmpC derepressed), Λ baumanniï ATCC15308, S. maltophilia ICB7569, S. aureus 133, M. catarrhalis ICB489, H. influenzae ATCC 49247, S. pneumoniae 113, B.fragiHs 6688, C perfringens DSM756, E. coli J62, and E. colt J62-TEM-3. y/

233

Table 4. Biological data

corn-	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]
1	0.25	0.25	0.5	0.5	0.125	4	8	4	8	8
2	0.125	0.125	0.25	0.125	£0.063	2			4	0.125	0.25
3	0.125	£0.063	0.125	£0.063	0.125	2	4	16	1		£0.063
4	0.125	0.25	0.5	0.125	0.25	4	16	8	1	4	£0 063
5	0.25	£0.063	0.125	0.25	0.125	4	4	32	1		0.125
6	0.125	0.25	0.125	£0.125	£0.125	4	8	16	1	32
7	0.5	1	1	0.5	0.5	8	16	8	2	4	£0.063
8	1	0.5	2	0.5	0.25	8	32	32	4		0.25
9	0.125	0.125	0.125	0.125	0.125	2	2	16	0.5	32	£0.063
10	0.5	2	1	1	4	8	8		8
11	0.125	£0.125	£0.063	£0.125	£0.063	1	2	16	0.5	32	0.125
12	0.5	0.25	0.5	0.25	0.25	4	8		4	8	0.125
13	0.5	1	1	0.25	0.5	8	16	8	1		£0.063
14	0.5	1	0.5	0.25	0.5	4	8	32	2		£0.063
15	0.5	1	1	0.5	0.5	8	8	8	2	4	£0.063
16	1	1	1	2	0.5	32	32	32	4	8	£0.063

234

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC Img/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
1			16			0.25	16	0.25	0.25	0.25
2	£0.063	0.5	16	16		0.25	32	0.125	0.125	0.25
3	0.125	0.5	8	8		0.25	16	0.125	0.125	0.25
4	£0.063	£0.063	16	2	2	0.25	8	0.125	0.25	0.25
5	0.25	0.5	4	8		0.5	16	0.25	0.25	0.25
6			4			0.25	16	0.25	0.25	0.25
7	0.25	£0.063	2	1	2	1	8	0.5	1	1
8	0.5	1	8	16		4		2	4	4
9	£0.063	0.25	4	8		0.25	16	0.125	0.125	0.125
10			2			0.5		0.5	0.5	0.5
11	0.125	0.5	4	8		0.25	8	0.25	0.25	0.25
12	0.25	£0.063	32	8	16	0.5	8	0.5	0.25	0.25
13	0.125	£0.063	4	4	2	0.5	32	0.5	0.5	0.5
14	0.25	0.5	8	16		1	32	0.5	0.5	0.5
15	£0.063	£0.063	2	2	0.5	1	8	0.5	0.5	0.5
16	1	£0.063		8	4	2	4	1	1	1

corn-	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]
17	2	2	2	1	£0.063	8	16	32	8		2
18	1	1	2	1	1	4	4	16	16	16	0.25
19	0.5	0.125	0.5	0.5	0.25	8	16		4
20	2	2	2	1	2	8	8	32	2		0.125
21	1	0.25	1	0.25	0.5	16	16		8		0.5
22	1	1	1	0.5	1	16	32	16	4	4	£0.063
23	0.125	0.25	0.5	0.125	0.5	2	2	2	0.5	16	£0.063
24	0.125	0.25	0.25	0.125	0.125	2	4	2	1	8	£0.063
25	0.125	0.25	0.25	0.125	0.125	2	4	4	2	8	£0.063
26A	£0.063	0,031	0.125	£0.063	£0.063	1	2	8	8	16	£0.063
26B	2	0.5	1	2	0.5	4	8	32	16
27A	0.25	0.125	0.25	0.25	0.125	4	4	4	4	4	£0.063
27B	2	1	4	1	1	16	32	16	16	8	0.125
28	0.125	0.125	0.125	0.125	0.125	4	8	32	0.5		0.125
29	0.25	0.25	0.5	0.25	0.25	8	16	8	2	8
30	0.125	£0.063	0.25	£0.063	£0.063	4	4	32	1		0.125

235

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
17	2	1	2	4		2	32	1	2	2
18	0.5	0.5	4	4		2	4	2	2	2
19			16			0.5	32	0.5	1	1
20	0.5	0.5	16	16		2	32	2	2	1
21	0.25	1	32	32		2	16	0.5	1	1
22	0.125	£0.063	2	4	2	1	8	0.5	1	1
23	£0.063	£0.063	1	4	2	0.25	1	0.125	0.125	0.25
24	£0.063	£0.063	2	2	2	0.125	2	0.125	0.25	0.5
25	£0.063	£0.063	4	2	2	0.25	4	0.125	0.125	0.125
26A	£0.063	2	32	8		0.125	32	£0.063	0.125	0.125
26B	2					2	32	1	2	2
27A	£0.063	0.5		8	4	0.25	8	0.25	0.25	0.25
27B	0.25	0.5		32	32	2	8	1	2	2
28	0.25	0.5	2	8		0.25	32	0.25	0.25	0.25
29			4			0.5	8	0.5	0.5	0.5
30	0.25	0.5	4	8		0.25	16	0.25	0.25	0.25

com-	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]
31	0.125	£0.063	0.25	£0.063	0.25	8	8	32	1		£0.063
32	1		0.5	0.5	0.5	16	32		2		£0.063
33	0.25	0.5	0.5	0.25	0.25	8	16	8	8	16	£0 063
34A	1	1	0.5	1	0.25	8	8	16	32	8	£0.063
34B	8	8	4	8	4	32	32	32	32	32	0.25
35	2	2	4	2	1	16	16	32	2		0.25
36A	0.125	£0.063	£0.063	0.125	£0.063	4	4	4	4	2	£0.063
36B	2	1	2	0.5	2	16		32	32	16	0.125
37	2	2	2	2	1	8	8		4		1
38	0.125	0.25	0.25	0.125	0.5	4	8	4	0.25	32	£0.063
39	0.25	0.5	0.5	0.25	0.5	2	4	2	0.5	16	£0.063
40	0.125	0.25	0.5	0.125	0.5	4	8	4	2	16	£0.063
41	0.25	0.5	0.25	0.125	0.25	4	4	4	1	4	£0.063
42	1	1	2	1	2	16	16	16	8	16	£0.063
43	0.5	0.5	1	0.25	1	8	8	8	0.5	32
44A	£0.063	£0.063	0.125	£0 063	0.125	1	2	1	2	2	£0.063

236

compound example No.	s train 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
31	0.25	0.25	8	4		0.25	32	0.125	0.25	0.25
32	0,75	0.5	8	3		2	32	1	2	1
33	0.125	£0.063	32	4	2	0.5	32	0.25	0.25	0.5
34A	£0.063	0.5		16	2	1	32	0.5	0.5	0.5
34B	0.5	8			32	16	32	4	4	8
35	1	1	32	16		4	32	2	8	4
36A	£0.063	0.5		8	2	0.125	8	0.125	£0.063	0.125
36B	0.5	4		32	32	4	32	2	2	2
37	0.5	1	4	16		4		2	2	2
38	£0.063	£0.063	2	4	2	0.25	4	0.125	0.25	0.25
39	0.25	0.25	2	16	8	0.25	4	0.125	0.25	0.25
40	£0.063	£0.063		4	2	0.25	8	0.125	0.25	0.25
41	£0.063	£0.063	4	2	1	0.25	8	0.25	0.25	0.25
42	0.25	0.125	16	8	4	1	16	1	1	1
43	0.125	£0.063	4	8	2	0.5	8	0.25	0.5	0.5
44A	£0.063	0.5	32	8	1	0.125	2	£0.063	£0.063	£0.063

237

com*	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]
44B	2	1	4	2	4	8	16	8	8	16	£0.063
45A	0.5	0.5	1	0.25	0.5	8	16	8	2	8
45B	2	2	4	1	4	16	32	32	4	32	£0.063
46	2	1	2	1	1	8	32	32	16	8
47	0.25	0.5	1	0.5	2	4	2		2		£0.063
48	2	4	4	2	1	8	16	32	8		0.5
49	1	2	2	1	2	8	16	32	4		0.125
50	0.5	0.5	1	1	0.5	8	16	32	2		0.125
51	2	4	2	2	2	16	16	32	4		0.5
52	1	0.5	1	0.25	1	4	4	16	1		2
53	0.5		0.5	0.5	2	16	16	32	4
54	0.5	0.5	0.5	0.25	1	4	8		4
55	0.5	1	0.5	0.25	0.25	16		32	4		0.25
56	2	0.5	4	0.5	0.5	32	32		4		1
57	1	2	2	1	1	32	32	16	2	32	£0.063
58	2	4	4	1	1	16	32	16	16		£0.063

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
44B	0.5	4				2	4	2	2	4
45A			8			0.5	1	0.5	0.5	0.5
45B	0.5	0.125	16	4	2	4	16	2	4	4
46	0.25	1		32	4	2	16	1	1	1
47	0.125	0.125	1	16	1	0.5	32	0.5	0.5	0.5
48	0.5	1	4	16		2		2	2	2
49	0.5	0.5	16	16		2		2	2	2
50	0.25	1	8	16		1		1	1	1
51	0.5	1	8	16		4		4	4	4
52	8	16	8	32		2		2	2	2
53			32			1		1	1	1
54			2			0.5	16	0.5	0.25	0.5
55	1	0.125	8	8		1		1	0.5	0.5
56	2	4	8	32		2	32	1	4	4
57	0.125	£0.063	4	1	2	2	32	1	1	2
58	0.5	£0.063	4	4	4	4	32	2	2	2

238

com-	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]
59	1	1	1	0.5	1	16	16	32	1		0.25
60	1	1	2	1	0.5	16	16	32	4		0.25
61	2	2	2	1	0.5	2	2	16	2	16	£0.063
62	1	0.5	1	0.5	0.125	4	8	32	2		0.125
63	0.5	0.25	0.5	0.25	0.5	8	8		16	16	0.5
64	0.5	0.25	0.5	0.5	0.5	8	16		8	32	16
65	0.5	0.25	0.5	0.25	0.125	16	32		8		0.25
66	2	1	4	2	2	32	32		4		1
67	0.5	2	0.5	0.25	0.125	8	32		4		0.25
68	0.125	0.25	0.125	0.125	0.125	2	8	32	2		£0.063
69	0.125	0.25	0.25	0.125	0.125	4	8		2		£0.063
70	0.125	0.25	0.25	0.125	0.125	4	4		2		0.125
71	2	1	4	1	1	16	32		4	4	0.25
72	0.5	0.25	1	0.5	0.25	8	8		4		0.25
73	0.5	0.5	0.5	0.5	0.5	16	32	32	16	32	£0.063
74	1	2	4	1	1	16	32	32	2	16	£0.063

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
59	1	0.5	32	16		2	32	2	2	2
60	1	1	16	16		2	32	2	2	2
61	0.25	£0.063	8	8	8	2	8	2	2	2
62	0.25	1	8	16		1	16	1	1	1
63	0.125	0.5	16	16		0.5	8	0.25	0.5	0.5
64	8	32	8			1	32	1	1	2
65	0.5	1	8	16		1	32	0.5	1	2
66	2	1		16	16	2	4	2	2	2
67	0.5	0.5	4	8		0.5	32	0.5	1	1
68	0.125	0.5	2	8		0.25	16	0.125	0.25	0.25
69	£0.063	£0.063	4	1	1	0.25	16	0.25	0.25	0.25
70	0.125	0.5	8	16		0.25	16	0.25	0.25	0.25
71	1	0.5		8		8	32	2	4	4
72	0.5	2	16	16		1	32	1	1	1
73	0.25	£0.063	32	8	4	1	32	0.5	0.5	1
74	0.25	£0.063	32	2	2	4	16	1	1	2

239

com-	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	(mg/LJ	[mg/L]	[mg/L]	[mg/L]	[mg/L]
75	0.25	0.5	0.5	0.125	0.25	8	16	8	2	4
76	0.5	0.5	1	0.5	1	16	16	32	4	16	£0.063
77	0.5	2	2	0.5	2	8	16		8
78	0.25	0.25	0.5	0.25	0.5	4	4	2	0.25	8	£0.063
79	0.5	0.5	0.5	0.25	1	8	8	4	0.5		£0.063
80	0.25	0.5	1	0.25		16	16	8	2	32
81A	4	8	16	4	8				8	16
81B	2	4	4	2	4				8	16
82	0.25	0.125	0.5	0.25	0.5	8	16	8	4	32	£0.063
83	0.125	0.25	0.25	0.125	0.5	2	4	4	0.25	16	£0.063
84	£0.063	0.125	0.125	£0.063	0.25	1	2	2	1	32	£0.063
85	0.25	0.5	0.5	0.25	0.25	4	8	8	2	32	£0.063
86	0.25	0.5	0.5	0.25	0.5	4	8	8	2	32	£0 063
87A	1	1	1	1	0.25	32			8		£0.063
87B	0.5	0.5	1	0.5	0.25	16	32	32	16	16	£0.063
88	£0.063	0.125	£0.063	£0.063	£0.063	1	1	1	2	4

240

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/Ll	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/LJ	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
75			16			0.5	1	0.25	0.5	0.5
76	0.25	£0.063	4	4	2	0.5	8	0.5	0.5	0.5
77						0.5	16	1	1	1
78	£0.063	£0.063	1	4	2	0.5	4	0.25	0.5	0.5
79	£0.063	£0.063	2	4	2	0.5	8	0.5	0.5	0.5
80			4			0.5	16	0.5	0.5	0.5
81A	2	0.25	32	16	8	8	32	8	8	8
81B	2	0.125	32	16	4	4	4	4	4	4
82	£0.063	£0.063	8	4	4	0.25	8	0.25	0.25	0.5
83	£0.063	£0.063	2	4	2	0.25	4	0.125	0.25	0.25
84	£0.063	£0.063	2	4	2	0.125	4	£0 063	0.125	0.125
85	£0.063	£0.063	8	4	4	0.5	8	0.25	0.25	0.5
86	£0.063	£0.063	4	4	2	0.25	16	0.25	0.25	0.5
87A	0.25	0.5		32	8	2	32	1	1	2
87B	0.125	1		16	16	1	32	0.5	1	2
88	£0.063	0.5	32	8	0.5	0.125	2	£0.063	£0.063	£0.063

compound example No.	strain 1 MIC [mg/L]	strain 2 MIC [mg/L]	strain 3 MIC [mg/L]	strain 4 MIC [mg/L]	strain 5 MIC [mg/L]	strain 6 MIC [mg/L]	strain 7 MIC [mg/L]	strain 8 MIC [mg/L]	strain 9 MIC [mg/L]	strain 10 MIC [mg/L]	strain 11 MIC [mg/L]
89	0.125	0.25	0.125	0.125	£0.063	1	1	1	1	4
90	0.5		1	0.25	0.5	32	32	32		4	0.5
91	0.125	0.125	0.25	0.125	0.25	2	4	2	1	16	£0.063
92	0.5	0.5	1	0.5	0.5	8	8	8	4	32	£0.063
93	£0.063	0.125	0.125	£0.063		1	1	1	1	4
94	0.125	0.125	0.125	0.125	0.125	2	2	2	2	4	£0.063
95	0.125	0.125	0.125	0.125	£0.063	1	2	2	2	4	£0.063
96	0.125	£0.063	£0.063	£0.063	£0.063	1	1	1	1	4	£0.063
97	£0.063	0.125	0.125	£0.063	£0.063	1	1	1	1	4	£0.063
98	0.125	0.125	0.125	0.125	£0.063	1	2	2	1	4	£0 063
99	0.125	0.25	0.25	0.125	£0.063	2	2	2	2	4	£0.063
100 A	0.125	0.25	0.125	0.125	£0.063	2	4	4	8	8	£0.063
100B	2	2	4	2		16	32	16	32	32
101	0.125	0.125	0.125	0.125	0.125	2	4	2	4	8	£0.063
102	0.125	£0.063	0.25	£0.063	£0.063	1	2	2	4	4	£0.063
103	2				2	16			32		£0.063

241

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
89	£0.063	0.5	32	8	1	0.125	4	£0.063	£0.063	0.125
90	0.5	0.5		4	16	1	0.5	0.5	0.5	1
91	£0.063	£0.063	2	4	2	0.125	4	0.125	0.125	0.125
92	0.125	£0.063	8	8	2	1	32	0.5	0.5	0.5
93			32			0.125	4	0.125	0.125	0.125
94	£0.063	0.5	32	8	0.5	0.25	8	0.125	£0.063	0.125
95	£0.063	0.5		8	2	0.125	4	0.125	£0.063	0.125
96	£0 063	0.5	32	8	1	0.125	4	£0.063	£0.063	£0.063
97	£0.063	0.5	32	4	0.5	0.125	4	£0.063	£0.063	£0 063
98	£0.063	0.5	32	8	2	0.125	8	0.125	0.125	0.125
99	£0.063	0.5	32	8	0.5	0.25	4	0.125	0.125	0.25
100 A	£0.063	0.5		8	2	0.25	32	0.125	0.125	0.25
100B						4	16	2	2	2
101	£0.063	0.5		8	2	0.125	8	£0.063	£0.063	0.125
102	£0.063	0.5		8	2	0.125	4	£0.063	£0.063	0.125
103	0.25	4			32

corn-	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain	strain
pound	1	2	3	4	5	6	7	8	9	10	11
example	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC	MIC
No.	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]	[mg/L]
104	1	1	1	1	0.5	16				16	£0.063
105	16
106	0.125	0.125	0.125	0.125	£0.063	1	2	1	2	4	£0.063
107	£0.063	0.125	0.25	£0.063	£0.063	1	1	1	1	4	£0.063
108	0.125	0.125	0.125	£0.063	£0 063	0.5	1	1	1	4	£0.063
109	0.125	0.125	0.125	0.125	0.125	2	2	2	2	8	£0.063
110	0.5	1	1	0.5	0.25	8	8	16	32	8	£0.063
111	8	8	16	4	8	32	32	32	32

242

compound example No.	strain 12 MIC [mg/L]	strain 13 MIC [mg/L]	strain 14 MIC [mg/L]	strain 15 MIC [mg/L]	strain 16 MIC [mg/L]	strain 17 MIC [mg/L]	strain 18 MIC [mg/L]	strain 19 MIC [mg/L]	strain 20 MIC [mg/L]	strain 21 MIC [mg/L]
104	£0.063	1			8	1	32	1	1	1
105
106	£0.063	0.5		8	1	0.125	8	0.125	£0.063	0.125
107	£0.063	0.5	32	8	0.125	0.125	4	£0.063	£0.063	£0.063
108	£0.063	0.5	32	8	1	0.125	4	£0.063	£0.063	0.125
109	£0.063	0.5		16	4	0.125	2	£0.063	0.25	0.125
110	£0.063	0.25		16	8	1	32	0.5	0.5	0.5
111	0.25	2				16	32	8	8	8

strain 1	£. coli ATCC25922
strain 2	K. pneumoniae 60
strain 3	E. doacae 34654
strain 4	Cfreundii K21/3034
strain 5	M. morganii 126/3048
strain 6	P. aeruginosa PAO1
strain 7	P. aeruginosa 2297 (AmpC wt)
strain 8	P. aeruginosa 2297-con (AmpC derepressed)
strain 9	A baumannii ATCC15308
strain 10	S. maltophilia ICB7569
strain 11	M. catarrhalis ICB489
strain 12	H. influenzae ATCC 49247
strain 13	S. pneumoniae 113
strain 14	S. aureus 133
strain 15	B. fragilis 6688

243

strain 16	C perfringens DSM756
strain 17	E. colt J62
strain 18	E. coli J62-TEM-3
strain 19	E. coli J62-TEM-3 + 4 pg/mL davulanic acid
strain 20	E. coli J62-TEM-3 + 4 pg/mL sulbactam
strain 21	E. coli J62-TEM-3 + 4 pg/mL tazobactam

Détermination of the in-vivo activity in mouse infection models

Formulations [00922] Commercial 10% aqueous mannitol solution was diluted with Aquadest to a 3% aqueous mannitol solution. Compounds of this invention were dissolved at 20-45 *C to form clear application solutions of a concentration in the range from 0.02 mg/mL to 3 mg/mL [00923] Commercial 10% aqueous mannitol solution was diluted with Aquadest to a 3% aqueous mannitol solution. Solid sodium acetate was added to obtain 2-20 mM sodium acetate solutions in 3% aqueous mannitol. Compounds of this invention were dissolved at 20-45 *C to form clear application solutions of a concentration in the range from 0.02 mg/mL to 3 mg/mL.

[00924] Compounds of this invention were dissolved In DMSO at 20-25 *C to form clear stock solutions of a concentration in the range of 60 mg/mL The stock solutions were diluted with 3% aqueous mannitol solution at 20-25 *C to form clear application solutions of a concentration in 15 the range of 2.1 mg/mL [00925] Compounds of this invention were dissolved at 20-45 *C in commercial lactated Ringefs solution to form clear application solutions of a concentration in the range from 0.02 mg/mL to 3 mg/mL

244 [00926] Compounds of this invention were dissolved at 20-45 *C In commercial Dulbecco's Phosphate Buffered Saline (DPBS) without calcium and magnésium to form clear application solutions of a concentration in the range from 0.02 mg/mL to 3 mg/mL [00927] D(+)-Gluco$e monohydrate was dissolved in Aquadest to a 5% aqueous glucose solution. Compounds of this invention were dissolved at 20-45 *C to form clear application solutions of a concentration in the range from 0.02 mg/mL to 3 mg/mL [00928] Compounds of this invention were dissolved at 20-45 ’C in commercial 0.9% saline to form clear application solutions of a concentration in the range from 0.02 mg/mL to 3 mg/mL

Peritonitis models [00929] Female CD-1 mice were infected intraperitoneally with a bacterial inoculum in 5% mucin that led to the death of the untreated group (n=5) within the first 24 hours of the experiment (“1 x 10* CFU - ~5 x ÎO’CFU per mouse depending on the virulence of the straïn used}. Strains that were used included but were not limited to wild-type f. coli Neumann, wildtype P. aeruginosa Walther, wild-type A baumannii ATCC15308 and résistant K. pneumoniae CL5761 (KPC-3 producer). Mice were treated via intravenous injection 30,60 and 120 minutes post infection with compounds of this invention (alone or in combination with a /Ma dama se inhibitor) as well as with control antibiotics including but not limited to meropenem. Lethalities were followed over 5 days and the 100% protective dose (ED100) was determlned.

Lung infection mode!

[00930] Female BALB/c mice anesthetized with isoflurane and infected intranasally with 32 μί of the bacterial inoculum (e.g. ~3.5 x 10⁷ CFU per mouse for P. aeruginosa PAO1). Mice were treated via intravenous injection 30,60 and 120 minutes post infection with compounds of this invention as well as with control antibiotics including but not limited to meropenem. Animais, including an untreated control group were sacrified after 24 hours. Lungs were aseptically u_z—

245 removed, homogenized, serially diluted and plated onto sheep-blood agar plates to détermine CFU counts.

Urinary tract infection model [00931] Female CD-1 mice were given 5% glucose solution as the sole source of drink5 ing water from 16 hours before the experiment to the end. Anesthetized mice were infected via the urethra with an uropathogenic E. coli strain (e. g. E. coli 70430001) in 0.9% NaCI with 0.25% agar-agar in a 25 pi volume (~5 x 10⁶ CFU per mouse). Mice were treated via intravenous injection 1,5,23, and 30 hours post infection with compounds of this invention as well as with control antibiotics including but not limited to meropenem. Mice, including an untreated control group were sacrifîed at 48 hours post infection. Bladders were aseptically removed, homogenized, serially diluted and plated onto Mueller Hinton agar plates to détermine CFU counts.

Claims

1. Compound of formula

A

CH₂), (I) in which

R¹ and R¹ independently of one another represent hydrogen, aminocarbonyl or (CiC«)-alkyl, or R¹ and R¹ together with the carbon atom to which they are bonded form a (C₃-C₈)cycloalkyl. R³ represents -(CH₂)_m-(SO₂)OH or -O-(CH₂)_o-(S0₂)0H, wherein m and o independently of one another represent an integer 0,1, 2 or 3,and wherein any CH₂-group contained in the residues which R³ represents may be substituted with one or two (C_x-C«)-alkyl-residues, X represents CR⁴ or N, R⁴ represents hydrogen or halogen,

represents a bond or an alkyl-chain having one, two, three or four carbon atoms,

247 whereby the alkyl-chain may be substituted with one, two, three or four substituents, selected independently of one another from the group consisting of carboxy, aminocarbonyl and (Cj-Qj-alkyl, whereby alkyl in tum may be substituted with a substituent selected from the group consisting of hydroxy, carboxy and aminocarbonyl,

Y represents a bond, O, NH or S,

A represents (C6-C₁₀)-aryl or 5- to 10-membered heteroaryl, whereby aryl and heteroaryl are substituted with a substituent of the fol· lowing formula

R^lb, R^îb and R^3b independently of one another represent hydrogen, amino, hydroxy, (CrC^-alkyl, (Ci-Cj-alkoxy, (Cj-Qj-cycloalkyl, 4-, 5- 6- or 7-membered heterocyclyl or 5- or 6-membered heteroaryl, whereby amino and hydroxy may be substituted with one or two substituents selected independently of one another from the group consisting of carbonyl, (C1-C4)alkylcarbonyl, mono- or di-tCj-GJ-alkylaminocarbonyl, and (CrQj-alkyl, whereby alkoxy, heterocyclyl and heteroaryl may be substituted with one, two or three substituents selected in- —

YA¹

248 dependently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, (C1-C4)alkylcarbonyl, (CrQj-alkoxy, mono- or di-fCx-Q)alkylamino, mono- or di-tCrCJ-alkylaminocarbonyl, -NHCH(=NH), -NH-C(=NH)(NH₂), -C(=NH)CH₃ and (Ci-Q)-alkyl, and whereby alkyl and cycloalkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, carbonyloxy, aminocarbonyl, carbonylamino, (Q-Qj-alkylcarbonyl, (Ci-C^-alkoxy, mono- or di-(Ci-C«)-alkylamino, mono- or di-fCi-C*)alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), CH(=NH)CH_ÎI (Ce-Cioï-aryl, 5- or 6-membered heteroaryl and 5- or 6-membered heterocyclyl, whereby heteroaryl and heterocyclyl in tum may be substituted with (Ci-C^-alkyl, and whereby amino in turn may be substituted with 5or 6-membered heteroaryl, or

R^a and R^3b together with the nitrogen atom to which they are bonded form a 5- to 7-membered heterocycle including one, two or three further heteroatoms selected from the sériés N, O and S and R^lb is as defined above,

R*^b represents hydrogen, amino, hydroxy, (Ci-CiJ-alkyl or (C1-C4)alkoxy, whereby amino and hydroxy may be substituted with one or two substituents selected independently of one another from the group consisting of (Ci-QJ-atkylcarbonyl, mono- or di-fCi-C^-alkylaminocarbonyl and (Ci-Cj-alkyl,

249 whereby alkoxy may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, (C₁-C*)-alkylcarbonyl, (Ci-Qj-alkoxy, mono- or di(Ci-QJ-alkylamino, mono- or di-tCi-Cj-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -CH(=NH)CH₃and (Ci-CjJ-alkyl, and whereby alkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, aminocarbonyl, (Ci-Qj-alkylcarbonyl, (C1-C4)alkoxy, mono- or di-(Ci-C4)-alkylamino, mono- or di-(CiQj-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂},CH^NHJCHj, (CiO-alkyl, (Ce-Cj-aryl and 5-or 6membered heteroaryl,

R^5b represents hydrogen or (C₁-C₄)-alkyl,

Q represents a bond, CH₂ or NH, k represents an integer 1 or 2, and • is the linkage site to the residue represented by A, and whereby aryl and heteroaryl further may be substituted with one or two substituents selected independently of one another from the group consisting of halogen, cyano, amino, hydroxy, (Cj-C^-alkyl, (C₂-C*)-alkoxy, mono- or di-tCi-QJ-alkylamino, amino-^-C^-alkyl, hydroxy-(Ci-C4)-alkyl or carboxy, whereby alkyl, alkoxy, afkylamino, amînoalkyl, hydroxyalkyl and carboxy in turn may be substituted with a substituent selected from the group consisting of halogen, (Ci-C«)-alkyl and carbonyl, and

I represents an integer 0,1,2 or 3,

250

2. Compound according to claim 1, characterized in that

R¹ and R² independently of one another represent hydrogen or (CrC^-aîkyl, or R¹ and R¹ together with the carbon atom to which they are bonded form a (Cj-Cg)cydoalkyl. R³ represents -(CH₂)_m-(SO₂)OH or -0-(CH₂)_o-(SO₂)0H, wherein m and o independently of one another represent an integer 0 or land wherein any CH₂-group contained in the residues which R³ represents may be substituted with one ortwo (Ci-C»)-alkyl-residues, X represents CR* or N, R⁴ represents hydrogen or halogen, Z represents a bond or an alkyl-chain having one, two or three carbon atoms, whereby the alkyl-chain may be substituted with one, two or three substituents, selected independently of one another from the group consisting of carboxy, aminocarbonyl and (C₁-C₄)-alkyl, whereby alkyl in turn may be substituted with a substituent selected from the group consisting of hydroxy and carboxy. Y represents a bond, 0, NH or S, A represents (C«-Cio)-aryl or 5- to 10-membered heteroaryl, whereby aryl and heteroaryl are substituted with a substituent of the following formula

251 wherein

R^lb, R^Ib and R^îb independently of one another represent hydrogen, amino, hydroxy, (Ci-C^-alkyl, 4-, 5-, 6-or7-membered heterocyclyl or 5- or 6-membered heteroaryl, whereby heterocyclyl and heteroaryl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, (Cj-Qj-alkylcarbonyl, (Ci-CiJ-alkoxy, mono- or di-(C₂-C«)-alkylamino, mono- or di-tCi-Cj-alkylaminocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), -C(=NH)CHj and (q-qj-alkyl, and whereby alkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, carbonyloxy, aminocarbonyl, carbonylamino, (C₂Cj-alkylcarbonyl, (Ci-QJ-alkoxy, mono- or di-fCi-Ci)alkylamino, mono- or di-fCi-CJ-alkylaminocarbonyl, -NHCH(=NH), -NH-C(=NH)(NH₂), -CHt=NH)CH3, (C6-C₁₀)-aryl, 5or 6-membered heteroaryl and 5- or 6-membered heterocydyl, whereby heteroaryl and heterocyclyl in turn may be substituted with (Ci-C«)-alkyl or

R^ïb and R^3b together with the nitrogen atom to which they are bonded form a 5-to 7-membered heterocycle including one, two or three further heteroatoms selected from the sériés N, O and S and R“ is as defined above,

252

R*^b represents hydrogen, amino, hydroxy, (CrC^-alkyl or (CrC,)alkoxy, whereby amino and hydroxy may be substituted with one or two substituents selected independently of one another from the group consisting of (Cj-Qj-alkylcarbonyl, mono- or di-fCi-C^-alkylamînocarbonyl and (CrQj-alkyl, and whereby alkyl may be substituted with one, two or three substituents selected independently of one another from the group consisting of halogen, hydroxy, amino, carbonyl, carboxy, aminocarbonyl, (CpC^-alkylcarbonyl, (Ci-C*)alkoxy, mono- or di-fCj-C^-alkylamino, mono- or di-(Cr Cj-alkylamînocarbonyl, -NH-CH(=NH), -NH-C(=NH)(NH₂), CH(=NH)CHj, (q-Ql-alkyl, (QrC₁₀)-aryl and 5- or 6membered heteroaryl,

R^a represents hydrogen or (Cj-CO-alkyl,

Q represents a bond, CH₂ or NH, k represents an integer 1 or 2, and * is the linkage site to the residue represented by A, and whereby aryl and heteroaryl further may be substituted with one or two substituents selected independently of one another from the group consîstîng of halogen, cyano, amino, hydroxy, (Ci-Cj-alkyl, (Ci-QJ-alkoxy, mono- or di-(Ci-C<)-alkylamino, amino-fCj-C^-atkyl, hydroxy-(Ci-C4)-alkyl or carboxy, whereby alkyl, alkoxy, alkylamino, aminoalkyl, hydroxyalky! and carboxy in turn may be substituted with a substituent selected from the group consisting of halogen, (Ci-C^-alkyl and carbonyl, and

I represents an integer 0 or 1

253 and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

3. Compound according to claim 1 or 2, characterîzed in that

R¹and R² independently of one another represent hydrogen or (Ci-CiJ-alkyl, or R¹and R¹ together with the carbon atom to which they are bonded form a (C₃-C_e)~ cyclo alkyl, R³ represents -(SOJOH or -O-ÎCHJo-ISOJOH, wherein o is an integer 0 or 1, and wherein any CH₂-group contained in the residues which R³ represents may be substituted with one or two (Ci-C^-alkyl-residues, X represents CH, Z represents an alkyl-chain having two or three carbon atoms, whereby the alkyl-chain may be substituted with one or two substituents selected independently of one another from the group consisting of carboxy, aminocarbonyl, methyl, hydroxymethyl, hydroxyethyl. Y represents 0 A represents phenyl or 5- or 6-membered heteroaryl, whereby phenyl and heteroaryl are substituted with a substituent ofthe following formula vÇ- - ^R iib R

254 wherein

R^lb, R^Zb and R³⁶ independently of one another represent hydrogen, amino, hydroxy, (C_t-C«)-alkyl or 4-, 5-, 6- or 7*membered heterocyclyl, whereby heterocyclyl may be substituted with one or two substituents selected independently of one another from the group consisting of amino, carboxy, mono- or di-(CiCj-alkylamino, and (Ci-C<)-alkyl, and whereby alkyl may be substituted with one or two substituents selected independently of one another from the group consisting of hydroxy, amino, carboxy, carbonyloxy, amînocarbonyl, carbonylamino, mono-ordi-(Ci-C»)alkylamino, mono- ordi-fCi-C^-alkylaminocarbonyl, -NHCH(=NH),-NH-C(=NH)(NH₂), phenyl, 6-membered heteroaryl and 5- or 6-membered heterocyclyl or,

R^a and R^3b together with the nitrogen atom to which they are bonded form a 6-membered heterocyde including one or two nitrogen atoms and R¹” is hydrogen,

R^<b represents hydrogen or amino, whereby amino may be substituted with one or two (C₂C<)-a1kyl substituents,

R®¹ represents hydrogen,

Q. represents a bond, k represents an integer lor2, and * is the linkage site to the residue represented by A, and whereby phenyl und heteroaryl further may be substituted with one or two substituents selected independently of one another from the group

255 consisting of halogen, cyano, amino, hydroxy, (Cj-C^-alkyl or hydroxy-(CiQ)-alkyl, whereby hydroxyalkyl in tum may be susbstituted with a carbonyl substituent, and

4. Compound according to any one of daims 1 to 3, characterized in that

R¹ and R² independently of one another represent hydrogen or methyl,

R³ represents -(SO₂)OH or -O-(5O₂)OH,

X represents CH,

Z represents an alkyl-chain having two or three carbon atoms, whereby the alkyl-chain may be substituted with one or two substituents, selected independently of one another from the group consisting of carboxy and methyl,

Y represents O,

A represents phenyl or 6-membered heteroaryl, whereby phenyl and heteroaryl are substituted with a substituent of the following formula wherein

R¹⁶ and R^2b represent hydrogen,

256

R^3b represents hydrogen, amino, hydroxy, (Ci-C^-alkyl or 4-, 5- or

6-membered nîtrogen-containing heterocyclyl.

whereby alkyl may be substituted with a substituent selected from the group consisting of hydroxy, amino, carboxy, carbonyloxy, mono- or di-(C₂-C«)-alkylamino, -NHCH(=NH), -NH-C(=NH)(NH₂), 5-or 6-membered nitrogencontaining heteroaryl and 5- or 6-membered nitrogencontaining heterocyclyl.

Q represents a bond, * is the linkage site to the residue represented by A, and whereby aryl and heteroaryl further may be substituted with one substituent selected from the group consisting of halogen, cyano, amino, hydroxy, (Ci-C«)-alkyl or hydroxy-fCj-C^-alkyl, and represents 0 and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

5. Compound according to any one of daims 1 to 4, characterized in that

R¹ and R¹ represent methyl,

R³ represents -O-(SO₂)OH,

X represents CH,

Y represents O,

A represents phenyl substituted with a substituent of the following formula

257 wherein

R¹¹¹ and R^îb represent hydrogen,

R³⁶ represents aminoethyl, azetidine, pyrrolidine or piperidîne,

Q represents a bond, * is the linkage site to the residue represented by A, and

I represents O and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

6. Compound according to any one of claims 1 to 5 characterized in that

R¹ a nd R² re prese nt methyl,

R³ represents-O-(SO₂)O H,

X represents CH,

Z represents a two carbon alkyl-chain, substituted with a carboxy substituent,

Y represents O,

A represents phenyl substituted with a substituent of the following formula

R^2b t'

258 wherein

R¹⁶ and R^ïb represent hydrogen,

R^3b represents aminoethyl, azetidine, pyrrotidine or piperidine,

Q represents a bond, * is the linkage site to the residue represented by A, and

Irepresents O and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

7. Compound according to claim 1, characterized in that

A represents a group selected from the following formulae

259

260

261 and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

8. Compound which is (2Z)-2-{2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoyl-3-hydroxyphenoxy}ethoxy]imino}-N[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxY)azetidin-3-yl]ethanamide (25.35) -3-{[(2Z)-2-(2-Am i no-l,3-t hiazol-4-yl)-2-{[2-(4-ca rba m ïmîdoyl-3-hydroxyph e noxy Jethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-su!fonicacid (25.35) -3-{[(2Z)-2-(2-AminO’l,3-thiazol-4-yl)-2-({2-[(6-carbamimidoylpyridin-3-yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-((2-[{6-carbamimidoytpyridin-3-yl)oxy]ethoxy}imino)-N-[(3S)-

2.2- dimethyl-4-oxo-l-(sulfooxy)azetidin-3-y1]ethanamide (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(5-carbamimidoylpyridin-2-yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol'4-yl)-2-({2-[(4-carbamimidoylphenyl)sulfanyl]- ethoxyJiminoJacetylJaminoJ^-methyMOxoazetidine-l-sulfonic acid (2Z)-2-(2-Amtno-l,3-thiazol-4-y!)-2-({2-[(4-carbamimidoylphenyl)sulfany1]ethoxy}imino)-N-[(3S)-

2.2- dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(4-carbamimidoy1phenyl)aminolethoxy}- imîno)acetyl]amino]-2-methyl-4-oxoazetidine-l-sulfonicacid (25.35) -3-{[(2Z)'2-(2-Amino-l,3-thiazoM-yl)-2-{[2-(4-carbamimïdoylphenoxy)- ethoxy]imino}acetyl]amino)-2-methyl-4-oxoazetidine-l-sulfonicactd (2Z)-2-(2-Amino-l,3-thiazol-4-y!)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[(2R,3S)-2methyl-4-oxo-l-(sulfooxy)a2etidin-3-yl]ethanamide {2R,3S}-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2’(4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid vv—

262 {[(2S,3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazo!-4-y!)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidin-l-yl]oxy}methanesulfonic acid (2Z)-2-(2-Amino-l,3-thiazoî-4’yl)-2-{[2-(4’Carbamimidoyl-3-methylphenoxy)ethoxy]imino}-N-[{3S)-

2.2- dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanarr)ide (25.35) -3-{[(2Z)-2-(2-AniinO'l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoyl-3-methylphenoxy)- ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[{2-carbamimidoylpyridin-4-yl)oxylethoxY}imino)-N-[(3S)-

2.2- dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2Z}'2-(2-Amino-l,3-thÎazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[2-oxo-l{suifooxy)-l'azaspirol3.4]oct-3-yl]ethanamide (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazoM-yl)-2-{[2-(4-carbamimidoylphenoxy)-2-methylpropoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-su!fomcacïd (25.35) -3-{t(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({[l-(4-carbamimidoylphenoxy)-2-methylpropan-2- ylloxy}imino)acetyI]amino}“2-methyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoyl-2-fluorophenoxy)- ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (2S,3S}-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoyl-2-chlorophenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[4-(N-hydroxycarbamimidoyl)phenoxy]ethoxy}- imino)acetyl]annino}-2-methyl-4Oxoazetidine-l’Sulfonic acid (2Z)-2-(2-Amino-l_/3-thiazol-4-yl}-2-({2-[(4-€arbamimÎdoylpyridin-2-yl)oxy]ethoxy)imino)-N-[(3S)-

2.2- dimethYl-4-oxo-l-(su!fooxy)azetidin-3-yl]ethanamide (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]-2-[(2-{4-[N(piperidin-4-y!)carbamimidoyl]phenoxy}ethoxY)imino]ethanatnide (2Z}-2-[(2-{4-[N-{2-Aminoethyl)carbamimidoyl]phenoxy}ethoxy)iminoî-2’(2’amino-l_/3-thiazol-4yl}-N-[(3S)-2,2-dimethyl-4-oxo-l-(su!fooxy}azetidin-3-yl]ethananiide w-—

263 (2Z)-2-{2-Amino-l,3-thiazol-4-yl)-2-({2-[4-(4,5-<iihydro-lH-imidazol-2-Yl}phenoxy]ethoxy}imino)-N[(3S)-2,2-dimethyl-4-oxo-l-(su!fooxy)azetidin-3-yl]ethanannide (2S and 2R)-2-({[(lZ)-l-(2-Amïno-l,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-l-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-carbamidinoyl-phenoxy)propanoicacid {2S and 2R)-2-({[(lZ)-l-(2-Amîno-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(su1fooxy)azetidin3-yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-carbamimidoylphenoxy)propanoicacid (25.35) -3-{[(2Z)-2-{2-Amino-l,3-thiazol-4-yl)’2’({2-I(6-carbamimidoylpyridazin-3-yl)oxy]ethoxy}imino)acety[]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (2Z}-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(6-carbamimidoy1pyridazin-3-yl)oxy]-ethoxy}imîno)-N[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(5-carbamimidoylpyrazin-2-yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-suifonic acid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazoi-4-yl}-2-({2-[(4-carbamimidoyl-l,3-thiazol-2-yl)oxy)- ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetÎdine-l-sulfonic acid (25.35) -3-{[(2Z}-2-(2-Amino-l,3-thiazol-4-yl}-2-(2-[(4-carbamimidoylthiophen-2-Y!)methoxy]imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonïcacid (2Z)-2-(2-Amino-l,3-thiazoM-yl)-2-({2-[(6’Carbamimidoy!-5-hydroxypyridin-3-yt)oxy]ethoxy}imino)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2Sand 2R)-2-({I(lZ)-l-(2-Amino-l,3-thiazo!-4-yf)-2-{[(3S)-2_t2-dimethyl-4-oxo-l-(sulfooxy)azetidin3-yl]amino}-2-oxoethy1idene]amino}oxy)-3-(4-carbamimidoyl-3-hydroxyphenoxy)propanoicacid (25.35) -3-{[(2Z)-2-{[2-(2-Amino-4-carbamimidoy!phenoxy)ethoxy]imino}'2-(2-amino-l,3-thiazo1-4yl)acety!]amino}-2-methyM-oxoazetidine-l-su!fonic acid (2Sand 2R)-2-({[(lZ)-l-{2-Amino-l,3-thiazo!-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l*(sulfooxy)-azetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-3-[(6-carbamimidoylpyridin-3-yl)oxy]propanoie acid (2S, 3S)-3-{[(2Z)-2-(2-Amino-l,3-thiazo!-4-yl)'2’[{3-(4-carbamimidoylphenoxy)propoxy]Imîno}-acetyl]-amino}-2-methYl-4-oxoazetidine-l-sulfonic acid «-a/

264 (2Z)-2-{2-Am i no-l,3-thiazo l-4-yl )-N-[( 3S)-l-hyd roxy-2,2-di m ethyl-4-oxoazetidi n-3-yl]-2-( {2-[4-(N {2-Kiminomethyl)amîno]ethyl}carbanriïmïdoyl)phenoxy]ethoxy}innÎno)ethanamide (2Z)-2-{2-Amino-l,3-thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxY)azetidin-3-yl]-2-{[2-(4-{N[(3S)-pyrrolidin-3-yl]carbamimidoyl}phenoxy)ethoxy]imino}ethanamide (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-{4-{N-[2-(dimethylamino)ethyl]carbamimidoyl}phenoxY)ethoxy]imino}-N’I(3S}'2,2-dimethyl-4-oxo-l-(sulfooxy)azetidîn-3-yl]ethanamîde (2Z)-2-(2-Amino-l_r3-thiazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[(3S)-2,2di m ethy l-4-oxo-l -(sulfooxy) a zetidîn-3-y IJetha na mïde (4S)-4-{[{4-[2-({[(lZ)-l-(2-Amino-l_t3-thiazol-4-yl)-2-([(3S}-2,2-dimethyM-oxo-l(sulfooxy)-azet-idin-3-yl]amino}-2-oxo-ethylidene]-amino}-oxy)-ethoxy]-phenyl}(imino)methyl]aminoFN,N-dimethyl-L-prolinamide (2Z)-2-(2-Amino-l,3-thiazo1-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]-2-{[2-(4-{N[(3S}-l-ethaninriidoylpyrrolidin-3'yl]carbamimidoyl}phenoxy)ethoxy]imino}ethanamide (2Rand 2S)-3-{4-[N-(2-Aminoethyl)carbamimidoy1]phenoxy}-2-({[(lZ)-l-(2-amino-l,3-thiazol-4-yl)-

2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-y!]amino}-2-oxoethylidene]amino}-oxy)-propanoic acid (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({[(2R and 2S)-l-(4-carbamimidoylphenoxy)-3-hydroxypropan2-yl]oxy}imino)-N-[{3S)-2,2-dÎmethyl-4-oxo-l-(su!fooxy)azetidin-3-yl]ethanamide

3’{{[(lZ)'l-(2-Amino-l,3-thiazol-4-yl)-2-{I(3S)-2_i2-dimethyl-4-oxo-l-(sulfooxy)azetidÎn-3-yl]amino}2-oxoethylidene]amino}oxy)'4-(4’Carbamimidoylphenoxy)butanoic acid (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}-N-[(2S,3S)-2methyl-4-oxo-l*(sulfooxy)azetidin-3-yl]ethanamide (2R,3S)-3-{I(2Z)-2-(2-Amino-l₍3-thiazol-4-yl)-2-{[3-(4-carbaniîmidoylphenoxy)propoxy]imino}acetyI]amino}-2-methyl-4-oxoazetidine-l-$ulfonicacid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(2-bromo-4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-{[{2Z)-2-(2-Amino-l,3-thiazol-4-yl}-2-{[2-{4<arbamimidamidophenoxy)ethoxy]imino}acety!]amino}-2-methyl-4Oxoazetidine-l-sulfonic acid

265 (25.35) -3-{[{2Z)-2’(2-AminO'l,3’thiazol'4’yl)-2’{[3-(4-carbamimidamidophenoxy)propoxy]imino}acetYl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (2Z)-2-{5-Amîno-l,2,4-thiadiazol-3-yi)’2-{[2-{4-carbamÎmidoylphenoxy)ethoxy]iniino}-N-[(2S_t3S)-lhydroxy-2-methyl-4-oxoazetidin-3-yl]ethanamide (2S,3S}-3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[2-(3-carbamimidoylphenoxy}ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-su!fonic acid (25.35) -3-({{2Z)-2-(2-Amino-l,3-thiazo1-4-yl)-2-[(2-{4-[N-{propan-2-yl)carbamimidoyl]phenoxy}- ethoxy)imino]acetyl}amino)-2-methyl-4-oxoazetidine-l-sulfonic acid (2S,3S}-3-{[{2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[{4-carbamimidoy1benzyl)oxy]imino}acety1]amino}2-methyl-4-oxoazetidine-l-sulfonîc acid (25.35) -3-{K2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[(4-carbamimîdoylthiophen-2- yl)methoxy]ethoxy}iniino)acetyl]amino}-2-methyl'4-oxoazetidine'l-sulfonicacid (2Z)-2-(2-Amino-l,3-thiazo!-4-yl)-2-{[(4-carbamimidoylbenzyl}oxy]imino}-N-[{3S)-2,2-dimethyl-4oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{[3-(4-carbamimidoylphenoxy)propoxy]imino}-N-[{3S)-2,2dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2S,3S}-3-{[{2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-({2-[4-carbamÎmidoyl-2-(hydroxymethyl}phenoxY]ethoxy}imino)acety!]amîno}-2-methyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-({(2Z)-2-(2-Amino-l,3-thiazol-4-y!)-2-[(2-{4-carbamimidoy!-2-[(formyloxy)methyl]phenoxy}ethoxy)imino]acetyl}amino)-2-niethy1-4-oxoazetidine-l-sulfonicacid (25.35) -3-ÎI(2Z)-2-(2-Amino-5-ch!oro-13-thiazol-4-yl}-2-{[2-(4-carbamimidoylphenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-{K2Z)-2-({2-[4-(2-Amino-2-inninoethyl)phenoxy]ethoxy}imino)-2’(2-amino-l,3-thiazol-4yOacetylJaminobZ-methyM-oxoazetidine-l-sulfonicacid (25.35) -3-({{2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-[{2-{4-[(2-formylhydrazinyl){imino}methyl)phenoxy}ethoxy)imino]acety!}amino)-2-fnethyl-4-oxoazetidine-l-sulfonicacid w—

266 (2S,3S}-3-(((2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-[(2-{4-[hydrazinyl(imîno)methyl]phenoxy}ethoxy)imino]acety!}amîno)-2-methyl-4-oxoazetidine-l-sulfonicacîd (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazo!-4-yl)-2’({2-[(5-carbamimidoyl-l_/3,4’thiadiazol-2- yî)oxy]ethoxy)imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid (25.35) -3-U(2Z)-2-(2-Amino-13-thiazol-4-yl)-2-{[2-(4-carbamimidoylphenoxy)ethoxy]- imino)acetyl]amino}’2-carbamoyl-4-oxoazetidine-l-su!fonicacid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-y!)-2-((2-[(3-carbamimidoyl-l,2-oxazo)-5- yl)oxy]ethoxy}imîno)acetyl]amino}-2-niethyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-{[(2Z)-2-(2-AminO'l,3-thiazol-4-yl)-2-({2-[4-(N-methylcarbamimidoy!)phenoxY]- ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-(((2Z)-2-(2-Amino-l,3-thiazol-4-Yl)-2-I(2-{4-[N-(2-hydroxyethyl)carbamimidoyl]phenoxy}ethoxy)imino]acetyl}amino)-2-methyl-4-oxoazetidine-l-sulfonicacid (25.35) -3-U(2Z)-2-(2-Amino-l,3-thiazol-4-y1)-2-{[2-(4-{N-[2-(formyloxy)ethy1]carbamidoyl}- phenoxy)ethoxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid (25.35) -3-{[(2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-{{2-[{3-carbamimidoyl-l-methyl-lH’pyrazol-5- yl)oxy]ethoxy}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonicacid (25.35) -3-{[{2Z)-2-(2-AminO'l,3-thiazol-4-yl)-2-({2-[(5-carbamimidoyl-l-methyl-lH-pyrazo!-3yl}oxy]ethoxY}imino)acetyl]amino}-2-methyl-4-oxoazetidine-l-sulfonic acid

N-[{4-[2-({[(lZ)-l’(2-Amino-l,3-thiazoi-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)ethoxY]phenyl]{imino)methyl]glycine (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-(i2-((2-carbamimidoyl-5-methyl-l,3-thiazol-4-yl)oxy]ethoxy}imino)-N-[(3S)-2,2-dimethy!-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide

2’t{Î(lZ)-l-i2-Amino-l,3-thiazoi-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(suifooxy)azetidin-3-y!]amino}2-oxoethylidene]amino}oxy}-3-(4-carbamîmidoylphenoxy)propanamide (2Z)-2-(2-Amino-l,3-thîazo1-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-y!]-2-[(2-{4-[N(pyridin-2-ylmethyl}carbamimidoyl]phenoxy}ethoxy)imino]ethanamide

267 ([(2S,3S)-3-{[(2Z}-2-[(2-{4-[N-(2’Aminoethyl)carbamîmidoYl]phenoxy}ethoxy)imino]-2-(2-aminol,3-thîazo1-4-yl)acetynamino}-2-methyl-4-oxoazetidin-l-yl]oxy}methanesu!fonïc acid {2Z)-2-{2-Amino-l,3-thiazoM-yl)-2-[(2-{4-[N-(2-carbamimidamidoethyl)carbamimidoyl]phenoxy}ethoxy)iminol-N-[(3S)-2,2-dimethyl-4-oxo-l-{sulfooxy)azetidin-3-yl]ethanamÎde

1- (2-{[{4-[2-({[(lZ)-l-(2-Amino-l,3-thiazo!-4-yl)-2-{[(3S)-2,2-dimethyl-4--oxo-l-(sulfooxy)azetidin-3yl]amino}-2-o^xoethylidene]amino}oxy)ethoxy]phenyl}(imino)-methyl]amino}ethyl)-lmethylpyrrolidinium chloride (2Z)-2-(2-Amino-l,3-thïazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxO'l’(sulfooxy)azetidin-3-y!]-2-[(2-{4[imino(piperazin-l-yl)methyl]phenoxy}ethoxy)imino]ethanamide (2Z)-2-(2-Amïno-l,3-thiazol-4-yl)-2-({[l-{4-carbamimidoylphenoxy)- (2R and 2S)-4-hydroxybutan-

2- yl]oxy}imino)-N-[(3S)-2,2-dimethyM-oxo-l-(sulfooxy)azetidin-3-y!]ethanamide (2Z)-2-{[2-({6-[N-(2-Aminoethyl)carbamimidoyl]pyridin-3-yl}oxy)ethoxy]imino}-2-{2-amino-l,3thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2Z)-2-[(2-(4-[N-(3-Aminopropyl)carbamimidoyl]phenoxy}ethoxY)Îmino]-2’(2-amino-l,3-thiazol-4yl)-N-[(3S)-2₍2-dimethyl-4-oxo-l-(sulfooxy)azetidîn-3-yl]ethanamide (2Z)-2-(2-Amino-l,3-thiazol-4-yl)-2-[{2-{4-[N-(l,3-dïaminopropan-2-yl)carbamimidoyl]phenoxy}ethoxY)imino]-N-[(3S)-2,2-dimethy1-4-oxo-l-{sulfooxy)azetidin-3-yl]ethanamîde (2Z)-2-{[2-(4-{N-[(2R)-l-Amïno-3-hydroxypropan-2-yl]carbaminiidoyl}phenoxy)ethoxy]imino}-2-(2amino-l,3-thiazol-4-yl)-N-[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2Z)-2-({2-[4-(5-Amino-l,4,5,6-tetrahydropyrimidin-2-yl)phenoxy]ethoxy}imino)-2-(2-amino-l,3thiazol-4-yl)-N-[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]ethanamide (2R and 2S) 3-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-

3- yl]amino}-2-oxoethylidene]amino}oxy)-2-(4-carbamimidoYlphenoxY)propanoie acid (25)-2-{{[(lZ)-l-(2-Amino-l,3-thiazoM-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxY)-3-(4-{N-[{3/î)-piperidin-3-yl]carbamimidoyl)phenoxy)propanoicacid

268 (2R)-2-({[(lZ}-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-3-(4-{N-[(3R)-piperidin-3-yl]carbamimidoyl}phenoxy)propanoic acid {[{3S)-3-{[(2Z)-2-(2-Amrno-l,3-thiazol-4-yl)-2-{[(4-carbamimidoYlbenzyl)oxy]iniino}acetyl]amino}-

2.2- dimethyl-4-oxoazetidin-l-y!]oxy}methane$uifonicacid (2Z)-2-[(2-{4-|5-(Aminomethyl)-4,5-dihydro-lH-imÎdazol-2-yl]phenoxy}ethoxy)imîno]-2-(2-aniino-

1.3- thïazo!-4-yl)-N-I(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-y!]ethanamide (3S)-3-({(2Z}-2-(2-Amino-l,3-thiazoM-y1)-2-[(2-{4-[N-(pyrazolidin-4-yl)carbamimidoyl]phenoxyJethoxy)imino]acetyl}amino)-2,2-dimethyl-4-oxoazetidine-l-sulfonicacid (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4’yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-sulfoazetÎdin-3-y1]amÎno}2-oxoethylidene]amino}oxy)-3-(4-{N-[{3S)-pyrrolidin-3-yl]carbamimidoyl}phenoxy)propanoicacid (2S)-3-{4-[N-(2-Amino-2-methylpropyl)carbamimidoyl]phenoxy}-2-({[(lZ}-l-(2-amino-13-thiazo1-

4-yl)-2*{((3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amino}-2-oxoethylidene]amino}oxyjpropa noie acid {2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazoM-yl)-2-{[(3S}-2,2-dimethy1-4-oxO'l-(sulfooxY)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-{4-{N-[2-(methylamino}ethy1]carbamimidoyl}phenoxyjpropanoic acid (2S)-2-({[(lZ)-l-(2-Amino-l_/3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-su1foazetidin-3-yl]amino}2-oxoethylidene]amino}oxy)-3-(4-{N-[(3R)-pyrrolidin-3-yl]carbamimidoyl}phenoxy)propanoie acid (2S)-2-({[{lZ)-l-(2-AminO’l,3-thiazo!-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-{4-[N-(piperidin-3-yl)carbaminiidoy1]phenoxy}propanoic acid (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazoM-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethy1idene]amino}oxy)-3-{4-[N-{pyrrolidin-2-ylmethyl)carbamimidoyl]phenoxy}propanoic acid

269 (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazoM-yl)-2-{[(3S)-2^-dimethyl-4-oxo-l-(su!fooxy)azetidin'3' yl]amino}-2-oxoethylidene]amino}oxy)-3-{4-|N-(piperidin-2-Ylmethyl)carbamimidoyljphenoxyjpropanoic acid (2S)-3-(4-[N-{trans-(R,RandS,S)-2-Aminocyclopropyl)carbaminiïdoyl]phenoxy}'2’({[(lZ)-l-{2amino-l,3-thiazo!-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-($u!fooxy)azetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)propanoic acid (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazoM-yl)-2-{[(3S)-2_/2-dimethyl-4-oxO'l-sulfoazetidin-3-yl]amino}2-oxoethylidene]aniino}oxy)-3-{4-{N-[(3S}-l-iTiethylpyrTor>din-3’yl]carbaniimidoyl}-phenoxyj-propanoic acid (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazoM-yl)'2-{[(3S}-2,2-dimethyl-4-oxo-l-($u!fooxy)azetidin-3yl]amino}-2-oxoethylidene]amîno}oxy)-3-{4-[N-(l,3-diaminopropan-2-yl)carbamimidoyl]phenoxyjpropanoic acid (2R)-2-({[(lZ)-l-(2-Amino-l,3-thiazol'4'yl)’2-{[(3S)-2_r2-dimethyl-4-oxo-l-{sulfooxy)azetidin-3yl]amino}-2-oxoethyiidene]amino}oxy)-3’{4-[N-(l,3-diaminopropan-2-yl}carbamimidoyljphenoxylpropanoic acid (2S)-2-({[(lZ)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-($iilfooxy)azetidin-3yl]amino}-2-oxoethy!idene]amino}oxy)-3-{4-[N-(lH-imidazol-2-ylmethyl}carbamimidoyl]phenoxy}propanoic acid (2R)-2-({[(lZ}-l-(2-Amino-l,3-thiazo!-4-yl}-2-{[{3S)-2,2-diniethy1-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-{4-[N-(lH-Îmidazo1-2-ylmethyl)carbamimÎdoyl]phenoxy}propanoic acid (2S)-3-{4-[N-(4-Aminopyrrolidin-3-yl)carbamîmidoyl]phenoxy}-2-{{[(lZ)-l*(2’amino-l,3-thiazol-4yl)’2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3-yl]amîno}-2oxoethy!idene]amino)oxy)propanoic acid (2S)’2-({[(lZ)-l-{2-Amino-l,3-thiazol-4-yl)-2-{[(3S}-2,2-dimethyl-4-oxo-l-(su!fooxy)azetidin-3y!]amino}-2-oxoethy!idene]amtno}oxy)-3-{4-[N-(azetidin-3-Yl)carbamimido¥l]phenoxy}propanoic acid v-**'^-

270 (2S)-2-({[(lZ)-l-{2-Amino-l,3-thÎazoM-yl}-2-{[(3S}-2,2-dimethyl-4-oxo-l’(sulfooxy)azetidin-3yl]amino}-2-oxoethy!idene]amino}oxy)-3-{4-[N-{piperidin-4-yl)carbamimidoyl]phenoxY}propanoic acid (2S)-2-([[(lZ}-l-(2-Amino-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amino}oxy)-3-{4-[N-{azetidin-3-yl)carbamimidoyl]phenoxy}propanoic acid (2S)-2-{{[(12)-l-(2-Amino-l,3-thiazol-4-yl)-2-{[(3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino)-2-oxoethylidene]amino}oxy)-3-(4-{N-[2-(pyrimidin-2-ylamino)ethyl]carbamimidoyl}phenoxy)propanoic acid (2R)-2-({[(lZ}-l-(2-Amino-l,3-thiazol-4-yl)-2-{[{3S)-2,2-dimethyl-4-oxo-l-(sulfooxy)azetidin-3yl]amino}-2-oxoethylidene]amïno}oxy)-3-{4-{N-[2-{pyrimidin-2-ylamino)ethyl]carbamimidoyl}phenoxyjpropanoic acid and the salts thereof, the solvatés thereof and the solvatés of the salts thereof.

9. Compound according to any one of claims 1 to 8 for use in a method of treating and/or preventing diseases, in particular bacterial infections, especially with Gram- négative bacteria.

10. Method for the préparation of a compound of formula (I) according to claim 1 comprising removing the protecting group from a compound of formula in which Pg represents a protecting group and R³-R³, A, I, X, Y and Z are as defined in claim

271

11. Method according to claim 10, characterized in that compound (II) is prepared by reacting a compound of formula (III) in which Pg represents a protecting group and A, I, X, Y and Z are as defined in claim 1, with a compound of formula in which R¹, R*and R³ are as defined in claim 1.

12. Use of a compound according to any one of claims 1 to 9 in the manufacture of a médicament for the treatment and/or prophylaxis of diseases.

13. Use of a compound according to any one of claims 1 to 9 in the manufacture of a medic-

15 ament for the treatment and/or prophylaxis of bacterial infections.

14. Médicament comprising at least one compound according to any one of daims 1 to 9 in combination with at least one further active compound.

272

15 Médicament according to claim 15, characterized in that the further active compound is a /Mactamase inhibitor.

16. Médicament comprising at least one compound according to any one of daims 1 to 9 in combination with at least one inert, non-toxic, pharmaceutically acceptable excipient.

5

17. Médicament according to any one of daims 15 to 17 for use in a method of treating and/or preventing bacterial infections.

18. Use of of at least one compound according to any one of daims 1 to 9 or a médicament according to any one of daims 15 to 18 in the manufacture of an agent for controlling bacterial infections in humans and animais.